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Abstract  
 
This study aimed to provide a comprehensive assessment of hospital utilisation among 
children and young people (CYP), addressing recommendations emerging from the 
Children and Young People’s Health Outcomes Forum that emphasised the importance 
of improving the health of young people. The burden of care for CYP with cancer on local 
and national healthcare systems is unknown and lack of data limits the ability to inform 
and improve service delivery. Therefore, I used a specialist population-based cancer 
register in CYP from Yorkshire, linked to hospital admissions data, to analyse healthcare 
utilisation after diagnosis and treatment for cancer. Additionally, clinical and 
sociodemographic factors that contributed to hospital utilisations during and after 
treatment were identified and discussed. 
The study included 3,151 cases of cancer aged 0-29 years diagnosed in Yorkshire during 
1996-2009, and admitted to hospital during 1997-2011. The study observed a steady 
increase in admissions over the period. Children had higher median number of 
admissions (median=25, Interquartile range (IQR): 8-44) than teenagers and young 
adults (TYA) (median=10, IQR: 3-20), and spent longer in hospital on average with 
median duration of three and one days per 100 person-days respectively. However, TYA 
with leukaemia experienced longer stays in hospital on average than children, with a 
median duration of eight and four days, respectively. Factors that influenced the pattern 
of admissions varied by cancer type, however relapse status, type of initial treatment and 
year of diagnosis were significantly related to hospitalisation independently. Cancer 
survivors had a significantly higher risk of morbidity compared with the general 
population after treatment completion (standardised hospitalisation rate (SHR) = 2.37, 
95% CI:2.26-2.49). 
Findings from this work demonstrate the variation in hospital activity by cancer type and 
age group, as well as the independent predictors of hospitalisation. This aids the 
continued development of high-quality cancer services to meet the needs of young 
people with regard to short-term and long-term care. 
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 Introduction 
1.1 Motivation 
In the UK, more than a third of a million people were diagnosed with cancer in 2013, and 
450 deaths caused by cancer each day [1]. Cancer is largely considered to be an elderly 
disease, as the majority of cancers, constituting almost 50% of cases, were diagnosed 
among people over the age of 70 [1]. Among children and young people (CYP) aged 0-
24 it comprises less than 1% of the total annual incidence [1] and 10% among cases 
aged 15-24 and 29 years [1, 2], however cancer is the leading cause of natural deaths 
among this group [3, 4]. 
The five-year disease-free survival rate for childhood (0-14 years of age) cancer has 
improved in the last three decades, from 30% to more than 80% for all cancers in general, 
although it varies across different diagnostic groups [5]. Treatment protocols have 
improved which have increased survival rates generally but also reduced the number of 
serious side effects and oncologists are better able to deal with relapsed disease 
alongside with the development of palliative care to manage end of life care [6]. Although 
the availability of specialist centres, centralised care, multicentre-trials or standardised 
treatments have not consistently been improved for each cancer type, there have been 
improvements across the spectrum of cancer types and there have been no declines in 
survival over time [6]. Other factors may therefore be attributable to some of the 
improvements for those cancers where such service improvements were not available 
which could include changes in patient profiles or characteristics over time. However, 
older children and young adults (15-24) have not shown similar improvements, which 
could be explained by the absence of centralised and standardised healthcare facilities 
and treatments, or limited recruitment into clinical trials, both nationally and 
internationally other could be due to the differences in biological of the disease and 
treatment tolerance or due to other multifactorial reasons such as physical and emotional 
challenges [7, 8]. 
Based on a comprehensive literature review of the current position in comparison with 
other countries, the Department of Health in England has undergone major changes in 
its healthcare services policy with the aim of improving healthcare delivery and outcomes 
for cancer patients [9]. In 2005, the National Institute for Health and Care Excellence 
(NICE) published guidelines to improve health outcomes among children and young 
people with cancer [10]. These guidelines provide CYP with specialist care services, 
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assuring multidisciplinary communication throughout the healthcare journey. These 
guidelines were improved in 2009 to allocate shared care services to provide care closer 
to patients’ homes. However, there were variations in the population coverage of 
specialist services around the UK [11]. The Department of Health aims to provide high 
quality and equal healthcare services, therefore analysis of the patterns of hospital 
activity could provide insights into the quality of care delivered to patients, by comparing 
the usage of hospital resources among patients that had similar diagnoses and treatment 
protocols, but received care from different providers. Whilst there has been an increase 
in focus on the long-term effects following cancer for children and TYAs as a result of 
improved survival, the pattern of healthcare activity, focusing on both short- and medium-
term treatment-related comorbidities following diagnosis of cancer, and the variation in 
uses of healthcare services according to cancer types, age group, gender and place of 
care after diagnosis have not been comprehensively studied in the published literature. 
The pattern of hospital admissions has barely been tackled in the UK. There is no 
evidence on the variation of hospitalisation use by cancer type, or the potential reasons 
for increases in the rate of hospitalisation among cancer survivors. Furthermore, the rate 
of hospital encounters after date of diagnosis could highlight short- and long-term 
treatment-related morbidity that increases the NHS burden and also impacts on patient 
well-being and quality of life. Understanding the types of hospital admission among 
cancer survivors could have a potential impact in the ability of healthcare planning to 
cope with cancer-related comorbidities in the first five years after diagnosis and beyond 
[12]. A study conducted in France found that the majority of hospital stays for all 
individuals admitted in 2007 were due to infectious diseases, nervous system 
complications and cancer treatments (chemotherapy and radiotherapy) [13]. Therefore, 
cancer and its associated complications had an enormous effect on both the patients 
and hospital budgets [13]. The French study was not specifically directed at cancer 
patients, but used a snapshot of cancer survivors from an insurance-based healthcare 
dataset looking at a range of diseases to provide a broad overview of the usage of 
hospital resources. The National Institute for Health and Clinical Excellence [2005] 
suggested that patients, especially TYAs, might be admitted during and after cancer 
treatment due to alopecia, weight loss or gain, acne, mouth sores, bleeding, infection, 
amputations, nausea and vomiting, and they are also thought to suffer from coping with 
these diseases more so than younger children and older adults [11]. This thesis focuses 
on CYP with cancer by comparing the pattern of hospital activity among CYP cancer 
survivors by varied demographic and clinical characteristics, such as treatment 
management factors including: place of care and type of treatment received. 
1.2 Study rationale 
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The NHS Cancer Plan aimed to provide equal services to the population in England [14]. 
In 2008, the National Cancer Survivorship Initiative was launched in response to the 
reformation of cancer strategy in 2007. The main objective was to ensure that 
appropriate services were attained by CYP (aged 0-24) after receiving cancer care. They 
aimed to motivate survivors to visit follow-up clinics to monitor their health status in both 
the short and long term. This national initiative was triggered by the fact that there were 
40,000 childhood cancer survivors, 60% of which had at least one hospital visit as a 
result of long-term treatment-related morbidity [15]. The survival rate among TYAs also 
improved, reaching 83% in 2009 [16]. The increased level of survivors has increased the 
burden on patient healthcare to cope with cancer and its treatment related comorbidities. 
CYP survivors spent more time in a hospital compared with their peers, which has huge 
impact on their overall quality of life and well-being, as well as exhausting hospital 
resources [17]. 
Analysis of hospital admissions could provide a solid knowledge base of managing 
cancer related services, such as treating complications due to cancer or cancer 
treatments [12, 18, 19]. Seventeen percent of the total acute care unit admissions was 
for cancer patients of all ages; almost 9% of these could be avoided by referring patients 
to palliative care [19]. Understanding the pattern of hospital activity among cancer 
patients could help in predicting cancer consequences, thus enhancing future treatment 
strategies [20]. 
Routine assessment is a key element in ensuring that equal services are provided for all 
patients. Therefore, studying the variation in admission rates adjusting for cancer types 
and treatment strategies could provide an insight into the amount of care delivered by 
various healthcare providers. Evidence based literature suggests specialist healthcare 
providers, such as principle treatment centres (PTCs), provided better outcomes in term 
of survival rates compared with non-specialist centres [11], more detail on explaining 
these services is provided in Section 2.4. However, the impact of the type of services 
provided on outcomes were absent in the literature, i.e. there was no evidence regarding 
the extent of variations in treatment management and the impact on health outcomes of 
CYP with cancer.  In previous studies it was explained that the poor outcomes among 
TYAs were driven by the fact that there was inequality in accessing healthcare facilities 
[21]. As a consequence, studying hospital activity could provide evidence to ensure that 
patients are treated effectively and efficiently, thereby providing the best outcomes for 
patients and ultimately leading to fewer complications and, thus, minimising the burden 
on patients and the NHS. Improvements in healthcare treatments have led to increased 
rates of survival [22]. However, it raises the concerns of treatment-related complications 
such as recurrent cancer [23, 24], physical and psychological defects [25, 26] and/or risk 
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of death among advanced cases or patients with poor prognosis [27, 28]. Childhood 
acute lymphoblastic leukaemia (ALL) treatment protocols experienced tremendous 
changes. In the UKALL XI trial, patients were treated at home, which lead to an increase 
in the mortality rate among patients from lower social classes, since it was difficult to 
cope with the complexity of these new treatment protocols [29] (more detail in Section 
2.3). The results of this research could provide comprehensive knowledge regarding the 
extent of hospital resources utilised by cancer survivors, to help in planning for services 
and minimising the allocation of unnecessary resources [18]. 
 
1.3 Summary of aims and study questions 
The thesis aims to identify the pattern of hospital activity among CYP (aged 0-29 years), 
taking into account discrepancies in gender, type of initial treatment and place where 
care was delivered. It will provide an assessment of the quality and equity of using 
hospital resources among varied healthcare providers (specialists and non-specialists). 
Consequently, it will provide healthcare commissioners and providers with the health 
service needs for CYP diagnosed with cancer, in terms of hospital admissions, their 
length of stay in hospital and related comorbidities from the date of diagnosis both during 
and following their treatment period. The main study aims and research questions are 
identified as follows: 
 
1.3.1 Aims 
1. To determine whether there has been any change in hospital activity rates post-
diagnosis from 1997 to 2011. 
2. To assess the variation in hospital activity in terms of the number of admissions 
and length of stay stratified by admission period (during treatment and after 
treatment completion) adjusting for treatment length among individuals 
diagnosed with cancer aged 0-29 years in Yorkshire. 
3. To identify the factors that influence the risk of hospital admission and length of 
stay among leukaemia, lymphomas, central nervous system (CNS) cancers, 
neuroblastoma, renal tumours, bone tumours, soft tissue sarcomas (STS) and 
germ cell tumours, adjusting for length of follow-up.  
4. To use hospital inpatient admissions to determine the extent of morbidity that 
lead to hospitalisation in terms of both short-term (during the treatment period) 
and long-term effects (after treatment completion). 
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1.3.2 Study questions 
1. How reliable is the cancer register and hospital episode statistics (HES) data in 
identifying type of treatment received, ethnic group and place of care?  
2. Did hospital activity vary during and after completion of treatment for each major 
diagnostic group, taking into account follow-up duration? Did this relationship 
vary by patient demographic characteristics such as gender, ethnic group and/or 
socioeconomic status? 
3. Was there variation in hospital activity by primary cancer and those individuals 
who relapsed compared to those who did not? 
4. Did hospital activity rates vary among survivors compared with those who died 
during the study follow-up period? Was any variation in hospital activity explained 
by place of care?  
5. Did the type of hospital admissions for the cancer cohort differ compared to the 
background population? 
6. What were the most common causes of admission according to cancer type, age 
group and gender? 
 
1.4 Thesis outline 
In order to provide a comprehensive background for this thesis, Chapter 2 includes a 
detailed overview of children and TYAs with cancer, background information on the 
epidemiology of cancer in term of incidence, survival, type of treatment received, and 
type of morbidity. The specialist healthcare plan started earlier among young children 
(aged 0-14) compared with older children and young adults (aged 15-29). Based on that, 
the following section in Chapter 2 provides an assessment of the differences in managing 
cancer by age, children compared with young adults, by identifying the concept of 
specialist services, looking at when it was introduced, and what is meant by centralised 
services (Section 2.4). This section provides a detailed review of the current 
management of healthcare services for CYP with cancer in the UK. It explains the 
procedures and policies that were released to accommodate the provision, and the 
places where cancer survivors have been treated are introduced so as to consider the 
variation in managing cancer by different cancer types and age groups, which could 
directly impact hospital usage. Following that, a detailed review of the current knowledge 
on hospital activity amongst survivors of CYP cancer is provided in Chapter 3. Provides 
details of the materials and methods used in extracting data, preparing it for further 
analysis, and details the statistical analysis process. The results are then summarised in 
four chapters: an overview of the study population and cancer related clinical 
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characteristics (Chapter 5); Chapter 6 describes patterns of hospital admissions and 
length of stay during and after treatment completion, taking into account varied 
demographic and clinical characteristics such as age, gender, ethnicity, type of initial 
treatment and proportion of specialist care; Chapter 7 presents the result of multivariable 
analysis providing a summary of the factors that influence the hospitalisation rate after 
diagnosis with cancer for all cancers combined and separately by histological sub-types; 
while Chapter 8 is designed to assess the morbidity that leads to hospitalisation, starting 
by explaining the frequency of case specific admissions during and after treatment 
completion and the excess hospitalisations compared with the background population. 
Chapter 9 then discusses the key results of the thesis and compares them with the 
available literature. It provides a summary of the main results, in terms of the factors 
influencing hospital admissions and length of stay and the excess morbidity among the 
cancer cohort. The study’s clinical implications, strengths, limitations and future work are 
also presented in Chapter 9. 
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 Epidemiology and Management of 
Healthcare Services 
2.1 Introduction 
This chapter includes a detailed overview of children and young people with cancer, 
alongside a discussion of the age boundary definitions and tumour classification 
schemes for CYP. Following this, the chapter provides detailed background information 
on the epidemiology of CYP cancer, including the incidence and survival by common 
cancer types, before giving an overview of the current management of healthcare 
services for children and TYAs with cancer in the UK. 
2.2 Children and young people’s cancer  
Despite cancer being relatively uncommon for CYP compared to adults, the incidence of 
cancer in younger people has steadily increased for most cancer types [30-32]. In 
addition, cancers among CYP can have devastating effects not only on those with cancer, 
but also on their families. Furthermore, cancer among CYP can have both short- and 
long-term implications as result of its treatment, and can reduce life expectancy. 
Moreover, cancer is one of the leading causes of death among children and TYAs [33]. 
Teenagers and young adults are in a transition period from childhood to adulthood. 
During this period, vital changes are taking place biologically, emotionally and socially. 
Carr et al.[2013] define the period of adolescence as: 
“A time of search of identity and a period of rapid physical, social and 
emotional development, it is associated with significant remodelling of the 
neuroplastic adolescent brain” Carr, et al. [2013]p.258[34]. 
Furthermore, TYAs diagnosed with cancer are in a critical phase, as they are often just 
starting their career paths. TYAs have distinctive types of cancer that differ 
morphologically from paediatric tumours and the tumours of older adults. TYAs can 
experience types of cancer that are predominant among younger children or older adults; 
these are embryonic tumours, such as Wilms’ tumour, rhabdomyosarcoma and 
neuroblastoma that are considered ‘late paediatric’, since these are usually predominant 
among children aged less than five [35]. The other type is adult cancers, such as 
melanoma, thyroid and nasopharyngeal cancers that usually occur later in life but when 
they occur among TYAs are considered as ‘early onset of adulthood’ [35]. Additionally, 
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TYAs have a uniquely high frequency of tumours such as Ewing sarcomas, germ cell 
tumours and Hodgkin lymphoma, which are present to a high extent among the 
aforementioned group (Figure 1) [36]. TYAs diagnoses and clinical outcomes also differ 
from other groups. They have worse prognostic factors than children or adults. For 
example, TYAs with ALL have higher pseudodiploidity of the Philadelphia chromosome 
compared with children, which is usually related to poor outcomes [8]. TYAs on the other 
hand, fare better than children in tolerating complex treatments such as chemotherapy 
and radiotherapy [37]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sources: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/incidence/age#heading-Two.    
2.2.1 Identifying age boundaries  
There is variation when specifying TYA age boundaries to differentiate these from 
children. It seems arbitrary and varies depending on different perspectives, whether 
clinical or statistical; most of the UK research used 13 or 15 to 24 to specify young people 
and refers to them as teenagers and young adults [3, 8, 38-40]. In the US, 15-29 year-
olds are included in adolescent studies, and ‘young adult’ studies in the US extend to 
those aged 35-39 years [2, 37, 41-43]. The common upper age limit for inclusion in 
paediatric epidemiological cancer research is 14 years; hence patients over the age of 
14 are traditionally not included in childhood cancer research. The Office for National 
Statistics often uses 14 as the upper limit for childhood cancer statistics, which is driven 
from a statistical perspective [44]. However, from a clinical perspective, each diagnostic 
group has different age boundaries depending on the biology of the cancer. To avoid 
overlapping patients between childhood and adolescence, the age of 15 seems more 
Figure 1:The five most common types of cancer among females (a) and males (b) 
diagnosed between 2009-2011. Data Sources [37]  
(a) 
(b) 
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appropriate to serve as the lower limit for TYA cancer research. Patients aged 25-29 
were included in teenage studies in the US [11]; however, this age group could have 
different frequencies of cancer compared with younger groups, and are usually treated 
using adult protocols in adult settings. Therefore, patients from this age group could 
reveal varied hospital activity because they received care in different settings, which 
could more accurately reflect adult activity patterns. Due to the dearth of knowledge 
regarding patients under the age of 30, in terms of incidence, survival, and the use of 
hospital activity, the effect of place of care and type of treatment (taking into account the 
length of treatment) on patterns of hospital activity, the current project addressed this 
lack of knowledge. More importantly, it took advantage of the availability of information 
among survivors aged up to 30 from the Yorkshire Specialist Register of Cancer in 
Children and Young People (YSRCCYP) that was used to extract the study population 
(details included in Chapter 4, Section 4.6.1). 
 
2.2.2 Cancer classification schemes  
Three classification schemes were commonly used to classify cancer; the International 
Classification of Disease-Oncology (ICD-O) [45], the International Classification of 
Childhood Cancer (ICCC) [46], and the Birch Classification [38]. These were made to 
facilitate and provide a more standardised comparison of the types of cancer, both 
nationally and internationally. 
Tumours occurring in CYP differ significantly from the more common adult cancers in 
terms of their biology and presentation. ICD-10 coding is used to classify adult cancers 
using primary site (topography), such as lung carcinoma and other epithelial cell cancers. 
A more helpful classification for CYP tumours is that based on ICD-O coding as it 
includes information on the morphological features of tumours as well the topography. 
However, carcinomas from non-epithelial cells, which are rare among adults but have a 
high incidence in TYAs, are not recorded in detail in the ICD-O. Childhood cancer usually 
originates from specific types of cells or histological types, rather than specific organs. 
The types of cancer that were classified in this scheme were mainly related to embryonic 
tumours, which commonly occur among children but to a lower extent among TYAs. The 
ICCC was not developed specifically for TYA cancers. Therefore, when TYA cancers 
were classified according to the ICCC scheme, a high percentage of cases were 
classified as “unspecified” [47]. Another classification scheme designed for TYAs was 
the Birch [38] TYA scheme, which is similar to ICCC in allocating cancer type using 
morphological codes, however includes additional groups to allocate cancers that are 
common among TYAs, such as melanoma and carcinoma. Although the Birch 
classification was found to be better suited to classify the TYA cancer diagnostic group 
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[48], it was not adapted for paediatric cancers, as melanomas and carcinomas do not 
occur among children. 
Nevertheless, in this thesis the hospital activity pattern were analysed for children and 
TYA. Hence, it was essential to have one scheme for both children and TYAs to provide 
comparable data. It would be ideal to have separate classification schemes for each age 
group, however, ICCC was found to properly classify cancer among TYA.  The variation 
in cancer outcomes among children and young people was assessed before and in 
classifying the TYA cancer, two classification schemes were used and compared: Birch 
and ICCC-3 [49]. In their study, it was found that ICCC only allocated 0.1% of cases as 
unknown, while 2% of cases were left with an unknown cancer type using the Birch 
classification scheme, additionally more cases were identified as ‘others’ using Birch 
compared with ICCC [49]. The current thesis used the same data sources and similar 
data catchments as the aforementioned studies, hence the use of ICCC to classify 
cancer types for children and TYA was reliable among the study setting, in addition to 
facilitating internal comparison between cancer types and the study age group [49]. 
2.3 Epidemiology of cancer 
2.3.1 Cancer incidence  
One out of 500 children develop cancer before the age of 14 [36]. While in the period 
2009 to 2011, there were around 4,556 cancer diagnoses per 100,000 persons aged 15-
24 in the UK [36]. In the UK, only 1% of the total cancer cases were diagnosed at the 
age of 15-29, although this increased by 0.5% from 2006 [21, 36]. Additionally, TYAs are 
50% more likely to be diagnosed with cancer than children under the age of 15 [36]. This 
pattern is similar in the USA [37, 50]. In 2006, TYAs accounted for almost 2% of the total 
cancer incidence in the USA [37], which is higher than in the UK [51]. 
Cancer incidence among CYP varies according to diagnostic type. Among patients under 
the age of 15, leukaemia and brain tumours are the most common types of cancer and 
account for almost half of the incidences, followed by lymphomas, which account for 10% 
of the total cases (Figure 2) [52]. 
Lymphomas are the predominant cancer among TYAs aged 15-24. In the UK, the 
standardised incidence rate of lymphoma was 421.7 per million person-years from 1995-
2009, followed by carcinoma and germ cell cancers, where the incidence rates were 
392.5 and 310.9 per million person-years, respectively. Leukaemia was the sixth most 
common type of cancer, just after cancers of the CNS and melanoma, although it had 
the highest related cause of death in this age group [36]. In the USA, similar types of 
cancer occurred among TYAs, with lymphomas (Hodgkin lymphoma - HL) being the 
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leading type of cancer (16%), followed by germ cell and CNS cancers at 15% and 10%, 
respectively [50]. 
2.3.2 Survival 
Cancer accounts for 10% of the total number of deaths among children older than one 
year old [18]. As a result of breakthroughs and improvements in treatment, including 
clinical trials, the survival rate of children has shown significant improvement, rising from 
30% at the end of the 1960s to 82% at the beginning of the 21st century [53]. However, 
the range of improvement gradually decreased, the biggest was between 1961/70 and 
1981/90, lower improvement was noticed between 1981/90 and 1991/2000 and no 
improvement in 1991/2000 and 2001/10 [54]. TYAs also had advantages resulting from 
enhancements in treatment protocols, especially from 1998-2009, as evidenced by the 
fact that the total five-year survival rate reached 84% in the North of England [55]. Overall, 
the survival of patients with leukaemia, lymphoma, Ewing sarcoma and CNS cancers 
has improved over time, although it was worse in TYAs aged 15-24 than in children under 
15 [55]. In 2009, Pearce suggested that this disadvantage in outcomes is related to the 
rare frequency of cancers, the distinctive biology of cancer, limited entrance to clinical 
trials, late prognosis, late referrals and a lack of standardised treatment [21].  
Over the last 40 years (1968 to 2008), the five-year survival rate increased from 46% to 
84% in the North of England, as evidenced by population-based registers [55]. This 
improvement could be due to the improvement in treatment in the 20th century, in 
particular for acute myeloid leukaemia (AML) in males, as their survival was not 
statistically different from females from 1998 to 2009 compared with earlier periods [55]. 
Lymphomas have the highest survival rate, reaching 89% in 2005; it increased by 5% 
from 1991 to 2005 among TYAs. Leukaemia had the poorest survival rate of only 49% 
in 1991, although this increased to 62% in 2005 [36]. The TYA survival rate markedly 
improved in 2009, reaching 84% overall, and CNS, germ cell tumours and melanoma 
had the highest survival rate (94%, 96% and 100%, respectively). In particular, AML and 
Ewing sarcoma showed the largest treatment improvements, as survival increased from 
0% in 1968 to about 50% in 2009 [55].  
2.3.3 Epidemiological risk factors  
2.3.3.1 Age  
Teenagers and young adults had a better prognosis than children, and the survival rate 
between 2002 and 2006 was better than for children and older adults, having 82.5% five-
year relative survival compared to 82.0% and 65.9% among children younger than 15 
years and adults older than 40 years, respectively [43]. However, the percentage of 
improvement per year was lower than for children with 58% compared to 52% among 
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children and TYA, respectively [43]. From 2002-2006, the survival rate for TYAs aged 
15-29 was significantly better than adults aged 40-49 in the USA, especially for 
leukaemia, lymphomas and non-gonadal germ cell cancers [51]. Although they  found 
better survival rates among TYAs younger than 40 years old, than adults aged above 40, 
they found that other non-specific types of leukaemia had poorer survival rates among 
younger groups [51]. Additionally, breast cancer among TYAs had worse outcomes, with 
an 80% five-year survival rate among patients aged 15-29 compared with 88% in patients 
aged 40-49 [51].  
2.3.3.2 Gender 
Cancer is more common among males, except for melanomas and carcinomas, which 
are more common in females [36]. From 1968 to 2009, females had significantly better 
survival rates than males. Additionally, they were 17% less likely to be at risk of death, 
after adjusting for age, period of diagnosis and deprivation, than males [55]. 
2.3.3.3 Ethnicity and socioeconomic status 
Survival among TYAs aged 15-24 suffering from haematological cancers (leukaemia and 
lymphomas) was not related to economic deprivation. In contrast, childhood cancer was 
related to socioeconomic status, as childhood leukaemia was negatively associated with 
deprivation, with the most affluent people having a greater risk of leukaemia [56].  In 
previous studies it was found that TYAs aged 15-25, in general, had better survival in 
the most affluent areas [55]. However, they did not take into account cancer stage or 
ethnicity, which are usually correlated with deprivation. In their study, non-Hodgkin 
lymphoma (NH) survival was better in the most affluent areas, while CNS cancer survival 
was worse in the most affluent areas [55]. These differences show that cancers in TYAs 
have varied biological causes between diagnostic groups and other age groups, which 
requires further research. Furthermore, it could be related to the location of specialised 
healthcare services, as CNS cancer specialist care in Northern England is located 
closest to less affluent survivors [55]. 
Several studies found correlations between cancer incidence and ethnicity in Europe and 
the UK [57, 58]. South Asians had higher cancer incidence for the majority of cancers 
than non-South Asians in the UK [59-61]. Although in Yorkshire the incidence of cancer 
among CYP was not significantly different between South Asians and non-South Asians, 
it was expected that South Asians would have approximately threefold the risk of cancer 
compared with non-South Asians in the future (2005-2020) [62]. The USA similarly found 
variations of cancer incidence by ethnicity, the incidence of leukaemia was lower among 
black young people compared with white young people.  
2.3.4 Evolving cancer treatment 
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There has been evolution in the management of cancer treatment, especially among 
haematological tumours such as leukaemia and lymphoma, however, limited 
development is observed among solid tumours such as CNS tumours, neuroblastomas 
and bone tumours [42]. Emphasis is now on ensuring that optimal therapy is 
administered at the minimum level of intensity to cure the patient, whilst reducing the risk 
of any side effects and late effects of treatment. However, the treatment among TYAs 
was not evolving at the same speed as that for children and older adults. TYAs have 
experienced slower and more stable improvements in survival compared with children 
which could be partly due to reduced availability of clinical trials [6, 63]. TYAs have 
experienced slower and more stable improvements in survival compared with children 
which could be partly due to reduced availability of clinical trials [64]. Furthermore, TYAs 
may be more likely to experience longer time to diagnosis due to personal and/or 
professional delays, and perhaps be less compliant with treatment protocols than 
younger children [65]. Clinical trials were used as a representative for improvements in 
cancer treatment, and TYA aged 15-29 had the lowest percentage of enrolment in clinical 
trials [30, 66], which also decreased each year compared with older adults whose 
enrolment rate improved each year [66]. In developed countries, such as Australia, the 
USA and the UK the accrual rate of TYA was lower than for younger children [63]. In the 
USA in 2000, the Children’s Oncology Group Adolescent and Yong Adult Committee was 
established, as a result there was an increase in clinical trials opened for TYAs in the 
period 2003 to 2005, thus an increase the involvement of TYAs in clinical trials [42]. 
Similarly, in the UK in 2005 there was encouragement for the availability of age specialist 
units for young people (more detail in Section 2.4), as these units were believed to 
increase the accrual rate among TYAs in clinical trials, hence improve treatment and 
quality of life among survivors [67]. 
2.3.5 Cancer related morbidity 
Children and young people with cancer might suffer from complications shortly after 
diagnosis or in the long term after completing treatment. During the treatment period, 
they might be admitted for infections, organ toxicity, malnutrition, nausea and bleeding, 
and these rates were higher among TYA than children [42, 50, 68]. Due to the increased 
survival pool among CYP, as presented earlier, in the UK there is an annual 3% increase 
in the number of survivors on average [69]. This increases concerns about the well-being 
of those survivors, not only in terms of survival rate, but also in terms of long-term well-
being by reducing treatment side effects. Different types of morbidity that survivors 
experience in the long term, i.e. in the five years following the date of diagnosis, include 
mental disorders such as stress and anxiety, or cognitive disorders [25, 70], 
cardiovascular diseases [71], recurrent neoplasms [24], death [28], endocrine diseases 
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[72], and loss of fertility [73]. Survivors were at higher risk of autoimmune diseases during 
the 1-year survival rate compared with the background population was 1.4, 95% CI: 1.3-
1.5) [74]. These types of morbidity were linked previously to the type of treatment 
delivered and its toxifying elements, such as anthracycline treatment that was directly 
related to an increased risk of cardiovascular consequences, and radiotherapy which 
was related to an increased risk of infertility [73]. These highlight that CYP are in 
continuous need for health services to cope with their diseases; the type of morbidity 
cases that might be experienced relate to the type of cancer as explained in the following 
sections. 
2.3.6 Leukaemia 
2.3.6.1 Incidence rate 
Leukaemia is the most common type of cancer among children under the age of 14, and 
it falls within the six most important diagnostic groups among TYAs (Figure 2). In both 
age groups, acute lymphoid leukaemia (ALL) was more predominant than acute myeloid 
leukaemia (AML), as presented in Figure 3, and was higher among young children than 
TYAs, peaking at the age of two to three [39, 75]. In the United States, leukaemia is the 
leading cause of cancer deaths among males younger than 39, and it was the second 
and third leading cause of death among young girls and women, respectively [76].  
 
 
Sources: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/teenagers-and-young-adults-cancers/incidence#heading-Three  
Figure 2: Incidences of common types of cancer among children aged 0-14 (a) and 15-
24 (b) (2006-2009) in the UK. Data Sources [38] 
 
 
 
(a) (b) 
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sources: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/childrens-cancers/incidence#heading-Four 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/teenagers-and-
young-adults-cancers/incidence#heading-One  
 
2.3.6.2 Evolving cancer treatment 
Leukaemia is one of the cancer types that has seen rapid improvements in treatment 
strategies, due to the availability of a range of clinical trials, in relation to the relatively 
high incidence among CYP. ALL was the predominant diagnostic group among children; 
hence it has been the focus of several clinical trials in the UK. The UKALL X trial, which 
included patients under the age of 15, added two courses of five-day intensive treatment 
for five and 20 weeks during remission, and, as a result, progress in improvement was 
attained, as the event-free survival rate reached 60%. The intensified treatment has 
progressed, though it still includes a similar age range (<15). From 1990-1997, the 
UKALL XI trial introduced a third intensive five-day treatment at 38 weeks. However, the 
intended improvement was not reached, as the event-free survival was unchanged. Thus, 
the overall survival improved from 73% in 1989 to 80% in 1997. This intensified protocol 
increased the toxicity in short- and long-term survivors, especially among low-risk 
patients. Because it included patients with all stages of cancer, the scope of improvement 
in terms of the rate of relapse was not described [29, 77]. The UKALL 97/99 trial limited 
the usage of radiation therapy to prevent the occurrence of CNS related diseases. These 
improvements produced an advantage in patient outcomes; it is now rare that a patient 
has defects in puberty or development as a result of cranial radiation [78]. One of the 
Figure 3: The average annual leukaemia incidence in million person-years in the UK, 
(a) children aged 0-14 and (b) TYAs aged 15-24.Data Sources: [41,74] 
(a) (b) 
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strategies for ALL trials is that all patients need to be treated for at least a two-year 
maintenance period (18 months for girls and 30 months for boys) [53]. Patients may need 
up to three years of hospital care [79]. TYAs were found to perform better when treated 
with the children’s protocol, hence paediatric trials increased their upper age limit to 
include young adults, and the UKALL trials have included patients up to 18 years old 
since UKALL97/99 and UKALL 2003. UKALL 2003 recruited patients from 2003 to 2011, 
and the upper age limit increased to include patients up to 20 years of age in 2006 and 
24 years in 2007 [80]. Starting from the UKALL XI trial, patients received their treatment 
at home rather than in hospital. This change in the type of administration of 
chemotherapy to children up to 18 years of age was strongly related to patient social 
class.  Currently, treatment for ALL in comparison with other diagnostic groups among 
children has been prolonged to three years [81]. Hence, it is important to understand the 
variation in treatment periods for each diagnostic group, because it could affect the 
pattern of using hospital resources, although this has not been studied before. Not only 
the therapeutic protocol, but also the prognostic process, has modified how patients are 
categorised. For example, patient categorisation now depends on the specific 
cytogenetic abnormalities and other characteristics of leukaemia cells, rather than the 
age of a child or the counts of white blood cells [82]. 
AML has also experienced an improvement in treatment plans, as evidenced by an 
increase in the number of treatment doses [82]. In the US, the improvement in AML 
treatments was directed not only by increasing the intensification of post-consolidation 
therapy, but also by providing supportive care to ensure proper administration of therapy 
[82]. Stem cell transplantation contributed to major improvements in the outcome of AML 
by using allogeneic transplantation that decreased the rate of death among patients with 
transplantation [82]. 
2.3.6.3 Survival 
Leukaemia childhood survival has improved over time; it increased from 75% in 1991-
1995 to 83% in 2001-2005 in the UK, and among TYAs it improved from 49.2% to 62.1% 
during the same period [31, 32]. The differences in survival could be related to the 
different biology of tumours among TYAs as opposed to children, and the noted 
improvement in prognosis and treatment was better addressed among children than 
TYAs. Indeed, the outcome differences highlight the significant improvement that has 
been made in the long history of treating childhood cancers. The survival rate for ALL 
significantly improved from 61% to 88.5% among US children from 1975 to 2002. 
Likewise, survival of AML massively improved from less than 20% to 58% and to 40% 
among children and TYAs (aged 15-19) respectively [82].  
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2.3.6.4 Cancer related morbidity 
Leukaemia survivors were at increased risk of recurrent malignancy, cardiovascular 
diseases, infertility, autoimmune disease and deficiency in growth development [33, 83-
87]. Endocrine disorders were higher among CYP with leukaemia compared with other 
cancer types; these rely on exposure to local radiation and chemotherapy [72]. The risk 
of recurrent malignancy among leukaemia survivors was higher among survivors that 
had radiation compared with survivors that did not receive radiotherapy [83]. The causes 
of infertility were related to the type of chemotherapy substance, an alkylating agent was 
directly related to decreasing the reproductive life among male and female survivors 
compared with their siblings [85, 86]. ALL survivors suffered higher levels of chronic 
conditions (odd ratio= 3.6: 95%CI: 3.0-4.5) and life-threating conditions (odd ratio= 3.6: 
95%CI: 3.0-4.5) than their siblings [88]. The risk of death as a result of cancer was higher 
among leukaemia CYP survivors than other cancer types [27]. 
2.3.7 Lymphoma 
2.3.7.1 Incidence 
Lymphomas are more common among TYAs than children. It is the leading type of 
cancer among TYAs and the third most common type of cancer among children; the 
incidence rate is 220 and 100 per one million person-years, respectively (Figure 2). 
Non-Hodgkin lymphoma (NHL) is predominant among children aged between 0 and 10, 
while it is less common among older children and young adults aged 11 to 24 (Figure 4). 
Hodgkin lymphoma (HL), on the other hand, is more common in older children, peaking 
at the age of 20 to 21 and reaching 40 per million person-years. 
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sources: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/childrens-cancers/incidence#heading-Six 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/teenagers-and-
young-adults-cancers/incidence#heading-One 
 
 
2.3.7.2 Evolving cancer treatment 
It is better to explain the change in treatment depending on specific diagnostic sub-
groups, because each sub-group has a specific prognosis and treatment regime. NHL 
survival has dramatically improved due to adjustments in treatment plans. It is worth 
noting that different strategies have been used for treating lymphoblastic lymphoma and 
non-lymphoblastic lymphoma. High doses of methotrexate were prescribed to patients 
with B-cell NHL (non-lymphoblastic lymphoma) and provided better outcomes, while for 
lymphoblastic lymphoma, the ALL strategy was administered [82]. One of the changes 
in HL was an increase in the intensity of the treatment, by administering the radiotherapy 
around the lymphoid which resulted in improved survival rates [89]. The HL trial focused 
on minimising treatment-related morbidity and maintaining the survival rate, as survival 
rate currently exceeds 90% [82]. 
2.3.7.3 Survival 
Children and TYAs have experienced improvements in overall survival from 83% to 87%, 
and 84% to 89% from 1991-1995 to 2001-2005 respectively in the UK [31, 32]. The transit 
of improvement among childhood HL occurred in 1980/90, with no significant 
improvement thereafter. While children with NHL saw improvement from 72.2% in 
1981/90 to 88.7% in 2001/10 [54]. The distinction in the trend of improvement could be 
(b) (a) 
Figure 4:The average annual lymphoma incidence in million person-years in the UK, (a) 
children aged 0-14 and (b) TYAs aged 15-24.Data Sources [41,74] 
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justified by the fact that NHL, as the most predominant lymphoma diagnostic group 
among children, was the focus of clinical trials and treatments and went through 
continuous improvements, which successfully increased the survival rate from 45% to 
88% in the US [82]. Another reason is that childhood HL had already reached satisfactory 
improvements as it reached 92.3% in 1991/2000. TYA with HL had a poorer survival rate 
from HL, while it was better than for older adults [43]. TYA with NHL saw faster 
improvements each year with 4.92% annual change compared with 0.67% among 
children; however the survival rate is higher among children than TYA [43]. TYA with HL, 
on the other hand, lagged behind the survival rates among younger children and older 
adults [90]. 
2.3.7.4 Cancer related morbidity 
As a result of the changes in the treatment intensity of HL, survivors were at high risk of 
autoimmune diseases, mental disorders, secondary malignancy and cardiovascular 
disease [25, 89, 91, 92]. The risk of mortality among HL was higher among older children 
aged 15-21 than younger children aged 10 and younger [92]. HL and NHL were at high 
risk of chronic disease compared with their siblings, it was higher among the HL group 
than the NHL group [93]. 
2.3.8 CNS tumours 
2.3.8.1 Incidence 
CNS tumours are the second most common type of cancer among children under 14 for 
both genders, and the third and fourth most common type among male and female TYAs, 
respectively (Figure 2). In particular, note that they are the second leading cause of 
cancer deaths among CYP in the US (aged <39) [76]. 
The average incidence rate of CNS cancers among children is 200 per million person-
years and 130 per million person-years among TYAs in the UK. There are variations in 
the incidences of CNS cancers among specific diagnostic groups between children and 
TYAs. Astrocytoma has the highest incidence among children, followed by intracranial 
tumours and ependymomas (Figure 5). Among TYAs (aged 15-24), the specific 
diagnostic groups of CNS cancers vary by gender, as astrocytomas were more common 
in males than females, whereas intracranial tumours more common in females [39]. 
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Sources: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/childrens-cancers/incidence#heading-Six  
http://www.cancerresearchuk.org/health-professional/cancer-statistics/teenagers-and-
young-adults-cancers/incidence#heading-One 
 
2.3.8.2 Evolving cancer treatment 
CNS tumours have received a decreased intensity of treatment (reduced length of 
therapy and reduced radiation dose) specifically tailored to reduce late effects of 
treatment and to improve the survival rate [82]. This is especially true for children less 
than 14 years old, where exposure to radiation is delayed or removed from the treatment 
plan. This group experienced greater improvement and lower long-term morbidity as a 
result of these treatment changes [82]. However, children with medulloblastoma / PENT 
experienced an increase in treatment intensity, by introducing chemotherapy before and 
after receiving radiotherapy, which resulted in improving disease free survival rates, as 
found in several international trials such as North American Pediatric Oncology Group  
and Children’s Cancer Group (CCG), and the European International Society of 
Paediatric Oncology (SIOP) [94]. CNS survivors were treated with surgery, radiotherapy 
and chemotherapy, where the radiotherapy was the most effective treatment. In the latest 
trials, the intensity of radiotherapy was managed based on the age of the patient and the 
biology of the tumour, children younger than three were usually not initially treated with 
radiotherapy due to its negative effect on the developing nervous system [95]. 
Additionally, increasing the intensity of chemotherapy and reducing the doses of 
radiotherapy among children resulted in improvements in event-free survival rates [95]. 
Less is known on the improvement in treatment among TYAs, however, among the 
Figure 5: The average annual incidences of brain tumours in million person-years in 
the UK, (a) children aged 0-14 and (b) TYAs aged 15-24.Data Sources: 
[41,74] 
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limited research it was found that the survival rates were better when they were treated 
with chemotherapy before and after radiotherapy, suggesting favourable outcomes for 
the use of chemotherapy among older groups [95]. 
2.3.8.3 Survival 
Among children aged younger than 15, the five-year survival rate of CNS had 
significantly improved from 70.1% in 1981/90 to 88.7% in 2001/10 [54]. From 2001-2005 
the survival rate of CNS was better among TYAs than children and older adults, the five-
year survival rate was 93% among TYAs, while it was 86% among children [90]. However, 
the pattern was not consistent among CNS detailed histological subtypes, ependymoma 
was better among TYAs, having a 96% survival rate, while it was 69.8% among children 
[43]. The survival rate of medulloblastoma was better among children than TYAs with 
75.6% among children and 65.4% among TYA [43]. In 2005, the overall survival rate for 
patients aged 15-24 reached 81.1% [31]. In the US, children less than four years old saw 
the best improvement, reaching 73.1%, whereas it was 53.1% in the early seventies, that 
was explained by the reduction in systematic chemotherapy, particularly for non-
medulloblastoma [96]. 
2.3.8.4 Cancer related morbidity 
CNS survivors were at risk of chronic illness compared with their siblings, with a relative 
rate of 7.1 (95% CI 6.3-8.2) [93]. More precisely, they were at highest risk of organic 
memory and brain dysfunctions compared with other cancer types, with an odd ratio of 
24.0 (95%CI: 13.4-43.2) [25]. The late psychiatrics morbidity was higher among children 
with CNS than TYAs [25]. Child, teenage and young adult CNS survivors in general suffer 
from mental disorders, and more use of antidepressants with cancer [97-100]. However, 
by assessing hospital admissions among long-term survivors it was found that CYP were 
at lower risk of admission due to serious psychological disorders compared with the 
background population [101]. The management of treatment similarly could influence the 
burden of health, TYA CNS survivors that were managed in  specialist centres were likely 
to have better survival rates than cases with limited specialist care [8]. The type of short- 
and long-term treatment effects varied by type of initial treatment; cases treated with 
radiotherapy were at risk of nausea, increased sleepiness and anorexia within two to six 
weeks after treatment, and the long-term effects might be reflected in reduced 
intelligence, especially among children younger than seven, and cerebrovascular 
disease [95]. 
2.3.9 Neuroblastoma 
2.3.9.1 Incidence 
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A neuroblastoma is more common among children and is classified as an embryonic 
tumour. The annual incidence of neuroblastoma among children aged less than 15 was 
11.6 per million person-years [68]. It was more common among children younger than 
four years of age than older children (Figure 6) [36, 75]. A 27.4 neuroblastoma incidence 
per million person-years occurred among children younger than five years, and it ranged 
between 0.5 and 2.6 per million among older children aged 5-19 years [50].  
 
Sources: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/childrens-cancers/incidence#heading-Nine  
Figure 6:The average annual incidences of neuroblastoma in million person-years in 
the UK among children aged 0-14.Data Sources: [36] 
 
2.3.9.2 Evolving cancer treatment 
The improvement in treatment was more favourable among high risk cases where they 
were exposed to high doses of chemotherapy and the use of autologous stem cell 
transplant [82]. However in more recent data, infants and children had better survival 
when they were treated with less intensified treatment, including lower doses of 
chemotherapy [102, 103]. 
2.3.9.3 Survival 
The rate of survival was stable among infants, however the survival rate reached 95% in 
1999/2001, and that was better than for older children where the survival rate was 65% 
[82]. This is similar to data extracted from the International Neuroblastoma Risk Group 
(INRG), based on diagnoses from North America, Europe and Japan, as the survival rate 
was poorer among the older group, and that was justified by the lack of centralised 
treatment among TYAs [104]. The difference in survival rate was related to the prognosis 
of the tumour as an infant, which had more favourable biology of disease than older 
children [82]. The survival rate of neuroblastoma among children improved from 57.0 to 
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66.5 from 1981/1990 to 1991/2000, and reached 68.2 in 2001/10, however, with no 
significant improvement in 2001-2010 [54].  
2.3.9.4 Cancer related morbidity 
Survivors of childhood neuroblastoma were at higher risk of depression than a 
comparison group [25, 105], however these might be for older children, as infants were 
less likely to be treated with cytotoxic chemotherapy than the older group [82]. They were 
at high risk of endocrine diseases such as diabetes, hearing loss, and ovarian 
insufficiency after having a stem cell transplant, these long-term illness mainly occurred 
in the high risk group treated with stem cell transplant [106]. Limited information was 
available on the type of morbidity occurring after treatment completion for all cases with 
neuroblastoma among TYAs. 
2.3.10 Renal tumours 
2.3.10.1 Incidence  
Wilms’ tumours are usually classified under embryonic tumours, and constitute the 
majority of renal tumours among children less than 14 years of age [82]. Among children 
younger than four, 90% of total kidney tumours are Wilms’ [5]. These types of tumours 
are common among children under the age of five, and less common among older 
children.  
The incidence of renal tumours that merged from the renal cells carcinoma increased by 
age (Figure 7), this type of tumour is more commonly found among older adults [107]. 
The incidence significantly increased over time from 2000 to 2011 among TYAs aged 
15-39 years, compared to older adults [41]. This increase relates to improvements in 
diagnosis of renal tumours and successfully diagnosing tumours at an early stage [30].  
 
Sources: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/kidney-cancer/incidence#heading-One 
Figure 7ː The average annual incidences of renal tumours in 100,000 person-years in 
the UK. Data Sources: [38]  
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2.3.10.2 Evolving cancer treatment 
The greatest improvements were in the 1980s, during which a new regime was 
introduced (doxorubicin) to high-risk patients [82]. The majority of Wilms’ trials focused 
on avoiding treatment-related morbidity [82, 108]. Hence, this type of cancer could see 
reduced hospital visits due to complications, in comparison with other diagnostic groups. 
The period of treatment and its intensity was reduced in the 90s, however, this did not 
reduce the favourable outcomes [82]. Recent trials on Wilms’ tumours in the UK found 
that patients treated with chemotherapy prior to surgery had better outcomes than 
patients who were immediately treated with surgery. The improvement, although not 
appearing in the survival rate, reduced the use of radiotherapy and intensive 
chemotherapy among patients with preoperative chemotherapy [109]. 
2.3.10.3 Survival 
Early in the 1970s, children with renal tumours cases were treated using vincristine and 
dactinomycin in combination with surgery, which resulted in a 70% survival rate [82]. In 
the US, during the 15-year period from 1987 to 2002, the survival rate showed little or no 
improvement among children with renal tumours, however, the rate was above 90%, 
which could be considered a favourable outcome [54, 82]. Among cases aged 17-55 the 
survival rate of Wilms’ tumours in an advanced stage was worse in the older group than 
in children [110]. This represents the variation in the renal survivor pool by age, and 
stage. TYAs had relatively better survival rates than older adults with 85.1% and 71.8% 
respectively, however, they saw significantly slower improvements than older adults by 
year [43].  
2.3.10.4 Cancer related morbidity 
Children and young people with renal tumours were significantly at higher risk of 
autoimmune diseases compared with the background population after being diagnosed 
with cancer [87]. Survivors of renal tumours were at lower risk of being hospitalised, 
hence low morbidity in long-term survivors, this is linked to the nature of the treatment, 
as renal tumours are treated with lower toxicity treatments compared with other cancer 
types [15]. Childhood renal survivors had the highest risk of diabetes compared with 
other cancer types, the relative risk of hospitalisation due to diabetes was 2.9 (95% CI: 
2.1-4.1) compared with background population [87]. 
2.3.11 Bone tumours 
2.3.11.1 Incidence 
The average annual incidence of bone tumours in TYAs is almost double that in children, 
40 and 20 per million person-years, respectively (Figure 8) [111]. Osteosarcoma is the 
most common bone cancer among children, followed by Ewing sarcoma. Both in females 
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and males aged 14-24, Ewing sarcoma and osteosarcoma are more common than 
chondrosarcoma (Figure 8). Ewing sarcoma is more common among TYAs than young 
children [5]. 
 
 
 
 
 
 
 
 
 
 
Sources: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/teenagers-and-young-adults-cancers/incidence#heading-One.  
2.3.11.2 Evolving cancer treatment 
Bone tumours, although not dramatically changed, have experienced some alterations 
regarding treatments among both children and adolescents, which successfully 
improved their survival rates [82]. The survival of osteosarcoma in the UK was worse 
than in Germany, where the variation seems due to the administration of multidrug 
chemotherapy in the 1980s [112]. However, recently the treatments have been similar 
among both countries after collaborations with the European and American 
Osteosarcoma Study Group (EURAMOS) that aim to improve long-term survival of bone 
tumours, as the survival rate among bone tumour survivors saw no significant 
improvement [113]. Bone tumours are treated with aggressive chemotherapy including 
12-15 courses that might last from 8-12 months, which is followed by local surgery for 
tumour extraction [114]. 
2.3.11.3 Survival 
The overall survival rate slightly improved, but was generally stable from 1991 to 2005, 
especially among children, in which the five-year survival rate stabilised at 61% [32]. The 
survival rate for osteosarcoma improved from 2003 to 2009, reaching 71% compared 
with 45% in the period 1975-79 [5]. The survival rate for Ewing sarcoma also increased 
from 42% to 72% during the same study period [5]. TYAs had a poorer survival rate 
compared with children and older adults [43, 54] 
Figure 8:The average annual incidences of bone tumours in million person-years 
among TYAs aged 15-24 in the UK. Data Sources: [112] 
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2.3.11.4 Cancer outcome and related morbidity 
Bone tumour survivors have a higher risk of chronic conditions compared with their 
siblings; and higher than other cancer types [93]. In addition to the risk of early recurrent 
malignancy, cardiopulmonary disease and mortality, bone tumour survivors suffer from 
physical and orthopaedic conditions [24, 115-118]. However, this research was based 
on questionnaires, hence subject to selectivity and recall bias.  
2.3.12 Soft tissue sarcoma (STS) 
2.3.12.1 Incidence 
STS is a rare tumour among CYP, accounting for 6% of total childhood cancer, and 4% 
of TYA cancers [39, 75]. Rhabdomyosarcoma was more common among children aged 
younger than five with an incidence of 6.5 per million person-years, while it was 3.9 
among TYAs [50]. The incidence of non-rhabdomyosarcoma was more common among 
TYAs with an incidence of 11.9 per million person-years, compared with 4.4 among 
children (Figure 9) [50]. 
 
Sources: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/childrens-cancers/incidence#heading-Seven 
Figure 9: The average annual incidences of soft tissue sarcoma in million person-years 
in the UK among children aged 0-14.Data Sources [41] 
 
2.3.12.2 Evolving cancer treatment 
Soft tissue sarcomas are more common among adults than children [119, 120]. Young 
adults had a lower response to treatment compared with children. Among all age groups 
90% had chemotherapy, 59% were treated with surgery and some had radiotherapy, 
while adults with localised tumours were mainly treated with surgery [121]. The use of 
chemotherapy was found to improve the overall survival rate, however it was suggested 
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to limit the use of chemotherapy to cases with unresectable tumours [122]. It was 
recommended that low risk groups be followed-up four to six months after treatment 
completion for any relapses, and high risk groups followed up every three to four months 
[121].  
2.3.12.3 Survival 
Children with STS had the worst survival rate compared with other cancer types, with 
73.4% improvement in 2001-2010 [54]. The survival of STS was better among children 
and older adults than TYAs [43, 90].  
2.3.12.4 Cancer related morbidity 
Soft tissue sarcoma had 1.23 relative risk of long-term morbidity related to hospitalisation 
[23]. These patients were at risk of chronic diseases compared with their siblings. They 
were hospitalised 1.82 relatively more than the background population and had 1.26 
longer stay [15]. However, these were admissions among long-term survivors for all 
types of admissions combined. Hence, there is limited knowledge of the type of morbidity 
that frequently occurred among STS and the factors that influenced the pattern of 
admission from the date of diagnosis. 
2.3.13 Germ cell tumours  
2.3.13.1 Incidence 
Germ cell tumours make up the third most common cancer group in teenagers and young 
adults. It is more common among older children aged above 15 years with an incidence 
of 30.9 per million person-years, whereas the incidence is less than 7 among children. It 
is more common among males than females. 
2.3.13.2 Evolving cancer treatment 
A wide range of trials have been presented for germ cell cases, these have focused on 
reducing the treatment toxicity, such as reducing doses of chemotherapy, thus improving 
overall survival rates [123]. However, the decision to reduce treatment needs to be 
confirmed by experienced oncologists. Further updated results show evidence of 
improved outcomes for germinoma survivors by reducing the doses of radiotherapy, 
suggesting prolonged survival period [124].  
2.3.13.3 Survival 
The survival rate among children younger than 15 years improved from 44% to 91% 
between 1971/75 and 2001/05 [32]. The five-year survival rate among TYA was 82% 
which was lower than children (survival rate= 91%), but was better than older adults 
(74%) [90]. The survival rate among testicular cancer in 2002-2006 was 96.1%, and it 
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was slightly lower for ovarian cancer, as the survival rate was 79.5% [43]. These were 
better among TYAs than older adults and were more significant for ovarian cancer.  
2.3.13.4 Cancer related morbidity 
Three percent of cases relapsed during the first 15 years after diagnosis [125]. In addition, 
as a result of chemotherapy, germ cell tumours experienced cardiovascular diseases 
and metabolic syndromes [125]. The rate of hospitalisation after adjusting for the 
background population was 1.7 for endocrine disease, more precisely, diabetes [87].  
2.4 Management of healthcare services  
The improvement in survival rates, as noted earlier, was more rapid among children than 
TYAs. This could be partly explained by the availability of historical epidemiological 
literature on childhood survivors and the earlier improvement in services by providing a 
multidisciplinary collaboration of varied healthcare providers, including surgeons, 
oncologists, radiotherapists and other clinical and non-clinical personnel. This 
collaboration is responsible for ensuring continuous health provision among childhood 
survivors, thus improving the quality of health after diagnosis with cancer, compared to 
40 years ago [126]. Although the multidisciplinary concept is available among TYA 
survivors, it is still developing and was formally established during the last 10 years after 
the release of the National Institute for Health and Care Excellence (NICE) guidelines in 
2005 [127]. 
In 2005, NICE introduced Improving Outcomes Guidance   for children and young people 
with cancer . It includes guidelines based on an evidence-based literature review and 
cover the following areas: 
 Age-appropriate support facilities and staff with appropriate training for this 
specialised field 
 Clinical protocols agreed with principal treatment centres (PTCs) 
 Participation in clinical trials 
Consequently, PTCs for children and teenagers were introduced as secondary or tertiary 
centres that provide: tumour-specific centres, a final diagnosis, an agreed upon 
treatment plan, specialist palliative care and a multidisciplinary team (MDT) for distinctive 
types of cancer that require intensive treatment (to be discussed in the following 
sections). Because of the limited number of specialists and low frequencies within 
multiple diagnostic groups, PTCs could be allocated only at the regional level. Therefore, 
shared care arrangements were established to provide specialist local patient care to 
reduce distance barriers, and, as a result, shared care units (SCUs) were assigned to 
provide supportive inpatient and outpatient care, palliative care and treatment under the 
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supervision of PTCs for children, and designated hospital for TYA. PTCs have the 
responsibility for administering types of treatments that are delivered in shared care 
units.[67].  
England had the worst survival rate in comparison with other European countries for all 
age group [128]. In Northern England, the five-year survival rate for TYAs (15-24) in 
general increased to 85%, and ALL, AML, NHL and bone tumours had the highest 
improvement rate during the study period (1968-2008) [55]. Consequently, the NHS set 
an outcome framework in England for 2013-2014, including essential indicators to reflect 
the coverage of health services and to ensure the equity and quality of health delivery 
and outcomes for all, such as: “an indicator of children and young adult people’s 
experience of healthcare”, “five-year survival of all cancer in children” and “one-year 
survival for all cancer” [129]. 
Clinical commissioning groups (CCGs) were give a target to improve the quality of 
healthcare services by providing a benchmark of current services. These groups were 
established by the NHS and NICE to be able to prioritise the necessary improvements. 
One of the main indicators was to set one- and five-year survival rates for all types of 
cancer in all age groups. The majority of survival studies among paediatric patients 
assess the one-year and five-year survival rates, while most of the TYA studies use only 
the five-year survival rate.  
The types of services cancer patients need after diagnosis are separated into two periods: 
the anti-cancer period and the supportive period [130]. Chemotherapy, radiotherapy and 
surgery are provided during the anti-cancer treatment period, and the supportive period 
entails palliative care, rehabilitation and follow-up visits, which can be taken during and 
after treatment. Cancer patients, in particular TYAs, are a very complex group and 
receive care in different settings, including both specialist and non-specialist SCUs. This 
raises the question as to whether two patients aged 16 treated in the UK, one in a 
specialist unit and the other in a non-specialist unit (either paediatric or adult), will exhibit 
variations in hospital activity rate. To answer this question, we need to be familiar with 
the healthcare services available for CYP in England, as listed below. 
2.4.1 Cancer units, cancer centres and principal treatment centres 
A cancer unit is considered to be a district facility that treats common types of cancer. It 
provides prognostic and basic treatment services, such as chemotherapy, while complex 
chemotherapy and radiotherapy is provided in a cancer centre. The units are allocated 
in local areas close patient residences, and are directed by a lead clinician. 
A cancer centre is a tertiary hospital that treats all types of cancer (both common and 
rare), and is usually placed to cover a wide-ranging area, similar to a regional authority. 
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In centres, a variety of cancer types are treated with experienced specialists where their 
experience gained by treating critical mass of cases, and the availability of multi-
disciplinary team.  
TYAs with cancer were treated in more than one setting, i.e., they could receive 
treatment in both cancer units and centres [8]. This lack of centralisation in receiving 
treatment could affect patient outcomes in terms of survival. TYAs are usually treated in 
specialist units in cancer centres, although not every cancer centre has such a unit. As 
a result, TYAs can be treated in extra-regional centres [8].  
The hierarchy of services is dependent on patient age, as mentioned in the 2005 NICE 
improved outcome guidelines; patients under 13 are treated in paediatric centres, 14 to 
18 year-old patients can chose between being treated in an age-appropriate centre such 
as a teenage cancer trust (TCT) units [131], that is located in a PTC or paediatric centre, 
and at the ages of 19 to 24 they have the choice of being treated in the TCT unit or adult 
centre. Australia, New Zealand and the USA have followed the UK TCT services, which 
indicate the success of this intervention in cancer specialist services [34, 127]. In 2009, 
there were some modifications to the guidelines, which encouraged the inclusion of 13 
year-old patients in TCTs. Some paediatric hospitals allocate specific wards for TYAs, 
and some adult settings provide similar services. PTCs, as described earlier, are regional 
settings that could be far from the residences of TYAs; however, the 2011 review of the 
IOG allocated more local “designated hospitals”, also known as shared care centres, to 
overcome transportation barriers facing TYAs and their families. 
After the IOG, the implementation of PTCs was established in the UK and Ireland, and 
currently there are 20 PTCs for children (Figure 10). These centres work as tertiary 
hospitals and provide diagnoses, treatment and supportive care. There are now 27 TCT 
units around the UK and six in development (allocated within PTCs). These units have 
been tailored to meet TYA needs and provide support plus inpatient and outpatient care 
in friendly environments [131]. There was only a marginal improvement in patient care 
provided in TCT units in terms of survival [34]. Over the last 30 years, paediatric services 
have developed to such an extent that currently almost 90% of children in the UK are 
treated in centralised settings by specialist paediatricians. Consequently, tremendous 
progress was observed among children as a result of encouraging their participation in 
clinical trials [132]. In response to the 2005 NICE IOG, recent trials expanded the age 
limit so that paediatric trials now have an upper age limit of 16 years, while adult trials 
have a lower limit of 18 years [34]. 
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Sources:http://www.cclg.org.uk/write/MediaUploads/Publications/PDFs/Children_and_
Young_People_with_Cancer_-_A_Parent's_Guide.pdf  
 
 
2.4.2 Centralised vs. decentralised 
Centralised healthcare can be defined as the availability of standardised clinical 
treatment in terms of clinical trials or specialised clinical centres [133], although 
alternative definitions according to the availability of specialist staff, or according to the 
number of patients being treated, also exist [7, 133]. Whereas children with cancer are 
referred directly to age-appropriate cancer specialist units [134], for TYAs they are more 
likely to be referred to an oncology specialist, a surgeon or a radiotherapist, rather than 
a centralised and comprehensive cancer unit [7, 37]. Improvements in survival have been 
shown for childhood cancer following the introduction of centralised healthcare settings 
[135]. However, the management of care among TYAs is more complex than children 
due to the age boundaries. Moreover, the availability of age appropriate TYA centres 
were only established in the last ten years after the introduction of the NICE guidelines 
in 2005; they were treated in paediatric or adult centres while the centralised centres 
have been well established among children aged less than 15 for more than 30 years 
[11]. In the UK, less than one third of TYAs with cancer were referred to a specialist unit, 
while the majority of children were referred to specialist centres [134, 135]. Similarly, in 
the US, more than 90% of children were referred to specialist centres, compared with 
24% of TYAs with cancer [37]. These variations suggest a lack of standardised 
Figure 10: Distribution of principal treatment centres for children in the UK and Ireland 
Data Sources:[13] 
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healthcare among TYAs with cancer, thus is inconsistent in managing cancer care 
among this age group, nationally and internationally. 
2.4.3 Specialist centres and multidisciplinary teams (MDTs) 
The definition of a specialist centre differs between childhood and adult settings. In 
paediatric settings, it is simply an age-appropriate centre regardless of the child’s tumour 
type, while in adult settings a specialist centre is a site-specific centre in which cancer is 
treated by cancer specialist consultants and in which surgery is performed by surgeons 
who have high surgery volumes for the same cancer type. For adults, a MDT approach 
is seen as provision of specialist services and patients are known to have better 
outcomes if they are mainly treated by MDTs [8]. TYAs bridge the gap between children 
and adults, and the definition of a specialist centre for this group is less well defined. The 
Calman Hine Report argued that patients between 16 and 25 years of age have the right 
to access a specialist unit [136], and this was addressed in the NICE guidelines, which 
state that MDTs are essential in any PTC for TYAs to ensure that patients are referred 
to high volume centres that are appropriate for the patients’ age as well as tumour site, 
and are located as near as possible to patients’ residences.  
When children are diagnosed with cancer, they are transferred automatically to age-
appropriate centres in the Children’s Cancer and Leukaemia Group [53], where their 
cases are discussed at the regional level by specialist MDTs and where their treatment 
plans are set. When TYAs are diagnosed, they will be transferred to an age and site 
specific centre or a PTC that has an MDT specialist in TYA cancer to choose the 
appropriate treatment plan and to allocate the appropriate place for receiving treatment. 
Despite recommendation for age- and site- specific centres for all TYAs with cancer, only 
CNS, STS and bone tumour site-specific centres exist in the UK. Whilst TYAs with other 
diagnoses are treated in PTCs. MDTs for TYAs usually contain paediatric oncologists, 
haematologists, clinical oncologists, paediatric surgeons, specialist nurses, pharmacists 
and dieticians directed by cancer specialist consultants, therefore including experts in 
childhood and adult cancers.  
Teenagers and young adults have various healthcare needs that exceed the needs of 
younger children, including accommodation of their disabilities due to cancer treatment 
[135]. Additionally, sharing their experiences with peers of a similar age could encourage 
TYAs to participate in clinical trials and increase compliance with treatment regimes.  The 
attention was raised  regarding the importance of providing TYAs with such a cooperative 
team [135]. Additionally, the relationship between the transition from paediatric to adult 
care for TYAs (aged above 18) and the quality of care in terms of satisfaction among 
long-term survivors has previously been studied  [137]. In their study, they emphasised 
that a collaborative work of “shared care” between the aforementioned providers is 
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necessary to facilitate this essential transition [137]. Therefore, it is essential that the 
MDT understands the importance of preparing TYAs during treatment and follow-up for 
survivors to be transferred to other settings depending on their age, i.e. patients 
diagnosed in late childhood could start their treatment in a paediatric facility and then 
continue their care in an adult setting.  
The effect of patterns of specialist care on survival has previously been measured in 
detail for patients under 24 years of age. The trend of specialist healthcare services over 
time was studied for CNS tumours among TYAs aged 16-24 [127]. In their study, an 
increase in multidisciplinary work between PTCs, paediatricians, adult oncologists and 
neurosurgeons was noticed was noticed over time. It was noticed that the improvement 
driven by the IOG was evidenced in the availability of more standardised treatments 
among CNS tumour patients [127]. This included having a multi-treatment strategy in 
which there was a combination of chemotherapy, radiotherapy and surgery. Additionally, 
they found that in the last cohort, the follow-up period was not sufficient; therefore, the 
impact of the aforementioned collaboration was not necessarily related with improved 
survival. 
The impact of PTCs on other types of diagnostic groups, such as lymphomas, leukaemia 
and other solid tumours that commonly exist among children and TYAs, have not been 
studied in depth. The relationship between speciality of care and hospital activity is also 
missing from the literature. Patients treated in specialist care settings can have a greater 
advantage in attaining optimal care, although little is known as to whether hospital activity 
varies directly or indirectly according to speciality of care.  
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 Hospital Activity Literature Review 
3.1 Introduction 
As described in Chapter 2, cancer survival rates among CYP have improved 
substantially over recent decades, from 20% in 1960 to 80% in 2005 [75], and despite 
the recommendation for all CYP to be treated in high-volume age- and site-specific 
centres [67], there are inconsistencies across England, especially for TYAs [8]. 
CYP cancer patients are usually admitted to hospital from the point of diagnosis to 
receive proper investigations and treatment, and they continue to be admitted after 
completion of treatment as a result of therapeutic-related conditions. The aim of this 
literature review was to identify the factors that influence hospitalisation use, such as: 
age, sex, socioeconomic status and ethnicity, place of care and treatment protocol. 
Furthermore, to identify whether the place of treatment was associated with the quantity 
of care patients receive. An additional question relates to whether hospital activity rates 
vary between long-term and short-term survivors. These aims were addressed through 
comprehensive analysis of the current knowledge regarding hospital activity delivered to 
CYP. 
The following section starts by providing a description of the search methodology 
adopted, and the search results. It is followed by a detailed assessment of the published 
evidence regarding the patterns of hospital activity and the related factors, as well as 
how it varies among survivors and patients who died during the follow-up period. Finally, 
there is a discussion of the available evidence, and clear gaps in the knowledge of 
hospitalisation rates are highlighted. 
3.2 Methods 
This literature review was based on searches carried out based on Ovid, one of the 
oldest online medical libraries, and specified three databases: Embase, Medline and 
Leeds University Library. Additional articles were drawn from the set of identified 
references or recommended by colleagues. Furthermore, Google Scholar was used as 
a supportive database to find full text articles. A PICO strategy was adopted, which 
includes the following elements: Patient or population, Intervention or exposure, 
Comparison group and Outcome to ensure a comprehensive literature search was 
completed based around a clearly formulated research question. Based on this strategy, 
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all of the keywords and medical subject heading terms, which provide synonyms for the 
search key words used, were tabulated (Table 1).  
The aims of the literature review included identifying the pattern of hospital admissions 
and length of stay delivered to TYAs compared with children, and how this is influenced 
by place of care. Hence, the ‘intervention’ occurs where the patient is receiving their care. 
The conjunction command ‘OR’ was used to allow for varied synonyms from the same 
field. For example, all the words that were found under the ‘outcome’ field were linked 
with ‘OR’. Subsequently, all the words were combined using the ‘AND’ command to 
restrict the results to the PICO terms. The results were restricted to papers published 
after 1st January 1996 and written in English. The quality of the documented hospital 
episode data was better after 1995 in England. Therefore, it was easier to understand 
the healthcare services that were delivered since that date. The results of the three 
databases were exported into Endnote and any duplicate files were removed. Full 
bibliographic details and paper abstracts were uploaded to be reviewed. Two steps were 
performed before reading the article in detail. First, the title was checked to determine 
whether it was relevant. Second, the abstract was read and only relevant papers were 
included. 
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Table 1: List of the literature review key words using the PICO strategy 
Outcome 
Study population (population and 
comparison group)umn4 
Intervention 
Activity* Adolescence* 
Adolescent* 
Adult* 
Teenager* 
Young people 
Young adult* 
Cancer* 
H#ematology 
Hematology 
Malignancy 
Malignant 
Tum#r* 
Tumour* 
Childhood 
Children 
Pe#diatric* 
Pediatric* 
Specialist 
Specialist centre 
Specialist unit* 
Place of care 
Teenager* trust 
Admission* 
Attendance 
Burden of morbidity 
Health burden 
Hospital contact 
Hospital activity* 
Hospital attendance 
Hospital burden 
Hospital contact 
Hospital rate 
Hospital service* 
Hospitali#ation 
Hospitali#ation rate 
Inpatient 
Inpatient activity* 
Length of stay* 
Bed day* 
Bed day* rate 
Resource* 
Service* 
Utili#ation 
Utili#ation of care 
Utili#ation of health care 
Utili#ation of hospital 
resource* 
Symbols: * = Truncation method used to retrieving all words with the same stem but with variant 
endings: # = Wildcard method used to retrieve words that had more than one possible spelling 
(British vs. American) 
 
3.3 Results 
After removing duplicate entries, a total of 601 articles were obtained from the three 
databases; details of the number of articles obtained through the searching process are 
illustrated in Figure 11. From these, only 217 were studied in detail because they had 
relevant titles and abstracts. Only 30 articles studied hospital activity and the use of 
hospital resources among CYP with cancer. Key data were extracted, including the study 
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period, study population, outcome measures and study strengths and weaknesses 
(Table 2). 
 
Figure 11: Flowchart of the number of articles identified in the literature review 
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Table 2: Summary of the systematic review 
A
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r,
 
(Y
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r)
 
Title 
Study 
region 
Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
R
o
s
s
, 
e
t 
a
l.
 [
2
0
0
3
] 
[1
3
8
] 
 
Psychiatric 
hospitalisations 
among survivors 
of cancer in 
childhood or 
adolescence 
Denmark Diagnosed 
1943-1970, 
admitted 
1970-1993, 
3,710 
individuals 
<20 All cancers Whether they 
receive 
radiotherapy 
or not 
Incidence rate 
of psychiatric 
admissions 
among cancer 
cohort 
compared with 
age, sex and 
period of 
admissions 
comparison 
group. 
70% of cases 
were at risk of 
psychiatric 
hospitalisation 
five years 
following 
diagnosis, the 
relative risk of 
admissions 
was 1.3, 
95%CI:1.1-
1.4). 
Used 
population 
based 
registries 
linked to 
administrative 
data. 
Contained 
historical data, 
hence 
treatment 
strategies were 
changed since 
then, 
additionally 
cases 
diagnosed 
from 1943-
1967 were lost 
from follow-up 
as data was 
not available 
back then. 
J
o
h
n
s
o
n
, 
e
t 
a
l.
 [
2
0
0
4
] 
[2
0
] 
Hospital 
attendance 
patterns in long 
term survivors of 
cancer 
Yorkshire, 
UK 
2001, 
385 
individuals 
15-44 All cancers Deprivation, 
education 
and 
employment 
Hospital follow-
up clinic 
attendance 
Most affluent 
have higher 
proportion of 
attenders, 
while least 
affluent have 
lower 
proportion of 
attenders 
(possibly low 
compliance in 
more deprived 
groups). 
Analysed the 
effect of 
deprivation 
and education 
on survival. 
Cross-
sectional, 
limited to long-
term survival 
five years after 
treatment, 
attendance 
limited to 
hospital follow-
up clinics. 
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Title 
Study 
region 
Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
Y
a
b
ro
ff
, 
e
t 
a
l.
 [
2
0
0
4
] 
[2
6
] 
Burden of illness 
in cancer 
survivors: 
findings from a 
population-
based national 
sample 
US 2000, 1,823 
cancer 
cohort and 
5,469 
control 
group 
15->7
0 
All cancers Time since 
diagnosis 
Compare 
health burden 
among cancer 
survivors 
compared with 
age, sex and 
educational 
attainment 
matched 
population. 
Health burden 
identified as: 
utility, 
morbidity, day 
lost from work 
and length of 
stay. 
Cancer 
survivors had 
poorer health, 
lower 
productivity, 
spent more 
time in 
hospital, lost 
large amounts 
of their working 
hours and 
experienced 
more 
morbidity. 
Assessed 
financial health 
burden 
(employment, 
loss of working 
hours and 
physically 
(diseases). 
The analyses 
were limited to 
adult survivors, 
didn’t adjust for 
age at 
diagnosis and 
their data were 
extracted from 
questioner, 
hence 
increased the 
chance of 
recall bias. 
R
o
s
e
n
m
a
n
, 
e
t 
a
l.
 [
2
0
0
5
].
[1
8
] Hospital 
resource 
utilisation in 
childhood 
cancer 
Indiana, 
US 
1995-1997, 
165 
individuals 
<18 CNS, 
lymphoid, 
solid 
tumours, 
myeloid 
leukaemia 
Gender, age, 
diagnostic 
group 
Number of 
hospitalisa-
tions, length of 
stay and cost 
Mean 44.5 bed 
days and 6.6 
admissions per 
patient, each 
patient had on 
average stay of 
6.7 bed days 
per admission. 
Assessed 
short term 
treatment 
effects 
Limited to 
three-year 
period after 
diagnosis, 
selection bias 
(only include 
patients with  
an available 
hospital 
administrative 
record), not 
population-
based. 
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Title 
Study 
region 
Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
T
h
e
 N
a
ti
o
n
a
l 
In
s
ti
tu
te
 f
o
r 
H
e
a
lt
h
 
a
n
d
 C
lin
ic
a
l 
E
x
c
e
lle
n
c
e
 [
2
0
0
5
] 
[1
1
] 
Guidance on 
Cancer Services 
Improving 
Outcomes in 
Children and 
Young People 
with Cancer: 
The Manual 
England Not 
Applicable 
0-24 All cancers Year of 
admission 
Rate of bed 
days inpatient 
and day case 
per 1,000 
people by 
years of 
admissions 
and age group 
Slight increase 
in the bed-days 
by year from 
1996-2002. 
Provided an 
overall trend of 
hospital stays. 
Was not clear 
if it was for 
cancer patient 
or for all 
admissions 
among CYP. 
H
e
n
d
ri
c
k
s
o
n
 a
n
d
 R
im
a
r 
[2
0
0
9
] 
[7
9
] 
Patterns of 
hospital 
resource 
utilisation of 
children with 
leukaemia and 
CNS tumours: a 
comparison of 
children who 
survive and 
those who died 
within three 
years of 
diagnosis 
US 2000-2004 
223 
individuals 
<18 CNS and 
leukaemia 
Cancer type, 
type of 
admission, 
vital sign 
(alive or died) 
Mean 
admission 
rates and 
frequency of 
admissions 
Range of 
admissions: 0-
33 and length 
of stay: 1-391 
days, average 
of 38.9 bed 
days per 
individual.  
Leukaemia 
survivors had 
higher inpatient 
activity, while 
CNS survivors 
had greatest 
use of ICU. 
Compared 
admissions 
between 
survivors and 
deceased 
individuals.  
Information 
about 
admission 
were collected 
using 
administrative 
data. 
Did not include 
teenagers and 
young adults. 
Cross-
sectional 
analysis of 
data at single 
point in time, 
used data from 
only one 
hospital 
setting.  
Simple 
analysis, no 
regression 
models. 
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Title 
Study 
region 
Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
P
o
c
k
e
tt
, 
e
t 
a
l.
 [
2
0
1
0
] 
[1
3
9
] 
The hospital 
burden of 
disease 
associated with 
bone 
metastases- and 
skeletal-related 
events in 
patients with 
breast cancer, 
lung cancer, or 
prostate cancer 
in Spain 
Spain Diagnosed 
in 2003, 
Followed up 
till 2006, 
28,162 
individuals 
Mean 
age 
60 
Breast 
cancer, lung 
cancer and 
prostate 
cancer 
Age and 
treatment 
Mean 
readmission, 
length of stay 
and cost 
Cancer cohort 
with 
metastases of 
cancer had 
higher mean 
number of re-
admission and 
stay for longer 
period than 
cancer cases 
with no 
metastases 
(mean length 
of stay= 8 vs 
18 for breast 
cancer, 15 vs 
22 for lung 
cancer and 12 
vs 19 for 
prostate 
cancer). 
Described the 
impact of 
metastasis of 
cancer on 
number of 
admission and 
length of stay. 
The hospital 
burdens were 
not adjusted by 
age at 
diagnosis, or 
the follow-up 
years or the 
place of 
diagnosis.  
In addition it 
was limited to 
adult cancer. 
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Title 
Study 
region 
Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
B
ra
d
le
y
, 
e
t 
a
l.
 [
2
0
1
0
].
[1
4
0
] 
Hospitalisations 
1998-2000 in a 
British Columbia 
population-based 
cohort of young 
cancer survivors: 
report of the 
Childhood/ 
Adolescent/ 
Young Adult 
Cancer Survivors  
Research 
Program 
Canada 1998-2000 
1,816 
individuals 
<20 All cancers Relapse, 
treatment type 
(radiation, 
chemotherapy 
and surgery), 
rural urban 
resident, 
region of 
residence and 
deprivation 
status (area-
based index 
using average 
income per 
person) 
Hospital 
admission: 
taken from 
discharge 
report.  
Odds ratio and 
relative rate of 
admissions 
comparing 
hospitalised 
survivors vs. 
non-
hospitalised 
survivors, and 
survivors with 
comparison 
population. 
Odds ratio of 
hospitalisation 
among cancer 
survivors 
higher than 
population (2.2 
vs. 1.5), length 
of stay higher 
among cancer 
survivors 
(relative risk 
(RR) is 1.71), 
survivors also 
had more day 
care visits RR 
2.99. 
Took into 
account socio-
economic 
status and 
clinical 
difference 
when 
comparing 
hospital 
admissions 
among five 
year survivors. 
Compared the 
pattern of 
hospitalisation 
between 
relapse cases 
and non-
relapsed 
cases. 
Possible 
selection bias 
since only the 
completed 
record was 
analysed; if 
patients had 
two 
admissions on 
the same day 
they took the 
longest stay 
hence could 
overestimate 
the length of 
stay.  
When 
calculating 
admission 
rates, did not 
take into 
account place 
of care. 
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A
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Title 
Study 
region 
Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
L
o
re
n
z
i,
 e
t 
a
l.
 [
2
0
1
1
] 
[1
4
1
] 
 
Hospital‐
related morbidity 
among 
childhood 
cancer survivors 
in British 
Columbia, 
Canada: Report 
of the childhood, 
adolescent, 
young adult 
cancer survivors 
CAYACS 
program 
British 
Columbia 
Canada 
1986-2000, 
1,374 
survivors 
and 13,740 
control 
group 
0-20 All cancers Gender, age, 
year of 
diagnosis, 
time since 
diagnosis, 
treatment 
modality, and 
relapse 
status 
Frequency of 
admission 
among cancer 
survivors 
compared with 
control group, 
and relative 
risk of 
morbidity 
The risk of 
morbidity 
decreased by 
follow-up 
years; 
survivors of 
bone tumours 
had higher 
morbidity risk 
compared with 
leukaemia 
survivors.  
Cancer 
survivors had 
higher risk of 
morbidity 
compared with 
control group 
for all causes 
especially for 
neoplasms and 
disease of the 
blood. 
Analysed the 
factors that 
affect hospital 
related 
morbidity, and 
identified the 
relative risk of 
admissions 
compared with 
control group. 
Limited 
childhood to 
long term 
survivors, did 
not assess the 
impact of 
deprivation, 
ethnicity and 
place of care 
on 
hospitalisation 
use in term of 
admissions 
only, i.e. did  
not assess 
burden of 
length of stay. 
M
a
d
d
a
m
s
, 
e
t 
a
l.
 
[2
0
1
1
] 
[1
4
2
] 
A person-time 
analysis of 
hospital activity 
among cancer 
survivors in 
England. British 
Journal of 
Cancer 
England 1990-2006 All 
ages 
group 
Colorectal, 
lung, 
prostate 
and breast 
cancer 
Age, gender 
and year 
since 
diagnosis 
Rate of 
hospital stay 
among 
survivors by 
years since 
diagnosis and 
age 
Number of 
days per 
person - days 
decreased by 
years since 
diagnosis. 
Using person 
time at risk in 
assessing the 
difference of 
length of stay 
by age and 
time since 
diagnosis. 
Did not adjust 
for treatment 
duration and 
limited to 
cancers 
among older 
adult. 
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Title 
Study 
region 
Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
M
a
d
d
a
m
s
, 
e
t 
a
l.
 [
2
0
1
1
] 
[1
4
3
] 
Levels of acute 
health service 
use among 
cancer survivors 
in the United 
Kingdom.  
European 
Journal of 
Cancer 
England 1990-2006, 
1,625,340 
survivors 
All 
ages 
group 
Colorectal, 
lung, 
prostate 
and breast 
cancer 
Age, gender, 
cancer type, 
years from 
diagnosis 
and years to 
death 
Percentage of 
survivors with 
hospitalisation 
in term of time 
spent in 
hospital by 
years since 
diagnosis and 
years to death. 
Cancer 
survivors had 
the highest 
level of 
hospitalisation 
during one-
year following 
diagnosis and 
before death. 
Assessed 
difference in 
proportion of 
hospitalisation 
by gender from 
date of 
diagnosis. 
The calculation 
of proportion of 
hospitalisation 
was based on 
grouping cases 
into categorical 
groups based 
on: temporal 
admission and 
level of 
utilisation 
rather than 
using 
continuous 
measure. 
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Title 
Study 
region 
Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
T
u
p
p
in
, 
e
t 
a
l.
 [
2
0
1
1
].
[1
3
] 
Hospitalisation 
admission rates 
for low-income 
subjects with full 
health insurance 
coverage in 
France 
France 2007 
40,155 
million 
insured by 
national 
income and 
4,791 
million 
covered by 
complemen
tary 
universal 
health 
insurance 
for low 
income 
people 
<60 Any disease 
requiring 
hospitalisa-
tion 
(including 
cancer) 
Age, sex 
hospital 
department 
of admission 
National health 
insurance 
reimburse-
ment to 
calculate type 
and rate of 
admission 
1.4 
hospitalisations 
per patient, the 
mean length of 
stay was 3.1 
days.  
Highest 
hospitalisation 
activity seen 
for females 
due to 
radiotherapy 
and 
chemotherapy 
Assessed 
hospitalisation 
patterns taking 
into account 
gender and 
treatment 
differences. 
Measured all 
types of 
admissions, 
not only 
cancer.  
Did not take 
into account if 
the admission 
was before or 
after diagnosis, 
nor whether 
patients died. 
K
u
rt
, 
e
t 
a
l.
 [
2
0
1
2
].
[1
2
] Hospitalisation 
rates among 
survivors of 
childhood 
cancer in the 
Childhood 
Cancer Survivor 
Study cohort 
US 1994-1996 
(baseline) 
and an 
updated 
question-
naire in 
2000-2005, 
10,366 
individuals 
0-20 Leukaemia, 
lymphoma 
(HL, NHL), 
CNS, bone, 
Wilms’ 
tumour 
neuroblast-
oma, STS 
Age, sex, 
cancer type, 
and detail 
treatment 
type 
Standardised 
incidence ratio 
among cancer 
survivors 
compared with 
general 
population 
1.6 times 
higher rate of 
hospitalisation 
than the 
background 
population 
Examined 
multiple factors 
that could 
affect 
hospitalisation 
among cancer 
survivors, 
using large 
cohort 
population. 
Questionnaire 
based so might 
have 
information 
bias (recall 
bias), period of 
diagnosis and 
length of 
survival was 
not recorded. 
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Title 
Study 
region 
Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
A
u
d
in
o
, 
e
t 
a
l.
 [
2
0
1
3
].
[1
4
4
] 
Length of stay 
and treatment‐
related 
complications 
are similar in 
paediatric and 
AYA patients 
with bone 
sarcoma in 
United States 
children's 
hospitals 
US 2006-2010 
835 
children 
and 562 
TYAs 
0-14, 
and 
15-28 
Bone 
sarcoma 
Age, sex, 
source of 
payment and 
hospital 
charge 
Mean length of 
stay(LOS) 
Mean LOS = 
4.6 
(children)and 
4.8 (TYA) 
Compared 
frequency of 
length of stay 
among 
children and 
TYAs, and 
identify the 
difference of 
cases of 
admissions. 
Hospital 
admission 
coverage 
limited to 25% 
of total 
paediatric 
population.  
Date/age at 
diagnosis and 
survival time 
were not 
recorded.  
Not clear if the 
admission was 
for recurrent 
cancer or 
primary 
cancer. 
B
e
rg
e
r,
 e
t 
a
l.
 [
2
0
1
3
].
[1
9
] The burden of 
cancer on the 
acute medical 
unit 
North 
west of 
England 
2011 
300 
individuals 
16-98 All cancer 
combined 
Age and sex ICU unit 
hospitalisation 
(length of 
stay).  
Comparing 
cancer patients 
with other 
patients 
without cancer 
matching on 
age and sex. 
Cancer 
patients had 
significantly 
longer stay in 
hospital (8.8 
vs. 7.2 days on 
average-
mean). 
Focused 
specifically on 
hospital 
activity within 
ICU. 
Cross-
sectional and 
do not adjust 
for follow-up 
period, date of 
diagnosis and 
period of 
survival was 
not recorded.  
 4
8
 
B
ir
c
h
 [
2
0
1
3
] 
[8
] 
Teenage and 
young adult 
cancer in 
England – the 
patient journey 
and experience 
England 2001-2006 
9,026 
individuals 
15-24 All types of 
cancer as 
specified in 
Birch (2002) 
scheme 
Cancer type 
and, place of 
care 
The impact of 
specialist 
services on 
survival 
outcome 
The coverage 
of specialist 
care varied by 
cancer type 
among TYA. 
There was 
significant 
variation in the 
relationship 
between levels 
of TYA 
specialist care 
and survival 
rate by cancer 
type. For some 
cancer types 
such as 
leukaemia, 
CNS tumours 
and lymphoma 
patients 
receiving 
higher levels of 
specialist care 
exhibited better 
survival rates. 
For most 
cancers, those 
with a higher 
proportion of 
specialist care 
had longer 
hospital stays 
than those with 
lower level of 
specialist care. 
HES data 
(national 
database) was 
linked to 
several cancer 
registers that 
cover the 
majority of 
England. 
Did not provide 
the pattern of 
hospitalisation 
for children.  
Did not 
adjusted for 
treatment 
duration when 
estimating the 
number of 
admissions 
and length of 
stay. 
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Title 
Study 
region 
Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
B
re
w
s
te
r,
 e
t 
a
l.
 [
2
0
1
4
] 
[1
0
1
] 
Subsequent 
hospitalisation 
experience of 
five-year 
survivors of 
childhood, 
adolescent, and 
young adult 
cancer in 
Scotland: a 
population-
based, 
retrospective 
cohort study 
Scotland 1981-2003 
6,980 
individuals 
0-24 All cancers Age, sex, 
deprivation 
(area-based 
Carstairs), 
follow-up 
period, 
diagnostic 
group 
Indirect 
standardised 
incidence ratio 
for calculation 
of bed days, 
acute hospital 
admission and 
psychiatric 
admission, 
absolute 
excess risk of 
bed days and 
admission, 
cause specific 
admission 
(ICD-10) 
Indirect 
standardised 
bed days 
ratio=3.7 per 
100 survival 
compared with 
population. 
Standardised 
rate of hospital 
admissions 
=2.8 per 100 
survival.  
CNS have the 
highest 
admission for 
acute care 
where most of 
these 
admissions are 
related to 
recurrent 
neoplasm, 
nervous 
system 
diseases.  
Hospital 
admission was 
higher among 
most deprived 
survivors. 
Population-
based study 
with long 
follow-up 
period, full 
details of the 
classification 
used for 
cancer and 
admission 
related 
causes. 
Limited to long 
term survivors 
(five years+), 
did not take 
into account 
period of 
diagnosis, 
treatment type 
or place of 
care. 
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Study 
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Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
d
e
 F
in
e
 L
ic
h
t,
 e
t 
a
l.
 [
2
0
1
4
] 
[7
2
] 
Hospital 
contacts for 
endocrine 
disorders in 
Adult Life after 
Childhood 
Cancer in 
Scandinavia 
(ALiCCS): a 
population-
based cohort 
study 
Scandinav-
ia 
1943-2008, 
43,909 
cancer 
registry 
0-20 All cancers Gender, age 
and cancer 
type 
Standardised 
hospitalisation 
rate (SHR) and 
absolute 
hospitalisation 
rate among 
cancer 
survivors 
compared with 
control group 
SHR= 4.8, 
highest risk 
was for 
leukaemia 
(SHR=7.3) 
followed by 
CNS tumours 
(SHR=6.6), the 
absolute risk of 
admission for 
endocrine 
disorders was 
1,000 per 
100,000 
person-years. 
Detailed 
analysis of 
hospital 
admission for 
endocrine 
disease sub 
types among 
short term 
survivors 
(within one 
year after 
diagnosis). 
Limited to one 
type of 
morbidity and 
did not adjust 
for treatment 
type. 
H
a
rg
re
a
v
e
s
 a
n
d
 
V
in
e
r 
[2
0
1
4
] 
[1
4
5
] Adolescent 
inpatient activity 
1990-2010: 
analysis of 
English Hospital 
Episode Statics 
data 
England 1999-2010, 
9,632,844 
hospital 
episodes 
0-19 Not cancer 
specific 
data 
Age, year of 
admission 
and causes 
of admission 
based on 
ICD-10 
chapter 
Number of 
admission per 
thousand 
person-years, 
trend of 
percentage of 
admission by 
year 
Number of 
admissions 
increased by 
age and it was 
higher among 
males in 
children and 
females in 
adolescents. 
Described the 
pattern of 
admission by 
age and year 
of admission. 
Was general 
for all cases 
regardless of 
the disease 
background. 
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Title 
Study 
region 
Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
H
o
lm
q
v
is
t,
 e
t 
a
l.
 [
2
0
1
4
] 
[8
7
] Adult life after 
childhood 
cancer in 
Scandinavia: 
diabetes mellitus 
following 
treatment for 
cancer in 
childhood 
Scandinav-
ia 
1940s-
2008, 
496 
survivors 
0-20 All cancers Cancer 
types, time 
since 
diagnosis 
Standardised 
incidence rate 
of admissions 
among cancer 
cohort 
compared with 
background 
population. 
Cancer 
survivors had 
1.6 higher rate 
of admissions 
than 
comparison 
group, and it 
was highest 
during the first 
five years 
following 
diagnosis. 
Assessed 
hospitalisation 
rate for long 
term, including 
50-year follow-
up period. 
Focused on 
one type of 
cause, specific 
hospitalisation- 
did not assess 
the impact of 
type of 
treatment on 
admission rate. 
M
a
h
a
r,
 e
t 
a
l.
 [
2
0
1
4
] 
[2
2
] 
Predictors of 
hospital stay and 
home care 
services use: A 
population-
based, 
retrospective 
cohort study in 
stage IV gastric 
cancer 
Ontario, 
Canada 
2005-2008, 
1,433 
individuals 
18-99 Gastric 
cancer 
Age, sex, 
deprivation, 
region, 
treatment 
(surgery) 
place of care 
(high volume 
specialist 
consultant, 
receipt of 
home care) 
Comparing 
relative rate of 
hospital stays 
among cases 
that received 
specialist care 
or home care 
compared with 
cases who had 
not.  
Patients who 
received care 
in high volume 
oncology had 
lower hospital 
stays than 
cases who did 
not.  
Additionally, 
cancer 
survivors were 
at increased 
risk of 
hospitalisation 
one month 
before death. 
Identified the 
impact of place 
of care on 
hospital stay 
among cases 
with terminal 
cancer and 
provided 
evidence of 
possible 
increase in 
hospitalisation 
before dying. 
Limited to adult 
survivors, 
focused on 
admissions 
occurring 
among cases 
with 
aggressive 
cancer (late 
stage). 
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period and 
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Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
S
ta
m
m
e
rs
, 
e
t 
a
l.
 [
2
0
1
4
] 
[6
8
] 
Cancer 
incidence, 
morbidity, and 
survival in 
Canadian first 
nation children: 
A Manitoba 
population‐
based study 
from the cancer 
in young people 
in Canada 
(CYP‐C) 
registry 
Manitoba, 
Canada 
2001-2008, 
240 
individuals 
0-15 All cancers Ethnicity and 
risk group 
(cases were 
assigned to 
three groups 
by oncologist 
giving: year 
of diagnosis, 
stage of the 
disease, type 
of surgeries 
and the 
availability of 
treatment). 
Standardised 
incidence rate 
of 
hospitalisation 
among cases 
from first 
nation (North 
American 
Indian) 
compared with 
non-first 
nation. 
There were no 
differences in 
number of 
admissions 
and length of 
stay between 
first nation and 
non-first nation 
cases.  
First nation 
cases with high 
risk group had 
higher number 
of admissions 
7.6 compared 
with 2.2 per 
1,000 days on 
treatment 
among cases 
with lower risk 
and longer stay 
(105.0 vs 18.0 
per 1,000 
days).  
Assessed the 
pattern of 
admissions 
and length of 
stay during the 
treatment 
period, and 
assessed the 
impact of race 
on 
hospitalisation 
pattern. 
Limited to 
children and 
included small 
number of 
cases, it was 
difficult to draw 
a conclusion of 
the impact of 
treatment type 
received, and 
year of 
diagnosis on 
the 
hospitalisation 
rate as it was 
hidden under 
the arbitrary 
method used 
in classifying 
groups based 
on level of risk. 
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Outcome 
measure 
Key findings Strengths Weaknesses 
v
a
n
 L
a
a
r,
 e
t 
a
l.
 [
2
0
1
4
].
[7
1
] 
Cardiovascular 
sequelae in 
long-term 
survivors of 
young peoples’ 
cancer: a linked 
cohort study 
Yorkshire 1991-2006 
3,306 
individuals 
0-14 
and 
15-29 
All cancers Age, sex, 
year of 
diagnosis, 
diagnostic 
group, 
deprivation 
(index of 
multiple 
deprivation) 
and initial 
treatment 
type 
Age and sex 
standardised 
incidence of 
cardiovascular 
disease for 
cancer cohort 
compared with 
population 
3.6% of 
survivors had 
at least one 
admission for 
cardiovascular 
disease during 
10 years from 
diagnosis (IQR 
7-13 years), 
hospitalisation 
rate for 
cardiovascular 
diseases was 
2.6 compared 
with 
population. 
Linked HES 
and a 
population 
based cancer 
register. 
Focused on 
one type of 
hospital 
admission for 
specific long-
term survivors.  
The place of 
care was not 
assessed in 
relation to the 
type and rate 
of admission. 
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Study 
region 
Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
Z
h
a
n
g
, 
e
t 
a
l.
 [
2
0
1
4
] 
[2
3
] 
Late morbidity 
leading to 
hospitalisation 
among five-year 
survivors of 
young adult 
cancer: A report 
of the childhood, 
adolescent and 
young adult 
cancer survivors 
research 
program. 
International 
Journal of 
Cancer 
British 
Colombia 
1981-1999, 
902 
survivors 
and 9,020 
comparison 
group 
20-24 All cancers Age, gender, 
region of 
residence, 
deprivation, 
cancer type, 
year of 
diagnosis 
and type of 
treatment 
Prevalence of 
admissions 
and relative 
rate of 
admissions 
compared with 
background 
population 
Cancer 
survivors were 
at 1.37 greater 
risk of 
hospitalisation 
than 
comparison 
group, and 
cancer treated 
with 
combination of 
chemotherapy, 
radiotherapy 
and surgery at 
higher risk of 
admission than 
cases with 
chemotherapy 
alone. 
Assessed 
factors that 
influence 
hospitalisation 
among cancer 
survivors. 
Limited to TYA 
and long-term 
survivors, and 
did not assess 
for place of 
care. 
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Study 
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Study 
period and 
population 
size 
Age 
Diagnostic 
group 
Study 
variables 
Outcome 
measure 
Key findings Strengths Weaknesses 
C
h
a
n
, 
e
t 
a
l.
 [
2
0
1
5
] 
[1
4
6
] 
A population 
based 
perspective on 
children and 
youth with brain 
tumours 
Ontario, 
Canada 
2003-2010, 
745 
individuals 
0-19 All cancers Age, gender 
and year of 
admission 
Rate of 
hospital 
admission per 
person year 
using 
population 
estimate 
Cases with 
malignant brain 
tumours had 
highest 
hospital 
admissions 
than benign 
tumours.  
The rate of 
admissions 
was slightly 
increased by 
year of 
admission. 
Assessed 
hospitalisation 
rate by 
different 
cancer grades: 
benign and 
malignant 
brain tumours. 
Did not assess 
the follow-up 
year, date of 
diagnosis or 
date of 
treatment 
completion. 
P
h
ill
ip
s
, 
e
t 
a
l.
 [
2
0
1
5
] 
[1
4
7
] 
Survivors of 
childhood 
cancer in the 
United States: 
prevalence and 
burden of 
morbidity 
USA 1975-2011, 
388,501 
survivors 
0-19 All cancers Age, gender, 
age at 
admission, 
year since 
diagnosis 
and ethnicity 
Prevalence of 
admissions by 
years since 
diagnosis 
There is an 
increase in 
long-term 
childhood 
survivors; 
morbidity 
increases by 
age 
Detailed 
description of 
pattern of 
admission by 
follow-up 
years, by 
gender, and 
specific 
morbidity. 
Did not assess 
for deprivation 
and type of 
treatment 
received. 
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[2
0
1
5
] 
[1
4
8
] 
Incidence, risk 
factors, and 
reasons for 
hospitalization 
among 
glioblastoma 
patients 
receiving 
chemo-radiation 
USA 2006-2010, 
196 
individuals 
23-90 Glioblastoma Age, marital 
status, type 
of 
radiotherapy 
Frequency of 
admission, 
length of stay 
and mortality 
43% of cases 
admitted 
during the 
treatment 
phase, and 
these were 
related to 
weaknesses 
and seizures. 
Assessed the 
rate of 
admission 
before, during 
and after 
receiving the 
treatment. 
Limited to 
specific cancer 
type with 
specific type of 
treatment. 
R
ic
h
a
rd
s
o
n
, 
e
t 
a
l.
 [
2
0
1
5
] 
[1
4
9
] 
Hospitalisation 
rates among 
survivors of 
young adult 
malignancies 
Ontario, 
Canada 
1992-1999, 
20,275 
survivors 
and 
195,847 
comparison 
group 
20-44 All cancers Age, sex and 
cancer types 
Hospitalisation 
rate per person 
year for 
survivors and 
comparison 
group, relative 
rate of 
admissions, 
adjusted 
relative rate 
(ARR) and 
absolute 
excess risk of 
hospitalisation. 
ARR was 1.51 
among cancer 
survivors 
compared with 
control group, 
upper GI had 
the highest 
hospitalisation 
rate followed 
by leukaemia.  
Rate of 
hospitalisation 
decreased by 
follow-up time. 
Assessed the 
hospitalisation 
rate by 
detailed 
cancer type, 
cause of 
admission and 
rate of 
admission by 
follow-up 
period. 
Limited to long 
term survivors, 
did not assess 
the effect of 
ethnicity, 
deprivation 
and treatment 
type on 
hospitalisation 
rate. 
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 [
2
0
1
6
] 
[7
0
] 
Late mortality, 
secondary 
malignancy and 
hospitalisation in 
teenage and 
young adult 
survivors of 
Hodgkin 
lymphoma: 
report of the 
Childhood/ 
Adolescent/ 
Young Adult 
Cancer 
Survivors 
Research 
Program and the 
BC Cancer 
Agency Centre 
for Lymphoid 
Cancer. 
British 
Columbia 
1970-1999, 
281 
survivors, 
2,810 
comparison 
group 
15-24 Hodgkin 
lymphoma 
Gender, age, 
region of 
residency, 
deprivation, 
year of 
diagnosis, 
treatment 
type and 
relapse 
status 
Incidence of 
hospitalisation 
and rate ratio 
of 
hospitalisation 
Cancer 
survivors were 
1.45 at higher 
rate of 
admissions 
than 
comparison 
group, the 
admissions 
were affected 
by year of 
diagnosis: 
cases 
diagnosed at 
the latest 
period have 
higher rate of 
admission, and 
cases treated 
with 
combination of 
modality had 
the higher rate 
ratio of 
admission 
compared with 
comparison 
group. 
Assessed 
hospitalisation 
rate, adjusted 
for varied 
demographic 
and clinical 
data, found 
morbidity 
specific 
admissions for 
TYA surviving 
from Hodgkin 
lymphoma. 
Limited to long 
term survivors, 
did not assess 
for the impact 
of follow-up 
period or place 
of care or 
include 
historical 
treatment data. 
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 [
2
0
1
6
] 
[1
5
0
] 
High 
hospitalisation 
rates in 
survivors of 
childhood 
cancer: A 
longitudinal 
follow-up study 
using medical 
record linkage 
Amster-
dam 
1996-1999 
1,382 
survivors 
and 26,583 
comparison 
group 
0-18 All cancers Gender, 
cancer type 
and 
treatment 
Hospitalisation 
rate among 
cancer 
survivors and 
control group, 
relative 
hospitalisation 
rate comparing 
cancer cohort 
with control 
group 
Cancer 
survivors are at 
continuous risk 
of admissions 
30 years 
following 
diagnosis with 
relative risk of 
2.2.  
Relative rate of 
admission was 
higher among 
CNS survivors 
than other 
cancer types. 
Assessed 
hospitalisation 
rate among 
cancer 
survivors 
compared with 
control group 
using 30 
follow-up 
years. 
Limited to long 
term childhood 
survivors aged 
above 18, and 
did not adjust 
for deprivation, 
ethnicity or 
place of care. 
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3.3.1 Hospital activity 
Analysis of hospital utilisation provides an understanding of health burden and morbidity 
thus facilitating the planning of services. However, no published study to date has 
analysed the pattern of hospital admissions of survivors both during and after completion 
of cancer treatment among CYP. With emerging evidence of patients experiencing a 
better quality of life in terms of their survival rates if treated (at least in part) in specialist 
centres for some cancer types such as leukaemia, CNS tumours and lymphoma [8], 
analysis of the different patterns of hospital usage among patients receiving mostly 
specialist services, compared with those receiving only limited or no specialist services, 
could provide policy makers with the evidence required to plan services needed for CYP 
survivors to receive optimum care. Such work will also identify those groups of cancer 
patients who exhibit the greatest burden on hospital services through side effects and 
late effects of therapy, therefore allowing healthcare planners to develop changes to care 
pathways to minimise hospital activity. 
3.3.2 Patterns of hospital activity 
From 1998 to 2000, there were 3.7 hospital episodes per 1,000 CYP under the age of 
24 in the UK [11]. As shown in Figure 12,there was a sharp drop in the usage of hospital 
beds in 1997/8 after an increase from 1995/6 to 1996/7, however usage began to 
increase in 1998/9 and continued increasing thereafter. The drop in usage was as a 
result of poor documentation during that time [11]. TYAs were the second highest patient 
group using inpatient hospital beds (Figure 12), just after children under the age of five 
(around 9 and 11 uses per 1,000 population, respectively). Patients under the age of five 
and TYAs aged 15-24 years had higher incidence rates compared with children aged 5-
14, which was reflected in their high usage of hospital beds [11]. Nevertheless, it is not 
clear whether these visits were for cancer patients or all patients in general. It is also not 
clear whether the visits were counted after the date of the diagnosis or the completion of 
treatment. The pattern of day-case services was related to patient age. The average day 
case bed days ranged from 12,800 for patients under the age 14 to 5500 for patient aged 
15-19 and 4,800 for patients aged 20-24 (Figure 12).The causes for these admissions 
were not recorded, as there was a dearth of available information regarding the 
relationship between hospital admissions and cancer among TYAs. Procedures, 
palliative care and allied health services were provided when needed; thus, such data 
was not routinely collected [11]. 
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Sources:https://www.nice.org.uk/guidance/csg7/resources/improving-outcomes-in-
children-and-young-people-with-cancer-update-773378893 
Figure 12:Trends in hospital episodes: inpatient bed days (a) and day case bed days (b) 
from 1995/1996-2001/2002 for children and young people in the UK. Data 
Sources [13] 
 
Cancer accounted for 3.5% of the total admissions among paediatric cases, and 5% of 
the total cancer admissions were for paediatric patients, which accounted for 100,000 
hospital admissions in the USA [79].  In their study they also stated that CNS cancer and 
leukaemia patients had a total of 8,653 bed days (38.8 bed days on average per child) 
and 39.7 hospital admissions on average per child [79]. Children had a higher risk of 
hospital admissions compared with adults, and needed more intensive care in 
comparison with elderly patients, which drains a large amount of hospital resources [12]. 
There was limited knowledge about the scope of hospital activity delivered to CYP in the 
UK. In the US, however,  the use of hospital resources among leukaemia and CNS 
cancer patients under the age of 18 have been studied previously [79]. However, they 
only assessed hospital patterns after diagnosis, not after completion of treatment; for 
example, leukaemia patients treated with chemotherapy required at least three months 
to recover and for their blood counts to return to normal. Additionally, in their study, 
leukaemia cases had significantly higher outpatient admissions compared with CNS 
cancers, while the latter group had a higher number of inpatient admissions [79]. These 
differences could be indicative of the type of treatment administered. Leukaemia patients 
usually receive chemotherapy on an outpatient basis. In contrast, CNS cancer patients 
usually require surgery and radiotherapy, which needs to be provided in a hospital setting. 
As a result, the type of treatment could affect the pattern of hospital activity. Few studies 
analysed the admission rate during the treatment period, but a study conducted in USA 
found that 43% of cancer cases were admitted to hospital due to treatment side effect 
such as weakness or a seizure [148]. Identifying these complications could help in 
planning for services to improve quality of life and reduce hospital utilisation. 
CYP who survived five to ten years after diagnosis had a high risk of hospitalisation, 
particularly among leukaemia, CNS and bone tumour diagnostic groups. The age-sex 
(a) (b) 
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standardised hospital admission rate ratios for cancer were, 4.5, 3.9 and 3.8, respectively, 
for each diagnostic group [101]. This was also supported by a population-based study in 
Yorkshire, UK [71].  In those studies they did not take into account relapses following the 
primary diagnosis, and they did not study the differences in hospital activity between the 
primary diagnosis and the activity after the recurrence of cancer [101]. It is essential to 
understand when the patient has been admitted to be able to understand the cause of 
the admission. In particular, was it as a result of treating the primary diagnosis or was it 
as a result of treating the recurrence of cancer following the primary diagnosis? 
It was observed in previse studies  that 3.6% of the total CYP (aged 0-29) long-term 
survivors in Yorkshire experienced at least one admission related to cardiovascular 
disease [71]. Leukaemia and bone tumours had the highest cardiomyopathy admissions, 
while patient with CNS tumours had the highest admissions for nervous system and 
cerebrovascular diseases [71]. The variations in the pattern of admission could be 
related to the type of treatment delivered by each cancer type, e.g., chemotherapy, 
radiotherapy, stem cell transplant or surgery. Thus, the type of treatment provided for 
these patients was analysed in relation to admission rates in the Scotland study [101], 
and found both the type of treatment and cancer type to influence the pattern of hospital 
admission, i.e. patients with the same cancer type did not necessarily have similar 
proportions of admissions if they were treated differently.  
Cancer survivors, in addition to the frequent hospital admissions, spent more time in 
hospital compared with individuals that had not experienced cancer in their life,14% of 
individuals who had cancer stayed longer than 10 days in hospital, compared with 8% of 
individuals with no cancer [26]. 
3.3.3 Patterns of hospital activity after completion of treatment 
 In some studies it was found that one-half of the admissions occurred 4.5 months after 
diagnosis [18], while others  found that admissions for autoimmune diseases were 
highest during the first five years following date of diagnosis [74]. However, in their study, 
they did not adjust for treatment type; hence, the potential cause of admission could be 
related to the type of treatment received. Patients receiving chemotherapy might be at a 
greater risk of hospital admission due to infections, while patients receiving radiotherapy 
could have a higher risk of ICU care. Therefore, it was necessary to take into account 
the variation in treatment plans (period of treatment, and type of anti-cancer protocol) 
when studying the variation in hospital activity across diagnostic groups. Within the 
limited range of literature, the analysis of hospitalisation rate was based on the five-year 
since diagnosis measure as a proxy for treatment completion, and they found an 
increase in the proportion of hospitalisation use among long-term survivors [23, 70, 72, 
141, 149, 150].  The highest proportion of admissions was among survivors of more than 
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five years, compared with cases who survived for fewer than five years after diagnosis 
as found in previous studies [147]. However, they did not assess the pattern of admission 
and related factors among those survivors from the date of diagnosis. 
Completion of treatment can vary depending on treatment type. Patients receiving 
chemotherapy may need up to three months recovery period after completion of 
treatment, while stem cell transplant patients may need up to 12 months of recovery 
(more detail in Chapter 4). Understanding the relationship between treatment type and 
duration of recovery will help to differentiate the type of admission and whether it is 
related to a treatment plan or a treatment complication.  
3.3.4 Key predictors of hospital activity 
3.3.4.1 Place of care 
The management of care has evolved during the last decade. Currently, childhood ALL 
patients receive most of their treatment at home [81]. This change in treatment 
administration and length of treatment may affect the pattern of hospital care in terms of 
hospital admissions and prolonged lengths of stays, i.e. it could reduce or increase the 
use of hospital inpatient bed days and treatment-related morbidity. 
Using a national population-based register,  The effect of specialist cancer services on 
TYA outcomes (patients aged 15-24) has been previously studied [8]. In their study, they 
used a proportional measure to classify the place of care based on their inpatient stay 
during treatment, rather than a dichotomous measure such as specialist vs non-specialist. 
This was done due to the fact that survivors could receive their care in more than one 
setting: including both specialist and non-specialist centres. While there were no 
differences in the number of admissions between survivors with mostly specialist and 
limited specialist services during treatment, survivors with some specialist care (defined 
as having 30-60% of their inpatient stays in specialist centres), tended to have a higher 
proportion of admissions than other levels of specialist care [8]. They also found that 
there was an increase in inpatient admissions in teenage cancer trusts (TCTs) which are 
usually affiliated to specialist centres, compared with non-specialist centres in Yorkshire 
and North Trent regions [8]. Nevertheless, this might indicate that the availability of 
specialist care centres could impact on hospital usage. Leukaemia and lymphoma had 
the lowest median number of admissions when they had limited specialist input during 
treatment, compared with patients who received mostly or some specialist care. 
Specialist cancer services provided for individuals with bone tumours and CNS cancers 
in the UK could be classified into age-related centres (TCTs) and tumour-specific centres. 
Bone tumours had the highest admissions if treated within TCTs and the lowest 
admissions if treated in tumour-specific centres, while CNS tumours had the highest 
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admissions if treated in tumour-specific centres. Despite the inverse relationship 
between hospital admissions and tumour-specific or age-specific centres, they both 
displayed the highest frequency of admissions if they received mostly specialist care 
compared with survivors with limited specialist input. This could highlight the fact that 
survivors who received the majority of their care during the treatment period in specialist 
units were more likely to be closely monitored in a multidisciplinary hospital setting.  The 
relation between the survival rates and the level of specialist care was assessed in earlier 
studies [8]. It was found that the pattern varied by cancer type: leukaemia, lymphoma 
and bone tumours had better survival rates when treated mostly in specialist centres, 
while for CNS, STS and germ cell tumours there were poorer survival rates when they 
received mostly specialist care [8]. However, this study focused entirely on TYA cancer 
survivors, and did not adjust for person-years of follow-up when analysing the pattern of 
hospitalisation. Additionally, the impact from the level of specialist care was assessed 
during the treatment period only, which was arbitrarily defined as 20 months following 
the date of diagnosis for all cancer types. Some studies used hospitals with high-volume 
oncology to identify specialist centres; a study that focused on cases with aggressive 
gastric cancer found a significant reduction in hospital stays when cases received care 
from a high-volume centre [22]. Cases with terminal cancer contributed to high hospital 
costs as they were more likely to receive aggressive treatment prior their death, and that 
increased hospital stays, thus increasing the use of hospital resources [151, 152]. 
However, receiving care from a specialist centre helped in reducing the unfavourable 
health burden by properly managing treatment and referring cases to proper home care 
services, which reduces the use of hospital resources [153]. This highlights the 
favourable impact of place of care on hospital usage, in term of hospital admissions and 
hospital stay, however, there is limited knowledge on the impact of place of care on 
hospital usage among children and TYA specific cancers with varied cancer stage. 
3.3.4.2 Gender  
Patterns of hospital activity could vary according to patient demographic characteristics 
and the type of hospital care delivered. The number of admissions could vary by gender 
boys with ALL historically had higher rates of admissions than girls when younger than 
10, however the rate is in the opposite direction during the adolescent period of ages 10-
19, where girls had higher rates of admissions [145]. This could be explained by the 
biological differences, as girls in the adolescent period might be more likely to visit 
hospitals for obstetric reasons. Similarly, when analysing long-term survivor data, 
females had higher hospital admissions than males [12]. This was supported by another 
long-term survivor study, where it was found that there were significantly more 
admissions among females compared with males, females having 1.56 times higher 
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rates of admissions than males [23, 140]. When comparing admissions among survivors 
with a control population, female cancer survivors had higher day case activity 
encounters and lower acute care admissions than the general population, while male 
cancer survivors had both higher acute care and hospital day case admissions than the 
control population [140]. The relationship between gender and hospital activity could 
therefore vary by type of admission. 
3.3.4.3 Age at diagnosis 
Hospital admission could also vary according to patient age; young children may need 
more intensive care than older children due to their sensitivity to treatment [12], for 
example, children were at more risk of cardiomyopathy due to exposure to anthracycline 
agents and were at more risk of intellectual disability and endocrine disease when treated 
with radiotherapy [14, 33, 154]. Furthermore, patients younger than 18 years were found 
to be more compliant with follow-up visits than those over the age of 18 years. This 
indicates that younger patients might be more compliant with healthcare treatment, which 
eventually may lower associated morbidity and subsequent hospital attendance after 
treatment completion.  In previous studies it was found excess hospitalisation among 
cases aged 25-29 years compared with older adults, suggesting an increase in 
hospitalisation use according to age [23]. On the other hand, based on data extracted 
from the Hospital Episodes Statistics (HES) in England, the pattern of admissions was 
higher among teenagers than children, this was explained by the fact that the mortality 
rate among teenagers in high-income countries is higher than children [145]. In their 
study, they explained the overall pattern of admissions regardless of the disease 
background, hence did not mainly focus on cancer cases. However, children aged 
younger than 19 had higher hospitalisation rates for endocrine disorders compared with 
the older age group [72], suggesting that hospitalisation patterns were affected not by 
age only, but by causes of admission. 
Hospital-based analysis in the US shows that TYAs (aged 15-28) had similar lengths of 
stay as younger children (<14 years old). However, there were significant increases in 
pain, renal failure and pulmonary effusions among TYAs compared with children [144]. 
The results of that study might be biased because the age at diagnosis and period of 
survival were not assessed. Additionally, although the calculation of length of stay was 
derived from hospital records, it was not clear whether it was from the primary diagnosis 
or a recurrence; hence, the result could be overestimated, i.e., patients could be counted 
more than once. 
3.3.4.4 Socioeconomic status 
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In the USA, based on questionnaire data, long-term survivors with low incomes had 
higher admission rates compared with high income cases; the authors suggest that this 
may be caused by the fact that low income cases were less likely to come to hospital for 
regular visits within 2 years of their aftercare [12]. Although healthcare access is different 
in the USA to the freely provided healthcare in the UK, the findings of the aforementioned 
studies  were not related to patient financial status, because patients with a lower income 
status were more likely to be provided with government-sponsored insurance for 
hospitalisation, but not for routine visits to preventive clinics [12].  The rate of admission 
among long-term cancer survivors had been studied in Canada using a population-based 
register that took into account the place of residency and socioeconomic status (SES) 
[140]. Using uni-variable analysis, SES was not significantly related to hospital 
attendance or place of residence among survivors [140]. Thus, they were assumed not 
to affect the risk of hospitalisation among survivors. However, others  found a significant 
effect of deprivation on the attendance at a follow-up clinic in Yorkshire, UK [20]. The 
most affluent patients were more likely to attend hospital than less affluent individuals. 
Therefore, the relationship between SES and hospital activity could vary between 
countries and should be considered an important risk factor for hospitalisation. 
3.3.4.5 Ethnicity  
Hospital admissions might be affected by population background, people with minority 
ethnicities were less likely to visit a specialist physician, while they were more likely to 
see a general practitioner [155]. These differences were explained by language barriers, 
poverty, transportation, physician’s attitude, or lack of understanding of the services 
provided to them [155, 156]. However, only one paper assessed the impact of ethnicity 
on hospital activity among cancer survivors. This study identified American Indian cases 
and referred to them as First nation and non-First nation cases. The reason for 
classifying into these groups is that those groups were from lower social classes, living 
in rural areas; additionally, they represented 13% of those minorities nationwide in the 
US [68]. However, there were no noticeable differences in terms of admissions or 
hospital stays as a result of cancer-related complications during the treatment period [68]. 
However, their results were based on a small sample size, which reduced the ability to 
identify significant differences and it was limited to children. Although some of the earlier 
studies included ethnicity in their study variables, when describing the study population 
they did not study its effect on hospitalisation [12, 26, 79]. The justification of not including 
ethnicity in studies conducted in England could be explained by incomplete records of 
ethnicity in the routinely administrative data, such as HES.  The incompleteness of 
recording ethnicity was attributed to the fact that it is based on multiple resources [157]. 
Clinicians, radiologists, pathologists and others participate in recording patient records 
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from which the datasets are extracted to the register. Although HES data is obtained 
from administrative datasets, the validity varies among the hospital trusts responsible for 
providing the raw information. 
3.3.4.6 Relapse 
Relapse following the primary diagnosis was found to be the greatest cause of 
hospitalisation due to cancer, and relapsed patients were generally hospitalised in 
intensive care units [140]. Those who experienced relapses had almost double the rates 
of admission compared to survivors who did not relapse [23, 140], highlighting the 
importance of this variable in any systematic evaluation of hospital activity. Cancer cases 
with bone metastasis and skeletal-related events experienced longer hospital 
admissions than survivors with no bone metastasis [139]. However, in their analysis they 
focused on older cases, hence there is limited knowledge on the impact of recurrent 
cancer on hospital use and length of stay among CYP. 
3.3.4.7 Cancer types 
In a study conducted in British Columbia, bone tumour survivors aged younger than 29 
years had a higher risk of hospitalisation than leukaemia survivors [141]. However, 
others demonstrated that CNS cancer patients had more inpatient visits than ALL 
patients [140]. Similarly,  in previous studies it had been found that CNS childhood 
survivors had the highest hospitalisation rates compared with other cancer types [150]. 
Additionally,  another study found than childhood brain tumour survivors had a higher 
incidence of psychiatric disorders than other cancer groups, adjusting for the background 
population [138]. These differences highlight the fact that hospitalisation use varies by 
cancer type and age group. Among CYP with brain tumours both malignant and benign 
tumours contributed to the use of hospital admissions, although the rate of admissions 
among malignant tumours was 14.9 times higher than benign tumours, and cases with 
benign tumours had longer hospital stays [146]. This highlights the importance of 
including both types of brain tumours when analysing the hospital burden to provide 
healthcare initiatives through accurate assessment of hospital needs among cancer 
survivors. 
3.3.4.8 Type of treatment 
Treatment type could also play a predominant role in the rate of admission; patients who 
received radiotherapy had higher admission rates among long-term survivors than 
patients receiving surgery, however it was not significant [140]. Cancer cases receive 
different types of treatment depending on the cancer type, prognosis, age at diagnosis, 
grade/stage and gender, as explained earlier in Section 2.3.4. The combination of 
chemotherapy, radiotherapy and surgery was found to increase the risk of hospitalisation 
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compared with surgery alone among long-term child survivors [141]. Long-term survivors 
of HL are at risk of recurrent cancer and both pulmonary and cardiovascular-related 
causes of hospitalisation. The author justifies this higher risk of morbidity as being due 
to the type of curative treatment administered [12]. Survivors of HL had the highest 
relative rate of admission when treated with a combination of chemotherapy, 
radiotherapy and surgery, compared with cases with other modalities [70]. It had been 
found in previous studies that cases treated with radiotherapy had higher rates of 
hospitalisation than cases treated with surgery alone [140, 150]. Others found no relation 
between radiotherapy and admissions among long-term survivors [138]. While some 
found that the risks of hospitalisation among cases treated with chemotherapy, rather 
than cases treated with surgery [71]. However these differences could be explained by 
the study outcome, as in some of those studies focused on admissions for specific 
morbidity [71, 158], While the rest assessed admissions for all morbidity combined [140, 
150]. Therefore, the type of treatment could have a varied influence on the hospitalisation 
rate, in terms of cancer type and type of morbidity. 
3.3.4.9 Deceased during follow-up 
Individuals with terminal illnesses such as cancer had the highest use of hospital 
resources, thus exhausted significant levels of hospital budgets [22]. These utilisations 
were found to be higher among cases who were less likely to survive [22]. However, 
there is dearth of information on the pattern of hospital admissions prior to death among 
CYP with cancer. Only three studies analysed hospitalisation use among survivors and 
cases who did not survive among children [79] and young adults [22, 143].  The utilisation 
of hospital resources among children under the age of 18 between three-year survivors 
and those who did not survive beyond two years following diagnosis were compared in 
previous studies [79]. In their study, they found that leukaemia patients who died within 
the first three years had a significantly longer length of stay (7.40 days on average) and 
higher use of the intensive care unit (ICUs). CNS cancer survivors also had a higher use 
of ICUs. This could be related to the type of treatment, because CNS cancer patients 
with high grade tumours require major surgical interventions and need to be monitored 
intensively [79]. CNS tumour cancer and leukaemia survivors had lower lengths of stay 
compared with patients who died. Consequently, this could increase the financial burden 
on hospitals. Of particular note, appropriate palliative care delivered to high-risk patients 
was found to lower the rate of hospital admissions and eventually save patients and their 
families travelling time to the hospital. A limitation of this study is that it did not take into 
account other diagnostic groups and used a single administrative database for data 
extraction, rather than using a population-based database. Although it was one of the 
first major studies of the utilisation of hospital services among child and adolescent three-
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year survivors compared to non-survivors, the author examined only two types of 
diagnostic groups in one healthcare setting.  The hospital utilisation in terms of time spent 
in hospital, time since diagnosis and time to death had been studied previously [143]. 
They found that survivors had the highest hospitalisation use one year after diagnosis 
and one year prior to death, highlighting the critical periods during which patients require 
access to high levels of NHS services [143]. However, the study did not assess 
hospitalisation rates for other types of cancer common among CYP. Another study 
assessed the pattern of hospital utilisation among cases aged 18 and older and found 
that the length of stay increased one month before death, however this pattern was lower 
among cases receiving home care [22]. Their analyses were limited to cases with 
advanced cancer, thus limiting the knowledge on cases with early stages of cancer. 
3.4 Strengths and weaknesses of earlier studies 
The existing literature highlighted the fact that CYP with cancer are at higher risk of 
hospitalisation and varied factors could impact the pattern of hospitalisation. However, 
the outcome measures for assessing hospital activity or hospitalisation varied, either in 
describing the variation in hospitalisation internally among cancer survivors or externally 
by comparing with the background population. The measures included incidence ratios 
[12, 22, 70, 72, 101, 146], odds ratios [20, 140], absolute rate ratios [101], relative rates 
[149, 150] or other similar summary measures [18, 20, 23, 79, 139, 141, 143-145, 147, 
148], hence this makes it difficult to draw clear conclusions on the effects of patient 
demographics and clinical characteristics on hospital use, as a way to monitor health 
services. Odds ratios were suitable for case-control studies in which the control group 
was matched with cases. However, patterns of care could be more ideally analysed using 
cohort analyses or retrospective cohort analyses by adjusting for explanatory variables 
using a suitable regression model, such as the Poisson or negative binomial models. 
The incidence ratio was acceptable because this takes into account patient 
characteristics (age and sex), although further analysis is needed to determine the effect 
of other factors, such as place of care, treatment type and length of treatment which none 
of the cited papers focused upon. Poisson regression could be used more efficiently to 
reduce bias in estimates by taking into account other variables that could affect the rate 
of admission. The literature on hospital activity to date has failed to take into account 
treatment duration among short-term survivors for both children and TYAs. 
Hospital-based analyses in the US have shown that TYAs (aged 15-28) had similar 
lengths of stay as younger children (<14 years old). However, there were significant 
increases in pain, renal failure and pulmonary effusions among TYAs compared with 
children [144]. The results of that study might be biased because age at diagnosis and 
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period of survival were not assessed. Additionally, although the calculation of length of 
stay was derived from hospital records, it was not clear whether it was from the primary 
diagnosis or recurrence; hence, the findings could be an over-estimation of time spent in 
hospital, since patients could be counted more than once. 
The relationship between deprivation and hospitalisation was analysed in a small number 
of studies. However, different indices of deprivation were used including: Carstairs score, 
patient income, education, employment, and Townsend score, which makes it difficult to 
compare the results accurately. However, there was some general consistency in that 
the most deprived populations had higher levels of hospital activity [12, 20, 79]. This 
could be because patients from lower SES tend to have lower treatment compliance due 
to treatment complexity, as shown in an earlier study [81].  
3.5 Conclusion 
Analysis of hospital burden among CYP cancer survivors was found to be a relatively 
new phenomenon and identified studies mainly focused on long-term survivors. Besides 
the small number of published studies, these used a wide range of outcome measures, 
sub-optimal study designs and lacked appropriate statistical analysis and adjustment for 
key variables.  
Several key variables such as age, gender, deprivation, ethnicity, type of treatment 
received and place of care were found to be directly related with patterns of hospital 
activity. The literature provided evidence of differences in hospital activity between short-
term survivors and patients who died within that period, however this was limited to three 
studies and these were not based on population-based data. Hospital admissions and 
patterns of care are crucially important among young people to estimate their health 
burden and related morbidity. The value of this knowledge will provide policy makers with 
evidence of the health burden among the increasing pool of survivors, to provide 
information to healthcare planners about the risks of hospitalisation due to treatment side 
effects, and to assess whether any reduction in the intensity of treatment in recent years 
has led to a lower risk of subsequent hospitalisation. 
To address this knowledge gap, information on all CYP newly diagnosed with cancer 
was extracted from a population-based cancer register and linked with HES data to 
provide a relatively objective estimate (at least compared to questionnaire-based study 
designs) of hospital admissions and length of stay for each individual. Additionally, a 
separate analysis was carried out extract patterns of hospital admissions among 
survivors from those who did not survive. 
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The thesis focused on eight specific diagnostic groups: leukaemia, lymphoma, CNS 
tumours, neuroblastoma, renal tumours, bone tumours, STS and germ cell tumours. 
These were the most common types of cancer diagnosed among the study population, 
as explained in the background section 2.3.1. Leukaemia and CNS tumours have been 
shown to have predominantly treatment-related complications due to the continuous 
changes in protocols. In contrast, survival rates for bone tumours have been stable over 
recent decades [42, 54], but have received less attention in terms of development and 
availability of new clinical studies and trials. In a national, population-based study in 
Finland from 1953 to 2010, there was continued improvement in cancer treatment, 
particularly for leukaemia, Hodgkin lymphoma and CNS cancers, which resulted in 
tremendous improvements in cancer survival [54]. However, bone tumours did not share 
the same level of improvement and this was because of the delay in enhancing cancer 
treatment [54]. The patterns of hospitalisation among these diagnostic groups could 
therefore be related to changes in treatment plans over time. These changes could affect 
patient outcomes in terms of survival [82], as well as long-term morbidity [101]. Thus, 
their effects on hospital activity and related morbidity have not previously been 
extensively studied. 
  
71 
 
 
 
 
 Material and Methods 
4.1 Introduction 
This chapter includes details of the study data sources and the analytical methods used. 
Additionally, details of technical elements are provided that were used to process the 
study variables in preparation for statistical analysis.  
This chapter starts by identifying the main outcome of this thesis, going through a 
detailed description of the study population. An overview of the YSRCCYP (Yorkshire 
Specialist Register of Cancer in Children and Young People) is given, as this was used 
to extract cases and was linked to HES. Individual level datasets were necessary to 
undertake both linkage and analysis, comprising sensitive and identifiable data, therefore 
details of ethical and regulatory approval, as well as data security arrangements, are 
highlighted in this chapter. The cancer classification scheme used to group cancer types 
is then described, followed by details of variables used to classify ethnicity and measure 
levels of material deprivation. The main variables derived in this study relate to the 
estimation of treatment duration, and the calculation of follow-up person-years 
throughout the admission period. These variables are explained and supported with 
visual examples in Sections 4.11.3 and 4.12.2. Finally, details of the statistical methods 
used, which were tailored to meet each aim (Section 4.12) are described. 
4.2 Study population  
The population comprised CYP aged 0–29 living in Yorkshire when diagnosed with 
cancer between 1996 and 2009. Hospital admissions were extracted from HES data 
(1997 to 2011). More details on the study sources are provided in Section 4.6. The study 
period was chosen so as to be able to assess the total health burden from the date of 
cancer diagnosis in line with the availability of high-quality HES data. 
4.3 Study design  
This study aimed to provide a comprehensive analysis of hospital patterns and burden 
among a cancer cohort of CYP in Yorkshire. Therefore, the study was a retrospective 
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observational study using linked population-based cancer registration and hospital 
admissions data. 
4.4 Study area 
Previous work has shown that the Yorkshire region mirrors the sociodemographic profile 
of England [56, 62, 159]. The former Yorkshire region contained a population of 2 million 
aged 0-29 during the 2011 census [44], which had increased from the 2001 census when 
the 0-29 population was about 1.3 million. In the study area, 38% of the population were 
aged 0-29, which is similar to the proportions for the rest of England [44]. The study area 
comprised a slightly higher South Asian population than the rest of England; 9% of the 
total population aged 0-29 were South Asian, compared to 8% for the rest of England, 
where the largest majority of the south Asian population were resident in West Yorkshire.  
4.5 Diagnostic group 
The classification of cancer was based on the International Classification of Childhood 
Cancer (ICCC-3rd edition) [46], which is commonly used to analyse cancer incidence 
among CYP, given the need to characterise these tumours according to their 
morphological features [48, 140]. More detail on the cancer classifications used was 
provided earlier in Chapter 2, Section 2.2.2. 
The current study focused on eight main cancer diagnostic groups: leukaemia, 
lymphoma, CNS tumours, neuroblastoma, renal tumours, bone tumours, STS and germ 
cell tumours. The inclusion of these types of cancer was based on agreement with clinical 
collaborators in terms of representing common diagnostic groups seen throughout the 
CYP age range. In addition, some of those diagnostic groups, such as leukaemia, were 
treated with aggressive treatment regimes, including for instance bone marrow 
transplants, hence these individuals may be at an increased risk of morbidity and thus 
may exhibit unusual hospital usage patterns. Leukaemia accounts for a third of all new 
cancers diagnosed among children aged up to 15 years [36], for which they usually 
receive intensive doses of chemotherapy for a longer duration compared with many other 
cancer types [160] diagnosed in CYP. CNS tumours account for a fifth of all cancers 
among cases aged under 30 years [56], and are usually associated with treatment 
incorporating high levels of radiation therapy, resulting in an increased risk of morbidity 
and mortality [161]. Lymphoma, neuroblastoma, renal tumours, bone tumours, STS and 
germ cell tumours were also selected based on their clinical importance and sufficient 
patient numbers, to ensure that robust estimates of disease burden can be reported. 
Carcinomas were not included in any detailed analyses as they were relatively rare, 
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contained a heterogeneous group of cancers and were treated using a range of different 
modalities. Similarly retinoblastoma and hepatic tumours were rare among those aged 
above 15 years, which limited the ability to study them in any substantial detail.  
4.6 Data sources 
Datasets were extracted from the YSRCCYP and linked to administrative hospital 
records to identify the number of hospital admissions and number of bed days after a 
diagnosis of cancer. 
4.6.1 Case data 
Information on the diagnosis and treatment of cancer was extracted from a population-
based register, YSRCCYP. The register has accrued cases since 1974 on children up to 
the age of 15 years, and in 1990 extended into the TYA age range (15–29 years) whilst 
living in the Yorkshire and Humber Strategic Health Authority. Primary notifications of 
childhood cancer diagnoses in the region were identified from the regional tertiary referral 
centre in Leeds, where over 90% of children are treated within the region. These are 
supported through other multiple sources of ascertainment including regional 
neuropathology services, the Haematology Malignancy Research Network (HMRN) and 
cross-checks with the National Cancer Registration Service currently held within Public 
Health England (PHE) and other specialist childhood tumour registers held in Newcastle 
(ongoing) and Manchester (until 2013). TYA cancers are primarily notified from PHE and 
supported through case lists recorded at MDT Meetings at the TYA PTC in Leeds, as 
well as regional neuropathology department and the HMRN. These notifications include 
details of date of diagnosis morphology and tomography codes (ICD-O-3) derived 
directly from the histopathology reports. Reports are scanned and copies retained for 
future reference, should codes evolve over time. Treatment data including: 
chemotherapy, radiotherapy and surgeries are pulled directly from medical records, 
either manually or more recently through electronic processes to improve the efficiency 
of data collection [49]. All registrations are actively followed-up through contact with 
hospital consultants and GPs, providing details of any subsequent treatment, relapse or 
death which has occurred since the period shortly after diagnosis [127]. Completeness 
in terms of case ascertainment is thought to be extremely high given the multiple sources 
of ascertainment [159, 162], with around 85-90% of all registrations histologically verified 
[62, 127, 159, 163].  
Key demographic, diagnostic and clinical data were extracted on the following variables: 
date of birth, gender, date of diagnosis, morphology and topography code, type of initial 
treatment, name of hospital provider when diagnosed and relapse status. It is worth 
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mentioning that the YSRCCYP has the advantage of covering 0-29 year olds and has 
more detailed information on type of treatment received and health status during follow-
up, including recurrence or metastases of malignancy [164], than the national cancer 
register. 
4.6.2 Hospital activity 
Information about hospital activity was extracted from HES, a national electronic 
database that contains details of all hospital services provided to patients in NHS funded 
trusts in England, including different datasets: elective, outpatient and accident and 
emergency (A&E) admissions and all data collected by the Health and Social Care 
Information Centre, more recently known as NHS digital (https://digital.nhs.uk/). 
Information on the services provided by each NHS trust has been collated for 
reimbursement purposes every financial year 1st April until 31st March [165]. The so-
called ‘payment by results’ [166] system was established in 2002-2003 to ensure that all 
healthcare providers were paid a standard price (see Section 4.11.3). Hospitalisation 
details include: diagnosis at admission, frequency of admissions and length of stay, 
hospital address and treating physician. Each patient has a unique identification number 
(NHS ID), and this is used to facilitate the follow-up care provided per individual inside 
England’s national boundaries. Inpatient admissions are the most established set of 
records. Patient admissions were recorded since 1989, but the data accuracy 
(completeness) and validity were only believed to be appropriate for research purposes 
after 1996 [48], therefore, all admissions since 1997 were included in the analysis. 
Outpatient admissions data have been recorded since 2002. A description of the 
information recorded in an outpatient setting is given in Chapter 6, Section 6.3. 
Emergency (A&E) admissions were documented from 2007, however, these were not 
included in this study as linked A&E admissions to the YSRCCYP have only recently 
become available in 2016.  
Using inpatient data solely in identifying the health burden among cancer cases, clearly 
would provide a limited assessment of hospital burden, as many more admissions will 
have occurred in outpatient or emergency settings. However, inpatient admissions have 
been considered to be informative resources for monitoring health services usage and 
have previously been used in long-term survival analyses [12, 49, 71, 143, 145, 167]. 
Furthermore, outpatient admissions have been analysed in this thesis to provide a 
perspective of the outpatient health burden, although the poor quality of diagnostic 
coding within these datasets limited any further analyses. 
Hospital activity was recorded at three levels [168]: 1) finished consultant episodes 
(FCEs), 2) spells, which are defined as sequential hospital encounters with different 
consultants which referred as hospital admissions, and 3) continuous inpatient spells 
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(CIPs), which can be defined as a hospital admissions for the same patient receiving 
care from different consultants and different providers/trusts within two days after 
discharge. FCE is the standard measurement unit for hospital activity and is considered 
to provide more accurate estimates of consultant workload and hospital resources [145] 
(Figure 13). However, in this project, spells were used to calculate the admission rate 
and the length of stay because they reduced the overlap in admissions for the same 
person. A single hospital admissions (also referred to as a spells which lasts from 
admission to discharge) could include multiple episodes that occurred during the same 
period of admission i.e. had the same admission date and occurred in the same hospital 
but with a different consultant. Similarly the length of stay was calculated as the total 
number of days based on each spell in hospital, using the date of admission for the first 
episode and date of discharge for the last episode during the same spell.  
All HES admissions were coded with up to 20 separate admission codes to determine 
the cause of admission. These 20 causes were coded using ICD 10, and were classified 
as either the primary (the first admission code) or secondary diagnosis (any of the 
admission codes following the first code) of admission. More detailed information on HES 
codes is available at http://digital.nhs.uk/hesdatadictionary. The diagnosis code of each 
admission was extracted from the first episode within the same admission; for the 
majority of cases in the study dataset, the first episode included the same primary 
diagnosis code as the subsequent episodes. Whilst this method might underestimate the 
occurrence of some causes that were coded as secondary diagnoses within any 
subsequence episodes, the majority of admissions (97.49%) contained only a single 
spell, therefore, this underestimation is likely to be small. 
HES data were used not only to identify hospital activity in detail, but to cross check with 
hospital information recorded on the YSRCCP to ensure consistent and optimal 
collection of data on ethnicity and type of treatment received. 
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Figure 13: Different classification of hospital admission for the same patient based on 
HES: finished consultant episodes (FCEs), spells and continuous inpatient 
spells (CIPs), Abbreviations: A=admission; D= discharge. Data Source: [169]  
 
4.6.3 Comparison group (background population) 
This study aimed to assess the excess hospitalisation rate among cancer survivors after 
completion of treatment with a matched background population. The background 
population were individuals living in Yorkshire who had at least one hospital episode 
recorded in HES. Matched data were extracted from HES according to age at admission, 
sex and year of admission (1997-2011). 
4.6.4 Population denominator data 
Annual mid-year, age and sex specific population estimates for Yorkshire were extracted 
from the Office for National Statistics (ONS) (www.statistics.gov.uk) to firstly estimate 
cancer incidence rates, and secondly to analyse the hospitalisation rates taking account 
the background population.  
The person-years denominator was defined as the time during which cases were 
believed to be at risk of any hospitalisation. The total person-years during the follow-up 
period was used to estimate the admission and number of bed days rate ratio and 
standardised admission rate (hospitalisation rate among the cancer cohort compared to 
the background population). The follow-up period started from the date of diagnosis to 
the date of the last admission (1997-2011) and was censored either at the date of death, 
date last seen on the register, or the end of the study period (31st December 2011) 
whichever came first.  
When estimating the admission duration (length of stay), a person-days denominator 
was used instead, estimated using the person-years method as above, but with the units 
re-scaled into days.  
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A separate calculation of person-years was carried out before and after treatment 
completion. For example; an individual might be followed-up before completion of 
treatment, while others might only be followed-up after completion of cancer treatment, 
i.e. have a linked hospital record or admissions limited to the period after treatment 
completion. Based on the previous scenario the first case would contribute to the total 
‘on treatment’ person-years calculation, while the second case would contribute to the 
post-treatment person-years calculation (see Section 4.12.2.1). 
Post-treatment cause specific person-years were also estimated, comprising the time 
(years) from treatment completion until first admission for a specific cause, and censored 
by date of death, emigration or end of the study period (31st December 2011). 
4.7 Data Linkage 
All cases extracted from the cancer register were matched to HES data using the patient 
NHS number, date of birth, sex and address (postcode) for inpatient and outpatient 
admissions. 
4.8 Inclusion criteria 
Only cases that were diagnosed between 1996 to 2009 and admitted during the period 
of 1997 to 2011 were included (Figure 14). Although the cancer register includes cases 
diagnosed before 1996, their hospital data could be incomplete within the HES. Any 
cases that were only admitted before their recorded date of diagnosis were eliminated 
from the study (N=164 cases), because the aim of this project was to look at post-cancer 
hospitalisation activity. The socioeconomic characteristics for those eliminated cases 
were not significantly different from the rest of the linked cases in terms of gender, age 
group, year of diagnosis, ethnicity or deprivation level. However, there was a significant 
difference in terms of diagnostic group as the majority of the 164 eliminated cases were 
CNS tumours (40%) and germ cells tumours (24%).  
A full description of the number of cases eligible to be included in the study is contained 
in Figure 14. More than 96% of the registry cases were successfully linked to HES. A 
sensitivity analysis was done to assess the differences in patient characteristics among 
linked and non-linked cases to check whether they were broadly similar in terms of their 
sociodemographic characteristics, including age, sex, year of diagnosis, diagnostic 
group, ethnicity and deprivation (see Section 5.3.2). 
Cases identified in the cancer register that had no recorded admissions were not 
included in the study analysis, as there was no information regarding the number of 
admissions, diagnosis on admission or their contribution towards hospital stay. It was not 
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possible to identify whether there were errors in data linkage, either due to non-matches 
or linkage mismatches. This could bias the results as some groups tended to be excluded 
more than others. However, based on a sensitivity analysis, the proportion of cases with 
no linked hospital record did not vary significantly compared to linked cases (full 
description in Section 5.3.2). 
 
 
Figure 14: Flowchart representing patient level inclusion criteria 
4.9 Data cleaning 
Admissions in HES were recorded multiple times for each case, i.e. each case could be 
admitted more than once during the study period. However, in addition to the true 
multiple admissions, there were also some duplicate HES admissions. The datasets 
were cleaned to remove these duplicates, if the following variables were all duplicated: 
HES ID, episode start date, episode end date, episode order, admission date, discharge 
date and admission methods as unique identifiers. The HES variable data were coded 
according to the HES inpatient data dictionary containing a clear definition of codes used 
in the database [165]. This guidance was used during the cleaning process to ensure 
consistency and accuracy during recoding and analysis of the data  
(http://digital.nhs.uk/hesdatadictionary).  
4.9.1 Dealing with missing data 
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The completeness of records in the cancer register was quite satisfactory for age, gender, 
date of diagnosis, cancer type and deprivation score, with 100% complete records. 
However, ethnicity and stage were poorly recorded. Details on the alternative methods 
to overcome this deficiency are fully described in the following sub-sections.  
4.9.1.1 Ethnicity 
People from minority ethnic groups could have unequal access to healthcare services 
[170, 171]. In the UK, it has been observed that CYP from minority ethnic groups receive 
the poorest quality of care [172]. Yorkshire has around 11% of the total South Asians 
aged 0-29 based on 2001 census data in England [62], where 9% of the total 0-29 years 
population in Yorkshire were South Asian, as described earlier in Section 4.4. Classifying 
ethnicity as South Asian vs non-South Asian could provide enough power to compare 
the pattern of hospital activity by ethnicity, as there was a considerable number of South 
Asians in West Yorkshire. In contrast, using a detailed classification group could limit the 
study power in assessing the equity of hospital services by ethnicity. A detailed 
discussion of the possible ethnicity classifications is provided below. 
Information about ethnicity was not accurately or routinely documented in the cancer 
register, nor in the HES database [62]. To overcome this problem, earlier studies  
classified patients in the cancer register as South Asian (Pakistani, Indian and 
Bangladeshi) or non-South Asian (other ethnicity), using the South-Asian Nam Pehchan 
and/or Name and Group Recognition Algorithm (SANGRA) to allocate ethnicity 
according to name and additional inspection, done in cases of discrepancy by local 
experts. SANGRA has sensitivity of 90.5% and specificity up to 97% in allocating cases 
to the right group [173-175]. In their paper, they used the HES data to cross check the 
grouping of ethnicity and found that only 2.4% of the cases had disagreement [62]. In 
addition to the earlier mentioned software, “Onomap” can be used to assign patients to 
more than 50 categories using an individual’s’ name. The strength of this software is in 
recognising the patient ethnicity using forename, last name, language and geographical 
origin. In a study conducted in Scotland, 99% of the cases were successfully linked to 
specific ethnic groups using Onomap [176]. In their study, the sensitivity of grouping 
individuals to the right group ranged from 22% for Africans to about 97% for British [176]. 
The sensitivity in grouping South Asians to the right group was only 75%, however if 
people who were Muslim from the Middle East were allocated to the South Asian group, 
the sensitivity analysis increased to 90%. Although this software was not primarily 
designed for South Asians only, it could be used for extra validation in addition to Nam 
Pehchan and/or SANGRA. Additionally, this programme has not been used previously 
to allocate ethnicity extracted from the cancer register in Yorkshire, or UK in cancer 
registries general. 
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The cancer register grouped cases into 13 groups based on their ethnic background 
using 2011 census data (Table 3). The YSRCCYP had a high level of missing ethnicity 
data (43.5%, n=1,497 out of 3,437), where the cases been recorded with unknown 
ethnicity.  
Therefore, three applications were used to identify ethnicity and cross check with what 
was recorded in HES. These were: 1) Nam Pehchan [174], 2) SANGRA [173], and 3) 
Onomap [176]. They allocated cases to suitable ethnicity groups based on their name, 
as explained earlier. Nam Pehchan and SANGRA identify the South Asian group, hence 
grouped cases into South Asian or non-South Asian categories (Table 4). Onomap 
groups ethnicity into 15 ethnic groups, which were then re-allocated into South Asian 
and non-South Asian categories (Table 5). HES had 13.5% missing ethnicity (n=449 out 
of 3,315 cases with linked records) and grouped cases into 19 types using the 2001 
census. was grouped into 19 categories using the 2001 census. Within HES, ethnicity 
could be recorded differently for the same person due to multiple admission records. If 
this was the case, then the most common ethnic group category was selected and these 
were also then re-grouped into South Asian and non-South Asian categories (Table 6) 
for comparison with previous epidemiological work in Yorkshire due to the relatively high 
number of south Asians resident in West Yorkshire [62]. 
The process used to identify ethnicity was done separately for each source, as presented 
in Figure 15. Ethnicity was re-allocated into South Asian and non-South Asian groups for 
each source. Then they were internally analysed for any disagreement in identifying 
ethnicity between the sources. When cases were identified differently in each source 
(n=19, 4%), HES datasets were used to determine the ethnicity as they were based on 
self-reported records. 
81 
 
 
Figure 15: Flowchart of the process done to identify ethnicity 
 
Table 3: The classification of ethnicity in the cancer register (YSRCCYP) 
Classification of ethnicity Re-classification 
British 
Non-South Asian 
Any other White background 
White and Black African 
White and Asian 
Any other mixed background 
Any other Asian background 
African 
Chinese 
Any other ethnic group 
Bangladeshi 
South Asian Indian 
Pakistani 
Not Known Missing 
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Table 4: The classification of ethnicity in Nam Pehchan and/or SANGRA 
 
 
 
 
Table 5: The classification of ethnicity in Onomap 
Classification of ethnicity                                  Re-classification 
Afghanistani 
Non-South Asian 
African 
Albanian 
Balkan 
Black Southern African 
Castillian 
Celtic 
Channel Islander 
Chinese 
Czech 
Danish 
East Asian & Pacific 
English 
European 
Finnish 
French 
German 
Ghanaian 
Greek 
Greek Cypriot 
Guyanese 
Hispanic 
Hong Kongese 
International 
Iranian 
Irish 
Italian 
Jewish 
Jewish And Armenian 
Maltese 
Muslim 
Nigerian 
Nordic 
Northern Irish 
Polish 
Portuguese 
Classification of ethnicity 
Non-South Asian 
South Asian 
Missing 
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Classification of ethnicity                                  Re-classification 
Romanian Muntenia 
Scottish 
Sierra Leonian 
Singaporean 
Somalian 
Spanish 
Swedish 
Turkish 
Welsh 
Bangladeshi 
South Asian 
Hindi Not Indian 
India North 
Indian Hindi 
Muslim Indian 
Pakistani 
Pakistani Kashmir 
Sikh 
South Asian 
Unclassified 
Missing Void 
Not Found 
 
Table 6: The classification of ethnicity in HES 
Classifications of ethnicity Re-classification 
African 
Non-South Asian 
Any other 
Any other Mixed background  
Black 
British 
Caribbean 
Chinese 
Irish 
Other  
Other Asian 
White 
White and Asian (Mixed)  
White and Black African (Mixed) 
Bangladeshi 
South Asian Indian 
Pakistani 
Not given 
Missing Not known 
Not stated 
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4.9.1.2 Staging 
Stage is a tool used to allocate tumours into different groups to identify how advanced 
the disease is based on the biological nature of the tumour around the time of 
presentation or diagnosis. This includes the location of the primary tumour, the size of 
the tumour, whether the tumour has metastasised to other organs or spread to lymph 
nodes. For some cancers, it is important to know how the cancer cells differentiate from 
the normal cells and are graded according to the level of differentiation. For example, 
grade I refers to low grade tumours where the cancer cell is similar to normal cells whilst 
grade IV refers to high grade tumours when the cell is completely different for the normal 
cells. It is widely used for clinical purposes to identify disease severity and subsequent 
planning of treatment.  
There are many different staging systems used depending on cancer type and these 
have changed over time due to developments in diagnostic accuracy and biological 
characterisation of tumours. Information on stage was known to be inconsistently 
recorded within the YSRCCYP and this also varied by cancer type [49]. In this study for 
all cancers combined, 1,653 (53%) survivors had data on stage missing and this ranged 
from 16% (leukaemia) to 100% (bone tumours) by cancer type.  Thus, there was no 
consistent method available to stage all tumours consistently across the various cancer 
types. CNS tumours and haematological tumours often use a proxy such as grade and 
white blood cell count (wcc) respectively , where the higher the grade and wcc, the 
greater the disease severity [49]. For CNS tumours, cancerous cells are unlikely to 
spread to other organs and it is the size of the tumour which is most important in 
differentiating stage [177]. Therefore for CNS tumours grade was used rather than stage 
based on the World Health Organisation (WHO) grading. 
Grade was used to estimate the treatment duration for cases with CNS tumours. That 
was done by classifying cases to low grade and high grade tumours using the WHO 
grading system; low grade tumours were identified as cases with grade I and II, while 
high grade tumours were cases with grade III and IV. Based on agreement with clinical 
collaborators, it was suggested that cases with low-grade glioma had the longest 
treatment duration of 18 months, as they needed to be under supervision to monitor the 
change in the tumours, whereby individuals might go more than a year without receiving 
treatment until the prognosis was confirmed. Those with high-grade glioma had the 
shortest treatment duration, especially for cases with radiotherapy alone lasting around 
six months. These treatment durations are explained in detail in Table 9. 276 out of 463 
CNS survivors had their grade identified using the cancer register (168 low grade and 62 
high grade), while 187 cases (40%) had missing grades. Those were identified 
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individually using the morphological code , to impute grade and their treatment durations 
updated accordingly [178].  
Stage is an important variable and is likely to affect the pattern of hospital admissions. 
Patients with worse prognosis (stage/grade IV) might have multiple hospital admissions 
compared to cases with better prognosis (stage/grade I). However, due to the high 
percentage of missing data and the inconsistent classification of stage or grade, this 
variable was not included in the regression modelling. Nonetheless, other variables such 
as relapse status and type of initial treatment, that could determine disease severity were 
considered for inclusion in the modelling. Stage is likely to be highly correlated with type 
of initial treatment, especially for CNS tumours, where those with high-grade CNS 
tumours treated with radiotherapy have shorter treatment durations than cases with low-
grade CNS tumours treated with radiotherapy. Therefore, including stage and type of 
initial treatment in the model was not valid as it breached one of the negative binomial 
conditions, which is the independence of all the predictor variables. 
 
4.10  Ethical approval and data security 
Ethical approval for this project was already in place because it was included as part of 
an ongoing research programme for the YSRCCYP: (MREC 0/3/1) investigating variation 
in hospital activity. The approval allows the processing of patient identifiable data without 
consent for research purposes through an exemption from the Health Research Authority 
Confidentiality Advisory Group (CAG 1-07(b)/2014). 
This project relied on the extraction of data on hospital activity for cancer patients aged 
0-29 from HES. Approval to work with HES data was provided by the Health and Social 
Care Information Centre [165], Data Access Advisory Group – DAAG reference: 
OC/HES/015, as part of the work approved within the YSRCCYP. 
To preserve statistical power and avoid disclosing any patient identifiable information, 
each cancer group was only studied in detail when there were more than 50 cases. The 
numbers in the tables were suppressed when there were fewer than five cases. All data 
were analysed within a secure server environment in the School of Medicine at the 
University of Leeds where only authorised registry personnel had access to the data and 
networked PCs. 
4.11  Demographic and clinical characteristics 
4.11.1 Proxy of deprivation 
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The frequency of hospital admissions and length of stay might vary due to socioeconomic 
status; people in the most deprived areas have been previously shown to have higher 
hospitalisation use among long-term survivors [101]. Therefore, hospitalisation usage 
was assessed in relation to deprivation. There were several proxies of deprivation 
Carstairs [179], Townsend [180] and Index of Multiple Deprivation (IMD) [181] that were 
previously used in childhood cancer epidemiological studies. Each uses certain 
components to estimate a deprivation score. Townsend is an area-based deprivation 
measurement using the following indices: unemployment, non-car ownership, non-home 
ownership and household overcrowding within a small area measure, such as electoral 
ward or super-output area [19]. The IMD [181] has the limitation of including health data 
that could overestimate the relationship between deprivation and health. To provide a 
comprehensive analysis, and for the sake of comparability with other studies conducted 
in the Yorkshire study region, the Townsend score was used as a proxy of deprivation 
[48, 127]. The use of an area-based measure could lead to ecological fallacy problems, 
as area-level associations may not be representative of those at an individual level 
because of the aggregation of data and loss of information [19]. To avoid that potential 
bias or at least to reduce its effect, the smallest area-based measure was used – ‘lower 
super output area’ – which constitutes a minimum of 1,000 people and a mean of 1,500 
people in England [182]; this could reduce the loss of individual level information. 
Deprivation scores were derived from the 2001 census and then categorised into five 
groups from the least to the most deprived based on the distribution of scores in Great 
Britain. 
4.11.2 Date of diagnosis 
To remain consistent in identifying accurate diagnosis dates among diagnostic groups, 
a hierarchy exists, ordered from lowest to highest priority, taken from the European 
Network of Cancer Registries [183, 184] (Box 1). The YSRCCYP register follows this 
guidance to determine an accurate diagnosis date, which I used within this thesis. The 
date of diagnosis from the registry was based on manual scrutiny of the original medical 
records, and adhered to rules on defining the diagnosis date set out by national cancer 
registration guidelines, also adopted and documented by the European Network of 
Cancer Registries [185]. Diagnosis dates were primarily determined via the date 
recorded on the histopathology report from when the biopsy specimen was taken. 
Otherwise, the earliest recorded date at which the diagnosis was confirmed via radiology 
(computed topography or magnetic resonance imaging) or other clinical confirmation 
was taken. Nevertheless, there may be some measurement error associated with the 
registry recorded data of diagnosis based upon this method, although any impact on 
analyses is likely to be mitigated due to regular cross-checks having been carried out 
87 
 
between the YSRCCYP, other regional specialist childhood registries, the National 
Registry for Childhood Tumours and National Cancer Registration Service [183]. The 
manner in which some tumours are diagnosed through surgical excision and the delays 
associated with confirmation of the date of diagnosis, some cases will have begun 
treatment or would have been hospitalised before the recorded date of diagnosis in the 
cancer register, thus this may result in an underestimation of the real hospital burden for 
some cases. 
Box 1: The hierarchy of defining date of diagnosis based on the European Network of 
Cancer Registries: [171]. 
 
4.11.3 Classification of ethnicity 
As described earlier in Section 4.9.1.1, cases were grouped into South Asian and non-
South Asians as those groups were appropriate for the study population. 
4.11.4 Identification of treatment modality and date of 
completion 
The Department of Health‘s Cancer Reform Strategy emphasises the importance of 
providing high-quality data on cancer outcomes and the survival population, to optimise 
health services planning to address their needs. However, the Department of Health 
found that data completion for stage of disease and treatment was inconsistent in the 
UK [186]. Cancer treatment information for this study was extracted from the YSRCCYP 
and HES. In the current study, we were interested in assessing admissions after date of 
diagnosis of primary cancer, and separately before and after date of initial treatment 
completion. In the YSRCCYP, the type of treatment (chemotherapy, radiotherapy, 
surgery, bone marrow transplant (BMT)) were stored in a separate database table and 
linked to each tumour registration using patient ID, type of tumour and date of diagnosis. 
However, this limited the ability to identify the type of initial treatment or the first line 
treatment, e.g. certain cases might have planned to receive chemotherapy alone, 
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however, the tumour may still have been present at the end of the chemotherapy regimen 
and therefore further treatment would be prescribed. 
As described in Section 4.6.2, each NHS healthcare provider in the UK is funded based 
on the delivery of their services, a policy known as PbR [187]. The PbR system is 
sensitive to case mix, such as type of treatment provided, length of stay, age of patient 
and other clinical and demographic characteristics of the patient. The completeness of 
the PbR report is the responsibility of each NHS provider, with data uploaded on a 
monthly basis to Healthcare Resource Groups (HRG). These reports are held by the 
Health and Social Care Information Centre (HSCIC), with the data available for research 
purposes subject to appropriate legal and regulatory approvals. HES are acknowledged 
to accurately represent the level of surgical procedures. The accuracy and completeness 
of recording of treatment within both the cancer register and HES has been analysed.  It 
has previously been found that the recording of major surgery was considerably high, 
while radiotherapy and chemotherapy were poorly recorded in HES [8]. Therefore, HES 
was used to cross-validate primarily the recording of surgical procedures in the cancer 
register, especially for patients with no record of treatment within the cancer register. 
Further validation of those from the cancer register with no record of treatment were 
checked against medical records and the original cancer register data collection notes. 
Results showed that of those with no record of treatment in the cancer register (n= 375), 
after validation a two-third (~70%) of these were accurately recorded as having received 
no actual treatment. 
4.11.4.1 Identification of initial treatment  
For surgery, based on clinical expertise, only major surgical interventions related to 
treatment were included. Supportive and diagnostic purpose surgeries, such as biopsies 
and exploratory surgeries for diagnostic purposes, or gastro-enterostomy or catheter 
insertion for supportive purposes, were not considered to be cancer-related major 
surgeries. A full list of diagnostic supportive and therapeutic surgeries is included in 
Appendix B. In HES, the operation codes were used to classify surgeries by surgery site 
[188]. The list of potential curative cancer-related surgeries was identified using the 
National Cancer Intelligence Network Major Resection Report [189]. 
Another major surgical list was generated based on current operations conducted on the 
study population, and was inspected and approved by a local consultant paediatric and 
adolescent haematologist. Both lists were cross-checked; a list of the surgical operations 
included in the study can be found in Appendix B. 
The date of treatment was documented in the cancer register, however each case might 
have multiple dates of treatment, in relation to primary or secondary tumour diagnoses, 
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thus the initial date was defined as the earliest date of delivery of treatment in cases with 
a single modality. The date of initial treatment for a patient with complex modality was 
not reliable, as they had several initial dates for each modality (chemotherapy, 
radiotherapy and surgery). In that case, a proxy table was created to estimate the 
expected time point where the treatment was considered as initial, i.e. planned as the 
first-line treatment based on discussions with clinical experts. Thus, Table 7 was created 
to summarise different treatment scenarios. This table was used when cases had the 
recorded date of each treatment modality. When cases had no record of treatment, the 
date of diagnosis was used. The dates for chemotherapy, radiotherapy and surgery were 
considered as initial therapy if they occurred during the predefined time points set out in 
Table 7 for each cancer diagnostic group and type of treatment modality. For CNS 
tumours, it was separated by histological type: low-grade tumour and high-grade tumour 
[111], as described earlier. 
In cases of discrepancy in the coding of treatment between the cancer register and HES 
in terms of date of treatment or type of treatment, the date chosen was the earliest date 
recorded as any following dates could relate to the continuation of subsequent treatment 
modalities. When there were discrepancies in documentation of treatment type, e.g. 
surgery alone in the cancer register and chemotherapy alone in HES, both treatments 
were assigned to cases if they were within the predefined initial treatment duration time 
period. All possible combinations of treatments from both datasets are illustrated in Table 
8. In the study dataset treatment modality was grouped into eight groups (Table 9). 
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Table 7: Classification tool used in identification of initial treatment 
Diagnostic group Gender 
Treatment duration from date of start of 
chemotherapy or date of diagnosis if patient 
didn't receive chemotherapy for cases treated 
with radiotherapy and/or surgery 
Leukaemia     
  ALL Female 24 months 
  ALL Male 36 months 
  AML Both 6 months 
  Other leukaemia 
 
24 months 
Lymphoma 
  
  Non-Hodgkin lymphoma Both 6 months 
  Hodgkin lymphoma Both 12 months 
  Other lymphoma 
 
12 months 
CNS 
  
  Low grade  Both 18 months 
  high grade  Both 6 months if radiotherapy alone / otherwise 12 
months 
Neuroblastoma  Both 3 months if surgery alone / otherwise 18 months 
Renal tumour Both 12 months 
Bone tumour Both 12 months 
STS Both 3 months if surgery alone / otherwise 12 months 
Germ cell tumour Both 3 months if surgery alone / otherwise 8 months 
Abbreviations: ALL= Acute lymphoblastic leukaemia; AML= Acute myeloid leukaemia; CNS= 
Central nervous system; STS= Soft tissue sarcoma. 
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Table 8: All possible combinations of treatment modality from the cancer register and 
HES 
Example modality in 
one of the data sources 
(HES or register) 
Example modalities in the other 
data source 
Final assigned treatment 
modalities 
Chemotherapy alone 
Radiotherapy alone/  
Chemotherapy and radiotherapy 
Chemotherapy and 
radiotherapy 
Surgery alone/  
Chemotherapy and surgery 
Chemotherapy and surgery 
Radiotherapy and surgery 
Chemotherapy, radiotherapy 
and surgery 
Chemotherapy, radiotherapy and 
surgery 
Chemotherapy, radiotherapy 
and surgery 
Radiotherapy alone 
Chemotherapy alone/  
Radiotherapy and surgery 
Chemotherapy and 
radiotherapy 
Surgery alone/  
Radiotherapy and surgery 
Radiotherapy and surgery 
Chemotherapy and surgery 
Chemotherapy, radiotherapy 
and surgery 
Chemotherapy, radiotherapy and 
surgery 
Chemotherapy, radiotherapy 
and surgery 
Surgery alone 
Chemotherapy alone/ 
Chemotherapy and surgery 
Chemotherapy and surgery 
Radiotherapy alone/ 
Radiotherapy and surgery 
Radiotherapy and surgery 
Chemotherapy and radiotherapy 
Chemotherapy, radiotherapy 
and surgery 
Chemotherapy, radiotherapy and 
surgery 
Chemotherapy, radiotherapy 
and surgery 
None recorded Any other treatment combination Other treatment combination 
 
 
Table 9: The classification code for the treatment variable 
Classification of treatment  Code Justifications 
Chemotherapy alone 1  
Radiotherapy alone 2  
Surgery alone* 3  
Chemotherapy and radiotherapy 4  
Chemotherapy and surgery 5  
Radiotherapy and surgery 6  
Combination of all 7  
Not recorded 8 No record of treatment 
* For the surgery variable, diagnostic aid procedures were not considered to be a cancer-related 
surgery. 
 
 
4.11.4.2 Estimated date of treatment completion 
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To answer the main research question of assessing the patterns of hospital admissions 
during the post-treatment phase, it was essential to know the date when treatment was 
completed. However, this information was not consistently available either in the cancer 
register or the HES dataset. Consequently, the approximate date of treatment completion 
was inferred based upon clinical knowledge (group of senior local paediatric and 
adolescent haematology and oncology consultants), using the following variables: 
diagnostic group, gender, type of initial treatment, whether the patient had a BMT or had 
ever relapsed. Based on agreement with clinical experts, a proxy indicator for duration 
of treatment in months was generated using the aforementioned variables (Table 10).   
 9
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Table 10: Expected duration of treatment completion according to diagnostic group, gender, bone marrow transplant and relapse status 
Diagnostic group Gender 
Treatment duration from start of 
chemotherapy, radiotherapy or surgery 
Bone marrow 
transplant 
Ever 
Relapsed 
Proxy date of 
end of 
treatment (from the latest date of treatment start date) 
(from date of 
transplant) 
(from date of 
relapse) 
Leukaemia   
1
2
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   ALL Female 24 months 
   ALL Male 36 months 
   AML Both 6 months 
   Other leukaemia  24 months 
Lymphoma  
 
   Non-Hodgkin lymphoma Both 6 months 
   Hodgkin lymphoma Both 12 months 
   Other lymphoma  12 months 
CNS 
  
   Low grade Both 18 months 
   High grade  Both 
6 months if radiotherapy alone / otherwise 12 
months 
Neuroblastoma  Both 3 months if surgery alone / otherwise 18 months 
Renal tumour Both 12 months 
Bone tumour Both 12 months 
Soft tissue sarcoma Both 3 months surgery alone / otherwise 12 months 
Germ cell tumour Both 3 months surgery alone / otherwise 8 months 
Abbreviations: ALL=Acute lymphoblastic leukaemia; AML= Acute myeloid leukaemia; CNS=Central nervous system
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4.11.4.3 Relapse status 
The follow-up process described in Section 4.6.1 outlines how relapse disease was 
ascertained. Relapse was defined as recurrent disease regardless of the site [190]. 
There could be more than one relapse event per patient of course, although this study 
focused only on the first relapse after primary diagnosis as the management of treatment 
differs after the second relapse, resulting in a biased assessment of health burden. 
Additionally, only a quarter of those who relapsed had more than one event, hence 
limiting the ability to study this group separately. 
4.11.4.4 Bone marrow transplant (BMT) 
Along with chemotherapy, radiotherapy and surgery, some cases require a further 
clinical intervention such as BMT. BMT is one of the treatment protocols available for 
chronic illness, limited mainly to AML patients affected by loss of bone marrow cells due 
to intensive treatment, therefore necessitating BMT. After the transplantation, the patient 
might need up to 12 months for their white blood count and immune system to return to 
normal levels. 
Information on BMT was recorded in the cancer register as one of the treatment 
modalities. In addition, HES data were cross-checked using the three digit Classification 
of Interventions and Procedures (OPCS) code version 4.5 [46], and from the main 
paediatric and adolescent oncology department at Leeds Teaching Hospitals NHS Trust 
where treatment was administered during admission. Figure 16 presents the sources 
and codes used to identify cases with BMT. The list of BMT operations extracted from 
the cancer register and HES data was cross-checked against the electronic records held 
by the Leeds General Infirmary for all such procedures carried out at the only PTC in the 
region for CYP. 
The date of the BMT was extracted from HES and compared to the date of diagnosis to 
check whether the transplant occurred after diagnosis or close to the date of diagnosis, 
hence ensuring that the transplant was related to the primary cancer and not due to 
another chronic diseases or second malignancy. 
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Figure 16: Validation of bone marrow transplant 
4.11.5 Type of admission 
For certain parts of the analysis (Section 6.2.1.5), the type of admission was recorded to 
compare the results with previously published hospital activity reports in the UK. The 
types of admission were grouped as either ‘planned’ (elective) or ‘unplanned’, as 
identified using the HES data dictionary (see Table 11). 
Table 11: Classification code for admission method 
Operation code  P7983 
relates to Bone 
marrow transplant
Operartion code 
W341-9 & W991 
relates to: Graft bone 
marrow and bone 
marrow transplant 
respectively
Speciality code in 
which the consultant 
was working during the 
period of care. 
Code 308 for bone 
marrow 
transplantation.
Patient diagnosed from 
1996-2009
Admission method Code Code descriptions 
Planned  
11 From waiting list 
12 Booked 
13 Planned 
Unplanned 
Emergency 
21 Via Accident and Emergency (A&E) 
22 Via general practitioner 
23 Via Bed Bureau 
24 Via consultant outpatient clinic 
28 Other means 
Maternity 
31 Baby was delivered after the mother's admission 
32 Baby was delivered before the mother's admission 
Others 
81 
Transfer of any admitted patient from another hospital 
provider other than in an emergency 
82 Other: babies born in healthcare provider 
83 
Other: babies born outside the healthcare provider, except 
when born at home 
84 
Admission by the admission panel of an HSPH; patient not 
entered on the HSPH 
89 From the admissions waiting list of an HSPH 
Not known 
98 Not applicable 
99 Not known 
Cancer 
register 
HES HES 
Leeds 
General 
Infirmary 
Validated using date of BMT 
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4.11.6 Place of care during the admission period and 
proportion of specialist care 
The pattern of admissions might vary depending on the type of hospital where cancer 
was diagnosed, or where the treatment was delivered, as explained earlier in Chapter 3, 
Section 3.3.4.1, and also on whether the services were delivered at specialist or non-
specialist hospitals. Consequently, it was essential to identify the hospital where services 
were delivered before classifying the hospital type (specialist or not). 
Identifying the main place of care for cancer patients, especially CYP, was difficult. 
Patients could be diagnosed in one NHS trust, but receive treatment at another, or they 
could be diagnosed and receive their initial treatment in the same trust, but during their 
treatment period, care might be delivered by a different trust.  The relationship between 
place of care and the survival rate among patients with colorectal cancer in the Northern 
and Yorkshire region was previously studied, and found that around 90% of patients 
were receiving care in the same trust where they were diagnosed; whilst only 75% 
maintained care from the same setting throughout the treatment journey [19].  
To identify the hospital where the patient received care during the admission period, 
individual hospital names were identified from the HES admission records based on the 
HES inpatient data dictionary [165] (Figure 17), and then flagged within the dataset as 
representing a specialist centre (either age or tumour-specific) based on the lists in Table 
12 and Table 13. This list was extracted from three online sources: The Children's 
Cancer and Leukaemia Group [53], the Teenage Cancer Trust [131] and Cancer Support 
for the Young (CLIC Sargent) [191]. Furthermore, these were individually checked 
though the hospital websites to identify age boundaries. These lists represent specialist 
centres available for CYP up to 2013, when data analysis began, ensuring accurate 
allocation of cases based on the level of specialist care, by appropriately identifying the 
type of hospital where they were admitted and treated. 
97 
 
 
 
 
 
Y
c
tr
_
id
 
A
d
m
id
a
te
 
P
ro
c
o
d
e
 
O
rg
a
n
is
a
ti
o
n
 
c
o
d
e
 
N
a
m
e
 
N
a
ti
o
n
a
l 
g
ro
u
p
in
g
 
H
ig
h
 l
e
v
e
l 
g
e
o
g
ra
p
h
y
 
990XX 26/10/19XX RR813 R1A 
Worcestershire Health And 
Care NHS Trust 
Y55 Q53 
09AXX 05/08/20XX RAE00 R1C Solent NHS Trust Y57 Q70 
2003XX 07/07/20XX RR801 R1D 
Shropshire Community 
Health NHS Trust 
Y55 Q60 
2006XX 30/08/20XX RR801 R1E 
Staffordshire And Stoke On 
Trent Partnership NHS Trust 
Y55 Q60 
Abbreviations: Admidate is the admission date; Procode is the provider code as described in 
detail in http://digital.nhs.uk/hesdatadictionary. 
Figure 17: Visual example of the method used to identify the name of the healthcare 
providers 
 
Table 12: List of CYP cancer treatment centres (hospitals) with location and age 
boundaries in UK and Ireland in 2013 
Hospital name City   Age boundaries 
Royal Aberdeen Children's Hospital  Aberdeen  0 to 16 years 
Royal Belfast Hospital for Sick Children  Belfast  0 to 16 years 
Birmingham Children's Hospital  Birmingham  0 to 12 and 13-18 years 
Queen Elizabeth Hospital Young Persons 
Unit  
Birmingham 16 to 18 years 
Royal Orthopaedic Hospital  Birmingham 13 to 18 years 
Bristol Royal Hospital for Children  Bristol 0 to 10 and 11 to 16 years 
Children's Hospital for Wales (CHW)  Cardiff 0 to 20 and 13-24 years 
Addenbrooke's Hospital  Cambridge 14 to 24 years 
Royal Hospital for Sick Children  Edinburgh  0 to 12 and 13 to 16 years 
Western General Hospital  Edinburgh 16 to 24 years 
Beatson West of Scotland Cancer Centre  Glasgow 16 to 24 years 
Royal Hospital for Sick Children (Yorkhill)  Glasgow  0 to 12 and 13 to 16 years 
Castle Hill Hospital  Hull 18 to 24 years 
Leeds General Infirmary Leeds 0 to 12 and 13-18 years 
St James’s University Hospital Young Adult 
Unit  
Leeds 17 to 24 years 
Leicester Royal Infirmary  Leicester 13 to 24 years 
Alder Hey Children's Hospital Liverpool 0 to12 and 13-19 years 
University College Hospital London 0 to 12 and 13 to 24 years  
The Royal Marsden London  0 to15 and 16-24 years 
Royal Manchester Children's Hospital  Manchester  0 to 12 and 13 to 24 years 
Extracted HES 
variables 
Hospital address provided by the National 
Administrative Codes Service  
Linked 
variables 
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Hospital name City   Age boundaries 
The Christie Hospital  Manchester 16 to 24 years 
The Freeman Hospital  Newcastle 18 to 24 years 
The Great North Children's Hospital  Newcastle 13 to 19 years 
Royal Victoria Infirmary  
Newcastle Upon 
Tyne  
0 to 13 years 
Queen’s Medical Centre  Nottingham 0 to 18 and 19 to 24 years 
John Radcliffe Hospital Oxford  Birth to18 years 
The Children's Hospital Sheffield Sheffield  Birth to 16 years 
Royal Hallamshire Hospital  Sheffield 16 to 24 years 
Weston Park Hospital  Sheffield 16 to 24 years 
Southampton General Hospital  Southampton  0 to15 and 16-24 years 
Royal Marsden Hospital  Surrey 16 to 24 years 
The Clatterbridge Cancer Centre  The Wirral 16 to 24 years 
 
Table 13: Other specialist hospitals (tumour specific) with cancer-specific expertise 
Hospital name 
Cancer-specific 
expertise 
Charing Cross Hospital CNS tumours 
James Cook Hospital CNS tumours 
Kings College Hospital CNS tumours 
National Hospital for Neurology and Neurosurgery CNS tumours 
Queens Hospital Romford CNS tumours 
Royal Free Hospital CNS tumours 
Royal Preston Hospital CNS tumours 
Royal Stoke University Hospital CNS tumours 
Salford Royal Hospital CNS tumours 
St George’s Hospitals, Tooting CNS tumours 
The Walton Centre CNS tumours 
University Hospital (Coventry) CNS tumours 
Great Ormond Street Hospital CNS tumours 
Hull Royal Infirmary CNS tumours 
Derriford Hospital 
CNS tumours and soft 
tissue sarcoma 
Churchill Hospital  Soft tissue sarcoma 
City Hospital Soft tissue sarcoma 
Frenchay Hospital (diagnostic surgery) Soft tissue sarcoma 
Manchester Royal Infirmary Soft tissue sarcoma  
Royal Devon and Exeter Hospital Soft tissue sarcoma 
Royal Liverpool Hospital (diagnostic and surgery) Soft tissue sarcoma 
Nuffield Orthopaedic Centre, Oxford Bone tumours 
Royal National Orthopaedic Hospital, Stanmore Bone tumours 
Royal Orthopaedic Hospital, Birmingham Bone tumours 
The Robert Jones & Agnes Hunt Orthopaedic Hospital, Oswestry Bone tumours 
 
99 
 
The proportion of specialist care received by the patient was calculated in two ways. The 
first method attempted to calculate this proportion based on the number of admissions 
to specialist cancer centres (Outcome 1) and the second method was based upon the 
number of days spent in specialist centres in each admission/spell (Outcome 2) 
Specialist cancer centres, as explained earlier in the introduction chapter, could 
represent either age specific (children and TYA PTC) or tumour specific centres, and 
reflect levels of high quality care. It was found that those diagnosed with cancer aged 
15-24 years and treated in specialist centres had better survival rates than TYA cases 
with limited access to specialist services [10]. However, in this study the proportion of 
specialist care was estimated using hospital stay only, i.e. the proportion of stay in 
specialist units compared to the overall length of time spent in hospital. Within this thesis, 
two different measures of hospital burden were used: frequency of hospital admissions 
and length of stay. This was to take into account individuals who may have fewer 
specialist admissions but spent extended periods of time in specialist units. Both 
methods were used when carrying out regression modelling to examine factors which 
influenced hospitalisation, in order to identify the independent effects of specialist care 
based on the study outcome: hospital admission or length of stay. 
Outcome 1: Proportion of specialist care based upon the number of admissions 
 𝐏𝐫𝐨𝐩𝐨𝐫𝐭𝐢𝐨𝐧 𝐨𝐟 𝐬𝐩𝐞𝐜𝐢𝐚𝐥𝐢𝐬𝐭 𝐜𝐚𝐫𝐞 𝐚𝐝𝐦𝐢𝐬𝐬𝐢𝐨𝐧𝐬 =
Total number of specialist care admissions per patient
Total number of admissions per patient
  
Outcome 2: Proportion of specialist care using number of days 
 𝐏𝐫𝐨𝐩𝐨𝐫𝐭𝐢𝐨𝐧 𝐨𝐟 𝐬𝐩𝐞𝐜𝐢𝐚𝐥𝐢𝐬𝐭 𝐜𝐚𝐫𝐞 𝐝𝐚𝐲𝐬 =
Total number of  days in specialist units per patient
Total number of days spent in hospital per patient
 
 
The proportion of admissions was then grouped into three categories, firstly to aid 
interpretation, and secondly, to compare the results to the published literature that 
assessed the impact of levels of specialist care on cancer outcomes [8] (Table 14). 
Table 14: Classification of levels of specialist care 
Code Category label Proportion of specialist care 
1 Limited specialist care <30% 
2 Some specialist care 30-60% 
3 Mostly specialist care >60% 
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4.11.7 Follow-up period 
As described earlier in Section 4.6.4 the follow-up period was calculated based on the 
linked data from the date of diagnosis until date of death, date of immigration, or the end 
of the study period (31st December 2011) whichever occurred first. The follow-up period 
was further categorised into two phases: 
1. On treatment phase: from date of diagnosis to date of treatment completion (the 
estimated date of treatment completion in Section 4.11.4.2 ), date of death, date 
of loss of immigration or date of the end of study period whichever occurs first. 
2. Post-treatment phase: date of treatment completion to the date of end of follow-
up (date of immigration, death or 31 December 2011, whichever occurred first). 
The follow-up period after treatment completion was subdivided further by: the 
censoring point from date of treatment completion: 0-2 years after date of 
treatment completion, 3-4 years after date of treatment completion, 5-7 years 
after date of treatment completion, ≥ 8 years after treatment completion. These 
were established to classify the pattern of admissions into ‘short’, ‘median’ and 
‘long term’ follow-up periods. 
4.12   Statistical methods 
4.12.1 Cancer incidence rates 
The incidence rates for all cancers overall and by main diagnostic group were assessed, 
using age and sex standardised incidence rates per 1,000,000 people and 95% 
confidence intervals using annual mid-year, age- and sex-specific population estimates . 
Additionally, the temporal trends in cancer incidence by year of diagnosis were assessed.  
4.12.2 Linked study population 
The study population was described according to clinical and patient demographics by 
comparing the distribution of cancers by age at diagnosis, sex, year of diagnosis, 
ethnicity, and deprivation for linked and non-linked cases using the Chi-squared test for 
categorical data, t-test for normally distributed continuous variables and the Mann-
Whitney U-test [192] for non-normally distributed variables. This was done to check for 
any significant selection bias. 
One of the study objectives was to check the completeness in documenting the initial 
type of treatment in the cancer cohort and HES datasets. Therefore, the distribution of 
cases by type of treatment and data source was calculated comparing data extracted 
from the cancer register and HES. Similarly, the number and percentage of cases treated 
with BMT and the number of cases experiencing a relapse were calculated and 
compared by cancer type. Furthermore, the number of admissions was compared by 
101 
 
level of specialist care and age at diagnosis. These were done to describe the 
management of the cancer cohort by cancer type, age, type of initial treatment and 
disease severity. The results are presented in Chapter 5. 
4.12.2.1 Estimating the number and rates of admissions and bed days  
The objective was to assess the frequency of hospital admissions and number of days 
spent in hospital among CYP by comparing the rates of hospital admission for each 
cancer type during two time periods: on treatment and post-treatment. This was carried 
out to estimate the burden of health among the cancer cohort from the date of diagnosis, 
and additionally, after treatment completion when patients are considered to be free of 
cancer. Furthermore, this should give an insight into the use of hospital services among 
short- (treatment phase), medium- (immediately after treatment completion) and long-
term survivors (more than three years after treatment completion).  
The rate of admission was analysed for all cancers combined and for main diagnostic 
groups, taking into account the number of years of follow-up. The rates were broken 
down by demographic characteristics such as age, sex, ethnicity and deprivation. 
In the current thesis, two measures of hospital activity were considered: 
1. Hospital admission rates – separated into inpatient and outpatient rates. 
Admission rates (per person per year, as described in Section 4.6.4) were 
estimated for all cancers combined and by main diagnostic group according to 
patient demographics and clinical characteristics. 
2. Number of days spent in hospital (inpatient) was defined as the total number of 
bed days during acute hospitalisation per 100 person per day from the date of 
admission until discharge.  
The following examples describe the method used to estimate the hospital rate per 
patient by identifying the number of admissions per patient and the number of follow-up 
years since diagnosis until the last admission or censoring (Table 15 and Figure 18).  
In Table 15 each row represents a single case. Numbers of admissions were calculated 
at three time points: the first time period was calculated from the date of diagnosis until 
date of treatment completion; the second period is from the 1st admission after treatment 
completion to the last admission during the study period (31st December 2011); the third 
period is the complete follow-up period from date of diagnosis until the end of the study 
period (31st of December 2011). 
 Column A in Table 15 represents the number of admissions in the three main 
time periods: total follow-up period from diagnosis, on treatment phase and post-
treatment period. The pink colour represents the further breakdown of the post-
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treatment period into distinct epochs (<3, 3-5, 5-7 and >8 years after treatment 
completion). 
 Column B represents the number of years patients were followed-up from the 
date of diagnosis until the end of the study follow-up period (31st December 2011) 
or censored due to death, emigration or loss to follow-up. 
 Column C represents the admission rate using the Outcome 3 formula. 
 1
0
3
 
Table 15:Example 1: estimating the hospital admission rate based on the number of admissions 
  (A) Number of admissions  (B) Follow-up period (years)  
(C) Hospital admission rate (admissions per 
year) (Outcome3*)  
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1 16 2 14 0 0 0 14 2.44 1.09 1.35 0.00 0.00 0.00 1.35 1.84 10.35 0.00 0.00 0.00 10.35 
2 7 0 0 7 0 0 7 4.58 0.62 2.99 0.97 0.00 0.00 3.96 0.00 0.00 7.20 0.00 0.00 1.77 
3 14 0 12 2 0 0 14 4.00 0.99 2.99 0.02 0.00 0.00 3.01 0.00 4.01 82.06 0.00 0.00 4.64 
4 3 0 2 0 1 0 3 5.74 0.68 2.99 1.99 0.09 0.00 5.07 0.00 0.67 0.00 11.76 0.00 0.59 
5 8 2 3 0 2 1 6 10.55 1.48 2.99 1.99 2.99 1.10 9.07 1.35 1.00 0.00 0.67 0.91 0.66 
6 19 2 10 2 3 2 17 10.62 1.05 2.99 1.99 2.99 1.59 9.56 1.90 3.34 1.01 1.00 1.26 1.78 
 
Blue represents the entire follow-up period, green the on treatment and post-treatment periods, and pink the breakdown of post-treatment follow-up.  
* Outcome 3: Hospital admission rate: Hospital admission rate =
Total number of admissions per follow−up period
Total follow−up year per person per follow−up period
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Figure 18: Example 2: hospital inpatient admissions on a time scale diagram 
 
The pattern of hospital admissions was analysed by year of admission (1997-2011). This 
was done to examine the general pattern of admissions across the study period, and to 
check whether the pattern altered after 2005 when the NHS produced guidance to 
improve young people’s outcomes by introducing age-appropriate specialist centres to 
ensure that centralised care was delivered equitably (see Chapter 2, Section 2.4). 
A univariable analysis was carried out to compare the pattern of the median rates of 
admission/admission duration, separately by age at diagnosis, sex, ethnicity, deprivation 
and relapse status for all cancers combined and by major histological sub-types. The 
difference of distribution of the rate of admissions/length of stay between age groups and 
cancer types was tested by different statistical tests depending on the distribution of the 
study variables: outcome or the dependent variable (the rate of admissions and length 
of stay) and the independent variables (age group and cancer type). t-test was used for 
normally distributed continuous outcome (dependent) variables and the Mann-Whitney 
U-test for testing the distribution of continuous non-normally distribute outcome variable 
and two independent variable. Kruskal–Wallis was also used when comparing between 
more than two independent group and non-normally distributed dependent variable. This 
was done to assess whether the hospital burden was significantly varied by age group 
and cancer types in each admission phase. 
The median number of admissions was calculated for each individual per one person-
years from date of diagnosis until the end of the follow-up period, including in treatment 
and post treatment phases, while the duration of each admission was estimated per 100 
bed-days per person. 
4.12.3 Hospital admission rate ratio and day rate ratio 
Rates of hospital admissions could be higher within the first year after diagnosis and is 
believed to follow a Poisson distribution (albeit, positively skewed) [72]. 
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In order to model the hospital admission rate ratio (HRR) and number of days in hospital 
rate ratio (DRR), a Poisson model using the total number of admissions/number of days 
for cancer patients as an outcome variable, adjusting for person-years/person-days as 
an exposure, was fitted to the data. The model fit was checked using two tests: the estat 
gof [193] command in Stata based upon the Chi-squared test, while the second test 
assessed the distribution of the observations using scatter plots, and any violation of the 
Poisson assumption would be determined if the mean of the distribution was not equal 
to the variance, inferring that negative binomial regression would be better implemented 
instead [194, 195]. 
After choosing the most appropriate model distribution, a model building process was 
conducted to determine which variables should be included in the final model for each 
diagnostic group. To determine this choice, the Bayesian information criterion (BIC) was 
chosen rather than Akaike’s information criterion [196]. There is evidence that the BIC is 
a more consistent approach in selecting the best-fitting model compared to AIC [197, 
198]. The choice of independent variables included in the models was based primarily 
on clinical importance and the variable type (categorical vs. continuous) was based on 
statistical importance. The BIC compares the probability that each assessed model is 
the true model in estimating the observed data (such as the mean of the outcome). 
Additionally, there is a natural penalty for including a larger number of independent 
variables, hence more emphasis on parsimonious models [198]. Furthermore, the 
number of cases within the main diagnostic groups could limit the study power, therefore 
BIC was felt to be a more appropriate choice than AIC, as it focuses on the least complex 
model that explains most of the variation in the data. 
A strength of the modelling approach was the ability to adjust for case mix when 
assessing rates of hospital admissions or length of stay. Casemix characteristics 
included: gender, age at diagnosis (continuous, categorical (children and TYA), or four-
year age bands (0-4, 5-9, 10-14, 15-19, 20-24, 25-29), year of diagnosis (categorical or 
continuous), ethnicity (South Asian vs non-South Asian), deprivation (Townsend score, 
continuous or categorical), proportion of specialist care admissions/specialist care days 
(continuous or categorical), ever relapsed (yes vs. no) and type of initial treatment 
(chemotherapy alone, radiotherapy alone, surgery alone, chemotherapy and 
radiotherapy, chemotherapy and surgery, radiotherapy and surgery, combination of all 
three modalities, no recorded treatment). These variables were chosen based on their 
potential impact in explaining variation in levels of hospitalisation, as identified in the 
literature in addition to clinical input (as described in Chapter 3). 
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Several sensitivity analyses were carried out to assess the impact of including or 
excluding certain groups from the analysis on the final results. These included the 
following: 
1. Patients who died during the study period compared to those who survived to the 
end of the study period. This was carried out for all cancers combined. Results 
are presented in Section 7.2.4. Patients who die may have higher hospital 
admissions compared with survivors, evident in the deterioration of their health 
in the period leading up to death. 
2. Comparison of the patterns of admission between relapsed and non-relapsed 
cases. It was hypothesised that those who had relapsed would have more 
admissions than non-relapsed cases. Results are presented in Section 7.2.3. 
3. Patients receiving a BMT vs. those that did not receive a BMT. The differences 
were assessed comparing leukaemia cases with the other cancer types adjusted 
for patient clinical and demographic characteristics. This was done to answer 
clinical concerns, whereby a patient who received a BMT may have more 
complex clinical needs than those who had not received a BMT. 
4.12.4 Causes of hospital admissions 
4.12.4.1 Description of morbidity related to hospitalisation 
In the HES data, individuals could have several diagnosis contained within a single 
admission, i.e. a patient could have a primary diagnosis code (the main reason for 
hospitalisation) and up to 19 additional secondary diagnosis codes (with no particular 
order of importance). An example of how the data might be arranged is presented in 
Table 16. The primary code was defined as the main reason for or cause of admission, 
while secondary causes were any diseases or complications that the individual may have 
that was suspected to be related to the primary diagnosis. For example: an individual 
might be admitted for myocardial infarction (MI) and have pre-existing diabetes. The MI 
would be considered as the main reason for admission and diabetes as the secondary 
cause of admission.  
In HES data, diagnosis of admissions are classified using the International Classification 
of Disease 10th edition (ICD-10). These codes include alpha numeric codes. In the 
current analysis, the first three digits were used to group causes into 22 chapter headings. 
A description of admission codes can be found at: http://digital.nhs.uk/hesdatadictionary.  
The number of cases with hospital admissions for all causes combined, and per specific 
cause of admission, were summarised. Additionally, the primary cause and secondary 
cause was summarised separately. This was done to check the consistency in coding, 
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and assess whether using the primary diagnosis might underestimate the impact of 
certain causes which could often be coded as a secondary diagnosis. 
Further analysis was carried out to assess the percentage of admissions for certain 
primary diagnoses before and after treatment completion for specific cancer types and 
for all cancers combined. This enabled a description to be made of the contribution of 
specific causes of admissions for future planning of services. This was performed by 
dividing the number of admissions occurring before/after the treatment period by the total 
number of admissions for each cause by cancer type. 
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Table 16: Example of how causes of admissions were recorded in HES 
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XX002 1* 22 10                  
XX002 14 20 3                  
XX002 2 1                   
XX002 8 19 17                  
XX008 7 2 5 18 4 21 21 6 8 14 20 9 17 22 15 3 15 13 11 1 
XX008 6                    
XX008 2                    
XX008 4 7 19 17                 
XX010 13                    
XX010 11 6                   
XX010 3 4 19 21                 
XX011 9 10 12                  
XX011 13                    
XX011 17                    
XX011 18 19 20 5 7 8 11              
XX012 4 3 7                  
XX012 12 17 2 4                 
* The causes of admission were recoded into 22 groups using ICD-10 (details of the code definitions are listed in Appendix A).  
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4.12.4.2 Observed time of admission after completion of cancer 
treatment 
In addition to determining overall hospital burden and the burden of cancer-related 
morbidity, the time to first hospitalisation after treatment completion was described for all 
causes and cause-specific admissions. In order to analyse the time to first admission 
after completion of cancer treatment, time to event (or survival) analysis was used. The 
date of treatment completion was the study entry date and the exit date was the first date 
of admission for each specific cause, and censored at date of death, date lost to follow-
up or end of study period, whichever occurred first. The time at risk (i.e. the time from 
treatment completion to hospital admission) was estimated by subtracting the entry date 
from exit date i.e. the time from study entry until date of occurrence of first event. The 
median time to hospitalisation and interquartile range was calculated for the total time at 
risk per main cancer type and age at diagnosis for all causes combined and per specific 
cause. The difference in time to hospitalisation by cancer type and age group was 
assessed using the Mann-Whitney U-test [192]. 
4.12.4.3 Cancer cohort compared with the background population 
Data on the general population of admissions was derived from all recorded admissions 
in HES during the period 1997 to 2011, and matched by age at the time of admission, 
sex and time period of admission, attributed to individuals who were resident in Yorkshire 
according to their postal address at the time of admission. The aim of this section was to 
assess the hospitalisation rate among the cancer cohort compared with all 
hospitalisations for children and TYA matched according to age, period and sex in the 
general population.  
In order to compare the hospital burden among survivors to the background population, 
the crude hospitalisation rate of admissions was estimated among the general population 
using the total number of individuals of the same age, sex and year of admission, with 
the first admission for a specific cause defined as the outcome variable divided by the 
annual mid-year age and sex specific population estimate. The total number of people in 
the population aged between 0 and 45 years was used as the exposure variable. This 
was used to estimate the expected rate of admission and then indirectly standardise the 
admission rate ratio for the cancer cohort. Among the cancer cohort, the total number of 
admissions for certain causes was defined as the outcome variable, while the total follow-
up period in years, as explained in Section 4.6.4, was defined as the exposure variable. 
The standardise hospitalisation rate (SHR) was estimated using indirect standardised 
hospitalisation rate ratios [199]. This approach allowed estimates to be made of the 
actual burden of specific causes of admissions among the cancer cohort after completion 
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of cancer treatment compared to the background population. This approach was similar 
to other studies that assess the rate of hospitalisation among CYP cancer survival 
compared with background population [101, 140]. Additionally, it was adopted for 
comparison purposes, to assess whether the excess rate of hospitalisation among CYP 
survivors varied by counties. The SHR was further analysed by age at diagnosis, gender 
and cancer type to identify any sub-group differences. All the analysis was carried out 
using Stata 14. 
The study results were summarised in four chapters to provide a comprehensive analysis 
of hospital burden among cancer survivors following date of diagnosis. Each chapter is 
aligned with the study aims and research question, with a description of the study 
population in Chapter 5, a detailed description of the hospital activity patterns for both 
the ‘on treatment’ and ‘post treatment’ phases in Chapter 6, the multivariable analysis of 
the factors influencing hospitalisation rates and length of stay in Chapter 7 and a detailed 
analysis of the cause-specific hospitalisations among cancer patients in Chapter 8. 
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 Understanding the Study Population 
5.1 Introduction 
In this thesis, we aimed to identify the healthcare burden among cancer survivors in 
Yorkshire. This section includes the cancer incidence among cases diagnosed between 
1996 and 2009 aged 0-29 years old. Additionally, a comprehensive description of the 
study populations, including demographic characteristics of age, ethnicity and 
deprivation, and clinical characteristics such as diagnostic cancer type, type of initial 
treatment, and proportion of specialist care are provided (Question 1). 
This chapter starts by assessing the pattern of cancer incidence by age at diagnosis, 
gender and the temporal pattern by year of diagnosis, to provide healthcare 
commissioners with an updated record of the pattern of cancer incidence. Additionally, 
to cross-check if the study population resembles the national incidence pattern and 
highlight the potential to extend the study result to the national level. The second part 
contains a sensitivity analysis to compare the distribution of linked cases with cases with 
no linked hospital record, by analysing the distributions of age, sex, ethnicity and 
deprivation among the cancer cohort. The last part in this chapter provides a descriptive 
analysis of the study population’s clinical characteristics, including distribution of type of 
initial treatment, BMT, relapse of disease and proportions of specialist care by cancer 
types. 
5.2 Methods 
Case information was extracted from the YSRCCYP to identify CYP cancer survivors 
before their 30th birthday and diagnosed between 1st January 1996 and 31st December 
2009 and living in Yorkshire when diagnosed. These were linked to hospital admissions 
extracted from HES from 1st April 1997 until 31st December 2011, using NHS number, 
date of birth, gender and postcode when diagnosed. The linkage method was the same 
for both inpatient and outpatient admissions (for more detail see Section 4.7). 
The cancer incidence rate was calculated using age and sex standardised incidence 
rates, using single mid-year population estimates as person-years (more detail in 
Chapter 4). 
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The differences between linked and non-linked cases were compared using chi-square 
tests for categorical data. The comparison was done for age group at diagnosis (0-14 or 
15-29 years), gender, period of diagnosis, cancer type (ICCC-3), deprivation using 
Townsend quintile [200] and ethnicity (South Asian or non-South Asian). 
5.3 Results 
5.3.1 Cancer incidence 
Leukaemia was the commonest diagnostic group among children aged 0-14 at diagnosis 
in both genders, with male and female incidence rates of 11.0 and 10.0 per million 
person-years, respectively. Among TYAs, germ cell tumours were the commonest 
diagnostic group for males (ASR=25.0; 95%CI 22.0-27.0 per million people). While, the 
commonest diagnostic group among females was lymphoma (ASR=12.0; 95% CI10.0-
13.0 per million people) (Table 17). There was a higher male cancer incidence compared 
with females (ASR=101.0 and 68.0 per million people, respectively). 
Overall, cancer incidence was higher among TYAs than children. The rate of incidence 
fluctuated based on the year of diagnosis, among children it peaked in 2002 (ASR=165 
per million people; 95%CI 135-195) and among TYAs peaked around 2005 (ASR=265 
per million people; 95%CI 228-301) (Figure 20).  
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Table 17: Distribution of cancer incidence per million people by age group, gender and diagnostic group (ICCC3) 
Cancer diagnostic 
Group (ICCC-3) 
Children (0-14 years) TYAs (15-29 years) Total (0-29 years) 
Male Female Male Female Male Female Total 
ASR* 95% CI¥ ASR 95%CI ASR 95%CI ASR 95%CI ASR 95% CI ASR 
95% 
CI 
ASR 95% CI 
Leukaemia 11.0 (10.0-
12.0) 
10.0 (8.0-
11.0) 
6.0 (5.0-
7.0) 
5.0 (4.0-
6.0) 
17.0 (15.0-
19.0) 
15.0 (13.0-
16.0) 
31.0 (29.0-
34.0) 
Lymphoma 5.0 (4.0-6.0) 3.0 (2.0-
4.0) 
14.0 (13.0-
16.0) 
12.0 (10.0-
13.0) 
19.0 (17.0-
21.0) 
14.0 (13.0-
16.0) 
33.0 (31.0-
36.0) 
CNS 8.0 (7.0-8.0) 6.0 (5.0-
7.0) 
7.0 (6.0-
8.0) 
6.0 (5.0-
7.0) 
15.0 (13.0-
16.0) 
13.0 (11.0-
14.0) 
27.0 (25.0-
29.0) 
Neuroblastoma 3.0 (2.0-3.0) 2.0 (1.0-
3.0) 
0.0 (0.0-
1.0) 
0.0 (0.0-
0.0) 
3.0 (2.0-
4.0) 
2.0 (2.0-
3.0) 
5.0 (4.0-6.0) 
Retinoblastoma 1.0 (1.0-1.0) 1.0 (0.0-
1.0) 
0.0 (0.0-
0.0) 
0.0 (0.0-
0.0) 
1.0 (1.0-
1.0) 
1.0 (0.0-
1.0) 
2.0 (1.0-2.0) 
Renal tumours 2.0 (2.0-3.0) 2.0 (1.0-
2.0) 
1.0 (0.0-
1.0) 
1.0 (0.0-
1.0) 
3.0 (2.0-
4.0) 
2.0 (2.0-
3.0) 
5.0 (4.0-6.0) 
Hepatic tumours 
0.0 (0.0-1.0) 0.0 (0.0-
1.0) 
1.0 (0.0-
1.0) 
0.0 (0.0-
0.0) 
1.0 (0.0-
1.0) 
1.0 (0.0-
1.0) 
2.0 (1.0-2.0) 
Bone tumours 
2.0 (1.0-2.0) 1.0 (1.0-
1.0) 
3.0 (2.0-
4.0) 
2.0 (1.0-
3.0) 
5.0 (4.0-
6.0) 
3.0 (2.0-
4.0) 
8.0 (7.0-9.0) 
STS 
3.0 (3.0-4.0) 2.0 (1.0-
3.0) 
4.0 (3.0-
5.0) 
4.0 (3.0-
5.0) 
8.0 (6.0-
9.0) 
6.0 (5.0-
7.0) 
13.0 (12.0-
15.0) 
Germ cell tumours 
2.0 (1.0-2.0) 2.0 (1.0-
2.0) 
25.0 (22.0-
27.0) 
3.0 (2.0-
3.0) 
26.0 (24.0-
29.0) 
4.0 (3.0-
5.0) 
31.0 (28.0-
33.0) 
Other epithelial tumours 
1.0 (0.0-1.0) 1.0 (0.0-
1.0) 
3.0 (2.0-
4.0) 
7.0 (6.0-
8.0) 
4.0 (3.0-
5.0) 
7.0 (6.0-
9.0) 
11.0 (10.0-
13.0) 
Other unspecified 
tumours 
0.0 (0.0-0.0) 0.0 (0.0-
0.0) 
0.0 (0.0-
0.0) 
0.0 (0.0-
0.0) 
0.0 (0.0-
0.0) 
0.0 (0.0-
1.0) 
1.0 (0.0-1.0) 
Total cancers 
38.0 (35.0-
40.0) 
29.0 (27.0-
32.0) 
64.0 (60.0-
67.0) 
39.0 (36.0-
42.0) 
101.0 (97.0-
106.0) 
68.0 (65.0-
72.0) 
170.0 (164.0-
175.0) 
Abbreviations: ASR - age and sex standardise incidence rates; CI - confidence interval; CNS - central nervous system; STS - soft tissue sarcoma 
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Figure 19: Age and sex standardise incidence rate per million people by year of 
diagnosis for cases aged 0-29 years at diagnosis 
 
 
Figure 20: Age and sex standardise incidence rate per million people by year at 
diagnosis for cases aged 0-14 years (a) and 15-29 years (b) 
 
5.3.2 Sensitivity analysis of the distribution of linked and non-linked 
cases 
There were 3,437 cases diagnosed with cancer between 1996 and 2009 aged 0-29 years 
in Yorkshire. Of those, 3,315 (96.2%) cases were successfully linked to at least one 
hospital record. After excluding cases that were only admitted before diagnosis, 3,151 
(95%) cases were eligible for analysis. 
The demographic and clinical characteristics of linked compared with non-linked cases 
is illustrated in Table 18. There were no statistical differences between the distribution of 
linked and non-linked cases in terms of gender, diagnostic group and deprivation. 
However, the distribution of cases by age at diagnosis, period of diagnosis and ethnicity 
were found to be statistically different. In both groups, there were disproportionately more 
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TYA cases than children, and more males than females. The majority of non-linked cases 
were diagnosed early in 1996 to 1999, this could indicate that the documentation of HES 
during that period was not as good as documentation in 2000-2004 and 2009-2010 when 
the payment by result started (more detail in Section 4.6.2). 
Table 18: Differences in patient characteristics between linked and non-linked cases 
with hospital episode statistic data 
Patient 
characteristics 
Non-linked Linked Total Test 
statistic 
(Chi2) 
P-
value N % N % N % 
Age at diagnosis 
0-14 21 17% 1,336 40% 1,357 39% 26.25 <0.001 
15-29 101 83% 1,979 60% 2,080 61%   
Gender 
Male 83 68% 1,968 59% 2,051 60% 3.76 0.055 
Female 39 32% 1,347 41% 1,386 40%   
Period of diagnosis 
1996-1999 67 55% 807 24% 874 25% 70.4 <0.001 
2000-2004 11 9% 1,270 38% 1,281 37%   
2005-2009 44 36% 1,238 37% 1,282 37%   
Diagnostic group ICCC-3 
Leukaemia 14 11% 624 19% 638 19% 18.5 0.07 
Lymphoma 31 25% 647 20% 678 20%   
CNS 22 18% 528 16% 550 16%   
Neuroblastoma <5 1% # 3% 104 3%   
Retinoblastoma <5 3% # 1% 38 1%   
Renal tumours <5 3% # 3% 103 3%   
Hepatic tumours <5 1% # 1% 32 1%   
Bone tumours <5 2% # 5% 155 5%   
STS 7 6% 266 8% 273 8%   
Germ cell tumours 24 20% 600 18% 624 18%   
Other epithelial 
tumours 
11 9% 220 7% 231 7%   
Other unspecified 
tumours 
<5 1% # 0% 11 0%   
Ethnicity¥ 
Non-South Asian 115 94% 3,006 91% 3,121 91% 29.8 <0.001 
South Asian 6 5% 309 9% 315 9%   
Unknown <5 1% 0 0% <5 0%   
Deprivation* 
Least deprived 25 20% 564 17% 589 17% 8.58 0.072 
2 31 25% 609 18% 640 19%   
3 19 16% 632 19% 651 19%   
4 13 11% 608 18% 621 18%   
Most deprived 34 28% 902 27% 936 27%   
Total 122 100% 3,315 100% 3,437 100%   
¥ The classifications of ethnicity were assigned using a combination of cancer register, HES 
data and name recognition software (SANGARA and Onomap) 
 *Townsend score 
# used to prevent disclosure of counts <5 
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5.3.3 Study population 
5.3.3.1 Linked cases: clinical characteristics 
For the following section, the results focus on cases with linked admissions, using only 
the main cancer diagnostic group. The number of cases were summarised by diagnostic 
group and patient characteristics: age at diagnosis, gender, ethnicity, deprivation and 
relapse status (Table 19). 
There were more TYA than children diagnosed with lymphoma, bone tumours, STS and 
germ cell tumours, whilst there were more children diagnosed with neuroblastoma and 
renal tumours. Overall, there were more male cases than females and most of them were 
of non-South Asian ethnic origin. The percentage of cases increased with an increased 
level of deprivation. 14% of cases relapsed at least once, and the number of relapsed 
patients was highest among cases diagnosed with bone tumours. 
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Table 19: Distribution of number of cases by diagnostic group and demographic characteristics 
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N % N % N % N % N % N % N % N % N % 
Age at diagnosis 
0-14 408 66.3 149 23.5 257 55.5 87 90.6 76 82.6 53 35.3 107 42.5 65 11.5 1,202 41.9 
15-29 207 33.7 486 76.5 206 44.5 9 9.4 16 17.4 97 64.7 145 57.5 499 88.5 1,665 58.1 
Gender  
Male 328 53.3 358 56.4 248 53.6 56 58.3 51 55.4 92 61.3 140 55.6 486 86.2 1,759 61.4 
Female 287 46.7 277 43.6 215 46.4 40 41.7 41 44.6 58 38.7 112 44.4 78 13.8 1,108 38.6 
Ethnicity 
Non-South 
Asian 
558 90.7 566 89.1 429 92.7 90 93.8 84 91.3 141 94.0 227 90.1 525 93.1 2,620 91.4 
South Asian 57 9.3 69 10.9 34 7.3 6 6.3 8 8.7 9 6.0 25 9.9 39 6.9 247 8.6 
Deprivation score 
Least 
deprived 
110 17.9 121 19.1 83 17.9 20 20.8 14 15.2 24 16.0 36 14.3 93 16.5 501 17.5 
2 114 18.5 111 17.5 96 20.7 25 26.0 15 16.3 27 18.0 41 16.3 110 19.5 539 18.8 
3 123 20.0 117 18.4 82 17.7 12 12.5 13 14.1 34 22.7 49 19.4 118 20.9 548 19.1 
4 98 15.9 114 18.0 85 18.4 17 17.7 23 25.0 27 18.0 49 19.4 102 18.1 515 18.0 
Most 
deprived 
170 27.6 172 27.1 117 25.3 22 22.9 27 29.3 38 25.3 77 30.6 141 25.0 764 26.6 
Relapsed 
No 515 83.7 555 87.4 396 85.5 75 78.1 82 89.1 112 74.7 206 81.7 531 94.1 2,472 86.2 
Yes 100 16.3 80 12.6 67 14.5 21 21.9 10 10.9 38 25.3 46 18.3 33 5.9 395 13.8 
Total 615 100.0 635 100.0 463 100.0 96 100.0 92 100.0 150 100.0 252 100.0 564 100.0 2,867 100.0 
Abbreviations: CNS = central nervous system; STS= soft tissue sarcoma; *Townsend deprivation index 
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5.3.3.2 Initial treatment  
Using the cancer register, 14% (375) of cases had no recorded details of any treatment 
having been received at or near the time of diagnosis. The HES data were used to cross-
check the type of treatment received using procedure codes, especially among those 
cases for which there was no recorded treatment. Details on identifying initial treatment 
and the data sources can be found in Section 4.11.3 
Recording of treatment was poor in HES compared with the cancer register, especially 
for radiotherapy, where the percentage of completeness was 5%, and major surgery was 
19% (Table 20). While, the percentage of treatment completeness in the cancer register 
was high, ranging from 85% to 97% (Table 20 and Table 21).  
Cases with no record of treatment in the cancer register (n= 375) were validated using 
medical notes (detail in Section 4.11.4.1), and a third (~70%) of those cases were cases 
with no actual recorded treatment. 
Table 20: Number of cases recorded and percentage of completeness by type of initial 
treatment identified by HES 
Type of initial 
treatment 
HES 
Total number of cases from all 
sources* 
N % N % 
Chemotherapy 1,552 75 2,060 100 
Radiotherapy 25 5 513 100 
Surgery 233 19 1,226 100 
Abbreviations: N =number of cases with the recorded treatment; %= percentage of 
completeness; *Identification of treatment using cancer register, HES and internal inspection 
through cases medical notes. 
 
Table 21: Number of cases recorded  and percentage of completeness by type of initial 
treatment identified by cancer register 
Type of initial 
treatment 
Cancer register 
Total number of cases from all 
sources* 
N % N % 
Chemotherapy 1,875 91 2,060 100 
Radiotherapy 499 97 513 100 
Surgery 1,042 85 1,226 100 
Abbreviations: N = number of cases with the recorded treatment; % = percentage of 
completeness; *Identification of treatment using cancer register, HES and internal inspection 
through cases medical notes. 
 
There was no formal field recording the date of treatment completion on the cancer 
register. A matrix was therefore created to identify the approximate date of completion 
of treatment. This method was described in detail in Section 4.11.4.2. The result of this 
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matrix found that, overall, chemotherapy alone, followed by chemotherapy and surgery, 
were the most common treatment modalities, followed by surgery alone (Table 23), with 
only 7% of cases having no recorded treatment. CNS tumours had the highest 
percentage of no recorded treatment. Possible reasons for having no recorded treatment 
could include death before the start of treatment, or minor surgical procedures (i.e. not 
considered to be curative treatment), or they may have truly not been treated. 
Based on the third Improving Outcomes Strategy report [9], it was recommended that 
cases diagnosed with cancer should not wait more than 31 days to receive their initial 
treatment to ensure optimal treatment is received equally [9]. However, the time to first 
initial treatment varied by age group and diagnostic group in the current analysis (Table 
22). Overall, the median time to initial treatment was within a month of diagnosis (median 
22, IQR=2-67), it was shorter among children than TYAs, where the medians were 0 and 
35 days, respectively. 
Table 22: Number of cases and median and inter-quartile range of total number of days 
until initial treatment from date of diagnosis 
Cancer type 
0-14 15-29 0-29 
N Median IQR N Median IQR N Median IQR 
Leukaemia 399 1 0 - 3 197 7 2 - 64 596 2 1- 11 
Lymphoma 
146 10 5 - 23 469 31 17-
118 
615 25 11- 68 
CNS 206 34 0 -103 159 49 0-139 365 38 0-122 
Neuroblastoma 
80 7 1 -126 7 104 33-
180 
87 7 1-131 
Renal tumours 
76 7 1 - 41 16 0 0-
1,133 
92 6 0-41 
Bone tumours 
51 27 12-
166 
92 89.5 89-
207 
143 64 18-
198 
STS 98 21 4-116 131 29 0-151 229 24 0-130 
Germ cell 
tumours 
58 0 0-35 494 35 12-58 552 34 5- 57 
Overall cancers* 1,114 5 1-38 1,565 33 8-93 2,679 22 2- 67 
Abbreviations:  
STS = soft tissue sarcoma  
N = number of cases  
IQR = interquartile range 
* Overall cancers is a total of cases with main cancer type with known treatment 
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Table 23: Distribution of number and percentage of cases by type of initial treatment and diagnostic group using International Classification of 
Childhood Cancer (ICCC-3) 
Diagnostic group 
ICCC-3 
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N %  N % N % N % N % N % N % N % N % 
Chemotherapy alone 528 86 399 63  47 10 26 27 29 32 56 37 55 22 40 7  1,180 41  
Radiotherapy alone <5 0 24 4  27 6  0 0 0 0 <5 1 <5 2 <5 0 62 2  
Surgery alone* <5 0 # 2 133 29  24 25  22 24  19 13  76 30 130 23 417 15 
Chemotherapy and 
radiotherapy 
47 8 78 12 34 7 5 5 <5 2 8 5 36 14 # 1 215 7 
Chemotherapy and 
surgery 
14 2 75 12 45 10 27 28 35 38 52 35 42 17 278 49 568 20 
Radiotherapy and 
surgery 
<5 0 11 2 31 7 <5 1 0 0 <5 1 # 2 89 16 139 5 
Chemotherapy, 
radiotherapy and 
surgery 
<5 0 16 3 48 10 <5 4 <5 4 <5 3 11 4 8 1 97 3 
No recorded treatment 20 3 20 3 98 21 9 9 0 0 # 5 23 9 12 2 189 7 
Total¥ 615 100 635 100 463 100 96 100 92 100 150 100 252 100 564 100 2,867 100 
*Only cancer related major surgeries, detail of surgery code is included in the appendices. 
¥ includes cases with minor surgeries, cases that died before treatment started, no record of treatment. 
# figures removed to avoid disclosure of potentially identifiable data. 
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5.3.3.3 Patients with bone marrow transplant (BMT) 
One of the essential variables for estimating the date of treatment completion was if a 
patient received a BMT, and when it had been received (as described in Section 
4.11.4.2). 
BMT was identified using the cancer register procedure code and the HES inpatient 
records (defined in Section 4.11.4.4). For further assurance, a list of patients having 
BMTs were provided from one of the principle treatment centres responsible for the 
majority of BMTs in Yorkshire, and cross-checked with the list of study cases. The cancer 
register identified only 7% of BMTs (12 out of 168), while HES identified 47% of BMTs 
(79 out of 168 total cases in the provided list). This was evidence of poor documentation 
of BMTs in the study data sources, where a total of 84 (53%) were not identified using 
either of the study sources.  
In total almost 6% (n=168) of cases had BMTs during the course of their treatment. 
Neuroblastoma cases had the highest percentage of BMT, followed by leukaemia cases, 
having 25% and 15%, respectively out of the total number of cancer cases (Table 24). 
Table 24: Distribution of cases with BMT by main cancer diagnostic group 
Diagnostic group 
Number of cases with 
BMT 
Percentage 
Total number of 
cases 
Leukaemia 95 15.4% 615 
Lymphoma 31 4.9% 635 
CNS <5 <1% 463 
Neuroblastoma 24 25.0% 96 
Renal tumours <5 <2% 92 
Bone tumours 8 5.3% 150 
STS  7 2.8% 252 
Germ cells tumours 0 0.0% 564 
Overall cancers 168 5.9% 2,867 
 
5.3.3.4 Relapsed cases 
Another important variable that could affect the estimation of treatment completion was 
patient relapse. Detail on the definition and source is in Section 4.11.4.3. There were 14% 
(n=395) of cases with a recorded relapse (Table 25)of which 23% (n=92) had multiple 
relapses. Bone tumours, neuroblastoma, STS and leukaemia had the highest 
percentage of relapses having 25%, 22%,18% and 16%, respectively (Table 25) 21% 
(n= 86) of relapsed cases had a BMT, and of those 65% (n=56) had a BMT after relapse. 
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Table 25: Distribution of number of cases by number of relapses 
Cancer group ICCC-
3 
Number of relapses Total number 
of cases 
1 ≥2 Total relapses 
N % N % N % N 
Leukaemia 81 81% 19 19% 100 16% 615 
Lymphoma 51 64% 29 36% 80 13% 635 
CNS 56 84% 11 16% 67 14% 463 
Neuroblastoma 16 76% 5 24% 21 22% 96 
Renal tumours # 70% <5 30% # 11% 92 
Bone tumours 24 63% 14 37% 38 25% 150 
STS  38 83% 8 17% 46 18% 252 
Germ cell tumours # 91% <5 9% # 6% 564 
Overall cancers 303 77% 92 23% 395 14% 2,867 
Abbreviation: ICCC-3 = International Classifications of Childhood Cancer; N = number of 
cases; CNS = central nervous system; STS = soft tissue sarcoma.  
# figures removed to avoid disclosure of potentially identifiable data 
 
5.3.3.5 Proportion of specialist care 
The place of care was extracted from cancer register to identify place of care when 
diagnosed, and from HES to identify place of care when admitted. The documentation of 
place of care in the cancer register was not complete as 40% of total cases had unknown 
hospital names when diagnosed. This could be due to patients being diagnosed abroad 
or their place of care not being documented in the cancer register. While in HES, the 
place of care when admitted was complete. Therefore, survivors were allocated to 
specific place of care – specialist or other non-specialist – using HES records. The 
healthcare providers at admission were considered as specialist if they were one of the 
childhood specialist oncology centres, principle treatment centres or tumour specific 
centres; a list of these centres was documented in Section 4.11.6. 
The place of care during admission was classified as to specialist healthcare setting or 
other non-specialist NHS healthcare setting, giving the hospital name and address as 
described in Section 4.11.6. 
The use of hospital care could vary by proportion of specialist care, thus it was important 
to assess the distribution of cases by the proportion of specialist care, before including 
them in the multivariable model. The proportion of specialist care was estimated in two 
different ways, depending on the study outcome: number of admissions or number of 
days. For the number of admissions, the number of specialist admissions during the 
study period was used, and when the number of days was the outcome in the 
multivariable analysis, the number of days spent in specialist admissions was used. 
(These were described earlier in Section 4.11.6.) The variations in hospital activity giving 
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the proportions of specialist care were compared by age group and cancer type for both 
groups using the proportion of specialist admissions and proportion of specialist stays. 
For all cases, the proportion of specialist care varied by cancer type and ranged from 
33% to 78% of total admissions. Cases with neuroblastoma had the highest percentage 
of ‘mostly specialist’ care, followed by bone tumours and leukaemia, where the 
percentages were 78%, 72% and 72%, respectively. ‘Other malignant epithelial tumours’ 
and ‘other and unspecified malignant neoplasms’ had the lowest percentage of ‘mostly 
specialist’ care (Figure 21). 
Children were likely to have higher specialist admissions than TYAs, having 74% and 
40% for children and TYA, respectively (Figure 22). This could indicate the availability of 
specialist hospitals for each age group. The study survivors population lived in Yorkshire 
during diagnosis, therefore the majority were admitted to Leeds General Infirmary, St 
James's University Hospital, or Sheffield Children's Hospital, having 41%, 49% and 7%, 
respectively, of all admissions to specialist units for survivors aged 0-29 years at 
diagnosis. However, the proportion varied by age group. Children aged up to 14 were 
commonly admitted to St James's University Hospital, followed by Leeds General 
Infirmary with 51% and 38%, respectively, while TYAs aged 15-29 were admitted to 
Leeds General Infirmary more regularly than St James's University Hospital with 49% 
and 45%, respectively (Figure 23). Children admitted to Sheffield Children's Hospital 
made up 9% of total admissions to a specialist unit, while this figure was only 1% for 
survivors aged 15-29 years. TYAs were more likely to be admitted to centres outside the 
Yorkshire boundary than children, as 2% of admissions to specialist units were for 
Newcastle Upon Tyne Hospitals including, the Freeman Hospital, Weston Park Hospital 
and the Royal Victoria Infirmary, compared with only 1% among children (Figure 23). 
Similarly, the percentage of admissions among TYAs was higher than children for the 
Royal Victoria Infirmary, and University Hospitals in Bristol. 
Among children, cases with leukaemia and lymphoma had the highest ‘mostly specialist 
admissions’ compared to other cancer types. Among TYAs, bone tumour survivors had 
highest ‘mostly specialist admissions’. The proportion of specialist stays were similar to 
the proportion of specialist admissions by diagnostic group and age group.  
The number of cases with no specialist care during the follow-up period, were mainly 
aged 20-24 and 25-29 years at diagnosis with 27% (n=228) and 46% (n=394) of the total 
number of cases having no specialist admissions, respectively. While this figure was less 
than 15% among cases diagnosed under 15 years of age.  
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Figure 21: Percentage of cases by proportion of specialist admissions for cases aged 
0-29 years and cancer types ICCC-3 
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Figure 22: Percentage of cases by proportion of specialist admissions for (a) children and (b) 
TYAs by cancer types ICCC-3 
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5.4 Summary 
Children, teenagers and young adults are the focus of this thesis, although the cancer 
incidence is rare among this age group, less than 1% for children aged up to 24 and 
around 10% among the 24-39 years of age population [36]. However, cancer has fatal 
effects among this age group, in addition to long-term disabilities and years lost in 
hospital [147]. Cancer incidence among the former area of Yorkshire resembles the 
England national average cancer incidence during 2011 to 2013 [75]. Additionally, the 
pattern of incidence by gender resembled the 2011 distribution of cancer incidence by 
gender in the UK, where cancers were more common among males than females aged 
0-29 at diagnosis. The incidence rate increased by age in England [75], which reflects 
the higher rate of cancer incidence among TYAs than children. 
Among the study population, leukaemia cases were the most common diagnostic group 
among children, followed by CNS tumours. Among TYAs the commonest diagnostic 
group was germ cell tumours among males and lymphomas among females, this pattern 
was similar to the UK incidence pattern [39]. 
The incidence of cancer was more common among males than females, and higher in 
teenagers than children. The rate of cancer incidence peaked in 2002 among children, 
and in 2005 among TYAs. 
Of the figures obtained, 96% were successfully linked records. The rate of linkage 
improved by time of diagnosis, the number of cases with non-linked records was higher 
in 1996-1999 than in 2000-2004 and 2005-2009. There were no significant differences 
Figure 23: Percentage of admissions to specialist unit by hospital names and age group 
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among the distribution of cases, and linked and non-linked cases by main survivor 
characteristics, such as gender, deprivation and type of cancer. 
Overall, chemotherapy alone, followed by chemotherapy and surgery, were the 
commonest treatment modalities, followed by surgery alone. 
Cases diagnosed with neuroblastoma and leukaemia had a higher number of BMTs than 
other diagnostic groups. Cases with bone tumours, neuroblastomas and leukaemia had 
higher percentages of relapses than other diagnostic groups. 
Finally, 54% of survivors received mostly specialist admission care during the follow-up 
period, where the percentage varied by cancer type and age. Bone tumours, leukaemia 
and hepatic tumours saw about 70% of survivors having mostly specialist care, while 
survivors of ‘other epithelial tumours’ and ‘other unspecified neoplasms’ had about 30% 
of their admissions in specialist settings. Children were more likely to receive most of 
their admissions in specialist settings than TYAs, having 74% and 40% of survivors with 
mostly specialist admissions, respectively. 
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 Patterns of Hospital Activity 
6.1 Introduction 
This chapter includes a description of hospital activity (inpatient and outpatient) following 
the date of diagnosis from 1996 to 2009 (Aim 1). Thus, describing the pattern of inpatient 
hospital activity post diagnosis of cancer, including hospital activity in the patients’ ‘on 
treatment’ and ’post treatment’ phases. In addition, the variation in the median number 
of hospital admissions and length of stay by age at diagnosis, gender, ethnicity, 
deprivation, cancer type and by relapse status are provided (Aim 2, Questions 2 & 3). 
Furthermore, a detailed assessment of the pattern of hospital admission / length of stay 
by follow-up period is also presented. 
6.2  Inpatient activity 
This section covered the following aspects: 
I. Assess the distribution of frequency of inpatient hospital admissions during the 
admission period (1997-2011). 
II. Assess the distribution of cases by age group (0-14 and 15-29 years at diagnosis), 
period of admission (on treatment vs. post-treatment). 
III. Assess the distribution of admissions by year and diagnostic group (to check how 
the frequency of admission varied over follow-up time). 
IV. Analyse the median rate of admission per person-years by age at diagnosis, 
gender, ethnicity and deprivation and follow-up period. 
V. Analyse the median rate of number of days spent in hospital per 100 person-days 
by age at diagnosis and follow-up period). 
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6.2.1 Hospital admissions 
6.2.1.1 Distribution of the number of inpatient admissions 
The distribution of the number of admissions during the study period were 
positively skewed, as the majority of cases had fewer than 100 admissions 
(complete admission period) (Figure 24) and fewer than 50 admissions per 
patient during the ‘on treatment‘ or ‘post-treatment’ phase (Figure 25).  
 
 
Figure 25: Distribution of hospital admissions per patient during treatment (a) and post-
treatment completion (b) 
 
  
Figure 24: Distribution of hospital admissions per patient post the date of diagnosis 
(a) 
0 
0 
(b) 
0 
0 
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6.2.1.2 Distribution of number of cases by age group and period of 
admission 
There were 61,971 post diagnosis inpatient admissions during the study period 1997-
2011 for the main diagnostic groups (leukaemia, lymphoma, CNS, neuroblastoma, renal 
tumours, bone tumours, STS and germ cell tumours) (Table 26). The majority of inpatient 
admissions occurred during the treatment period due to treatment purposes or treatment 
complications. Children had a higher number of admissions than TYAs and there was a 
significant difference during the treatment period, the interquartile range was 8-38 
inpatient admissions and 2-17 admissions for children and TYAs, respectively. 
Table 26: Summary table of the number of post diagnosis admissions grouped by 
period of admission (1997-2011) 
Age¥ 
Complete study period On treatment Post-treatment 
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0-14 35,689 25 
1-185  
(8-44) 30,017 22 
1-147  
(8-38) 5,672 4 
1-152  
(2-8) 
15-29 26,282 10 
1-313 
 (3-20) 19,814 8 
1-167  
(2-17) 6,468 3 
1-181  
(1-7) 
0-29 61,971 14 
1-313  
(5-32) 49,831 12 
1-167  
(4-28) 12,140 3 
1-181 
(2-7) 
Abbreviations: IQR= Interquartile rage; ¥ Age at diagnosis; *Total is not equal to the sum of on 
treatment and post-treatment, as it includes the number of admissions for cases with no initial 
treatment. 
The follow-up period from diagnosis until the last admission or censoring ranged from 0-
16 years, with a median follow-up per person of seven years. During the treatment period 
the follow-up period ranged from 1-2 years with a median of one year. During the post-
treatment admission period it ranged between1 and 9 years with a median of five years. 
There was a small difference in the range of follow-up between children and TYAs (Table 
27). During the on treatment phase, children were followed-up for two years whilst TYAs 
were typically followed-up for a year. This could be related to leukaemia patients being 
followed up for three years from diagnosis whilst completing treatment, whereas TYAs 
with leukaemia were usually followed-up for two years during treatment. 
The rate of admissions was 40 times higher during the treatment period compared to the 
period after completion of treatment. Children, on average (median), had a higher 
number of inpatient admissions per person per year during both the on treatment and 
post-treatment phase, compared to TYAs (1.8 and 1.1 admissions per person per year, 
respectively) (Table 28). 
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Table 27: Summary of the number of follow-up years by period of admission 
Age 
Complete study period On treatment Post-treatment 
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0-14 9,195 7 
0-16 
(3-11) 
2,142 1 
0-14 
(1-2) 
7,053 5 
0-16 
(1-9) 
15-29 12,909 6 
0-16 
(3-10) 
2,477 1 
0-15 
(1-1) 
10,431 5 
0-16 
(1-9) 
0-29 22,104 7 
0-16 
(3-10) 
4,620 1 
0-15 
(1-2) 
17,484 5 
0-16 
(1-9) 
Abbreviations: IQR= Interquartile rage; ¥ Age at diagnosis. 
 
Table 28: Summary of admissions per person-years by period of admission and age at 
diagnosis 
Age 
Total follow-up 
Period* On treatment Post- treatment 
M
e
d
ia
n
 
R
a
n
g
e
 
IQ
R
 
M
e
d
ia
n
 
R
a
n
g
e
 
IQ
R
 
M
e
d
ia
n
 
R
a
n
g
e
 
IQ
R
 
0-14 11.5 
0.18-
1,500 
3.51-
27.5 
42.1 
0.7-
234.0 
23.0-
61.0 
1.8 
0.19-
156.8 
0.78-
4.20 
15-29 4.2 
0.2-
1,000 
1.5-
13.6 
23.0 
0.4-
1,000 
9.4-41.8 1.1 0.2-81.1 0.5-2.4 
0-29 6.3 
0.2-
1,500 
2.0-
20.0 
32.0 
0.4-
1,000 
11.0-
50.8 
1.3 
0.2-
156.8 
0.6-3.2 
Abbreviations: IQR= Interquartile rage; * Follow-up period from date of diagnosis until last 
admission or censoring. 
 
6.2.1.3 Distribution of number of admissions by year of admission and 
diagnostic group (ICCC-3) 
The periods of admission were grouped into four time periods to facilitate interpretation 
of the results. There was a slight increase in the percentage of admissions from 2% in 
1997 to 6% in 2010 (Figure 26). These admissions were mainly for leukaemia cases 
having 40% of total admissions (Table 29). The number of inpatient admissions was 
highest during the 2005-2008 admission periods, having 34% of total admissions (Figure 
26). 
The hospital admissions were also analysed further by years (1997 to 2011). The rate of 
admission peaked around 2006, where it reached more than 9% of the total admissions. 
During the diagnosis period, incidence rates among children peaked during 2002 and 
this could explain the first peak in the admission rate (Chapter 5). Additionally, TYAs had 
the highest incidence rate in 2005 and this could explain the second peak in admission 
rate in 2005-2008 (Chapter 5). 
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Figure 26: The pattern of inpatient hospital encounters by admission period (1997-
2011). Symbols: β Start from 1st of March 1997 (HES annual year); * 
provisional data may include missing admissions 
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Table 29: Distributions of number of admissions by year of admission (1997-2011) and diagnostic groups (ICCC-3) 
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N % N % N % N % N % N % N % N % N % 
1997β 462 33 244 17 142 10 108 8 43 3 159 11 153 11 103 7 1,414 100 
1998 1,153 43 489 18 236 9 107 4 68 3 151 6 278 10 172 6 2,654 100 
1999 1,331 42 618 19 286 9 113 4 86 3 237 7 377 12 147 5 3,195 100 
2000 1,639 42 885 22 360 9 195 5 103 3 198 5 275 7 291 7 3,946 100 
2001 1,762 37 1,141 24 592 12 148 3 135 3 394 8 347 7 301 6 4,820 100 
2002 1,804 37 1,147 24 548 11 253 5 142 3 294 6 363 7 297 6 4,848 100 
2003 1,906 41 1,046 22 490 10 262 6 87 2 296 6 346 7 256 5 4,689 100 
2004 2,126 43 1,148 23 593 12 165 3 117 2 281 6 307 6 257 5 4,994 100 
2005 2,187 40 1,345 25 583 11 117 2 156 3 327 6 331 6 385 7 5,431 100 
2006 2,242 39 1,309 23 615 11 186 3 206 4 380 7 424 7 364 6 5,726 100 
2007 2,277 41 1,190 21 540 10 230 4 122 2 418 7 412 7 418 7 5,607 100 
2008 1,766 40 889 20 488 11 168 4 124 3 330 8 352 8 266 6 4,383 100 
2009 1,613 35 1,050 23 560 12 113 2 124 3 387 8 331 7 463 10 4,641 100 
2010 1,546 41 649 17 615 16 146 4 116 3 172 5 323 9 197 5 3,764 100 
2011* 688 37 291 16 322 17 109 6 37 2 80 4 167 9 165 9 1,859 100 
Total 24,502 40 13,441 22 6,970 11 24,20 4 1,666 3 4,104 7 4,786 8 4,082 7 61,971 100 
Symbols: ¥ Calendar annual year (1st of January to 31st December); βStart from 1st of March 1997 (HES annual year); * provisional data may include missing 
admissions.
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The admissions were mainly for cases diagnosed with leukaemia and lymphoma, where 
around 40% and 20% of the total number of admissions occurred respectively, during 
the admission period 1997-2011 (Figure 27). 
Cases diagnosed with leukaemia accounted for 40% of the total admission in 1997-2000, 
and in 2009-2011 it decreased to account for 35% of the total admissions. In contrast, 
CNS, germ cell tumours and other epithelial tumours increased at the end of the 
admission period from 9% to13%, 6% to 7% and 2% to 5%, respectively. 
 
 
Figure 27: Percentage of inpatient hospital encounter by period of admission and 
diagnostic group 
 
6.2.1.4 Distribution of admissions by year of diagnosis and diagnostic 
group (ICCC-3) 
The percentage of admissions by year of diagnosis were assessed to determine whether 
the differences in documentation of admission varied by time of diagnosis (Figure 28). 
Cases diagnosed in 1996 (3%) had the lowest percentage of admissions and that could 
be justified by the quality of documentation during that period. The linkage of HES data 
became available from March 1997, so admissions before 1997 were not available in the 
requested data warehouse. The trend in admissions was not stable during the diagnosis 
period, as it began to increase after 1996, then decrease in 1999 and return to increase 
to reach its peak in 2001 with 9% of total admissions and then decreased in 2003 with 
8%. After that the percentage of admissions increased to reach the highest point of 10% 
in 2005. These changes could represent the level of cancer incidence during each year, 
where 2001 and 2005 had the highest cancer incidence having 304 and 205 per million 
person-years (Section 5.3). 
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Additionally, these changes could be related to changes in treatment intensity, as the 
majority of the study, saw the main cancers such as leukaemia having more intensive 
treatment during the twenty-first century, as explained earlier in Chapter 2.  
 
Figure 28: Percentage of admissions by year of diagnosis 
 
6.2.1.5 Distribution of inpatient admissions by type of admissions 
(elective and emergency), gender and age in years 
The distribution of admissions was assessed by gender and method of admission for 
comparative purposes with other published papers, and to check the capability of the 
current analysis to reflect nationwide hospital activity.  The recurrent admissions in 2009 
among CYP (aged 0-24 years during admission) was analysed in previous studies [201]. 
They found the number of emergency admissions was higher among children aged <1 
when admitted, compared to people aged under 24. 
The percentage of inpatient admissions by age at diagnosis showed that the rate of 
admission decreased with age. Rates of admission by age demonstrated two clear peaks: 
first around the age of one and the second at the age of three to four years for emergency 
admissions, and they were also higher among boys than girls (Figure 29). The rate of 
emergency admissions peaked among cases aged three years. 
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Figure 29: Percentage of admissions by age (years) at diagnosis (a) and age at 
admission (b), admission type and gender (1996-2011) 
 
6.2.1.6  Distribution of inpatient admissions by diagnostic group 
The number of inpatient admissions during 1996-2011 for individuals aged 0-29 at 
diagnosis were highest among patients diagnosed with leukaemia (median=38, IQR=17-
55), followed by patients diagnosed with bone tumours (median=28, IQR=12-38), 
compared with other diagnostic groups (Figure 30). 
Children diagnosed at the age 0-14 with leukaemia had higher numbers of inpatient 
admissions (median=44, IQR=30-58), followed by bone tumours (median=35, IQR=19-
43) compared with other diagnostic groups (Figure 31 a). Individuals aged 15-29 years 
had higher numbers of admissions when diagnosed with bone tumours (median=23, 
IQR=10-32), followed by leukaemia (median=20, IQR=10-42), compared with other 
diagnostic groups (Figure 31 b). 
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Figure 30: Number of inpatient post diagnosis admissions by main diagnostic group for 
cases aged 0-29 years 
 
 
Figure 31: Number of inpatient post diagnosis admissions by main diagnostic group for 
cases aged 0-14 years (a) and 15-29 years (b) at diagnosis 
 
6.2.1.7 Median rate of admission 
6.2.1.7.1 Median inpatient admission rate per person-years and diagnostic 
group 
The median rate of admission per person-year was almost 12 times higher during the on 
treatment phase compared with the post-treatment phase (Figure 32). Overall, the rate 
of admission was higher for individuals diagnosed with leukaemia and neuroblastoma, 
followed by bone tumours during the post diagnosis period, with medians of 6.4, 4.7 and 
5.8 per person-year compared with other diagnostic groups. During the on treatment 
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phase, admission rates were significantly higher for cases with bone tumours (p-
value<0.001), with a median of 16 admissions per person-year. Children had significantly 
higher median rate of admissions than TYA during treatment phase ( median= 16.2 and 
9.10 per person-year respectively, p-value<0.001) and after treatment phase 
(median=0.64 and 0.39 per person-year respectively, p-value<0.001). 
Among children, the median rate of admissions was significantly higher for cases 
diagnosed with bone tumours, in both the on treatment and post-treatment phase, 
compared with other diagnostic groups, resulting in 21 and 1.6 admissions per person-
years during these phases, respectively (p-value <0.001) (Figure 33 a). 
The median rate of admissions per person-year was significantly higher among cases 
diagnosed with leukaemia and bone tumours among TYAs during the on treatment 
phase, with a median of 14 admissions per person-year (Figure 33 b). During the post-
treatment phase, the median rate of admissions was higher for patients surviving from 
both neuroblastoma, leukaemia and bone tumours, compared with other diagnostic 
groups, with around one admission on average per person-year.  
 
 
Figure 32: Median rate of inpatient admissions per person-years by admission period 
and diagnostic group 
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Figure 33: Median rate of inpatient admissions per person-years by admission period 
and diagnostic group for children aged 0 -14 (a) and aged 15-29 (b) years at 
diagnosis 
 
6.2.1.7.2 Median inpatient admission rate per person-years, diagnostic 
group and gender 
The median rate of admissions was higher among males compared with females, except 
for lymphoma and germ cell tumours (Figure 34). 
There was a slight excess in the number of inpatient admissions among females 
compared with males, p-value<0.001, 2 compared with 2.5 median admissions per 
person-year, respectively (Figure 34). Overall, the rate of admissions was higher among 
females than males, which could be related to the follow-up years, males being followed 
up for longer periods than females, having 12,944.32 compared with 9,159.684. Without 
adjusting for person-year, males had higher numbers of admissions compared with 
females. 
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Figure 34: Median rate of admission per person-year by diagnostic group and gender 
6.2.1.7.3 Median inpatient admission rate per person-years, diagnostic 
group and ethnicity 
South Asian individuals had higher median rates of inpatient admissions than non-South 
Asians during the admission period 1997-2011 for the majority of diagnostic groups, 
except for STS (Figure 35). The difference in admission rates was most pronounced 
among renal tumours and STS. South Asians with renal tumours appeared to have more 
than double the rate of inpatient admissions compared with non-South Asians and three-
times higher admission rates when diagnosed with germ cell tumours. In contrast, non-
South Asians diagnosed with STS experienced three-times higher admission rates 
compared to South Asians. 
The common morbidities leading to hospital admissions were compared by ethnicity and 
it was found that South Asians had fewer admissions for neoplasm purposes, compared 
with non-South Asians (67% compared with 76%, respectively, of the total causes of 
admissions) – data not shown.  
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Figure 35: Median rate of admission per person-years by diagnostic group and ethnicity 
 
6.2.1.7.4 Median inpatient admission rate per person-years, diagnostic 
group and deprivation 
The rate of inpatient admissions was slightly higher among cases living in the least 
deprived areas compared to those from the most deprived areas for all cancers 
combined. However, the pattern differed by cancer type, as the most deprived cases with 
CNS tumours, leukaemia, lymphoma and renal tumours had the higher rates of 
admissions than least deprived cases (Figure 36). 
 
Figure 36: Median rate of admission per person-years by diagnostic group and 
deprivation category 
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6.2.1.7.5 Median inpatient admission rate per person-years, diagnostic 
group and relapsed. 
The rate of inpatient admissions was higher among cases with relapses of the disease 
compared with non-relapsed cases for the majority of diagnostic groups (median=9 vs 2 
admissions per person-year) (Figure 37). 
 
 
Figure 37: Median rate of admission per person-years by diagnostic group and relapse 
status 
 
Further analysis was carried out to examine the rate of relapse by time in months since 
diagnosis for the three most common diagnostic groups: leukaemia, lymphoma and CNS 
tumours. Bone tumours were also examined further, as this group had the highest 
number of cases with relapses of the disease. 
The median number of inpatient admissions for leukaemia cases with relapses began to 
increase 12 to 15 months after the date of diagnosis and continued to increase, 
exceeding the rate of inpatient admissions among non-relapsed cases (Figure 38). 
Lymphoma relapsed cases had higher rates of admission than non-relapsed cases from 
the date of diagnosis up to and beyond 4 years follow-up (Figure 39). CNS tumour 
admission rates were higher from the date of diagnosis among relapsed cases compared 
with non-relapsed cases and decreased 16 to 19 months after diagnosis (Figure 40). 
Despite the fact that the number of admissions among CNS cases was similar among 
non-relapsed and relapsed cases, using the number of days spent in hospital, the pattern 
of hospital activity was higher among relapsed compared with non-relapsed cases 
through the follow-up months. 
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For bone tumours, relapsed cases exceeded the number of admissions on average from 
date of diagnosis, compared to non-relapsed cases, then decreased thereafter to be 
equivalent to the non-relapsed cases 12-14 months after diagnosis. Admission rates 
fluctuated and peaked at two points 16-18 months and 28-31 months after diagnosis, 
then more than 48 months post diagnosis (Figure 41). 
 
Figure 38: Distribution of median number of inpatient admissions(a) and number of 
days (b) by months since diagnosis and relapsed for leukaemia survivors 
diagnosed from 1996-2009 
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Figure 39: Distribution of median number of inpatient admissions(a) and number of 
days (b) by months since diagnosis and relapse status for lymphoma 
survivors diagnosed from 1996-2009 
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Figure 40: Distribution of median number of inpatient admissions (a) and number of 
days (b) by months since diagnosis and relapse status for central nervous 
system tumours diagnosed from 1996-2009 
 
 
Figure 41: Distribution of median number of inpatient admissions (a) and number of 
days (b)by months since diagnosis and relapse status for bone tumours 
survivors diagnosed from 1996-2009 
 
The pattern of post diagnosis inpatient admissions in months was assessed before and 
after the time of relapse, in order to check the general pattern of inpatient admissions for 
selected diagnostic groups (leukaemia, lymphoma and bone tumours). The median 
number of inpatient admissions increased sharply around the time of relapse, and 
decreased sharply thereafter (Figure 42).  
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Figure 42: Distribution of median number of inpatient admissions by months since 
diagnosis before and after relapse for relapsed cases diagnosed 1996-2009 
The trajectories of admissions were assessed from the date of relapse to the end of the 
follow-up period among survivors with relapses, compared with non-relapsed survivors 
for selected cancer types. This was done to answer clinical concerns among relapse 
survivors, especially leukaemia survivors who might be in severe need of hospital care 
within a year of relapse. Additionally, in earlier sections, the admissions among relapsed 
survivors were almost double the median number of admissions for non-relapsed 
survivors, especially one year following the date of diagnosis for leukaemia, lymphoma 
and CNS tumour survivors. It was necessary to assess whether the difference in 
admissions among relapsed survivors was consistent during the follow-up period 
preceding the date of relapse, compared with non-relapsed survivors where the date of 
diagnosis was used instead. 
Relapsed leukaemia survivors had a lower median number of admissions 11 months 
following the date of relapse than non-relapsed cases, then the median number of 
admissions became higher among relapsed survivors compared to non-relapsed 
survivors in the 12 to 31 months following the date of relapse/diagnosis. However, these 
differences were modest – one or two admissions within a three-month period between 
both groups (Figure 43). While, in terms of length of stay, relapsed survivors stayed for 
almost double the length of non-relapsed survivors during the first three months after the 
date of relapse/diagnosis. 
Lymphoma survivors had the highest admissions and lengths of stay among relapsed 
survivors, compared with non-relapsed survivors preceding the date of relapse/diagnosis 
from 11 to 48 months (Figure 44). The pattern fluctuated and the gap was wider 24-27 
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months following the date of relapse/diagnosis, with seven compared with one admission, 
on average, for relapsed and non-relapsed survivors. Similarly, 24 to 31 months after 
relapse/diagnosis, relapsed survivors had a five-fold longer stay than non-relapsed 
survivors. 
The difference of number of admissions and length of stay was modest between relapsed 
and non-relapsed CNS tumour and bone tumour survivors following the date of 
relapse/diagnosis (Figure 45 and Figure 46). 
 
 
Figure 43: Distribution of median number of inpatient admissions(a) and number of 
days (b) by months since diagnosis/relapse and relapsed status for 
leukaemia survivors 
 
Figure 44: Distribution of median number of inpatient admissions(a) and number of 
days (b) by months since diagnosis/relapse and relapsed status for 
lymphoma survivors. 
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Figure 45: Distribution of median number of inpatient admissions(a) and number of 
days (b) by months since diagnosis/relapse and relapsed status for CNS 
tumours survivors 
  
 
Figure 46:Distribution of median number of inpatient admissions(a) and number of days 
(b) by months since diagnosis/relapse and relapsed status for bone tumours 
survivors 
 
In this part of the analysis, the trend in admissions among relapsed cases by year of 
admission were checked to monitor the proportion of relapsed cases each year. In Figure 
47, the proportion of admissions steadily decreased by year of diagnosis from 0.31 
admissions in 1997 to 0.16 admissions in 2011, reflecting a decrease in the percentage 
of relapsed cases in each year. 
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Figure 47: The trend in proportion of admissions and percentage of cases with relapses 
by year of admission 
 
6.2.1.8 Death during follow-up period 
The pattern of admission, as discussed in Chapters 2 and 3, could be higher among 
cases that do not survive the first five years after diagnosis. The pattern of hospital 
admissions could be higher toward the end of life due to complexity of the disease and 
its treatment. Out of 2,867 cases, 595 (21%) died during the study period, with the time 
to death ranging between 0 and 14 years following the date of diagnosis, with a median 
of 1.5 years. The trajectory of admissions censored at four years before the date of death 
reflect that the median number of admissions saw a slight increase from seven to nine 
admissions, between three and one year prior to death (Figure 48). 
 
Figure 48: Median number of admissions by time to death in years for all cancer in 
combined 
 
6.2.1.9 Distribution of cases / admissions during follow-up period and 
diagnostic group 
The distribution of cases based on period of admission is illustrated in Table 30, to 
understand the frequency of health services, given the number of cases that contributed 
in each period. The rate of admission by person-years decreased during the admission 
period from diagnosis until the end of follow-up period and began to increase again more 
than eight years following treatment completion (Figure 49, Figure 50). 
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Table 30: Number of cases by period of admission (on treatment and post-treatment) 
and main diagnostic group 
 
Children TYA 
Cancer types 
ICCC-3 
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0
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rs
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3
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5
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3
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tr
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5
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rs
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o
s
t-
tr
e
a
tm
e
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t 
≥
8
 y
e
a
rs
 p
o
s
t-
tr
e
a
tm
e
n
t 
Leukaemia 408 303 60 54 34 200 101 40 22 15 
Lymphoma 142 72 22 25 17 454 203 110 99 68 
CNS 237 152 79 72 43 173 90 49 36 24 
Neuroblastoma 80 42 11 9 # 9 6 <5 <5 0 
Renal tumours 73 46 16 13 10 10 10 # <5 5 
Bone tumours 53 23 9 6 <5 94 42 17 22 9 
STS 100 51 18 19 18 123 48 22 27 20 
Germ cell 
tumours 
49 37 14 19 17 440 151 74 83 60 
Overall cancers 1,142 726 229 217 148 1,503 651 320 293 201 
Abbreviations: CNS = central nervous system; STS = soft tissue sarcoma  
# figures removed to avoid disclosure of potentially identifiable data 
 
 
Figure 49: Median rate of admission per person-years for individuals aged 0-29 at 
diagnosis by follow-up period and diagnostic group 
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Figure 50: Median rate of admission per person-years for individuals aged 0-14 (a) and 
15-29 (b) at diagnosis by follow-up period and diagnostic group 
 
6.2.1.10 Number of admissions by level of specialist care 
The proportion of survivors with specialist admissions varied by cancer type and age 
group; children had a higher proportion of their admissions in specialist units than TYAs 
after being diagnosed with cancer (Section 5.3.3.5). The median rate of admission by 
level of specialist intake was analysed during treatment and after treatment completion 
for the main cancer types. This was done to understand whether differences in the 
admission rates were consistent in the treatment phase and post-treatment phase. The 
significant difference in admissions between cases with mostly specialist care compared 
with cases with limited specialist care during the follow-up period was evident during the 
treatment phase. For all cancers combined, the median rate of admission for cases with 
mostly specialist care was 35 admissions, while for cases with limited specialist care it 
was 15 admissions. The difference was consistent by cancer type, however, survivors of 
lymphomas and germ cell tumours had similar median numbers of admissions for cases 
with mostly specialist and limited specialist care (Table 31). The median number of 
admissions, similarly, was higher among cases receiving the majority of their care in 
specialist units, compared to cases that had limited specialist care with different types of 
treatment. Survivors treated with chemotherapy had, on average, a higher number of 
admissions compared with other treatment types (Table 32). 
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Table 31: Number of admissions, median and interquartile rage by level of specialist care and admission period 
Cancer types 
Total period On treatment Post-treatment 
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Leukaemia                
Limited specialist care 3,310 661 15 8 35 2,548 630 11 6 25 762 465 5 2 15 
Some specialist care 2,190 580 29 13 47 1,818 580 24 10 38 372 4351 4 2 9 
Mostly specialist care 19,002 2,904 43 28 58 16,525 2,897 38 24 51 2,477 1,8881 5 3 8 
Lymphoma                
Limited specialist care 6,713 2,765 15 6 24 5,089 2,653 14 7 21 1,624 2,201 2 1 6 
Some specialist care 599 311 11 6 28 361 307 9.5 5 18 238 270 6 2 12 
Mostly specialist care 6,129 1,815 18 12 27 4,833 1,814 15 10 23.5 1,296 1,463 2 1 8 
CNS                
Limited specialist care 1,164 1,009 4 2 8 679 680 3 1 6 485 515 2.5 1 6 
Some specialist care 742 470 5 3 11 518 333 4 2 9 224 219 3 2 5 
Mostly specialist care 5,064 1,560 13 4 32 3,705 1,324 9 2 26 1,359 913 6 3 12 
Neuroblastoma                
Limited specialist care 177 84 6 1 21 133 81 8 1 21 44 72 3.5 1.5 8.5 
Some specialist care 58 29 5 4 9 43 29 5 1.5 20 15 24 3 3 3 
Mostly specialist care 2,185 411 29 9 40 1,922 375 25.5 5 36 263 272 3 2 5 
Renal tumours                
Limited specialist care 175 172173 4 1 10 60 173 2 1 6 115 152 3.5 1.5 7 
Some specialist care 213 144 13 7 19 149 144 8 4 12 64 126 3 2 8 
Mostly specialist care 1,278 436 15 8 30 1,043 435 15.5 8 27 235 363.6 2 1 5 
Bone tumours                
Limited specialist care 373 219 6 2 18 265 167 3 2 13 108 119 3.5 2 9 
Some specialist care 306 87 20.5 6.5 42 264 87 18 3 35 42 63 3 2 6 
Mostly specialist care 3,425 559 30 21 40 3,064 552 27.5 19 35 361 353 4 1 8 
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Cancer types 
Total period On treatment Post-treatment 
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STS                
Limited specialist care 477 529 5 2 12 333 419 4 1 10 144 382 3 2 5 
Some specialist intake 507 256 6 3 24 405 231 6 2 17 102 184 3 1.5 7.5 
Mostly specialist care 3,802 848 19 5 35 3,111 805 18.5 5.5 32 691 592 4 2 9 
Germ cell tumours                
Limited specialist care 1,160 2,012 2 1 6 712 1,975 1.5 1 5 448 1,807 2 1 3 
Some specialist care 605 570.24 5 2 10 410 543 2.5 2 8 195 480 2 1 4 
Mostly specialist care 2,317 1,775 8 4 11 1,841 1,751 8 3 11 476 1,524 2 1 5 
Overall cancers                
Limited specialist care 13,549 7,452 7 2 16 9,819 6,778 7 1 15 3,730 5,712 3 1 6 
Some specialist care 5,220 2,446 9 3 22.5 3,968 2,253 8 2 20 1,252 1,800 3 2 7 
Mostly specialist care 43,202 10,307 21 8 40 36,044 9,956 18 8 35 7,158 7,367 4 2 8 
Abbreviations: CNS = central nervous system; STS = soft tissue sarcoma; IQR = interquartile range 
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Table 32: Number of admissions, median and interquartile range by level of specialist care, type of initial treatment and period of admissions 
Type of treatment 
Total period On treatment Post-treatment 
Admissions 
Median 
number of 
admission IQR Admissions 
Median 
number of 
admission IQR Admissions 
Median 
number of 
admission IQR 
Chemotherapy              
Limited specialist care 11,803 14 7 24 8,949 12 6 20 2,854 3 1 8 
Some specialist care 4,448 15 7 33 3,513 12 6 26 935 3 2 8 
Mostly specialist care 41,115 26 13 44 34,983 22 11 38 6,132 4 2 8 
Radiotherapy             
Limited specialist care 3,407 5 2 18 2,585 5 1 17 822 2 1 5 
Some specialist care 812 9 3 18 593 7 2 13 219 4 2 6 
Mostly specialist care 5,300 16 6 33 4,435 15 4 31 865 4 2 7 
Surgery              
Limited specialist care 3,481 3 1 8 2,105 2 1 7 1,376 2 1 4 
Some specialist care 1,674 5 3 12 1,164 3 2 8 510 3 1 5 
Mostly specialist care 11,732 11 5 27 9,292 10 3 23 2,440 4 1 7 
Abbreviations: IQR = interquartile range 
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6.2.2 Number of days spent in hospital 
6.2.2.1 Median number of days by age at diagnosis and diagnostic group 
Individuals diagnosed with bone tumours generally spent more time in hospital compared 
with other diagnostic groups (median=7.4 days per 100 person-days). Children spent 
more time in hospital compared with TYAs for the majority of diagnostic groups 
(median=3 vs 1 day per 100 person-days, respectively) except for individuals diagnosed 
with leukaemia (median=4 vs 8 days per 100 person-days for children and TYAs, 
respectively) and germ cell tumours (median=0.38 vs 0.44 days per 100 person-days for 
children and TYAs, respectively) (Figure 51). 
During the treatment phase, individuals diagnosed with bone tumours spent more days 
in hospital compared with other diagnostic groups, around 29 days per 100 person-days 
on average, p-value<0.001. Children spent more time in hospital compared with TYAs 
for the majority of diagnostic groups (median=12 vs 6 days per 100 person-days, 
respectively, p-value<0.001), except for leukaemia (median=12 vs 27 days per 100 
person-days for children and TYAs, respectively) (Figure 52). 
During the post-treatment phase, individuals diagnosed with bone tumours and 
leukaemia spent more time in hospital compared with other diagnostic groups 
(median=0.4 and 0.32 days per 100 person-days, respectively). Children spent more 
time in hospital than TYAs (median=0.28 vs 0.21 days per 100 person-days, 
respectively), except cases diagnosed with lymphoma and bone tumours, however the 
differences between the number of days spent in hospital and age group were very small. 
 
Figure 51: Median rate of number of days spent in hospital per 100 person-days during 
the admission period (1997-2011) by diagnostic group and age group 
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Figure 52: Median rate of number of days spent in hospital per 100 person-days during 
the on treatment phase (a), and post treatment (b) by diagnostic group and 
age group 
 
6.2.2.2 Median number of days by follow-up period 
The number of days patients spent in hospital generally decreased according to follow-
up time for all diagnostic groups, except for bone tumours and renal tumours, as they 
started to increase eight years following the date of treatment completion (Figure 53 for 
all ages and Figure  according to age group). 
 
 
Figure 53: Median number of days patients aged 0-29 years at diagnosis spent in 
hospital per 100 person-days by diagnostic group and follow-up period since 
diagnosis 
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Figure 54:Median number of days patients aged 0-14 (a) and 15-29 (b) years at 
diagnosis spent in hospital per 100 person-days by diagnostic group and 
follow-up period since diagnosis 
6.3 Outpatient admissions 
The aim of the study was to analyse the healthcare burden among the cancer cohort, so 
as to monitor and improve their health outcomes. Cancer cases could receive care from 
both inpatient and outpatient services. Therefore, outpatients were analysed by linking 
outpatient admissions on HES with cancer registers for patients. 
The information of outpatients was available from 2003 to 2011. Out of 2,861 survivors 
diagnosed 2003-2009, 2,831 (99%) survivors had linked outpatient records, when using 
date of birth, gender, NHS ID number and postcode at diagnosis. The percentage of 
outpatient admissions was calculated by dividing the total number of outpatient 
admissions for each specific cancer group by total outpatient admissions. Leukaemia 
cases accounted for 50% of total outpatient admissions among children (0-14), followed 
by CNS with about 16%, while each of the remaining diagnostic groups had lower than 
10% of admissions (Table 33 and Figure 56). For TYAs, lymphoma cases had the 
highest percentage of admissions, followed by germ cell tumours. 
For overall cancers, males had the higher number of outpatient encounters than females. 
Among children, males had a higher percentage of admissions than females, except for 
CNS tumours. Among TYAs, females had a higher percentage of outpatient admissions 
than males, except for leukaemia and germ cell tumours (Table 34).  . 
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Table 33: Distribution of number of outpatient admissions by diagnostic group and age at diagnosis 
Diagnostic 
group ICCC-3 
0-14 15-29 0-29 
Number 
of cases % 
Number 
of 
events % 
Number 
of cases % 
Number 
of events % 
Number of 
cases % 
Number of 
events % 
Leukaemia 371 33 30,181 50 244 12 9,627 19 615 20 40,959 36 
Lymphoma 141 13 4,632 8 494 24 14,475 28 635 20 19,779 17 
CNS 221 20 9,874 16 242 12 5,251 10 463 15 15,465 14 
Neuroblastoma 67 6 2,475 4 29 1 334 1 96 3 2,834 2 
Retinoblastoma # 3 1,265 2 <5 0 0 0 # 1 1,265 1 
Renal tumours 71 6 2,796 5 21 1 407 1 92 3 3,257 3 
Hepatic tumours 13 1 730 1 15 1 174 0 28 1 904 1 
Bone tumours 43 4 1,829 3 107 5 2,498 5 150 5 4,593 4 
STS 86 8 3,717 6 166 8 3,133 6 252 8 7,015 6 
Germ cell 
tumours 
60 5 1,708 3 504 25 10,048 19 564 18 11,851 10 
Other epithelial 
tumours 
21 2 617 1 195 10 5,553 11 216 7 6,271 5 
Other unspecified 
tumours 
<5 0 91 0 # 0 212 0 # 0 303 0 
Overall 1,128 100 59,915 100 2,023 100 51,712 100 3,151 100 114,496 100 
Abbreviations: CNS = central nervous system; STS = soft tissue sarcoma  
# figures removed to avoid disclosure of potentially identifiable data 
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It was not possible to identify diagnosis at admission for the outpatient visit, as 99.5% of 
these admissions were coded as ‘factors influencing health status and contact with 
health services’. Therefore, we had only estimates of the proportions of admissions by 
age group, gender and cancer type to understand the pattern of admission among cancer 
survivors, in terms of outpatient visits with the previously described inpatient admissions. 
Furthermore, it was not possible to identify the treatment received during their visit, 
whether it was to receive treatment or due to suffering from treatment complications. This 
was due to coding issues. 
Table 34: Distribution of number of outpatient admissions by diagnostic group, age at 
diagnosis and gender 
Diagnostic group 
ICCC-3 
0-14 15-29 
Male Female Male Female 
N % N % N % N % 
Leukaemia 17,797 50% 13,535 49% 5,509 20% 4,118 17% 
Lymphoma 3,161 9% 2,143 8% 6,832 24% 7,643 32% 
CNS 5,204 15% 5,010 18% 2,207 8% 3,044 13% 
Neuroblastoma 1,337 4% 1,163 4% 217 1% 117 0% 
Retinoblastoma 746 2% 519 2% <5 0% <5 0% 
Renal tumours 1,716 5% 1,134 4% 240 1% 167 1% 
Hepatic tumours 468 1% 262 1% 75 0% 99 0% 
Bone tumours 1,081 3% 1,014 4% 1,443 5% 1,055 4% 
STS 2,425 7% 1,457 5% 1,512 5% 1,621 7% 
Germ cell 
tumours 987 3% 816 3% 8,637 31% 1,411 6% 
Other epithelial 
tumours 369 1% 349 1% 1,267 5% 4,286 18% 
Other unspecified 
tumours <5 0% 90 0% <5 0% 212 1% 
Overall 35,292 100% 27,492 100% 27,939 100% 23,773 100% 
 
 
Figure 55: Distribution of outpatient admissions by diagnostic group and age at 
diagnosis 
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The median number of outpatient admissions was higher among leukaemia survivors 
compared with other cancer types, during the on treatment period (median=77.5, IQR= 
40-111, Table 35). After treatment completion, the highest median number of outpatient 
admissions among childhood survivors was for leukaemia (median=29, IQR=19-40), and 
among TYA survivors was for lymphoma (median=14, IQR=8-24). The median number 
of admissions during the treatment period was almost triple the rate of outpatient 
admissions after treatment completion among children, and it was double among TYAs 
with leukaemia. 
Children had a higher median number of outpatient admissions than TYAs by almost the 
double during both the treatment phase (median=35 and 16, respectively) and after 
treatment completion (median=24 and 12, respectively).  
The trends in the proportions of admissions by type of admissions (inpatient and 
outpatient) were analysed, from the year 2003 to 2010 (Figure 56), where the outpatient 
data were available for analysis. The trends in proportion of admissions by admission 
type were fairly steady from 2003 to 2010, and the ratio of inpatient to outpatient 
admissions was similar during this period, having a ratio of 1:3 admissions. 
 
 
Figure 56: Trend of proportions of admissions 2003-2011 by type of admissions 
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Table 35:Median number and interquartile range of outpatient admission by period of admissions period by cancer types and age group 
Cancer types ICCC-
3 
On treatment Post-treatment Overall 
0-14 15-29 0-14 15-29 0-14 15-29 
Median IQR Median IQR Median IQR Median IQR Median IQR Median IQR 
Leukaemia 77.5 40-111 22.5 11-66 29 19-40 12 0-32 80 29-124 21 0-60 
Lymphoma 21 14-37 18 10-29 19 13-31 14 8-24 31 19-47 24 
12-
39 
CNS 28 11-49 16 8-30 29 12-47 6 0-20 37.5 18.5-66.5 15.5 0-35 
Neuroblastoma 28 16-47 14 10-31.5 17 10-32 0 0-0 27 18-56 0 0-7 
Renal tumours 25 13-45 16 8-24 17 12-23 2.5 0-22 33 16-56 3 0-25 
Bone tumours 29 20-44 18 12-25 21 12-33 11 0-24 46 23-62 20.5 3-36 
STS 22.5 13-36.5 16 6-31 22.5 11.5-48 5.5 0-16 31.5 15-61 11 0-28 
Germ cell tumours 20 9-23 10 6-15 19 12-31 12 7-19 26.5 16-37 18 
10-
26 
All cancers 35 16-67 16 9-30 24 14-38 12 3-21 39 20-79 19 7-34 
Abbreviations: ICCC-3 = International Classifications of Cancer Type 3rd edition, CNS = central nervous tumours, STS = soft tissue sarcoma, IQR = 
interquartile range 
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6.4 Summary 
The Cancer Forum in Australia identified cancer survivors as any cases diagnosed with 
cancer, and survivorship as starting from the date of diagnosis until a person reaches a 
balance in their life [202]. However, the focus of cancer epidemiological research was on 
long-term survivors who were disease-free for more than five years [17, 71, 72, 87]. This 
highlights the paucity of information on short-term survivors from the date of diagnosis, 
which limits the ability to provide those cases with optimal care, i.e. sufficient services 
designed to meet survivors’ future needs. Consequently, the equity in accessing health 
services from the date of diagnosis has not been studied before, highlighting a significant 
literature gap in health services and quality of life among short-term survivors. Therefore, 
this chapter aimed to fill this gap by describing the patterns of admission from date of 
diagnosis; this was broken down into treatment period and post-treatment period. It was 
found that there were clear disproportions in admissions and length of stay in the two 
follow-up periods – on treatment and post-treatment – by age group at diagnosis, sex, 
ethnicity and deprivation, using the binary analysis adjusting for person-years and 
treatment duration by cancer type.  
Children with bone tumours had higher hospital admissions and lengths of stay 
compared with other diagnostic groups, in both periods: on treatment and post-treatment. 
In addition, among TYA it was higher for cases with leukaemia and neuroblastoma. 
Females had higher rates of admission than males adjusting for person-years. Cases 
diagnosed with leukaemia had a higher number of BMTs than other diagnostic groups. 
Cases with bone tumours, neuroblastoma and leukaemia had higher percentages of 
relapses than other diagnostic groups. Therefore, these cancers are expected to have 
higher rates of admissions due to the cancer or its related treatment. 
On average, children had higher numbers of admissions than TYAs during the study 
period. The number of admissions was four times higher during the treatment period than 
the post-treatment period. After adjusting for person-years, children had three times 
more admissions than TYAs. The difference in admissions between gender was minor, 
however South Asians had higher rates of admission, on average, compared with non-
South Asians, except for those with STSs, and the difference was significant among 
cases diagnosed with bone tumours or STSs. The median rate of admission increased 
with increasing level of deprivation. Relapse cases had four times the rate of admissions 
than non-relapsed cases. The rate of admission and length of stay decreased during the 
follow-up period from date of diagnosis to the end of admission follow-up period. Children 
stayed longer in hospital compared with TYAs for all cancers combined, however TYAs 
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with leukaemia stayed longer than children during the on treatment phase. During the 
post-treatment phase, TYAs with neuroblastoma or renal tumours stayed longer than 
children. Outpatient admissions for children were higher among cases with leukaemia, 
and for TYAs were higher for cases diagnosed with lymphoma for females and germ cell 
tumours for males. 
These results were based on binary analysis, hence the combination of demographics 
and clinical factors were not adjusted for in this chapter. Therefore, in Chapter 7, a 
multivariable analysis is adopted to quantify the hospital burden among the study 
population, taking into account population case mix. In addition, the hospital burden will 
be assessed in terms of type of cancer-related morbidity after completion of cancer 
treatment, in Chapter 8. 
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 Hospital Activity Rate Ratio 
7.1 Introduction 
Hospitalisation rate ratios (HRR) and Hospital days rate ratio (DRR) are presented in this 
chapter, based on multivariable modelling, to identify factors influencing patterns of 
admissions and lengths of stay for all cancers combined and by specific histological type 
(leukaemia, lymphoma, CNS, neuroblastoma, renal tumours, bone tumours, STS and 
germ cell tumours) (Aim 3, Question 4). In addition, this chapter includes a series of 
sensitivity analyses of the differences in hospital admissions between: 1) survivors and 
cases who died during the study period; 2) relapsed and non-relapsed cases; and 3) 
cases receiving a BMT compared to cases who did not receive a BMT. 
One of the explanatory variables was the proportion of specialist care admissions. (More 
detail on how proportions of specialist care were identified can be found earlier in Section 
4.11.6.) The amount of specialist care was estimated differently for each outcome. For 
the number of admissions, it was the total number of specialist admissions divided by 
the total number of admissions. While for the duration of admissions, it was the total 
number of bed days spent in specialist centre divided by total number of bed days spent 
in hospital. 
7.2 Modelling 
7.2.1 Inpatient hospital admissions 
7.2.1.1 Model selection 
A negative binomial regression model was significantly better than a Poisson model in 
describing the data for all diagnostic groups, based upon AIC and BIC (more detail in 
Section 4.12.3). The choice of variable form varied by diagnostic type. For example, 
leukaemia cases having age at diagnosis included in the model as a categorical term (0-
14 vs 15-29) and year of diagnosis, deprivation score and proportion of specialist 
admission as continuous terms, proved a better fit model. Whilst for lymphoma cases the 
best model fit occurred when all explanatory variables were in continuous form.  
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Table 36: Explanatory variables and model fit assessment (AIC and BIC) by diagnostic group (ICCC-3) 
Variables included in the model 
Leukaemia 
N=615 
Lymphoma 
N=635 
CNS 
N=463 
Neuroblastoma N=96 
AIC BIC AIC BIC AIC BIC AIC BIC 
Model selection (gender and age as continuous)     
Poisson 21678.88 21692.14 20648.77 20662.13 11110.38 11122.79 4319.58 4327.28 
Negative binomial 5965.61 5983.29 5593.57 5611.39 3537.29 3553.84 886.57 896.83 
Age variable (including gender)      
Continuous (by year 0-29) 5965.61 5983.29 5593.57 5611.39 3537.29 3553.84 886.57 896.83 
Categorical (0-4,5-9, 10-14,15-19,20-24,25-29) 5969.09 6004.46 5598.15 5633.78 3532.16 3565.26 883.10 903.61 
Categorical (0-14,15-29) 5965.16 5982.85 5598.59 5616.40 3564.78 3581.33 884.89 895.15 
Year of diagnosis (gender, age, deprivation)     
Continuous (1996-2009) 5919.07 5941.18 5557.36 5579.62 3520.00 3540.69 884.35 907.43 
Categorical (1996-1999, 2000-2004,2005-2009) 5929.29 5955.82 5560.47 5587.19 3523.47 3548.30 885.95 911.60 
Deprivation score (gender and age) 
Continuous (least to most deprived) 5920.80 5947.33 5558.68 5585.40 3517.38 3542.21 886.06 911.71 
Categorical (least deprived,2,3,4,most deprived) 5922.83 5962.62 5562.05 5602.13 3518.13 3555.37 889.86 923.20 
Proportion of specialist care (age, gender, deprivation, year of diagnosis)  
Continuous 5921.99 5952.94 5559.75 5590.92 3506.75 3535.71 887.67 915.88 
Categorical (limited specialist care <30%, some 
specialist care 30%-69%, mostly specialist care ≥
70% ) 5922.83 5958.20 5560.37 5596.00 3504.94 3538.04 886.98 917.75 
All variables        
Age, gender, year of admission, deprivation score, 
ethnicity, proportions of specialist care, relapsed and 
treatment type 5842.27 5908.59 5296.847 5368.11 3324.99 3391.20 835.64 884.36 
Abbreviations: AIC = Akaike’s information criterion and BIC = Bayesian information criterion 
The variable between brackets is the variable included in the model 
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Table 37: Explanatory variables and model fit assessment (AIC and BIC) by diagnostic group (ICCC-3). 
 
Renal tumours 
N=92 
Bone tumours N=150 
STS 
N=252 
Germ cell tumours 
N=564 
Overall 
N =3,151 
Variables included in the model AIC BIC AIC BIC AIC BIC AIC BIC AIC BIC 
Model selection (gender and age as continuous)       
Poisson 2819.85 2827.41 4764.64 4773.67 10571.91 10582.5 7945.58 7958.59 106119.1 106137.3 
Negative binomial 796.80 806.89 1376.72 1388.77 2171.30 2185.42 3826.09 3879.43 27103.31 27127.53 
Age variable (including gender)        
Continuous (by year 0-29) 796.80 806.89 1376.72 1388.77 2171.30 2185.42 3862.09 3879.43 27103.31 27127.53 
categorical (0-4,5-9, 10-14,15-19,20-
24,25-29) 803.08 832.26 1373.88 1397.96 2170.34 2198.57 3838.98 3873.66 27083.39 27131.83 
categorical (0-14,15-29) 797.11 807.20 1381.60 1393.65 2176.88 2191.00 3871.99 3889.33 27177.54 27201.76 
Deprivation score (gender and age)        
Continuous (least to most deprived) 797.68 810.29 1377.64 1392.70 2171.56 2189.21 3833.66 3872.67 27105.01 27135.29 
Categorical (least deprived, 2,3,4, 
most deprived) 804.11 824.28 1383.26 1407.34 2174.47 2202.71 3829.85 3881.87 27109.43 27157.88 
Year of diagnosis (gender, age, deprivation)       
Continuous (1996-2009) 782.17 797.30 1379.797 1406.89 2156.34 2177.52 3747.1 3790.45 26971.05 27007.38 
Categorical (1996-1999, 2000-
2004,2005-2009) 781.56 799.22 1372.49 1402.59 2156.82 2181.53 3777.43 3825.11 26998.15 27040.54 
Proportion of specialist care (age, gender, deprivation, year of diagnosis)    
Continues 775.45 793.10 1360.05 1393.17 2150.12 2174.83 3709.05 3756.73 26929.8 26972.19 
categorical (limited specialist care 
<30%, some specialist care 30%-
69%, mostly specialist care ≥70%) 777.64 797.81 1362.29 1398.42 2146.99 2175.22 3701.88 3753.90 26912.45 26960.89 
All variables          
Age, gender, year of admission, 
deprivation score, ethnicity, 
proportions of specialist care, 
relapsed and treatment type 754.72 787.51 1314.88 1378.10 1961.91 2018.38 3486.66 3577.70 25727.1 25830.04 
Abbreviation: AIC = Akaike’s information criterion and BIC = Bayesian information criterion  
The variable between brackets is the variable included in the model 
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7.2.1.2 Estimation from the final model 
The total number of inpatient admissions which occurred on or after the date of diagnosis 
for each patient was the dependent variable (outcome), and the number of person-years 
was considered as the exposure (follow-up person-years). Complete methodological 
details can be found in Section 4.12.3. 
The study predictor variables (gender, age at diagnosis, year of diagnosis, proportion of 
specialist admission, ethnicity, deprivation, relapsed status and treatment type) were 
included based on their clinical importance. The pattern of admission could be affected 
by several variables, as explained in Chapter 3. For example, children may visit the 
hospital often during treatment due to the intensity of treatment, hence admissions due 
to treatment complications. Additionally, males with leukaemia have a longer treatment 
duration than females, consequently are more likely to have hospital visits than females. 
Furthermore, the clinical characteristics, such as type of initial treatment, might directly 
influence the pattern of hospital admissions. Patients receiving surgical interventions 
were likely to visit the hospital before the date of surgery for a routine check-up before 
the operation and may have follow-up visits for health status and post-operative care. 
Therefore, the entire demographic and clinical variables available in the datasets were 
included, even if they were not statistically significant. 
The HRR was estimated, (i) overall for all cancers combined, and (ii) subdivided 
according to diagnostic group: leukaemia, lymphoma, CNS, neuroblastoma, renal 
tumours, bone tumours, STS and germ cell tumours. 
7.2.1.2.1 Leukaemia 
For leukaemia cases, there was no difference in the rate of admission and gender or age 
at diagnosis (Table 38). The rate of admission increased significantly by 10% (P-value 
<0.002) by each year increase in year of diagnosis. HRR of relapsed cases had double 
the rate of non-relapsed cases and was statistically significant. Cases with leukaemia 
treated with radiotherapy alone had a significantly lower HRR than cases treated with 
chemotherapy alone (HRR=0.26, 95%CI:0.10-0.68). While, cases treated with a 
combination of chemotherapy and radiotherapy or combination of chemotherapy and 
surgery had a greater HRR than cases treated with chemotherapy alone, after adjusting 
for person-years of 1.34 and 2.09 times higher admission rates, respectively. 
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Table 38: Inpatient hospital admission rate ratio (HRR) by demographic and clinical 
characteristics for leukaemia (n= 615) 
Characteristics HRRβ 95% CI P-value 
Gender 
  
 
Male 1 (ref)   
Female 1.00 0.87 - 1.14 0.958 
Age at diagnosis    
0-14 1 (ref)   
15-29 1.11 0.93-1.33 0.261 
Year of diagnosis 1.10 1.08-1.12 <0.001 
Deprivation* 1.01 0.99-1.03 0.409 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 1.10 0.85-1.42 0.495 
Proportion of specialist care¥ 1.15 0.94-1.42 0.285 
Relapsed    
No 1 (ref)   
Yes 2.22 1.85-2.67 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.26 0.10-0.68 0.006 
Surgery alone 1.07 0.22-5.32 0.930 
Chemotherapy and radiotherapy 1.34 1.02-1.77 0.038 
Chemotherapy and surgery 2.09 1.32-3.32 0.002 
Radiotherapy and surgery NA NA NA 
Chemotherapy, radiotherapy and surgery 0.45 0.14-1.40 0.166 
No recorded treatment 1.91 1.01-3.60 0.045 
Abbreviations: HRR = hospital admission rate ratio; NA = not applicable i.e. there were no 
individuals; ref = reference category  
β The hospital admission rate ratio was estimated adjusting for person-years at risk 
* Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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7.2.1.2.2 Lymphoma 
Among lymphoma cases, the HRR was not statistically different between gender and 
age (Table 39). However, there was a statistically significant increase in the rate of 
admission by 10% (95%CI: 8-13%) by year of diagnosis. Relapsed cases had four-times 
significantly higher rate of admission than cases with no relapse. The rate of admission 
by initial treatment type was significantly lower among cases treated with radiotherapy 
alone, surgery alone or radiotherapy and surgery than cases treated with chemotherapy 
alone by 88%, 76% and 80%, respectively. 
Table 39: Inpatient hospital admission rate ratio (HRR) by demographic and clinical 
characteristics for lymphoma (n=635) 
Characteristics HRRβ 95% CI P-value 
Gender 
  
 
Male 1 (ref)   
Female 1.03 0.89-1.20 0.659 
Age at diagnosis 1.00 0.99-1.01 0.970 
Year of diagnosis 1.10 1.08-1.13 <0.001 
Deprivation* 1.00 0.97-1.02 0.866 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 1.17 0.89-1.53 0.255 
Proportion of specialist care¥ 1.07 0.87-1.30 0.540 
Relapsed    
No 1 (ref)   
Yes 4.11 3.27-5.18 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.11 0.07-0.17 <0.001 
Surgery alone 0.24 0.14-0.42 <0.001 
Chemotherapy and radiotherapy 0.91 0.72-1.15 0.426 
Chemotherapy and surgery 0.78 0.61-1.00 0.049 
Radiotherapy and surgery 0.20 0.11-0.36 <0.001 
Chemotherapy, radiotherapy and surgery 0.96 0.59-1.56 0.866 
No recorded treatment 0.29 0.17-0.49 <0.001 
Abbreviations: HRR = hospital admission rate ratio; ref = reference category  
β The hospital admission rate ratio was estimated adjusting for person-years at risk  
* Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
 
. 
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7.2.1.2.3 Central nervous system (CNS) tumours 
The rate of hospitalisation decreased significantly by 3% with age among cases with 
CNS tumours (Table 40). There was a 4% significant increase in the rate of admission 
by year of diagnosis. The rate of admission was higher among cases living in the most 
deprived areas compared with cases living in the least deprived areas (24%, 95% CI:6%-
45% cases with deprivation scores on the 75th percentile compared to those on the 25th 
percentile, data not shown), this agreed with the pattern of admission and deprivation in 
the univariable analysis in Section 6.2.1.7.4. Relapsed CNS cases had almost double 
the rate of admission per person-year compared with non-relapsed cases and was 
significant (P-value <0.001). Cases treated with radiotherapy alone, surgery alone, 
radiotherapy and surgery, or with no recorded treatment had significantly lower rates of 
admission than cases treated with chemotherapy alone by 63%, 72%, 67% and 79% 
respectively. 
Table 40: Inpatient hospital admission rate ratio (HRR) by demographic and clinical 
characteristics for central nervous system (CNS) (n=463) 
Characteristics HRRβ 95% CI P-value 
Gender 
 
 
 
Male 1 (ref)   
Female 0.99 0.82-1.19 0.903 
Age at diagnosis 0.97 0.96-0.98 <0.001 
Year of diagnosis 1.04 1.02-1.07 0.001 
Deprivation* 1.04 1.01-1.07 0.006 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 1.00 0.68-1.48 0.985 
Proportion of specialist care¥ 1.25 0.97-1.61 0.080 
Relapsed    
No 1 (ref)   
Yes 1.93 1.49-2.50 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.37 0.22-0.61 <0.001 
Surgery alone 0.28 0.20-0.38 <0.001 
Chemotherapy and radiotherapy 1.15 0.75-1.77 0.528 
Chemotherapy and surgery 1.25 0.85-1.85 0.253 
Radiotherapy and surgery 0.33 0.21-0.52 <0.001 
Chemotherapy, radiotherapy and surgery 0.94 0.64-1.37 0.728 
No recorded treatment 0.21 0.15-0.30 <0.001 
Abbreviations: HRR = hospital admission rate ratio; ref = reference category 
βThe hospital admission rate ratio was estimated adjusting for person-years at risk 
*Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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7.2.1.2.4 Neuroblastoma 
Females with neuroblastoma had fewer hospital admissions than males by 14% 
(95%CI:0.57-1.30), but this was not statistically significant (Table 41). Neuroblastoma 
treated with radiotherapy alone or radiotherapy and surgery showed a significantly lower 
rate of admission than cases with chemotherapy alone by 95% and 97%, respectively. 
Cases with no treatment had a 92% significant lower rate of admission than cases 
treated with chemotherapy only. 
Table 41: Inpatient hospital admission rate ratio (HRR) by demographic and clinical 
characteristics for neuroblastoma (n=96) 
 
  
Characteristics HRRβ 95% CI P-value 
Gender    
Male 11 (ref)   
Female 0.86 0.57-1.30 0.475 
Age at diagnosis    
0-4 1 (ref)   
5-9 1.34 0.76-2.38 0.316 
10-14 0.52 0.15-1.85 0.313 
15-19 0.28 0.06-1.24 0.093 
20-24 4.53 0.53-38.95 0.169 
25-29 2.60 0.95-7.14 0.064 
Year of diagnosis 1.03 0.97-1.09 0.353 
Deprivation 0.99 0.93-1.06 0.745 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.89 0.34-2.35 0.816 
Proportion of specialist care 0.91 0.43-1.91 0.796 
Relapsed    
No 1 (ref)   
Yes 1.35 0.82-2.22 0.235 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone NA NA  
Surgery alone 0.05 0.03-0.09 <0.001 
Chemotherapy and radiotherapy 0.47 0.19-1.14 0.096 
Chemotherapy and surgery 0.75 0.45-1.24 0.256 
Radiotherapy and surgery 0.03 0.00-0.57 0.020 
Chemotherapy, radiotherapy and surgery 0.72 0.26-1.94 0.511 
No recorded treatment 0.08 0.03-0.24 <0.001 
Abbreviations: HRR = hospital admission rate ratio; NA = not applicable i.e. there were no 
individuals in this category; ref = reference category 
βThe hospital admission rate ratio was estimated adjusting for person-years at risk 
*Deprivation criteria was classified using Townsend score  
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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7.2.1.2.5 Renal tumours 
Cases with renal tumours showed a 4%, 95%CI: 1-7% increase in the rate of admission 
for every single year increase in age, and a significant 14%, 95% CI:7-21% (Table 42) 
increase in admission for each increase in year of diagnosis, i.e. cases diagnosed 
recently had higher rates of admission. There was a significant increase in the rate of 
admission among cases with all of their admissions in specialist care, compared with 
cases with no specialist admissions. Cases with proportion of specialist score on the 75th 
percentile (100% of admissions was in specialist centre) had 1.66-times higher rate of 
admissions than cases on the 25th percentile (45% of their admissions was in specialist 
centre) (95%CI:1.16-2.36, data not shown). Relapsed cases with renal tumours had 
three-fold the rate of admission than cases with no relapse and this effect was significant. 
Cases with surgery alone had 68% lower rate of admission compared with cases treated 
with chemotherapy alone and was statistically significant. 
Table 42: Inpatient hospital admission rate ratio (HRR) by demographic and clinical 
characteristics for renal tumour (n=92) 
 
Characteristics HRRβ 95% CI P-value 
Gender    
Male 1 (ref)   
Female 1.02 0.66-1.59 0.934 
Age at diagnosis 1.04 1.01-1.07 0.005 
Year of diagnosis 1.14 1.07-1.21 <0.001 
Deprivation 0.99 0.93-1.06 0.792 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.72 0.31-1.69 0.452 
Proportion of specialist care 2.65 1.34-5.22 0.005 
Relapsed    
No 1 (ref)   
Yes 3.69 1.82-7.48 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone NA NA  
Surgery alone 0.32 0.16-0.65 0.001 
Chemotherapy and radiotherapy 1.63 0.36-7.31 0.524 
Chemotherapy and surgery 0.81 0.49-1.34 0.408 
Radiotherapy and surgery NA NA  
Chemotherapy, radiotherapy and surgery 0.70 0.25-1.97 0.495 
No recorded treatment NA NA  
Abbreviations: HRR = hospital admission rate ratio; NA = not applicable i.e. there were no 
individuals in this category; ref = reference category.  
 βthe hospital admission rate ratio was estimated adjusting for person-years at risk 
*deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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7.2.1.2.6 Bone tumours 
The rate of admission among bone tumour cases decreased for every single year 
increase in age by 3% and was statistically significant (95%CI:1%-5%) (Table 43). The 
rate of admission was significantly higher among cases diagnosed in later study periods; 
HRR was almost double in 2000-2004 than in 1996-1999 and in 2005-2009. Relapsed 
cases had a significantly increased rate of admissions than non-relapsed cases. Cases 
with radiotherapy alone or surgery alone had 85% and 81% lower rates of admission 
than cases treated only with chemotherapy. Cases with no treatment were 92% less 
likely to be admitted than cases treated with chemotherapy only. 
  
173 
 
Table 43:Inpatient hospital admission rate ratio (HRR) by demographic and clinical 
characteristics for bone tumours (n=150) 
  
Characteristics HRRβ 95% CI P-value 
Gender    
Male 1 (ref)   
Female 1.21 0.89-1.64 0.222 
Age at diagnosis 0.97 0.95-0.99 0.015 
Year of diagnosis    
1996-1999 1 (ref)   
2000-2004 1.95 1.20-2.91 0.006 
2005-2009 2.31 1.34-2.94 0.001 
Deprivation    
Most deprived 1 (ref)   
2 0.98 0.43-1.09 0.107 
3 0.99 0.51-1.21 0.271 
4 0.89 0.49-1.31 0.369 
Least deprived 1.29 0.58-1.48 0.755 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.80 0.47-1.87 0.864 
Proportion of specialist care    
Mostly specialist admission 1 (ref)   
Some specialist admission 0.67 0.39-1.20 0.186 
Limited specialist admission 1.00 0.57-1.52 0.788 
Relapsed    
No 1 (ref)   
Yes 1.79 1.23-2.43 0.005 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.16 0.04-0.64 0.010 
Surgery alone 0.18 0.10-0.33 <0.001 
Chemotherapy and radiotherapy 0.86 0.44-1.66 0.643 
Chemotherapy and surgery 0.88 0.63-1.24 0.481 
Radiotherapy and surgery 0.13 0.04-0.46 0.002 
Chemotherapy, radiotherapy and surgery 0.89 0.37-2.13 0.792 
No recorded treatment 0.07 0.03-0.16 <0.001 
Abbreviations: HRR-Hospital admission rate ratio; ref-reference category. βthe hospital admission 
rate ratio was estimated adjusting for person-years at risk .*deprivation criteria was classified 
using Townsend score.  
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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7.2.1.2.7 Soft tissue sarcoma (STS) 
Cases with STS had an 11% increase in the rate of admissions for each single year 
increase in diagnosis year. South Asians diagnosed with STS had significantly lower 
rates of admission than non-South Asians (HRR= 0.58, 95%CI: 0.36-0.95) (Table 44). 
Relapsed cases had double the rate of admission than non-relapsed cases and this was 
statistically significant. Cases treated with radiotherapy alone, surgery alone, a 
combination of radiotherapy and surgery, or had no record of treatment had significant 
lower rates of admissions compared with cases treated with chemotherapy alone by 92%, 
94%, 95% and 84%, respectively. 
Table 44: Inpatient hospital admission rate ratio (HRR) by demographic and clinical 
characteristics for soft tissue sarcoma (STS) (n=252) 
  
Characteristics HRRβ 95% CI P-value 
Gender    
Male 1 (ref)   
Female 1.09 0.83-1.43 0.518 
Age at diagnosis 1.00 0.99-1.02 0.540 
Year of diagnosis 1.11 1.07-1.15 <0.001 
Deprivation 0.97 0.94-1.01 0.159 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.58 0.36-0.95 0.032 
Proportion of specialist care¥ 0.79 0.53-1.18 0.252 
Relapsed    
No 1 (ref)   
Yes 2.09 1.47-2.98 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.08 0.03-0.27 <0.001 
Surgery alone 0.06 0.04-0.09 <0.001 
Chemotherapy and radiotherapy 0.86 0.57-1.29 0.459 
Chemotherapy and surgery 1.08 0.73-1.60 0.684 
Radiotherapy and surgery 0.05 0.02-0.13 <0.001 
Chemotherapy, radiotherapy and surgery 0.59 0.31-1.10 0.097 
No recorded treatment 0.16 0.08-0.30 <0.001 
Abbreviations: HRR = hospital admission rate ratio; ref = reference category  
βthe hospital admission rate ratio was estimated adjusting for person-years at risk 
*deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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7.2.1.2.8 Germ cell tumours 
Females with germ cell tumours had a 27% higher rate of admissions compared with 
males in the univariable analysis, and it was consistent in the multivariable analysis after 
adjusting for other social and clinical variables (Table 45). Children aged 5-9 years at 
diagnosis had a lower rate of admission compared with younger children aged 0-4 at 
diagnosis, with a difference of 46%. Similarly, TYAs aged 20-24 and 25-29 had lower 
rates of admission compared with children aged 0-4 years at diagnosis (HRR= 44% and 
57%, respectively). In addition, the rate of admission increased significantly for each 
increase in single year of diagnosis by 12%. Cases receiving limited specialist care had 
significantly lower rates of admission than cases receiving mostly specialist care, with 
differences of 24%. Relapsed cases has almost double the rate of admissions than cases 
with no relapses, which was a significant effect. Cases treated with radiotherapy alone, 
surgery alone, chemotherapy and surgery, radiotherapy and surgery, a combination of 
all, or had no recorded treatment had significant lower rates of admission than cases 
treated only with chemotherapy by 92%, 88%, 55%, 82% and 89%, respectively. 
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Table 45: Inpatient hospital admission rate ratio (HRR) by demographic and clinical 
characteristics for germ cell tumours (n=564) 
  
Characteristics HRRβ 95% CI P-value 
Gender    
Male 1 (ref)   
Female 1.27 0.99-1.63 0.058 
Age at diagnosis    
0-4 1 (ref)   
5-9 0.36 0.17-0.78 0.009 
10-14 0.66 0.38-1.14 0.136 
15-19 0.68 0.44-1.05 0.082 
20-24 0.56 0.37-0.84 0.006 
25-29 0.43 0.29-0.64 <0.001 
Year of diagnosis 1.12 1.10-1.15 <0.001 
Deprivation 1.03 1.00-1.05 0.059 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 1.04 0.75-1.46 0.799 
Proportion of specialist care    
Mostly specialist admission 1 (ref)   
Some specialist admission 1.11 0.85-1.45 0.444 
Limited specialist admission 0.76 0.61-0.93 0.008 
Relapsed 
 
  
No 1 (ref)   
Yes 1.90 1.34-2.71 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.08 0.02-0.35 0.001 
Surgery alone 0.12 0.09-0.18 <0.001 
Chemotherapy and radiotherapy 1.45 0.58-3.61 0.428 
Chemotherapy and surgery 0.45 0.33-0.63 <0.001 
Radiotherapy and surgery 0.14 0.10-0.21 <0.001 
Chemotherapy, radiotherapy and surgery 0.88 0.42-1.09 0.739 
No recorded treatment 0.11 0.05-0.22 <0.001 
Abbreviations: HRR = hospital admission rate ratio; ref = reference category  
βThe hospital admission rate ratio was estimated adjusting for person-years at risk 
*Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
 
177 
 
7.2.1.2.9 Overall cancers 
For all cancers combined, there were no differences in gender and rate of admission. 
However, the rate of admission decreased with every single year increase in age by 2%. 
There was an 8% increase in the rate of admission for every single year increase in year 
of diagnosis, a significant change. There was a significant increase in the admission by 
8% (95% CI:2%-15%,P-value=0.011) among individuals with deprivation score on the 
75th percentile compared with those on the 25th, data not shown. The rate of admission 
was 29% and 21% lower per person-year among cases receiving some and limited 
specialist care, respectively, compared with cases receiving mostly specialist care, with 
a significant effect (Table 46). Relapsed cases had significantly more than double the 
rate of admissions than non-relapsed case. Cases treated with a combination of 
chemotherapy and radiotherapy had a significant higher rate of admission, by 18% 
compared to cases treated with chemotherapy alone. While all other treatment regimes, 
whether single or complex modalities, had a lower rate of admission than cases treated 
with chemotherapy alone; which was statistically significant. 
  
178 
 
Table 46: Inpatient hospital admission rate ratio (HRR) by demographic and clinical 
characteristics for all cancers combined (n=3,151) 
 
 
7.2.2 Number of days in hospital rate ratio (DRR) 
7.2.2.1 Model selection 
The choice of the variable form for the length of stay analysis was similar to the hospital 
admission rate ratio, and was based on the BIC and AIC criteria (Table 47). The choice 
of the variable form varied by diagnostic group, whilst each diagnostic group was 
modelled separately. Negative binomial regression had a better fit than the Poisson 
regression model.  
 
 
.  
Characteristics HRRβ 95% CI P-value 
Gender    
Male 1 (ref)   
Female 1.05 0.97-1.13 0.230 
Age at diagnosis 0.98 0.98-0.98 <0.001 
Year of diagnosis 1.08 1.07-1.09 <0.001 
Deprivation 1.02 1.00-1.03 0.011 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.91 0.79-1.05 0.200 
Proportion of specialist care    
Mostly specialist admission 1 (ref)   
Some specialist admission 0.71 0.63-0.81 <0.001 
Limited specialist admission 0.79 0.72-0.87 <0.001 
Relapsed    
No 1 (ref)   
Yes 2.63 2.35-2.93 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.19 0.14-0.26 <0.001 
Surgery alone 0.17 0.15-0.19 <0.001 
Chemotherapy and radiotherapy 1.18 1.01-1.37 0.036 
Chemotherapy and surgery 0.69 0.62-0.77 <0.001 
Radiotherapy and surgery 0.14 0.12-0.17 <0.001 
Chemotherapy, radiotherapy and surgery 0.77 0.62-0.95 0.014 
No recorded treatment 0.52 0.46-0.59 <0.001 
Abbreviations: HRR = hospital admission rate ratio; ref = reference category  
 βThe hospital admission rate ratio was estimated adjusting for person-years at risk 
 *Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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Table 47: Explanatory variables and model fit assessment(AIC and BIC) criteria by diagnostic group (ICCC-3) 
Variables included in the model 
Leukaemia 
N=615 
Lymphoma 
N=635 
CNS 
N=463 
Neuroblastoma N=96 
AIC BIC AIC BIC AIC BIC AIC BIC 
Model selection (gender and age as continuous)     
Poisson 91379.9 91393.11 71037.78 71051.14 42146.1 42158.5 15522.3 15529.98 
Negative binomial 7748.44 7766.13 6920.37 6938.18 4791.87 4808.42 1132.88 1143.17 
Age variable (including gender)      
Continuous (by year 0-29) 7748.44 7766.13 6920.37 6938.18 4791.87 4808.42 1132.88 1143.17 
Categorical (0-4,5-9, 10-14,15-19,20-24,25-29) 7733.81 7769.18 6919.33 6954.96 4787.95 4821.05 1129.32 1149.83 
Categorical (0-14,15-29) 7729.19 7746.88 6932.17 6949.98 4794.46 4811.01 1133.62 1143.87 
Year of diagnosis (gender, age, deprivation) 
    
Continuous (1996-2009) 7729.17 7751.28 6920.54 6942.81 4787.45 4808.14 1133.25 1146.07 
Categorical (1996-1999, 2000-2004,2005-2009) 7727.43 7753.96 6918.98 6945.71 4787.94 4812.77 1135.87 1151.26 
Deprivation score (gender and age) 
Continuous (least to most deprived) 7730.64 7757.17 6922.41 6949.13 4764.01 4788.83 1134.06 1149.45 
Categorical (least deprived, 2,3,4, most deprived) 7722.14 7761.93 6920.42 6960.50 4775.40 4812.64 1134.24 1157.32 
Proportion of specialist care (age, gender, deprivation, year of diagnosis)  
Continues 7732.62 7763.57 6892.09 6923.27 4766.01 4794.97 1135.84 1153.79 
Categorical (limited specialist care <30%, some 
specialist care 30%-69%, mostly specialist care 
≥70% ) 
7734.16 7769.53 6901.36 6936.99 4762.64 4795.74 1133.32 1153.83 
All variables        
(age, gender, year of admission, deprivation 
score, ethnicity, proportions of specialist care, 
relapsed and treatment type) 
7649.63 7720.38 6724.60 6795.86 4725.99 4792.19 1125.58 1164.04 
Abbreviations: AIC = Akaike’s information criterion and BIC = Bayesian information criterion  
The variable between brackets is the variable included in the model 
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Table 48: Explanatory variables and model fit assessment (AIC and BIC) criteria by diagnostic group (ICCC-3) 
Variables included in the model 
Renal tumours 
N=92 
Bone tumours N=150 
STS 
N=252 
Germ cells tumours 
N=564 
Overall 
N =3,151 
AIC BIC AIC BIC AIC BIC AIC BIC AIC BIC 
Model selection (gender and age as continuous)       
Poisson 
9832.6 9840.2 
23002.1
5 23011.19 37517.13 37527.72 33505.47 33518.5 420669. 420687.6 
Negative binomial 1004.8 1014.9 1855.30 1867.34 2837.17 2851.28 5170.34 5187.7 35081.5 35105.74 
Age variable (including gender)        
Continuous (by year 0-29) 1004.8 1014.9 1855.30 1867.34 2837.17 2851.28 5170.34 5187.7 35081.5 35105.74 
categorical (0-4,5-9, 10-14,15-
19,20-24,25-29) 1010.5 1030.7 1849.37 1873.46 2841.66 2869.90 5163.13 5197.8 35055.5 35103.97 
categorical (0-14,15-29) 1004.9 1015.0 1859.08 1871.13 2839.04 2853.15 5173.59 5190.9 35116.4 35140.60 
Deprivation score (gender and age)        
Continuous (least to most deprived) 1005.8 1018.4 1856.83 1871.88 2838.60 2856.24 5156.19 5177.9 35053.5 35107.97 
Categorical (Least 
deprived,2,3,4,Most deprived) 1007.1 1027.3 1862.28 1886.37 2843.44 2871.68 5141.7 5176.4 35053.1 35126.37 
Year of diagnosis (gender, age, deprivation)       
Continuous (1996-2009) 1006.1 1021.2 1852.49 1870.56 2837.81 2858.98 5114.50 5153.52 35034.6 35095.2 
Categorical (1996-1999, 2000-
2004,2005-2009) 1006.0 1023.7 1849.29 1870.36 2838.80 2863.51 5134.74 5178.09 35043.5 35110.2 
Proportion of specialist care (age, gender, deprivation, year of diagnosis)    
Continuous 1000.7 1018.3 1843.09 1867.17 2833.10 2857.80 5114.37 5157.72 35013.1 35079.7 
categorical (limited specialist care 
<30%, some specialist care 30%-
69%, mostly specialist care ≥
70% ) 
1002.1 1027.3 1847.23 1874.32 2835.03 2863.26 5110.49 5158.17 35024.5 35097.2 
All variables          
(age, gender, year of admission, 
deprivation score, ethnicity, 
proportions of specialist care, 
relapsed and treatment type) 
1000.7 1033.5 1784.19 1838.38 2722.40 2778.87 4978.01 5060.37 34493.2 34614.3 
Abbreviations: AIC = Akaike’s information criterion and BIC = Bayesian information criterion.The variable between brackets is the variable included in the model 
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7.2.2.2 Estimations from the final model 
7.2.2.2.1 Leukaemia 
Females diagnosed with leukaemia at the age of 0-29 had 19% more hospital days than 
males per person-day at risk, but was not statistically significant (Table 49). TYAs aged 
15-29 at diagnosis had 2.27-fold longer stays per bed-day per person than children aged 
0-14 at diagnosis, a significant effect. Cases with AML stayed longer by 96% compared 
with ALL (data not shown). Patients receiving limited specialist day care, had longer 
stays than cases receiving the majority of their hospital stays in a specialist unit, but this 
was not significant. Relapsed cases had 2.5-fold significantly longer stays in hospital 
than non-relapsed cases. Cases treated with radiotherapy alone had significant 80% 
shorter hospital stays than cases treated with chemotherapy alone, while cases treated 
with chemotherapy and surgery had 2.27-times longer hospital stays than cases treated 
with chemotherapy alone. 
 
Table 49: Inpatient number of days in hospital rate ratio (DRR) by demographic and 
clinical characteristics for leukaemia cases (n=615) 
Characteristics DRRβ 95% CI P-value 
Gender 
  
 
Male 1 (ref)   
Female 1.19 1.01-1.42 0.043 
Age at diagnosis    
0-14 1 (ref)   
15-29 2.27 1.82-2.84 <0.001 
Year of diagnosis 1.05 1.02-1.07 <0.001 
Deprivation* 1.01 0.99-1.04 0.298 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 1.09 0.81-1.49 0.561 
Proportion of specialist care¥ 0.96 0.73-1.27 0.794 
Relapsed    
No 1 (ref)   
Yes 2.50 1.99-3.14 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.20 0.06-0.67 0.008 
Surgery alone 0.58 0.08-4.35 0.595 
Chemotherapy and radiotherapy 1.05 0.75-1.47 0.762 
Chemotherapy and surgery 2.27 1.29-3.99 0.004 
Radiotherapy and surgery NA   
Chemotherapy, radiotherapy and surgery 0.35 0.08-1.45 0.146 
No recorded treatment 4.07 2.28-7.28 <0.001 
Abbreviations: DRR = number of days in hospital rate ratio; ref = reference category  
βThe number of days in hospital rate ratio was estimated adjusting for person-days at risk 
*Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist days per admission per patient
Total number of days per admission per patient
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7.2.2.2.2 Lymphoma 
Among cases with lymphoma aged 0-29 at diagnosis, there was a 4% increase in 
number of days for each single year increase in year of diagnosis (95% CI:1-7%:P-
value=0.011). Cases who received a higher proportion of specialist care had significantly 
longer hospital stays than cases with limited specialist day care (DRR=2.22, 95%CI:1.69-
2.91). Relapsed lymphoma cases had 4.25-times significantly longer stays than non-
relapsed individuals. Cases treated with radiotherapy alone, surgery alone, radiotherapy 
and surgery, or a combination of all had shorter hospital stays than cases treated with 
chemotherapy alone by 94%, 86%, 87% and 55%, respectively. 
Table 50: Inpatient number of days in hospital rate ratio (DRR) by demographic and 
clinical characteristics for lymphoma cases (n=635) 
Characteristics DRRβ 95% CI P-value 
Gender    
Male 1 (ref)   
Female 0.87 0.71-1.07 0.181 
Age at diagnosis 1.00 0.99-1.02 0.883 
Year of diagnosis 1.04 1.01-1.07 0.011 
Deprivation* 0.99 0.96-1.02 0.542 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 1.24 0.86-1.78 0.253 
Proportion of specialist care¥ 2.22 1.69-2.91 <0.001 
Relapsed    
No 1 (ref)   
Yes 4.25 3.09-5.83 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.06 0.03-0.10 <0.001 
Surgery alone 0.14 0.03-0.10 <0.001 
Chemotherapy and radiotherapy 0.91 0.07-0.30 0.548 
Chemotherapy and surgery 1.23 0.67-1.24 0.214 
Radiotherapy and surgery 0.13 0.06-0.27 <0.001 
Chemotherapy, radiotherapy and surgery 0.45 0.23-0.88 0.020 
No recorded treatment 1.35 0.59-3.07 0.477 
Abbreviations: DRR = number of days in hospital rate ratio; ref = reference category  
βThe number of days in hospital rate ratio was estimated adjusting for person-days at risk 
*Deprivation criteria was classified using Townsend score 
¥Amount of specialist care =
Total number of specialist days per admission per patient
Total number of days per admission per patient
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7.2.2.2.3 Central nervous system (CNS) tumours 
Females diagnosed with CNS tumours had significantly shorter stays than males (28%, 
95%CI: 5-45%). The rate of stays increased significantly by year of diagnosis by 8% per 
person-day at risk. The rate of hospital days increased significantly with levels of 
deprivation, i.e cases with deprivation score on the 75th percentile had 1.77-fold longer 
stay than those on the 25th percentile (95%CI:1.43-2.19, P-value=<0.001), data not 
shown. CNS tumours had significantly shorter stays with increased levels of care 
received in specialist centre (DRR=0.69, 95%CI:0.48-0.98). Relapsed cases had 1.9-
times significantly longer stays than non-relapsed cases. Cases treated with surgery 
alone had shorter hospital stays, by 47%, than cases treated with chemotherapy alone 
(Table 51). Additionally, cases showing no record of treatment had 56% shorter hospital 
stays than cases with chemotherapy alone. 
Table 51: Inpatient number of days in hospital rate ratio (DRR) by demographic and 
clinical characteristics for central nervous system cases (n=463) 
Characteristics DRRβ 95% CI P-value 
Gender 
  
 
Male 1 (ref)   
Female 0.72 0.55-0.95 0.018 
Age at diagnosis 1.00 0.98-1.01 0.676 
Year of diagnosis 1.08 1.04-1.12 <0.001 
Deprivation* 1.12 1.07-1.16 <0.001 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 1.16 0.65-2.04 0.618 
Proportion of specialist care¥ 0.69 0.48-0.98 0.040 
Relapsed    
No 1 (ref)   
Yes 1.90 1.29-2.80 0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.66 0.33-1.32 0.245 
Surgery alone 0.53 0.32-0.85 0.009 
Chemotherapy and radiotherapy 1.53 0.82-2.87 0.185 
Chemotherapy and surgery 1.52 0.86-2.69 0.153 
Radiotherapy and surgery 0.83 0.41-1.65 0.589 
Chemotherapy, radiotherapy and surgery 0.93 0.53-1.64 0.813 
No recorded treatment 0.44 0.26-0.73 0.002 
Abbreviations: DRR = number of days in hospital rate ratio; ref = reference category  
βThe number of days in hospital rate ratio was estimated adjusting for person-days at risk 
*Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist days per admission per patient
Total number of days per admission per patient
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7.2.2.2.4 Neuroblastoma 
There were no statistical differences among neuroblastoma cases in terms of hospital 
stays, except for cases treated initially with surgery alone, as they had 92% (95%CI:70-
97%) shorter hospital stays than cases treated with chemotherapy alone 
Table 52: Inpatient number of days in hospital rate ratio (DRR) by demographic and 
clinical characteristics for neuroblastoma cases (n=96) 
Characteristics DRRβ 95% CI P-value 
Gender 
  
 
Male 1 (ref)   
Female 1.40 0.72-2.73 0.316 
Age at diagnosis 0.97 0.93-1.01 0.208 
Year of diagnosis 1.04 0.94-1.15 0.475 
Deprivation* 1.06 0.96-1.17 0.286 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.65 0.14-3.00 0.586 
Proportion of specialist care¥ 1.13 0.38-3.35 0.822 
Relapsed    
No 1 (ref)   
Yes 1.18 0.58-2.43 0.647 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone NA NA  
Surgery alone 0.08 0.03-0.23 <0.001 
Chemotherapy and radiotherapy 0.41 0.11-1.54 0.189 
Chemotherapy and surgery 0.83 0.40-1.73 0.623 
Radiotherapy and surgery 0.13 0.01-2.11 0.150 
Chemotherapy, radiotherapy and surgery 0.53 0.12-2.38 0.407 
No recorded treatment 
1.63 0.45-5.89 0.457 
Abbreviations: DRR = number of days in hospital rate ratio; NA = not applicable i.e. there 
were no individuals in this category; ref = reference category  
βThe number of days in hospital rate ratio was estimated adjusting for person-days at risk 
*Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist days per admission per patient
Total number of days per admission per patient
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7.2.2.2.5 Renal tumours 
Similar to neuroblastoma there were no statistical differences in terms of patient 
characteristics and hospital stay among renal tumour cases, except for the proportion of 
care in specialist units. Cases with proportion of specialist care on the 75th percentile 
(100% of their hospital stay was in specialist unit) had 2.26-times longer stay than cases 
on the 25th percentile (95%CI: 1.42-3.59, 48% of their stay was in specialist unit), data 
not shown. 
Table 53: Inpatient number of days in hospital rate ratio (DRR) by demographic and 
clinical characteristics for renal tumour cases (n=92) 
Characteristics DRRβ 95% CI P-value 
Gender 
  
 
Male 1 (ref)   
Female 1.24 0.64-2.42 0.524 
Age at diagnosis 1.03 0.99-1.08 0.117 
Year of diagnosis 1.05 0.96-1.14 0.269 
Deprivation* 0.97 0.89-1.07 0.604 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.76 0.20-2.84 0.679 
Proportion of specialist care¥ 4.82 1.98-11.78 0.001 
Relapsed    
No 1 (ref)   
Yes 2.28 0.80-6.48 0.123 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone NA NA  
Surgery alone 0.71 0.26-1.95 0.511 
Chemotherapy and radiotherapy 1.66 0.19-14.87 0.649 
Chemotherapy and surgery 1.91 0.94-3.86 0.073 
Radiotherapy and surgery NA NA  
Chemotherapy, radiotherapy and surgery 0.58 0.13-2.62 0.479 
No recorded treatment NA NA  
Abbreviations: DRR = number of days in hospital rate ratio; NA = not applicable i.e. there were 
no individuals in this category; ref = reference category  
βThe number of days in hospital rate ratio was estimated adjusting for person-days at risk 
*Deprivation criteria was classified using Townsend score 
¥Amount of specialist care =
Total number of specialist days per admission per patient
Total number of days per admission per patient
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7.2.2.2.6 Bone tumours 
The rate of hospital stays decreased by single increase in age by 2%, and increased by 
year of diagnosis, but was not significant. While, it was significantly higher among cases 
diagnosed during 2005-2009, as they had two-fold longer stays than cases diagnosed in 
1996-1999. Relapsed cases had 1.68-times longer stays than non-relapsed cases and 
this effect was significant. Cases treated with radiotherapy alone, surgery alone, a 
combination of radiotherapy and surgery, or had no record of treatment had shorter 
hospital stays than cases treated with chemotherapy alone by 96%, 89%, 93% and 97%, 
respectively. 
Table 54: Inpatient number of days in hospital rate ratio (DRR) by demographic and 
clinical characteristics for bone tumour cases (n=150) 
Characteristics DRRβ 95% CI P-value 
Gender 
  
 
Male 1 (ref)   
Female 1.17 0.84-1.65 0.350 
Age at diagnosis 0.98 0.96-1.01 0.208 
Year of diagnosis    
1996-1999 1 (ref)   
2000-2004 1.61 0.99-2.62 0.054 
2005-2009 2.35 1.51-3.66 <0.001 
Deprivation* 1.05 1.00-1.11 0.057 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 1.14 0.54-2.43 0.725 
Proportion of specialist care¥    
Mostly specialist intake 1 (ref)   
Some specialist intake 0.98 0.46-2.08 0.948 
Limited specialist intake 1.15 0.69-1.90 0.596 
Relapsed    
No 1 (ref)   
Yes 1.68 1.15-2.44 0.007 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.04 0.01-0.17 <0.001 
Surgery alone 0.11 0.06-0.19 <0.001 
Chemotherapy and radiotherapy 0.52 0.26-1.05 0.069 
Chemotherapy and surgery 0.81 0.56-1.18 0.275 
Radiotherapy and surgery 0.07 0.02-0.28 <0.001 
Chemotherapy, radiotherapy and surgery 0.74 0.28-1.96 0.545 
No recorded treatment 0.03 0.01-0.07 <0.001 
Abbreviations: DRR= number of days in hospital rate ratio; ref = reference category  
βThe number of days in hospital rate ratio was estimated adjusting for person-days at risk 
*Deprivation criteria was classified using Townsend score  
¥Amount of specialist care =
Total number of specialist days per admission per patient
Total number of days per admission per patient
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7.2.2.2.7 Soft tissue sarcoma (STS) 
The rate of hospital days increased by each single year increase in age at diagnosis by 
3% per person-days (Table 55). South Asians had 61% fewer hospital days than non-
South Asians, which was significant (95%CI:29-78%, P-value=0.002). Cases receive 
with proportion of specialist care on the 75th percentile (100% of their hospital stay was 
in specialist unit) had 1.57 times longer stay than those on the 25th percentile 
95%CI:1.20-2.06 (40% of their stay was in specialist unit, data not shown). Cases treated 
with radiotherapy alone, surgery alone and a combination of radiotherapy and surgery 
had shorter hospital stays than cases treated initially with chemotherapy alone by 92%, 
25% and 95%, respectively. 
Table 55: Inpatient number of days in hospital rate ratio (DRR) by demographic and 
clinical characteristics for soft tissue sarcoma cases (n=252) 
Characteristics DRRβ 95% CI P-value 
Gender 
  
 
Male 1 (ref)   
Female 1.20 0.85-1.68 0.306 
Age at diagnosis 1.03 1.01-1.05 0.010 
Year of diagnosis 1.01 0.97-1.06 0.576 
Deprivation* 0.98 0.94-1.03 0.459 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.39 0.22-0.71 0.002 
Proportion of specialist care¥ 2.13 1.36-3.35 0.001 
Relapsed    
No 1 (ref)   
Yes 1.10 0.70-1.74 0.679 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.08 0.02-0.33 <0.001 
Surgery alone 0.75 0.05-0.12 <0.001 
Chemotherapy and radiotherapy 0.76 0.45-1.29 0.313 
Chemotherapy and surgery 1.05 0.63-1.76 0.840 
Radiotherapy and surgery 0.05 0.01-0.15 <0.001 
Chemotherapy, radiotherapy and surgery 0.73 0.32-1.66 0.457 
No recorded treatment 0.51 0.26-1.01 0.053 
Abbreviations: DRR = number of days in hospital rate ratio; ref = reference category 
βThe number of days in hospital rate ratio was estimated adjusting for person-days at risk 
*Deprivation criteria was classified using Townsend score 
¥Amount of specialist care =
Total number of specialist days per admission per patient
Total number of days per admission per patient
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7.2.2.2.8 Germ cell tumours 
The rate of hospital days decreased significantly by 3% for every single year increase in 
age at diagnosis among germ cell tumour survivors (Table 56). The rate of hospital stays 
increased significantly by 13% for every single year increase in year of diagnosis. The 
rate of hospital stays were shorter as deprivation level decreased, and it was statistically 
significant among cases living in the least deprived group compared to those living in the 
most deprived areas. Patients who lived in the least deprived areas had 50% shorter 
stays than cases who lived in the most deprived areas. Relapsed cases had three-fold 
the rate of stay compared to non-relapsed cases, with a highly significant effect. Cases 
initially treated with radiotherapy alone, surgery alone, a combination of chemotherapy 
and surgery, a combination of radiotherapy and surgery, a combination of all, or no 
record of treatment, had significantly shorter hospital stays than cases with 
chemotherapy alone, having 96%, 87%, 60%, 91% and 93%, respectively. Although not 
significant, survivors treated with a combination of chemotherapy and radiotherapy 
stayed longer than survivors having chemotherapy alone (DRR= 2.14, 95%CI:0.60-7.60). 
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Table 56: Inpatient number of days in hospital rate ratio (DRR) by demographic and 
clinical characteristics for germ cell tumour cases (n=564) 
Characteristics DRRβ 95% CI P-value 
Gender 
  
 
Male 1 (ref)   
Female 0.92 0.65-1.30 0.639 
Age at diagnosis 0.97 0.96-0.99 0.008 
Year of diagnosis 1.13 1.10-1.17 <0.001 
Deprivation*    
Most deprived 1 (ref)   
2 0.72 0.49-1.04 0.083 
3 0.44 0.31-0.63 0.000 
4 0.97 0.66-1.42 0.874 
Least deprived 0.50 0.34-0.75 <0.001 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.77 0.48-1.23 0.271 
Proportion of specialist care¥ 0.65 0.47-0.90 0.009 
Relapsed    
No 1 (ref)   
Yes 3.00 1.76-5.12 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.04 0.00-0.29 0.002 
Surgery alone 0.13 0.08-0.22 <0.001 
Chemotherapy and radiotherapy 2.14 0.60-7.60 0.239 
Chemotherapy and surgery 0.40 0.26-0.64 <0.001 
Radiotherapy and surgery 0.09 0.05-0.16 <0.001 
Chemotherapy, radiotherapy and surgery 0.73 0.24-2.22 0.584 
No recorded treatment 0.07 0.03-0.18 <0.001 
Abbreviations: DRR = number of days in hospital rate ratio; ref = reference category  
βThe number of days in hospital rate ratio was estimated adjusting for person-days at risk 
*Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist days per admission per patient
Total number of days per admission per patient
 
 
7.2.2.2.9 Overall cancers 
For all cancers combined, the DRR was higher among the youngest age group (aged 0-
4 years at diagnosis); it was statistically different for all age groups, except cases aged 
15-19. The rates ranged from 23% to 27% lower than cases aged 0-4. The rate of 
hospital stays increased significantly in relation to year of diagnosis (DRR=1.04: 95% 
CI:1.03-1.06), deprivation levels (DRR=1.02, 95%CI: 1.01-1.04) and amount of specialist 
care (DRR=1.26, 95%CI: 1.11-1.44). Relapsed cases had 2.39-times significantly higher 
DRR than non-relapsed cases. Cases initially treated with radiotherapy alone, surgery 
alone, a combination of chemotherapy and surgery, radiotherapy and surgery, a 
combination of all, or had no record of treatment had significantly shorter hospital stays 
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than cases treated with chemotherapy alone by 78%, 74%, 28%, 85%, 45% and 23%, 
respectively. 
 
Table 57: Inpatient number of days in hospital rate ratio (DRR) by demographic and 
clinical characteristics for all cancers combined  (n=3,151) 
Characteristics DRRβ 95% CI P-value 
Gender 
  
 
Male 1 (ref)   
Female 1.13 1.02-1.25 0.230 
Age at diagnosis    
0-4 1 (ref)   
5-9 0.77 0.64-0.94 0.010 
10-14 0.73 0.60-0.88 0.001 
15-19 1.04 0.87-1.23 0.691 
20-24 0.75 0.64-0.89 0.001 
25-29 0.77 0.65-0.90 0.002 
Year of diagnosis 1.04 1.03-1.06 <0.001 
Deprivation* 1.02 1.01-1.04 <0.001 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.92 0.76-1.10 0.350 
Proportion of specialist care¥ 1.26 1.11-1.44 0.001 
Relapsed    
Yes 1 (ref)   
No 2.39 2.06-2.78 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.22 0.15-0.32 <0.001 
Surgery alone 0.26 0.22-0.30 <0.001 
Chemotherapy and radiotherapy 1.13 0.92-1.38 0.238 
Chemotherapy and surgery 0.72 0.63-0.83 <0.001 
Radiotherapy and surgery 0.15 0.11-0.19 <0.001 
Chemotherapy, radiotherapy and surgery 0.55 0.42-0.74 <0.001 
No recorded treatment 0.77 0.65-0.90 0.001 
Abbreviations: DRR = number of days in hospital rate ratio; ref = reference category 
βThe number of days in hospital rate ratio was estimated adjusting for person-days at risk 
*Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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7.2.3 Relapsed during study period 
The rate of hospital admissions and hospital stays adjusting for person-years and days 
at risk, as well as patient characteristics was assessed to identify the effect of relapse on 
patterns of hospital activity, compared to those individuals who never relapsed. 
Overall, there were no differences in the pattern of admissions or length of stay among 
patient characteristics for relapsed and non-relapsed cases (Table 58). The rate of 
admission decreased with increasing age at diagnosis, and increased for every yearly 
increase in year of diagnosis. DRR was higher among females compared with males. 
Table 58: Inpatient hospital admission rate ratio (HRR) by demographic and clinical 
characteristics for non-relapsed and non-relapsed cases (n=2,734 and 417 
respectively) 
Characteristics 
 
Non-relapsed cases Relapsed cases 
HRRβ 95% CI P-value HRRβ 95% CI P-value 
Gender   
 
  
 
Male 1 (ref)  
 1 (ref)  
 
Female 1.04 0.96-1.13 0.346 1.10 0.91-1.32 0.314 
Age at diagnosis 0.98 0.98-0.99 <0.001 0.97 0.96-0.98 <0.001 
Year of diagnosis 1.08 1.07-1.10 <0.001 1.07 1.04-1.10 <0.001 
Deprivation 1.02 0.80-1.09 0.01 1.01 0.98-1.04 0.555 
Ethnicity      
Non-South Asian 1 (ref)  
 1 (ref)  
 
South Asian 0.93 0.80-1.09 0.362 0.77 0.54-1.10 0.157 
Proportion of specialist care     
Mostly specialist 
admission 
1 (ref)   1 (ref)   
Some specialist 
admission 
0.71 0.62-0.81 <0.001 0.89 0.61-1.29 0.524 
Limited specialist 
admission 
0.78 0.70-0.87 <0.001 1.01 0.79-1.29 0.933 
Initial treatment  
 
  
 
Chemotherapy alone 1 (ref)  
 1 (ref)  
 
Radiotherapy alone 0.18 0.13-0.25 <0.001 0.26 0.10-0.71 0.009 
Surgery alone 0.17 0.15-0.19 <0.001 0.15 0.09-0.23 <0.001 
Chemotherapy and 
radiotherapy 
1.23 1.04-1.46 0.017 0.96 0.70-1.33 0.812 
Chemotherapy and 
surgery 
0.69 0.61-0.77 <0.001 0.73 0.58-0.92 0.008 
Radiotherapy and 
surgery 
0.14 0.11-0.17 <0.001 0.25 0.12-0.56 0.001 
Chemotherapy, 
radiotherapy and 
surgery 
0.62 0.46-0.81 <0.001 1.09 0.75-1.59 0.658 
No recorded 
treatment 
0.53 0.46-0.61 <0.001 0.48 0.35-0.68 <0.001 
Abbreviations: HRR = hospital admission rate ratio; ref = reference category   
βThe hospital admission rate ratio was estimated adjusting for person-years at risk  
*Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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Table 59: Inpatient number of days in hospital rate ratio (DRR) by demographic and 
clinical characteristics for non-relapsed and relapsed cases (n=2,734 and 417 
respectively) 
Characteristics 
Non-relapsed Relapsed 
DRRβ 95% CI P-value DRRβ 95% CI P-value 
Gender 
  
 
   
Male 1 (ref)   1 (ref)   
Female 1.14 1.02-1.28 0.017 1.06 0.86-1.30 0.572 
Age at diagnosis      
0-4 1 (ref)   1 (ref)   
5-9 0.76 0.61-0.95 0.015 0.85 0.59-1.24 0.398 
10-14 0.66 0.53-0.82 <0.001 1.00 0.73-1.37 0.997 
15-19 0.66 0.83-1.23 0.921 1.06 0.78-1.45 0.708 
20-24 1.01 0.62-0.91 0.003 0.74 0.52-1.06 0.097 
25-29 0.75 0.65-0.94 0.008 0.65 0.45-0.93 0.018 
Year of diagnosis 1.05 1.03-1.06 <0.001 1.06 1.03-1.09 <0.001 
Deprivation* 1.03 1.01-1.06 0.002 1.03 1.00-1.06 0.098 
Ethnicity       
Non-South Asian 1 (ref)   1 (ref)   
South Asian 0.95 0.78-1.16 <0.001 0.71 0.48-1.04 0.075 
Amount of specialist 
care¥ 
1.31 1.13-1.51 <0.001 0.95 0.69-1.29 0.727 
Initial treatment      
Chemotherapy alone 1 (ref)   1 (ref)   
Radiotherapy alone 0.21 0.21-0.32 <0.001 0.11 0.10-0.76 0.013 
Surgery alone 0.27 0.22-0.32 <0.001 0.94 0.07-0.17 <0.001 
Chemotherapy and 
radiotherapy 
1.19 0.94-1.50 0.14 0.94 0.66-1.34 0.749 
Chemotherapy and 
surgery 
0.74 0.63-0.87 <0.001 0.64 0.49-0.82 <0.001 
Radiotherapy and 
surgery 
0.13 0.10-0.17 <0.001 0.44 0.19-1.01 0.054 
Chemotherapy, 
radiotherapy and 
surgery 
0.48 0.34-0.68 <0.001 0.67 0.44-1.01 0.053 
No recorded treatment 0.83 0.69-0.99 0.039 0.38 0.26-0.55 <0.001 
Abbreviations: DRR = number of days in hospital rate ratio; ref = reference category  
βThe number of days in hospital rate ratio was estimated adjusting for person-days at risk 
*Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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7.2.4 Not survived during study period 
The rate of admissions was analysed separately among cases who survived for the 
entire duration of the study period compared with cases who died. 
The difference was in the level of specialist care admissions, with those who remained 
alive having a 22% significantly lower rate of admissions when cases had limited 
specialist care admissions compared with cases receiving mostly specialist care 
admissions, while cases who died had 18% more admissions compared with those who 
received a higher proportion of specialist care admissions. 
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Table 60: Inpatient hospital admission rate ratio (HRR) by demographic and clinical 
characteristics for survived and deceased cases (n=2,493 and N=658) 
Characteristics 
Survived Deceased 
HRRβ 95% CI P-value HRRβ 95% CI P-value 
Gender   
 
  
 
Male 1 (ref)   1 (ref)   
Female 1.19 1.12-1.28 <0.001 1.03 0.91-1.16 0.681 
Age at diagnosis 0.97 0.97-0.98 <0.001 0.97 0.96-0.98 <0.001 
Year of diagnosis 1.15 1.14-1.16 <0.001 1.06 1.04-1.07 <0.001 
Deprivation 1.01 1.00-1.02 0.220 1.00 0.98-1.02 0.803 
Ethnicity      
Non-South Asian 1 (ref)   1 (ref)   
South Asian 1.02 0.91-1.15 0.702 0.95 0.76-1.18 0.628 
Proportion of specialist care     
Mostly specialist 
admission 
1 (ref)   1 (ref)   
Some specialist 
admission 
0.82 0.74-0.91 <0.001 0.95 0.76-1.18 0.632 
Limited specialist 
admission 
0.78 0.71-0.84 <0.001 1.18 1.02-1.37 0.023 
Relapsed      
No 1 (ref)   1 (ref)   
Yes 1.66 1.47-1.88 <0.001 1.05 0.93-1.19 0.413 
Initial treatment      
Chemotherapy 
alone 
1 (ref)   1 (ref)   
Radiotherapy alone 0.23 0.18-0.30 <0.001 0.18 0.11-0.28 <0.001 
Surgery alone 0.21 0.19-0.24 <0.001 0.31 0.23-0.42 <0.001 
Chemotherapy and 
radiotherapy 
1.08 0.94-1.25 0.265 0.82 0.68-0.98 0.033 
Chemotherapy and 
surgery 
0.59 0.54-0.64 <0.001 0.95 0.81-1.12 0.576 
Radiotherapy and 
surgery 
0.24 0.20-0.28 <0.001 0.19 0.12-0.30 <0.001 
Chemotherapy, 
radiotherapy and 
surgery 
0.87 0.71-1.06 0.169 0.63 0.49-0.82 <0.001 
No recorded 
treatment 
0.37 0.33-0.41 <0.001 0.76 0.62-0.92 0.004 
Abbreviations: HRR = hospital admission rate ratio; ref = reference category 
 βThe hospital admission rate ratio was estimated adjusting for person-years at risk  
*Deprivation criteria was classified using Townsend score  
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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7.2.5 Distribution of HRR by year of diagnosis prior- and post-
introduction of payment by result 
The rate of admissions adjusting for patient characteristics and years at risk was 
analysed before and after the introduction of the NHS payment by results policy in  
2003/2004 (details of this policy can be found in Section 4.6.2). The rate of admission 
was 53% higher after introducing the payment by result policy, compared with the rate 
of admission among cases diagnosed before introducing that policy, and it was 
statistically significant.  
Table 61: Inpatient hospital admission rate ratio (HRR) by demographic and clinical 
characteristics for overall cancers (n=3,151) 
 
 
 
Characteristics HRRβ 95% CI P-value 
Gender    
Male 1 (ref)   
Female 1.05 0.97-1.14 0.230 
Age at diagnosis 0.98 0.98-0.99 <0.001 
Year of diagnosis    
Before introducing payment by results 1 (ref)   
After introducing payment by results 1.53 1.41-1.66 <0.001 
Deprivation 1.01 1.00-1.03 0.026 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.93 0.80-1.07 0.302 
Proportion of specialist care    
Mostly specialist admission 1 (ref)   
Some specialist admission 0.69 0.61-0.78 <0.001 
Limited specialist admission 0.74 0.67-0.82 <0.001 
Relapsed    
No 1 (ref)   
Yes 2.51 2.24-2.80 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.18 0.13-0.24 <0.001 
Surgery alone 0.16 0.14-0.19 <0.001 
Chemotherapy and radiotherapy 1.20 1.03-1.40 0.022 
Chemotherapy and surgery 0.68 0.61-0.76 <0.001 
Radiotherapy and surgery 0.14 0.11-0.17 <0.001 
Chemotherapy, radiotherapy and surgery 0.77 0.62-0.96 0.020 
No recorded treatment 0.52 0.46-0.59 <0.001 
Abbreviations: HRR = hospital admission rate ratio; ref = reference category 
 βThe hospital admission rate ratio was estimated adjusting for person-years at risk  
*Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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7.2.6 Distribution of hospital admission rate ratio after completion 
of cancer treatment among cases treated with a BMT 
compared with cases not treated with a BMT 
 
During the post-treatment period, females had lower rates of admissions than males 
(HRR= 20%, 95%CI: 6-33%,P-value = 0.008). The number of admissions per person-
year increased with increasing age at diagnosis by year, and with increasing year of 
diagnosis, i.e. TYA survivors had more admissions after treatment completion compared 
with childhood survivors. The increase in admissions by age was consistent for the main 
diagnostic groups and increased ranging from 3% to 17% after treatment completion, 
except for germ cell tumour survivors, where the rate of admission decreased by 5% with 
single year increases in age (data not shown). Cases diagnosed earlier had significantly 
fewer admissions compared with cases diagnosed more recently (Table 62). Cases with 
a BMT had almost double the rate of admissions than cases with no BMT, and was 
seven-times greater among cases with relapses compared with non-relapsed cases, in 
which both were significant differences. The rate of admission and relapse was between 
6- and 47-times by diagnostic group. Cases treated with radiotherapy alone, surgery 
alone, and a combination of radiotherapy and surgery had lower rates of admission 
compared with cases treated with chemotherapy alone. 
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Table 62: Inpatient hospital admission rate ratio (HRR) after completion of cancer 
treatment n=1,723 (cases with admissions after treatment completion) 
 
  
Characteristics HRRβ 95% CI P-value 
Gender    
Male 1 (ref)   
Female 0.79 0.67-0.94 0.008 
Age at diagnosis 1.04 1.03-1.05 <0.001 
Year of diagnosis 1.16 1.13-1.19 <0.001 
Deprivation 1.01 0.99-1.04 <0.001 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.81 0.58-1.13 0.314 
Proportion of specialist care    
Mostly specialist admission 1 (ref)   
Some specialist admission 1.12 0.85-1.48 0.419 
Limited specialist admission 0.84 0.69-1.04 0.110 
BMT    
No 1 (ref)   
Yes 1.93 1.28-2.93 0.002 
Relapsed    
No 1 (ref)   
Yes 7.06 4.95-10.06 <0.001 
Initial treatment    
Chemotherapy alone 1 (ref)   
Radiotherapy alone 0.25 0.15-0.42 <0.001 
Surgery alone 0.29 0.23-0.36 <0.001 
Chemotherapy and radiotherapy 0.57 0.40-0.82 0.003 
Chemotherapy and surgery 0.64 0.50-0.82 0.001 
Radiotherapy and surgery 0.18 0.13-0.26 <0.001 
Chemotherapy, radiotherapy and surgery 1.23 0.75-0.02 0.418 
No recorded treatment 0.39 0.18-0.84 0.016 
Abbreviations: HRR = hospital admission rate ratio; ref = reference category  
 βThe hospital admission rate ratio was estimated adjusting for person-years at risk  
*Deprivation criteria was classified using Townsend score 
¥ Amount of specialist care =
Total number of specialist admission per patient
Total number of admission per patient
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7.2.6.1 Distribution of HRR after completion of cancer treatment among 
cases treated with a BMT: leukaemia cases compared with other 
diagnostic groups 
A subset analysis for cases treated with a BMT compared the pattern of admissions after 
completion of cancer treatment among leukaemia survivors with all other cancer 
survivors who received a BMT (Table 63). It was found that leukaemia cases treated with 
a BMT had higher rates of admission compared with cases with any other cancer type, 
but this was not significant (HRR= 1.05, 95%CI:0.42-2.62). Additionally, relapsed cases 
had three-times higher numbers of admissions per person-year than cases with no 
relapse.  
Table 63: Inpatient hospital admission rate ratio (HRR) for cases treated with a BMT 
after completion of cancer treatment n=68 
 
Characteristics HRRβ 95% CI P-value 
Gender    
Male 1 (ref)   
Female 1.27 0.50-3.27 0.615 
Age at diagnosis 1.05 0.97-1.13 0.199 
Year of diagnosis 1.13 0.91-1.16 0.069 
Deprivation 1.03 0.14-1.39 0.643 
Ethnicity    
Non-South Asian 1 (ref)   
South Asian 0.44 0.19-1.90 0.389 
Proportion of specialist care    
Mostly specialist admission 1 (ref)   
Some specialist admission 0.57 0.15-2.22 0.420 
Limited specialist admission 1.44 0.27-7.77 0.668 
Cancer type    
Other diagnostic group 1 (ref)   
Leukaemia 1.15 0.42-2.85 0.762 
Relapsed 
 
  
No 1 (ref)   
Yes 3.95 1.62-9.66 0.003 
Initial treatment 
  
 
Chemotherapy alone 1 (ref) 
 
 
Radiotherapy alone NA  NA 
Surgery alone NA  NA 
Chemotherapy and radiotherapy 0.17 0.03-0.99 0.049 
Chemotherapy and surgery 2.57 0.82-8.01 0.104 
Radiotherapy and surgery NA  NA 
Chemotherapy, radiotherapy and surgery 2.57 0.03-1.32 0.094 
No recorded treatment NA NA  
Abbreviations: HRR = hospital admission rate ratio; NA = not applicable i.e. there were no  
individuals in this category; ref = reference category 
βThe hospital admission rate ratio was estimated adjusting for person-years at risk  
*Deprivation criteria was classified using Townsend score 
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7.2.7 Sensitivity analysis before and after identifying type of initial 
treatment 
The following section conducts an in-depth sensitivity analysis to identify the differences 
that can be detected, which could affect the outcome if the initial treatment was not 
identified. This took the form of comparing the results from two chapters: Chapter 6 and 
7. 
7.2.7.1 Impact on the descriptive chapter results 
The current thesis is interested in identifying the initial type of treatment for primary 
diagnosis, which was the planned treatment after being diagnosed with cancer. However, 
the study data sources, the cancer register and HES, do not identify the initial treatment 
(the first-line treatment). For example, if cases received chemotherapy, radiotherapy and 
surgery they were assigned as having them all, regardless of the time gap between the 
date of diagnosis and the treatment, or the time difference between complex modalities. 
The sensitivity analysis was done to compare the distributions of cases by type of 
treatment received after diagnosis, using what was recorded in the cancer register and 
HES (all recorded treatments) with the initial treatment only that was identified using a 
predefined proxy; and that was the study main outcome. 
After the sensitivity analysis (identifying the initial treatments), the distribution in the type 
of treatment modality was altered for all diagnostic groups especially lymphoma. The 
major difference was among chemotherapy alone and surgery, where the percentage of 
cases allocated to them increased, while a combination of chemotherapy and 
radiotherapy decreased, as did all modalities in combination (Table 64 and Table 65). 
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Table 64: Distribution of cases by type of treatment (all treatment) and diagnostic group 
Diagnostic 
group ICCC-3 
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N % N % N % N % N % N % N % N % N % 
Chemotherapy 
alone 
505 82 365 57 45 10 26 27 28 30 49 33 52 21 35 6 1,105 39 
Radiotherapy 
alone 
<5 0 21 3 29 6 <5 0 <5 0 <5 1 4 2 <5 0 60 2 
Surgery alone* <5 0 # 2 114 25 18 19 19 21 11 7 62 25 127 23 362 13 
Chemotherapy 
and radiotherapy 
60 10 106 17 40 9 5 5 <5 3 12 8 37 15 <5 1 267 9 
Chemotherapy 
and surgery 
14 2 72 11 43 9 25 26 37 40 53 35 38 15 279 49 561 20 
Radiotherapy 
and surgery 
<5 0 9 1 34 7 <5 1 <5 0 <5 3 6 2 91 16 145 5 
Chemotherapy, 
radiotherapy and 
surgery 
<5 0 21 3 55 12 5 5 <5 4 5 3 14 6 12 2 118 4 
No recorded 
treatment 
30 5 31 5 103 22 16 17 <5 1 14 9 39 15 15 3 249 9 
Total¥ 615 100 635 100 463 100 96 100 92 100 150 100 252 100 564 100 2,867 100 
* Only cancer related major surgeries, detail of surgery code is included in the appendices 
¥ includes cases with minor surgeries, cases died before treatment started, no record of treatment  
 # figures removed to avoid disclosure of potentially identifiable data 
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Table 65: Distribution of cases by type of treatment (initial treatment) and diagnostic group 
Diagnostic group 
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N % N % N % N % N % N % N % N % N % 
Chemotherapy alone 528 86 399 63  47 10 26 27 29 32 56 37 55 22 40 7  1,180 41  
Radiotherapy alone <5 0 24 4  27 6  0 0 0 0 <5 1 <5 2 <5 0 62 2  
Surgery alone* <5 0 # 2 133 29  24 25  22 24  19 13  76 30 130 23 417 15 
Chemotherapy and 
radiotherapy 
47 8 78 12 34 7 5 5 <5 2 8 5 36 14 # 1 215 7 
Chemotherapy and 
surgery 
14 2 75 12 45 10 27 28 35 38 52 35 42 17 278 49 568 20 
Radiotherapy and 
surgery 
<5 0 11 2 31 7 <5 1 0 0 <5 1 # 2 89 16 139 5 
Chemotherapy, 
radiotherapy and 
surgery 
<5 0 16 3 48 10 <5 4 <5 4 <5 3 11 4 8 1 97 3 
No recorded 
treatment 
20 3 20 3 98 21 9 9 0 0 # 5 23 9 12 2 189 7 
Total¥ 615 100 635 100 463 100 96 100 92 100 150 100 252 100 564 100 2,867 100 
* Only cancer related major surgeries, detail of surgery code is included in the appendices 
¥ includes cases with minor surgeries, cases died before treatment started, no record of treatment 
# figures removed to avoid disclosure of potentially identifiable data 
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7.2.7.2 Impact on the modelling process 
A subset analysis was done to model the data using all treatments and another model 
with initial treatment and the pattern of admission showed similar results by patient 
characteristics (data not shown). 
7.3 Summary 
Negative binomial modelling provided a better model fit in describing the variation in 
hospital activity. The factors that influenced the rate of admissions and hospital durations 
varied by cancer subtype. For all cancers combined, there were no statistical differences 
between gender and rate of admission. However, there were significant differences in 
hospital stays and gender among cases diagnosed with leukaemia and CNS tumours. 
Female cases with leukaemia had significantly longer hospital stays than males, while 
females with CNS tumours had significantly shorter stays than males. 
Rates of admissions were significantly higher among younger age groups for the majority 
of diagnostic groups, except for renal tumours. The relationship between age at 
diagnosis and length of stay was significant among those with leukaemia, STS and germ 
cell tumours. For leukaemia and STS, a longer length of stay was associated with 
increased age at diagnosis, while for germ cell tumours a shorter length of stay was 
associated with increased age at diagnosis. The rate of admission increased by year of 
diagnosis among most diagnostic groups. Additionally, there were significant increases 
in the rate of hospital days by year of diagnosis, i.e. cases stayed longer in hospital when 
cases were diagnosed more recently, compared with cases diagnosed earlier on. 
The relationship between deprivation and rate of admission was significant among cases 
diagnosed with CNS tumours, and it was higher in most deprived areas. Similarly, most 
deprived cases had the longest hospital stays compared with the least deprived cases, 
when diagnosed with CNS and germ cell tumours. Differences by ethnic group were only 
significant among cases diagnosed with STS, where South Asians had lower rates of 
admission and shorter hospital stays than non-South Asians. 
The rate of admission was significantly higher among cases who received a higher 
proportion of admissions in specialist units, when diagnosed with renal tumours or germ 
cell tumours. The proportion of specialist care was significantly related to length of stay 
among survivors of lymphoma, CNS, STS, renal tumours and germ cell tumours. 
Lymphoma, renal tumours and STS had longer stays when they received a higher 
proportion of care in specialist units, whilst CNS tumours and germ cell tumours had 
shorter stays when they received a higher proportion of care in specialist units. 
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Relapsed cases had significantly higher rates of admissions and longer hospital stays 
than non-relapsed cases and this difference was statistically significant.  
Cases treated with chemotherapy alone had the highest rate of admissions and longest 
hospital stays, while cases who received radiotherapy had the lowest rate of admission 
and shortest hospital stays for most diagnostic groups. Cases treated with a BMT had 
significantly higher rates of admission after completion of cancer treatment compared to 
those who did not receive a BMT. 
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 Morbidity Related to Hospitalisation 
8.1 Introduction 
This chapter includes a description of the cause-specific hospitalisations among the 
cancer cohort, followed by a summary of the difference in admission patterns before and 
after cancer treatment, according to the cause of hospital admission and cancer type 
(Aim 4).  
In addition, the median time to first admission for all causes combined and by specific 
cause are explored. This was done to provide healthcare providers and patients with an 
overview of the healthcare burden following cancer. 
Finally, excess hospitalisation rates were estimated by comparing hospital admissions 
after completion of cancer treatment among cancer cohorts with hospital admissions 
among age, sex and year of admission in the matched background population 
(Questions 4 and 5). 
8.2 Overview of type of morbidity for the complete follow-up 
period 
8.2.1 Distribution of inpatient admissions by primary cause of 
admission (ICD-10) and diagnostic group (ICCC-3) 
During the post-diagnosis period for all diagnostic groups, the majority of inpatient 
admissions were attributable to neoplasms, followed by admissions classified as factors 
influencing health status and contact with health services. Individuals aged 0-29 
diagnosed with leukaemia had a higher number of inpatient admissions compared with 
other diagnostic groups, followed by lymphoma having 37% and 20% respectively from 
date of diagnosis onward (Table 66 and Table 67).
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Table 66: The distribution of inpatient admissions (spells) by main cause of inpatient admissions (ICD-10) and diagnostic group (ICCC-3) 
 
Admission type ICD-10 
Leukaemia Lymphoma CNS Neuroblastoma Retinoblastomas Renal tumours 
N % N % N % N % N % N % 
Certain infectious and 
parasitic diseases 
538 2 110 1 65 1 46 2 7 1 44 3 
Neoplasms 19,010 78 10,759 80 4,372 63 1,860 77 633 75 1,079 65 
Diseases of the blood and 
blood-forming organs and 
certain disorders involving 
the immune mechanism 
907 4 362 3 171 2 90 4 19 2 48 3 
Endocrine, nutritional and 
metabolic diseases 
79 0 39 0 74 1 8 0 1 0 23 1 
Mental and behavioural 
disorders 
7 0 15 0 6 0 1 0 0 0 0 0 
Diseases of the nervous 
system 
33 0 19 0 213 3 27 1 0 0 1 0 
Diseases of the eye and 
adnexa 
50 0 12 0 89 1 1 0 9 1 1 0 
Diseases of the ear and 
mastoid process 
92 0 8 0 23 0 6 0 5 1 8 0 
Diseases of the circulatory 
system 
55 0 44 0 12 0 7 0 0 0 20 1 
Diseases of the respiratory 
system 
482 2 197 1 134 2 34 1 9 1 59 4 
Diseases of the digestive 
system 
332 1 241 2 143 2 56 2 2 0 44 3 
Diseases of the skin and 
subcutaneous tissue 
87 0 64 0 31 0 6 0 3 0 11 1 
Diseases of the 
musculoskeletal system and 
connective tissue 
148 1 101 1 57 1 10 0 1 0 6 0 
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Admission type ICD-10 
Leukaemia Lymphoma CNS Neuroblastoma Retinoblastomas Renal tumours 
N % N % N % N % N % N % 
Diseases of the genitourinary 
system 
68 0 76 1 32 0 6 0 1 0 39 2 
Pregnancy, childbirth and the 
puerperium 
67 0 282 2 123 2 1 0 0 0 10 1 
Certain conditions originating 
in the perinatal period 
1 0 0 0 1 0 0 0 0 0 0 0 
Congenital malformations, 
deformations and 
chromosomal abnormalities 
18 0 15 0 83 1 6 0 1 0 23 1 
Symptoms, signs and 
abnormal clinical and 
laboratory findings, not 
elsewhere classified 
722 3 528 4 559 8 115 5 38 5 132 8 
Injury, poisoning and certain 
other consequences of 
external causes 
661 3 195 1 168 2 58 2 21 3 50 3 
External causes of morbidity 
and mortality 
0 0 0 0 0 0 0 0 0 0 0 0 
Factors influencing health 
status and contact with 
health services 
1,145 5 374 3 614 9 82 3 90 11 68 4 
Codes for special purposes 0 0 0 0 0 0 0 0 0 0 0 0 
All admissions 24,502 100 13,441 100 6,970 100 2,420 100 840 100 1,666 100 
Abbreviations: N = number of admissions; CNS = central nervous system 
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Table 67: The distribution of inpatient admissions (1997-2011) by main cause of admissions (ICD-10) and diagnostic group (ICCC-3) (continued) 
Admission type (ICD-10) 
Hepatic 
tumours Bone tumours STS 
Germ cell 
tumours 
Other 
epithelial 
neoplasms 
Other 
unspecified 
neoplasm Overall cases 
N % N % N % N % N % N % N % 
Certain infectious and parasitic 
diseases 
12 2 32 1 64 1 51 1 9 0 2 2 980 1 
Neoplasms 379 72 3,254 79 3,592 75 2,770 68 1,355 55 69 62 49,132 75 
Diseases of the blood and 
blood-forming organs and 
certain disorders involving the 
immune mechanism 
5 1 135 3 172 4 78 2 23 1 4 4 2,014 3 
Endocrine, nutritional and 
metabolic diseases 
2 0 13 0 33 1 41 1 44 2 1 1 358 1 
Mental and behavioural 
disorders 
0 0 1 0 4 0 12 0 1 0 0 0 47 0 
Diseases of the nervous 
system 
0 0 6 0 18 0 25 1 13 1 0 0 355 1 
Diseases of the eye and 
adnexa 
1 0 3 0 16 0 14 0 7 0 0 0 203 0 
Diseases of the ear and 
mastoid process 
3 1 3 0 20 0 7 0 7 0 0 0 182 0 
Diseases of the circulatory 
system 
5 1 19 0 24 1 37 1 20 1 2 2 245 0 
Diseases of the respiratory 
system 
23 4 28 1 69 1 54 1 28 1 3 3 1,120 2 
Diseases of the digestive 
system 
8 2 51 1 82 2 131 3 169 7 3 3 1,262 2 
Diseases of the skin and 
subcutaneous tissue 
0 0 30 1 35 1 38 1 28 1 1 1 334 1 
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Admission type (ICD-10) 
Hepatic 
tumours Bone tumours STS 
Germ cell 
tumours 
Other 
epithelial 
neoplasms 
Other 
unspecified 
neoplasm Overall cases 
N % N % N % N % N % N % N % 
Diseases of the 
musculoskeletal system and 
connective tissue 
3 1 59 1 48 1 48 1 51 2 0 0 532 1 
Diseases of the genitourinary 
system 
1 0 39 1 44 1 98 2 55 2 0 0 459 1 
Pregnancy, childbirth and the 
puerperium 
5 1 31 1 60 1 59 1 171 7 1 1 810 1 
Certain conditions originating in 
the perinatal period 
0 0 0 0 1 0 2 0 0 0 0 0 5 0 
Congenital malformations, 
deformations and chromosomal 
abnormalities 
0 0 2 0 24 1 21 1 7 0 0 0 200 0 
Symptoms, signs and abnormal 
clinical and laboratory findings, 
not elsewhere classified 
21 4 89 2 178 4 274 7 213 9 8 7 2,877 4 
Injury, poisoning and certain 
other consequences of external 
causes 
17 3 135 3 126 3 153 4 54 2 3 3 1,641 2 
External causes of morbidity 
and mortality 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Factors influencing health 
status and contact with health 
services 
39 7 174 4 176 4 169 4 223 9 15 13 3,169 5 
Codes for special purposes 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
All causes 524 100 4,104 100 4,786 100 4,082 100 2,478 100 112 100 65,925 100 
Abbreviations: N = number of admissions; STS = soft tissue sarcoma 
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8.2.1.1 Distribution of inpatient admissions by primary cause of 
admission (ICD-10) and period of admission 
Admissions for neoplasms were common among the cancer cohort in both on treatment 
and post-treatment periods (Table 68). Admission for ‘certain infectious diseases’, 
‘neoplasms’, ‘diseases of the blood’, ‘diseases of the respiratory’, ‘certain conditions 
originating in the perinatal period system’ and ‘symptoms, signs and abnormal clinical 
and laboratory findings’ were more common during the on treatment phase (Figure 57, 
Figure 58 and Figure 59). The remaining causes included ‘endocrine diseases’ (including 
metabolic disorders 40%, disorders of other endocrine glands 35%, diabetes mellitus 8%, 
disorders of the thyroid gland 8% – data not shown), ‘mental disorders’ (the 47 mental 
inpatient admissions – in total one third – were due to mental and behavioural disorders 
due to psychoactive substance use, while four out of seven mental inpatient admissions 
among leukaemia cases were for mood disorder – data not shown) and ‘musculoskeletal 
diseases’, which were more common during the post-treatment inpatient admissions 
compared to the on treatment phase. 
 
  
211 
 
 
Table 68: Number of inpatient admissions by period of admission and cause of 
admission (ICD-10) 
Admission type ICD-10 
On treatment* Post-treatment* Total admission 
N % N % N % 
Certain infectious and parasitic 
diseases 
764 1.56 175 1.44 939 1.54 
Neoplasms 40,648 83.03 5,752 47.38 46,400 75.94 
Diseases of the blood and blood-
forming organs and certain 
disorders involving the immune 
mechanism 
1,617 3.30 338 2.78 1,955 3.20 
Endocrine, nutritional and 
metabolic diseases 
93 0.19 207 1.71 300 0.49 
Mental and behavioural disorders 10 0.02 33 0.27 43 0.07 
Diseases of the nervous system 134 0.27 142 1.17 276 0.45 
Diseases of the eye and adnexa 59 0.12 98 0.81 157 0.26 
Diseases of the ear and mastoid 
process 
68 0.14 92 0.76 160 0.26 
Diseases of the circulatory system 93 0.19 119 0.98 212 0.35 
Diseases of the respiratory system 582 1.19 448 3.69 1,030 1.69 
Diseases of the digestive system 490 1.00 535 4.41 1,025 1.68 
Diseases of the skin and 
subcutaneous tissue 
142 0.29 147 1.21 289 0.47 
Diseases of the musculoskeletal 
system and connective tissue 
179 0.37 286 2.36 465 0.76 
Diseases of the genitourinary 
system 
170 0.35 215 1.77 385 0.63 
Pregnancy, childbirth and the 
puerperium 
76 0.16 508 4.18 584 0.96 
Certain conditions originating in the 
perinatal period 
3 0.01 1 0.01 4 0.01 
Congenital malformations, 
deformations and chromosomal 
abnormalities 
58 0.12 109 0.90 167 0.27 
Symptoms, signs and abnormal 
clinical and laboratory findings, not 
elsewhere classified 
1,499 3.06 1,003 8.26 2,502 4.10 
Injury, poisoning and certain other 
consequences of external causes 
847 1.73 654 5.39 1,501 2.46 
Factors influencing health status 
and contact with health services 
1,426 2.91 1,278 10.53 2,704 4.43 
Total* 48,958 100 12,140 100 61,098 100 
* Includes main diagnostic group where their initial treatment was identified using the study 
matrices, number of included cases was 2,867. 
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Figure 57: Percentage of inpatient admissions (1997-2011) for all cases aged 0-29 
years at diagnosis by admission cause (ICD-10) according to period of 
admission (on and post-treatment) 
 
 
Figure 58: Percentage of inpatient admissions (1997-2011) for all cases aged 0-29 
years at diagnosis by admission cause (ICD-10) according to period of 
admission (on and post-treatment) 
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Figure 59: Percentage of inpatient admissions (1997-2011) for all cases aged 0-29 
years at diagnosis by admission cause (ICD-10) according to period of 
admission (on and post-treatment) 
 
8.2.1.2 Distribution of inpatient admissions by primary cause of 
admission (ICD-10), diagnostic group (ICCC-3) and period of 
admission (on treatment and post-treatment) 
The rate of inpatient admissions during the study period (on treatment vs. post-treatment) 
was analysed by causes of specific admissions (ICD-10) and diagnostic group (ICCC-3) 
to assess the different rates of admission on and post-treatment. 
Admissions for ‘certain infectious diseases’ was higher during the on treatment phase, 
especially among cases diagnosed with bone tumours, with more than 90% of the total 
admissions occurring during the on treatment phase, compared with less than 10% 
during the post-treatment admissions (Figure 60).In contrast, cases diagnosed with germ 
cell tumours had a higher number of admissions for ‘certain infectious diseases’ during 
the post-treatment period. 
Admissions for ‘endocrine, nutritional and metabolic diseases’ were higher during the 
post-treatment period, except for cases diagnosed with neuroblastoma or bone tumours, 
where admissions were higher during the on treatment phase (Figure 60). 
The admissions for ‘mental and behavioural disorders’, ‘diseases of the nervous system’ 
and ‘diseases of the eye’ were higher post-treatment compared to the on treatment 
phase for the majority of diagnostic groups, except for leukaemia, where the pattern of 
admission was in the opposite direction (higher during treatment than post-treatment) 
(Figure 61). 
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Similarly, bone tumour cases had different patterns of admission by period of admission 
from other diagnostic groups; they had a higher percentage of admissions during the on 
treatment phase than post-treatment phase for the following causes: ‘endocrine, 
nutritional and metabolic diseases’, ‘diseases of the nervous system’, ‘diseases of the 
eye’, ‘diseases of the ear’, ‘diseases of the digestive system’ and ‘diseases of the 
musculoskeletal system’ (Figure 60, Figure 61 and Figure 63). Cases admitted for 
‘diseases of the circulatory system’ were higher during the post-treatment period, except 
for cases diagnosed with CNS and neuroblastoma (Figure 62). 
Cases diagnosed with lymphoma, CNS, renal tumours and germ cell tumours had  a 
higher number of admissions during the post-treatment phase than the on treatment 
phase, in contrast with other diagnostic groups for the admissions for ‘diseases of the 
respiratory system’ (Figure 62).  
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Figure 60:The percentage and number of admissions for ’certain infectious and parasitic diseases’ (a),’ neoplasms’ (b), ’diseases of the blood 
and blood-forming organs and certain disorders involving the immune mechanism ’(c) and ‘endocrine, nutritional and metabolic 
diseases’ (d) and number of cases by diagnostic group and period of admission (on treatment and post-treatment) 
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Figure 61:The percentage and number of admissions for ‘mental and behavioural disorders’ (a),‘diseases of the nervous system’ (b), diseases 
of ‘diseases of the eye and adnexa’ (c) and ‘disease of ear and mastoid process‘ (d) and number of cases by diagnostic group and 
period of admission (on treatment and post treatment) 
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Figure 62:The percentage and number of admissions for ‘diseases of the respiratory system’ (a), ‘diseases of the circulatory system’ (b) number 
of cases, diseases of the digestive system’ (c) and ‘diseases of the skin and subcutaneous tissue’ (d) by diagnostic group and period of 
admission (on treatment and post-treatment) 
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Figure 63:The percentage and number of admissions ‘diseases of the musculoskeletal system and connective tissue’ (a), diseases of the 
genitourinary system (b), ‘pregnancy, childbirth and the puerperium’ (c) and ‘congenital malformations, deformations and chromosomal 
abnormalities’ (d) number of cases by diagnostic group and period of admission (on treatment and post-treatment) 
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Figure 64:The percentage and number of admissions for ‘symptoms, signs and abnormal clinical and laboratory findings, not elsewhere 
classified’ (a), ‘injury, poisoning and certain other consequences of external causes’ (b) and ‘factors influencing health status and 
contact with health services’ (c) and number of cases by diagnostic group and period of admission (on treatment and post-treatment
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8.2.2 Distribution of inpatient admissions by secondary causes of 
admission (ICD-10) and diagnostic group (ICCC-3) 
In HES, the reason for admission, or the cause of admission was recorded in two groups. 
Primary diagnosis, i.e. the first diagnosis code of admission and defined as the main 
cause of admission, or the reason that caused the patient to receive hospital care. The 
other group was the secondary diagnosis of admission and is defined as any morbidity 
related to the primary diagnosis and external cause. For example, a patient could be 
admitted to hospital for heart disease and he might happen to have diabetes, the main 
cause will be to treat the heart disease and the secondary diagnosis is diabetes, as it is 
related to the primary cause of admission [203].  
The majority of second causes of admissions were classified as ‘factors influencing 
health status’, followed by ‘neoplasms’ and ‘symptoms, signs and abnormal clinical and 
laboratory findings’ (Table 69 and Table 70). The rate for ‘musculoskeletal disease’ 
admissions were considerably high and represented the fourth highest secondary cause 
of admission, especially among neuroblastoma cases, having 23% of the total secondary 
admissions (n= 1,023 out of 4,400 neuroblastoma admissions). 
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Table 69: The distribution of secondary causes of admissions (ICD-10) by diagnostic group ICCC-3 
Secondary cause of admission (ICD-
10) 
Leukaemia Lymphoma CNS Neuroblastoma Retinoblastoma 
Renal 
tumours 
N % N % N % N % N % N % 
Certain infectious and parasitic diseases 1,338 4 438 3 191 2 122 3 36 5 82 3 
Neoplasms 3,203 10 1,429 9 1,308 12 942 21 67 10 551 18 
Diseases of the blood and blood-forming 
organs and certain disorders involving 
the immune mechanism 
2,138 7 686 4 318 3 267 6 45 6 136 4 
Endocrine, nutritional and metabolic 
diseases 
599 2 244 2 398 4 122 3 8 1 42 1 
Mental and behavioural disorders 102 0 132 1 111 1 51 1 1 0 3 0 
Diseases of the nervous system 313 1 193 1 1,014 9 115 3 0 0 12 0 
Diseases of the eye and adnexa 148 0 47 0 282 3 39 1 16 2 12 0 
Diseases of the ear and mastoid process 164 1 38 0 132 1 53 1 4 1 10 0 
Diseases of the circulatory system 347 1 237 2 164 2 72 2 2 0 183 6 
Diseases of the respiratory system 799 3 692 4 176 2 63 1 26 4 86 3 
Diseases of the digestive system 706 2 382 2 238 2 72 2 4 1 85 3 
Diseases of the skin and subcutaneous 
tissue 
236 1 118 1 45 0 21 0 13 2 11 0 
Diseases of the musculoskeletal system 
and connective tissue 
403 1 1,519 10 567 5 1,023 23 116 17 461 15 
Diseases of the genitourinary system 255 1 231 1 74 1 70 2 3 0 118 4 
Pregnancy, childbirth and the puerperium 22 0 95 1 58 1 2 0 0 0 1 0 
Certain conditions originating in the 
perinatal period 
16 0 2 0 10 0 6 0 0 0 0 0 
Congenital malformations, deformations 
and chromosomal abnormalities 
322 1 50 0 317 3 61 1 20 3 92 3 
Symptoms, signs and abnormal clinical 
and laboratory findings, not elsewhere 
classified 
8,200 26 1,143 7 1,224 11 212 5 25 4 189 6 
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Secondary cause of admission (ICD-
10) 
Leukaemia Lymphoma CNS Neuroblastoma Retinoblastoma 
Renal 
tumours 
N % N % N % N % N % N % 
Injury, poisoning and certain other 
consequences of external causes 
526 2 219 1 141 1 55 1 15 2 43 1 
External causes of morbidity and 
mortality 
1,166 4 390 3 317 3 85 2 25 4 87 3 
Factors influencing health status and 
contact with health services 
10,086 32 7,313 47 3,703 34 947 22 274 39 933 30 
Codes for special purposes 0 0 0 0 1 0 0 0 0 0 2 0 
Total 31,089  15,598  10,789  4,400  700  3,139  
Abbreviations: N = number of admissions; CNS = central nervous system 
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Table 70: The distribution of secondary causes of admissions (ICD-10) by diagnostic group ICCC-3 
Secondary cause of 
admissions (ICD-10) 
Hepatic 
tumours 
Bone tumours STS 
Germ cells 
tumours 
Other 
epithelial 
neoplasm 
Other 
unspecified 
neoplasm 
Overall 
diagnostic 
group 
N % N % N % N % N % N % N % 
Certain infectious and 
parasitic diseases 
23 3 158 2 206 3 64 1 53 2 9 5 2,720 3 
Neoplasms 102 11 1,328 19 1,554 20 1,238 21 739 22 40 23 12,501 14 
Diseases of the blood and 
blood-forming organs and 
certain disorders involving 
the immune mechanism 
18 2 242 4 360 5 138 2 54 2 11 6 4,413 5 
Endocrine, nutritional and 
metabolic diseases 
41 4 136 2 131 2 110 2 77 2 2 1 1,910 2 
Mental and behavioural 
disorders 
0 0 15 0 85 1 124 2 47 1 0 0 671 1 
Diseases of the nervous 
system 
2 0 79 1 80 1 158 3 41 1 2 1 2,009 2 
Diseases of the eye and 
adnexa 
0 0 8 0 47 1 26 0 11 0 0 0 636 1 
Diseases of the ear and 
mastoid process 
3 0 24 0 59 1 12 0 13 0 0 0 512 1 
Diseases of the circulatory 
system 
8 1 66 1 60 1 75 1 63 2 2 1 1,279 1 
Diseases of the respiratory 
system 
24 3 161 2 173 2 186 3 81 2 1 1 2,468 3 
Diseases of the digestive 
system 
46 5 197 3 154 2 105 2 115 3 3 2 2,107 2 
Diseases of the skin and 
subcutaneous tissue 
5 1 65 1 43 1 30 1 11 0 1 1 599 1 
Diseases of the 
musculoskeletal system 
and connective tissue 
12 1 1,316 19 1,314 17 430 7 166 5 1 1 7,328 8 
  
2
2
4
 
Secondary cause of 
admissions (ICD-10) 
Hepatic 
tumours 
Bone tumours STS 
Germ cells 
tumours 
Other 
epithelial 
neoplasm 
Other 
unspecified 
neoplasm 
Overall 
diagnostic 
group 
N % N % N % N % N % N % N % 
Diseases of the 
genitourinary system 
40 4 85 1 104 1 112 2 46 1 4 2 1,142 1 
Pregnancy, childbirth and 
the puerperium 
1 0 12 0 19 0 11 0 63 2 0 0 284 0 
Congenital malformations, 
deformations and 
chromosomal 
abnormalities 
47 5 3 0 99 1 66 1 27 1 0 0 1,104 1 
Symptoms, signs and 
abnormal clinical and 
laboratory findings, not 
elsewhere classified 
213 23 358 5 798 10 273 5 282 8 35 20 12,952 14 
Injury, poisoning and 
certain other 
consequences of external 
causes 
16 2 130 2 101 1 72 1 36 1 3 2 1,357 1 
External causes of 
morbidity and mortality 
28 3 290 4 255 3 197 3 54 2 7 4 2,901 3 
Factors influencing health 
status and contact with 
health services 
283 31 2,169 32 2,301 29 2,416 41 1,423 42 56 32 31,904 35 
Codes for special purposes 0 0 0 0 0 0 0 0 0 0 0 0 3 0 
Total causes 914 100 6,842 100 7,944 100 5,856 100 3,402 100 177 100 90,850 100 
Abbreviations: N = number of admissions; STS = soft tissue sarcoma 
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8.3 Duration to first admission after completion of cancer 
treatment  
8.3.1 The median time of admission after treatment completion by 
cause of admission and age at diagnosis 
The aim of this subset analysis was to identify the group with the earliest admission for 
specific causes, given their age at diagnosis and type of cancer. The results of this 
section could help healthcare providers and planners to predict the period likely for each 
diagnostic group to return to hospital after recovering from cancer. 
The follow-up time was calculated from the date of treatment completion until the date of 
first admission for certain causes, or censored at the date of death, last seen in the 
cancer register or end of the study period (31st December 2011) whichever occurred first.  
The median time of first admission was subdivided by age at diagnosis (0-14, 15-29 and 
for all ages 0-29 years), this was carried out based on clinical interest in understanding 
whether there were differences in time to first admission by age group, given the potential 
differences in treatment management (paediatric vs young adults setting). The time at 
risk was estimated for cases with at least one hospital admission after completion of their 
initial treatment, and summary estimates were calculated for the median and interquartile 
range to first admission.  
Any causes with less than five cases for one of the age groups was eliminated from the 
analysis, and the time to first admission was analysed for any one age group with a 
sufficient number of cases (more than five). The significance of the difference was 
estimated using the Mann-Whitney test (as detailed in Chapter 4). 
8.3.1.1 Certain infectious and parasitic diseases 
Out of 2,304 cancer survivors that were followed up after initial treatment completion, 
223 (10%) had at least one admission for certain infectious diseases and contributed 
347 person-years of follow-up time. This was broken down by age group with 133 (14%) 
out of 922 childhood survivors and 90 (6.5%) out of 1,382 TYA survivors, who contributed 
143 and 205 person-years of follow-up time, respectively. Children were admitted earlier 
than TYAs for the majority of diagnostic groups, except for STS where the median was 
1 year and 0.67 years for children and TYAs, respectively (Figure 65). The difference 
was significantly different among cases with leukaemia (median=138 days and 310 days 
for children and TYAs, respectively, P-value= 0.003). 
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Figure 65: Median time to first admission for certain infectious and parasitic diseases 
by age at diagnosis, diagnostic group after initial treatment completion 
 
8.3.1.2 Neoplasms 
Out of 2,304 cancer survivors that were followed up after initial treatment completion, 
599 (26%) had at least one admission for neoplasms (disease of the recurrence of 
malignancy or subsequent primaries combined) and contributed to 812 person-years of 
follow-up time. This was broken down by age group with 310 (34%) out of 922 childhood 
survivors and 289 (21%) out of 1,382 TYA survivors, who contributed to 277 and 535 
person-years of follow-up time, respectively. Neoplasm admissions were earlier among 
children than in TYAs (P-value <0.001), except for germ cell tumours, but that was not 
statistically significant. The difference was significant among cases with leukaemia 
having a median of 79 days compared with 237 days for children and TYAs, respectively 
(P-value <0.001) (Figure 66). The difference was also significant among lymphoma 
cases (median=78 days and 361 days for children and TYAs, respectively, P-
value<0.001) and CNS (median=105 and 380 days for children and TYAs, respectively, 
P-value=0.007). 
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Figure 66: Median time to first admission for neoplasms by age at diagnosis, diagnostic 
group after initial treatment completion 
 
8.3.1.3 Diseases of the blood and blood-forming organs and certain 
disorders involving the immune mechanism 
Out of 2,304 cancer survivors that were followed up after treatment completion, 183 (8%) 
had at least one admission for diseases of the blood, contributing to 234 person-years 
of follow-up time. This was broken down by age group with 102 (11%) out of 922 
childhood survivors and 81 (6%) out of 1,382 TYA survivors, contributing to 89 and 144 
person-years of follow-up time, respectively (Figure 67). Children were more likely to be 
admitted earlier than TYAs for all cancers (median=67 days and 239 days respectively, 
P-value <0.001) except for STS. The difference was statistically significant among cases 
surviving leukaemia (median= 63.55 and 124 days for children and TYAs, respectively, 
P-value=0.015) and lymphoma (median= 53 and 320 days, P-value=0.001, respectively). 
Children with lymphoma had the shortest time at risk compared with other diagnostic 
groups, while TYAs had the shortest time at risk when surviving from STS. 
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Figure 67:Median time to first admission for diseases of the blood and blood-forming 
organs and certain disorders involving the immune mechanism by age at 
diagnosis, diagnostic group after initial treatment completion 
 
8.3.1.4 Endocrine nutritional and metabolic diseases 
Out of 2,304 cancer survivors that were followed up after treatment completion, 179 (8%) 
had at least one admission for endocrine nutritional and metabolic diseases, which 
contributed to 596 person-years of follow-up time. This was broken down by age group 
with 86 (9%) out of 922 childhood survivors and 93 (7%) out of 1,382 TYA survivors, 
contributing to 241 and 355 person-years of follow-up time, respectively. Children were 
admitted significantly earlier than TYAs for endocrine-related complications (P-value= 
0.016). The difference was significant among survival from leukaemia (median=136 days 
and 457 days for children and TYAs, respectively, P-value=0.036). Children surviving 
from leukaemia had the shortest time at risk compared with other diagnostic groups, 
while TYAs had the shortest time at risk when surviving from STS (Figure 68). 
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Figure 68: Median time to first admission for nutritional and metabolic diseases by age 
at diagnosis, diagnostic group after initial treatment completion 
 
8.3.1.5 Mental and behavioural disorders 
Out of 2,304 cancer survivors followed up after treatment completion, 115 (8%) had at 
least one admission for mental and behavioural disorders, contributing to 511 person-
years of follow-up time. This was broken down by age group with 31 (9%) out of 922 
childhood survivors and 84 (7%) out of 1,382 TYA survivors, contributing to 136 and 375 
person-years of follow-up years, respectively. TYAs were likely to be admitted earlier 
than children for mental disorders, except for STS (Figure 69). Children and TYAs 
surviving from CNS had the shortest median time to first admission for mental disorders 
(median=3 and 1 year/s for children and TYAs, respectively). 
 
 
Figure 69: Median time to first admission for mental and behavioural disorders by age 
at diagnosis, diagnostic group after initial treatment completion 
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8.3.1.6 Diseases of the nervous system 
Out of 2,304 cancer survivors that were followed up after treatment completion, 143 (6%) 
had at least one admission for diseases of the nervous system, contributing to 420 
person-years of follow-up time. This was broken down by age group with 61 (7%) out of 
922 childhood survivors and 82 (6%) out of 1,382 TYA survivors, contributing to 161 and 
259 person-years of follow-up time, respectively. Children experienced earlier 
admissions for diseases of the nervous system than TYAs for all cancers combined, 
while TYAs surviving from CNS had earlier admissions than children (median=2 and 1.4 
years for children and TYAs, respectively) (Figure 70). 
 
Figure 70: Median time to first admission for diseases of the nervous system by age at 
diagnosis, diagnostic group after initial treatment completion 
 
8.3.1.7 Diseases of the eye and adnexa 
Out of 2,304 cancer survivors that were followed up after treatment completion, 70 (3%) 
had at least one admission for diseases of the eye and adnexa, which contributed to 217 
person-years of follow-up time. This was broken down by age group with 47 (5%) out of 
922 childhood survivors and 23 (2%) out of 1,382 TYA survivors, contributing to 137 and 
80 person-years of follow-up time, respectively. TYAs experienced earlier admissions for 
eye complications than children for overall cancers combined (median=2.5 and 1.6 years 
for children and TYAs, respectively), but not for CNS survivors (Figure 71). 
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Figure 71: Median time to first admission for diseases of the eye and adnexa by age at 
diagnosis, diagnostic group after initial treatment completion 
 
8.3.1.8 Diseases of the ear and mastoid process 
Out of 2,304 cancer survivors followed up after treatment completion, 43 (2%) had at 
least one admission for diseases of the ear and mastoid process, which contributed to 
217 person-years of follow-up time. This was broken down by age group with 34 (4%) 
out of 922 childhood survivors and 9 (1%) out of 1,382 TYA survivors, contributing to 137 
and 80 person-years follow-up time, respectively. Children surviving from leukaemia 
were admitted earlier for diseases of the ear than CNS survivors, where the median was 
0.5 and 2 years, respectively (Figure 72). 
 
 
Figure 72:Median time to first admission for diseases of the ear and mastoid process 
by age at diagnosis, diagnostic group after initial treatment completion 
 
8.3.1.9 Diseases of the circulatory system 
Out of 2,304 cancer survivors followed up after treatment completion, 115 (5%) had at 
least one admission for diseases of the circulatory system, which contributed to 397 
person-years of follow-up time. This was broken down by age group with 44 (5%) out of 
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922 children survivors and 71 (5%) out of 1,382 TYA survivors, contributing to 137 and 
260 person-years of follow-up time, respectively.  
Children were admitted earlier than TYAs for circulatory diseases, except for leukaemia 
survivors where the median was significantly shorter for TYAs than for children, having  
less than a year (227 days) and four years respectively (P-value= 0.03) (Figure 73). 
Overall, lymphoma childhood survivors were admitted earlier than other diagnostic 
groups, while TYAs with leukaemia were admitted earlier than other diagnostic groups. 
 
 
Figure 73: Median time to first admission for diseases of the circulatory system by age 
at diagnosis, diagnostic group after initial treatment completion 
 
8.3.1.10 Diseases of the respiratory system 
Out of 2,304 cancer survivors that were followed up after treatment completion, 229 (12%) 
had at least one admission for diseases of the respiratory system, which contributed to 
770 person-years of follow-up. This was broken down by age group with 101 (14%) out 
of 922 childhood survivors and 128 (10%) out of 1,382 TYA survivors, and contributed 
to 345 and 424 person-years of follow-up time, respectively. Children had shorter median 
times to first admission than TYAs, except for leukaemia, CNS, and STS with no 
significant differences observed (Figure 74). 
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Figure 74: Median time to first admission for diseases of the respiratory system by age 
at diagnosis, diagnostic group after initial treatment completion 
 
8.3.1.11 Diseases of the digestive system 
Out of 2,304 cancer survivors that were followed up after treatment completion, 209 (9%) 
had at least one admission for diseases of the digestive system, which contributed to 
680 person-years of follow-up time. This was broken down by age group with 92 (10%) 
out of 922 childhood survivors and 117 (8%) out of 1,382 TYA survivors, and contributed 
to 278 and 402 person-years of follow-up time, respectively. Children had a shorter 
median time to admission than TYAs, where the medians were 1 and 2.5 years for 
children and TYAs, respectively (not significant) (Figure 75). 
 
Figure 75: Median time to first admission for diseases of the digestive system by age at 
diagnosis, diagnostic group after initial treatment completion 
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8.3.1.12 Diseases of the skin and subcutaneous tissue 
Out of 2,304 cancer survivors followed up after treatment completion, 66 (3%) had at 
least one admission for diseases of the skin and subcutaneous tissue, contributing to 
157 person-years. This was broken down by age group with 29 (3%) out of 922 childhood 
survivors and 37 (3%) out of 1,382 TYA survivors, contributing to 49 and 108 person-
years of follow-up time, respectively. Children had significantly shorter median times to 
first admission compared with TYAs (median=252 days vs 752 days, respectively, P-
value= 0.03) and this pattern was observed for all diagnostic groups except for lymphoma 
(Figure 76). 
 
 
Figure 76: Median time to first admission for diseases of the skin and subcutaneous 
tissue by age at diagnosis, diagnostic group after initial treatment completion 
 
8.3.1.13 Diseases of the musculoskeletal system and connective 
tissue 
Out of 2,304 cancer survivors that were followed up after treatment completion, 216 (9%) 
had at least one admission for diseases of the musculoskeletal system and connective 
tissue, which contributed to 385 person-years of follow-up time. This was broken down 
by age group with 125 (14%) out of 922 childhood survivors and 91 (7%) out of 1,382 
TYA survivors, contributing to 133 and 252 person-years of follow-up time, respectively. 
Children had a significantly shorter median time at risk compared with TYAs 
(median=115 days and 368 days, respectively, P-value= <0.001) (Figure 77). 
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Figure 77: Median time to first admission for diseases of the musculoskeletal system 
and connective tissue by age at diagnosis, diagnostic group after initial 
treatment completion 
 
8.3.1.14 Diseases of the genitourinary system 
Out of 2,304 cancer survivors followed up after treatment completion, 122 (5%) had at 
least one admission for diseases of the genitourinary system, which contributed to 359 
person-years of follow-up time. This was broken down by age group with 40 (4%) out of 
922 childhood survivors and 82 (6%) out of 1,382 TYA survivors, contributing to 108 and 
251 person-years of follow-up time, respectively. Children had shorter median times at 
risk compared with TYAs, except for leukaemia (Figure 78). 
 
 
Figure 78: Median time to first admission for diseases of the genitourinary system by 
age at diagnosis, diagnostic group after initial treatment completion 
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8.3.1.15 Pregnancy, childbirth and the puerperium 
Out of 2,304 cancer survivors followed up after treatment completion, 77 (3%) had at 
least one admission for pregnancy, childbirth and the puerperium, which contributed to 
316 person-years of follow-up time. This was broken down by age group with 8 (1%) out 
of 922 childhood survivors and 69 (5%) out of 1,382 TYA survivors, and contributed to 
60 and 255 person-years of follow-up time, respectively. TYAs on average (median) were 
admitted earlier for pregnancy and puerperium related causes than children (medians of 
three and eight years, respectively, P-value= 0.001). The median time to first admission 
for pregnancy related conditions among TYAs (69 cases) was earlier among germ cell 
tumour survivors than lymphoma and CNS tumour survivors (Figure 79). 
 
Figure 79: Median time to first admission for pregnancy childbirth and the puerperium 
by age at diagnosis, diagnostic group after initial treatment completion 
 
8.3.1.16 Congenital malformations, deformations and chromosomal 
abnormalities 
Out of 2,304 cancer survivors followed up after treatment completion, 65 (3%) had at 
least one admission for congenital malformations, deformations and chromosomal 
abnormalities, which contributed to 142 person-years of follow-up time. This was broken 
down by age group into 45 (5%) out of 922 childhood survivors and 20 (1%) out of 1,382 
TYA survivors, contributing to 111 and 31 person-years of follow-up time respectively. 
TYAs were admitted earlier than children for all groups except CNS tumours, however 
this was not significant (median=338 and 157 days for children and TYAs, respectively).  
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Figure 80: Median time to first admission for congenital malformations, deformations 
and chromosomal abnormalities by age at diagnosis, diagnostic group after 
initial treatment completion 
 
8.3.1.17 Symptoms, signs and abnormal clinical and laboratory 
findings not elsewhere classified 
Out of 2,304 cancer survivors followed up after treatment completion, 534 (23%) had at 
least one admission for causes classified as symptoms, signs and abnormal clinical and 
laboratory findings, which contributed to 1,098 person-years of follow-up time. This was 
broken down by age group with 289 (31%) out of 922 childhood survivors and 245 (18%) 
out of 1,382 TYA survivors, contributing to 412 and 687 person-years of follow-up time 
respectively. Children on average (median) were admitted earlier than TYAs (median = 
less than one year and almost two years, respectively, P-value <0.001) (Figure 81), 
except for renal tumours but was not significant. 
 
 
Figure 81: Median time to first admission for symptoms signs and abnormal clinical and 
laboratory findings not elsewhere classified by age at diagnosis, diagnostic 
group after initial treatment completion 
 
CNS
Renal tumours
Overall cancers
0 1 2 3 4 5 6 7
Years from treatment completion
Median time to first admission  0-14 Median time to first admission  15-29
Median time to first admission  0-29
Leukaemia
Lymphoma
CNS
Renal tumours
Bone tumours
STS Germ cell 
tumours
Overall cancers
0 2 4 6 8 10
Years from treatment completion
Median time to first admission  0-14 Median time to first admission  15-29
Median time to first admission  0-29
238 
 
8.3.1.18 Injury, poisoning and certain other consequences of external 
causes 
Out of 2,304 cancer survivors followed up after treatment completion, 142 (6%) had at 
least one admission for causes classified as injury, poisoning and certain other 
consequences of external causes, contributing to 397 person-years of follow-up time. 
This was broken down by age group into 59 (6%) out of 922 childhood survivors and 83 
(6%) out of 1,382 TYA survivors, and contributed to 154 and 243 person-years of follow-
up time, respectively. Children had shorter median times at risk compared with TYAs 
except for lymphoma and CNS tumour survivors (Figure 82). The difference was 
significant for leukaemia survivors (median=119 and 460 days for children and TYAs, 
respectively). 
 
Figure 82: Median time to first admission for injury poisoning and certain other 
consequences of external causes by age at diagnosis, diagnostic group after 
initial treatment completion 
 
8.3.1.19 External causes of morbidity and mortality 
Out of 2,304 cancer survivors that were followed up after treatment completion, 272 (12%) 
had at least one admission for causes classified as external causes of morbidity and 
mortality, and contributed to 671 person-years of follow-up time. This was broken down 
by age group with 127 (14%) out of 922 childhood survivors and 145 (10%) out of 1,382 
TYA survivors, contributing to 253 and 418 person-years of follow-up time, respectively. 
Children were admitted earlier (median less than a year and two years for children and 
TYAs, respectively, P-value= 0.002) than TYAs except for those with bone tumours and 
STS, but this was not significant (Figure 83).  
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Figure 83:Median time to first admission for external causes of morbidity and mortality 
by age at diagnosis, diagnostic group after initial treatment completion 
 
8.3.1.20 Factors influencing health status and contact with health 
services 
Out of 2,304 cancer survivors followed up after treatment completion, 1,218 (53%) had 
at least one admission for causes classified as factors influencing health status and 
contact with health services, which contributed to 2,484 person-years of follow-up time. 
This was broken down by age group into 592 (64%) out of 922 childhood survivors and 
626 (45%) out of 1,382 TYA survivors, contributing to 694 and 1,789 person-years of 
follow-up time, respectively. Children had shorter median times to first admission for the 
majority of diagnostic groups compared with TYAs (median 0.30 and 1.56 years for 
children and TYA, respectively, P-value= <0.001) (Figure 84). 
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Figure 84: Median time to first admission for first admission to factors influencing health 
status and contact with health services by age at diagnosis, diagnostic group 
after initial treatment completion 
 
8.3.1.21 Total admissions 
Out of 2,304 cancer survivors followed up after treatment completion, 1,723 (75%) had 
at least one hospital admission, contributing to 2,553 person-years of follow-up time. This 
was broken down by age group into 776 (84%) out of 922 childhood survivors and 947 
(69%) out of 1,382 TYA survivors, contributing to 687 and 1,866 person-years, 
respectively. For all causes of admissions combined, children experienced a shorter time 
to first admission compared with TYAs (median= 0.17 and 1.17 years for children and 
TYAs, respectively, P-value= <0.001). The shortest admission times overall were among 
leukaemia and bone tumour survivors. Furthermore, the time to first admission for these 
two diagnostic groups was significantly shorter among children than TYAs (P-value= 
<0.001 and 0.005 respectively) (Figure 85). 
  
Figure 85: Median time to first admission for first admission to overall cases in 
combined by age at diagnosis, diagnostic group after initial treatment 
completion 
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8.4 Excess hospitalisation rate compared with background 
population 
In this section, the health burden after completion of cancer treatment in terms of rate of 
admission among the cancer cohort compared with the background population was 
analysed. Among the age-sex and admissions year matched background population, 
there was 2,236,680 individuals aged 0-45 years and were admitted at least once to 
hospital and contributed to over than 6 million admissions. The standardised mortality 
ratio technique was used to estimate the excess standardised hospitalisation ratio (SHR) 
among cancer cohort. For the background population, the rate was calculated by dividing 
the total number of admissions (first admission per cause) by single age, sex and mid-
year population estimates. The rate of admissions among matched attained age, sex 
and year of admission for the background population was used to standardise rate 
among cancer cohort (more detail in Section 4.7). 
The follow-up years (1997-2011) among the cancer cohort was from the date of 
treatment completion until the date of the first admission (primary or secondary diagnosis 
at admission) and censored at date of death, loss of follow-up or end of the study period 
(31stDecember 2011). The SHR was subdivided by age at diagnosis, gender and cancer 
types. Late effects of cancer and its treatment were identified as five-year survival from 
date of diagnosis [15, 24, 101, 140, 149], however, use of this method would illuminate 
a number of admissions that occurred after treatment completion and before the five-
year cut-off point, hence underestimating the burden of health preceding the date of 
treatment completion. 12,474 admissions were found in the current analysis that 
occurred after treatment completion, but within five years of the date of diagnosis. 
The rate of admission was higher among the cancer cohort compared with the 
background population for all admission diagnoses combined (SHR=2.37, 95% CI:2.26-
2.49), except for those due to pregnancy (SHR= 0.9, 95% CI:0.7-1.2) (Table 71). The 
highest SHR was for admissions due to ‘diseases of the blood’, followed by ‘neoplasms’ 
and then ‘endocrine and metabolic diseases’ including diabetes, having SHR=55.8, 49.6 
and 32.1, respectively. 
Overall, leukaemia survivors had the highest SHR (SHR=10.0, 95%CI:9.1-11.0), whilst 
germ cell tumour survivors had the lowest SHR compared with other diagnostic groups, 
adjusting for the background population (SHR=1.52, 95%CI:1.37-1.69) (Figure 86, Table 
71 and Table 73). Leukaemia survivors had the highest SHR for ‘certain infectious 
diseases’, ‘neoplasms’, ‘diseases of the blood’ and ‘respiratory diseases’ compared with 
other diagnostic groups, having SHR=44.4, 144.7, 139.9 and 12.3 respectively (Figure 
86 and Table 71). 
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CNS tumour survivors had the highest SHR for ‘mental and behavioural disorders’ and 
‘diseases of the nervous system’ compared with other diagnostic groups (SHR=23.4 and 
70.9, respectively) (Figure 86 and Table 71). While, renal tumour cases had the highest 
SHR for ‘circulatory system diseases’ (SHR=41.67, 95%CI:24.7-70.4) followed by 
leukaemia survivors (SHR=22.4 95% CI:15.8-31.7) (Figure 86 and Table72)  
Children had a higher SHR than TYAs for all causes combined (SHR=6.94 and 1.68 
respectively, Figure 87). However, admissions for ‘endocrine and metabolic diseases’ 
were higher among TYAs than children (SHR=10.69 and 15.29 for children and TYAs, 
respectively). The difference in the hospitalisation rate was significant for ‘neoplasms’, 
‘diseases of the blood’ and ‘circulatory diseases’ among children and TYAs, where the 
rate was three- to five-fold higher among children (Figure 87). 
For all causes of admissions combined, males had a higher SHR than females after 
completion of cancer treatment (SHR=2.81 and 2.04, respectively, Figure 88). However, 
that was mainly for ‘neoplasms’, ‘diseases of the blood’, and ‘diseases of the nervous 
system’. While for the other causes, females had a higher SHR, such as ‘endocrine and 
metabolic diseases’, ‘mental and behavioural diseases’ and ‘diseases of the circulatory 
system’ than males.  
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Table 71: Standardised hospitalisation ratio after completion of treatment by primary cancer type and cause of admissions (ICD-10) 
 
Causes of admissions 
(ICD-10) 
All cancers Leukaemia Lymphoma CNS 
N SHR LCI UCI N SHR LCI UCI N SHR LCI UCI N SHR LCI UCI 
All diagnosis combined* 1,723¥ 2.37 2.26 2.49 438 10 9.1 11 388 1.5 1.3 1.6 257 3.5 3.1 3.9 
Certain infectious and 
parasitic diseases 
223 16.5 14.5 18.8 97 44.4 36.4 54.2 47 17.1 12.9 22.8 26 16.5 11.2 24.2 
Neoplasms 598 49.6 45.8 53.8 193 144.7 125.6 166.6 142 35.9 30.5 42.3 97 85.4 70 104.2 
Diseases of the blood and 
blood-forming organs and 
certain disorders involving 
the immune mechanism 
183 55.8 48.3 64.6 69 139.9 110.5 177.1 45 45.9 34.3 61.5 22 60.5 39.8 91.8 
Endocrine, nutritional and 
metabolic diseases 
179 32.1 27.8 37.2 40 44.8 32.8 61 39 23.7 17.3 32.4 43 69.5 51.6 93.8 
Mental and behavioural 
disorders 
115 13.7 11.4 16.5 16 16.6 10.2 27.2 36 15 10.8 20.8 18 23.4 14.8 37.2 
Diseases of the nervous 
system 
142 14.1 12 16.6 10 6.7 3.6 12.4 15 5.1 3.1 8.5 74 70.9 56.5 89 
Diseases of the eye and 
adnexa 
70 9.9 7.8 12.5 12 9.9 5.6 17.5 4 2.3 0.9 6.2 35 44.1 31.7 61.4 
Diseases of the ear and 
mastoid process 
43 6.5 4.9 8.8 15 10.4 6.3 17.2 5 4.3 1.8 10.4 8 9 4.5 18 
Diseases of the 
circulatory system 
114 7.9 6.6 9.5 32 22.4 15.8 31.7 28 6.5 4.5 9.4 13 10.8 6.3 18.7 
Diseases of the 
respiratory system 
226 6.7 6 7.6 83 12.2 9.9 15.2 66 7.1 5.5 9 28 6.5 4.5 9.4 
Diseases of the digestive 
system 
209 2.3 2 2.7 55 3.8 2.9 5 60 2.5 1.9 3.2 31 3.3 2.3 4.6 
Diseases of the skin and 
subcutaneous tissue 
66 3.1 2.5 4 26 9.7 6.6 14.3 13 2.2 1.3 3.7 9 4.3 2.3 8.4 
Diseases of the 
musculoskeletal system 
and connective tissue 
216 6.4 5.6 7.3 34 8 5.7 11.2 55 5.7 4.4 7.5 30 9.7 6.8 13.9 
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Causes of admissions 
(ICD-10) 
All cancers Leukaemia Lymphoma CNS 
N SHR LCI UCI N SHR LCI UCI N SHR LCI UCI N SHR LCI UCI 
Diseases of the 
genitourinary system 
121 3.2 2.7 3.8 29 5.3 3.7 7.7 27 2.2 1.5 3.3 11 2.6 1.4 4.7 
Pregnancy, childbirth and 
the puerperium 
77 0.9 0.7 1.2 10 0.8 0.4 1.5 37 1.1 0.8 1.5 13 1.3 0.8 2.2 
Congenital malformations,  
deformations and 
chromosomal 
abnormalities 
64 11.6 9.1 14.8 14 10.5 6.2 17.8 3 2.8 0.9 8.7 20 25.8 16.7 40 
Symptoms, signs and 
abnormal clinical and 
laboratory findings  not 
elsewhere classified 
531 7.5 6.9 8.1 192 22.9 19.9 26.4 112 5.2 4.3 6.2 92 12.3 10 15 
Injury, poisoning and 
certain other 
consequences of external 
causes 
142 10.1 8.6 11.9 47 18.7 14.1 24.9 30 10.7 7.5 15.3 18 10.8 6.8 17.1 
Factors influencing health 
status and contact with 
health services 
1,263 32.2 30.4 34 361 88.6 79.9 98.3 279 18.1 16.1 20.3 196 48 41.8 55.3 
Abbreviations: N = observed number of cases; SHR = standardised hospital ratio; LCI = 95% lower confidence interval; ULI = 95% upper confidence interval; 
STS = soft tissue sarcoma 
* not a total of all admissions as each survivor could be admitted more than once for different causes. 
¥ total of all cases with admissions after treatment completion. 
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Table 72: Standardised hospitalisation ratio after completion of treatment by primary cancer type and cause of admissions (ICD-10) 
Causes of admissions ICD-10 
Neuroblastoma Renal tumours Bone tumours 
N SHR LCI UCI N SHR LCI UCI N SHR LCI UCI 
All diagnosis combined* 48 4.3 3.3 5.7 68 4.6 3.6 5.8 85 3.9 3.2 4.9 
Certain infectious and parasitic diseases 4 4.5 1.7 11.9 6 5.3 2.4 11.9 11 25 13.8 45.1 
Neoplasms 14 
111.
1 
65.8 187.6 21 63.7 41.5 97.7 31 74.5 52.4 106 
Diseases of the blood and blood-forming organs and 
certain disorders involving the immune mechanism 
3 36.8 11.9 114 6 39.4 17.7 87.6 8 68 34 136 
Endocrine, nutritional and metabolic diseases 4 39.2 14.7 104.5 7 34.2 16.3 71.7 7 35.5 16.9 74.4 
Mental and behavioural disorders 2 31.7 7.9 126.7 0 NA NA NA 2 5.9 1.5 23.6 
Diseases of the nervous system 3 13.9 4.5 43.2 5 13 5.4 31.4 8 22.7 11.4 45.5 
Diseases of the eye and adnexa 2 8.7 2.2 34.8 1 2.8 0.4 20 2 8.8 2.2 35.2 
Diseases of the ear and mastoid process 3 6.2 2 19.1 2 3.1 0.8 12.6 1 6.6 0.9 46.9 
Diseases of the circulatory system 2 17.3 4.3 69 14 41.7 24.7 70.4 4 7.6 2.8 20.2 
Diseases of the respiratory system 7 4 1.9 8.3 14 5.6 3.3 9.5 13 10.8 6.3 18.6 
Diseases of the digestive system 3 1.5 0.5 4.5 9 2.7 1.4 5.2 6 1.9 0.8 4.1 
Diseases of the skin and subcutaneous tissue 1 3.7 0.5 26.4 2 3.6 0.9 14.5 4 4.8 1.8 12.7 
Diseases of the musculoskeletal system and 
connective tissue 
10 30.8 16.6 57.2 17 24.5 15.2 39.4 17 14.2 8.8 22.9 
Diseases of the genitourinary system 4 7 2.6 18.8 9 7.5 3.9 14.4 7 4.4 2.1 9.2 
Pregnancy, childbirth and the puerperium 0 NA NA NA 1 0.6 0.1 4.2 4 0.9 0.3 2.4 
Congenital malformations, deformations and 
chromosomal abnormalities 
4 14.1 5.3 37.4 12 26.6 15.1 46.8 1 6.3 0.9 44.7 
Symptoms, signs and abnormal clinical and laboratory 
findings, not elsewhere classified 
9 6.4 3.3 12.3 19 7.7 4.9 12 20 7.8 5 12.1 
Injury, poisoning and certain other consequences of 
external causes 
3 3.2 1 10.1 7 6.2 2.9 12.9 1 2.5 0.4 18 
Factors influencing health status and contact with 
health services 
34 62.5 44.6 87.4 53 45.4 34.7 59.4 66 44.9 35.2 57.1 
Abbreviations: N = observed number of cases; SHR = standardised hospital ratio; LCI: 95% lower confidence interval; ULI= 95% upper confidence interval; 
STS = soft tissue sarcoma; NA = not applicable  * not a total of all admissions as each survivors could be admitted more than once for different causes. 
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Table 73: Standardised hospitalisation ratio after completion of treatment by primary cancer type and cause of admissions (ICD-10) 
Causes of admissions ICD-10 Soft tissue sarcomas Germ cell tumours 
 N SHR LCI UCI N SHR LCI UCI 
All diagnosis combined* 126 1.8 1.5 2.2 301 1.3 1.2 1.5 
Certain infectious and parasitic diseases 14 11.9 7.1 20.1 15 4.6 2.8 7.6 
Neoplasms 44 40.6 30.2 54.6 48 13.4 10.1 17.8 
Diseases of the blood and blood-forming organs and 
certain disorders involving the immune mechanism 
12 41.8 23.7 73.6 15 19.4 11.7 32.2 
Endocrine, nutritional and metabolic diseases 14 29.7 17.6 50.1 24 17.2 11.5 25.7 
Mental and behavioural disorders 13 19.1 11.1 32.9 28 9.4 6.5 13.6 
Diseases of the nervous system 10 11.8 6.3 21.9 17 6.3 3.9 10.1 
Diseases of the eye and adnexa 4 7 2.6 18.7 9 4.7 2.4 9 
Diseases of the ear and mastoid process 5 10.2 4.3 24.6 3 2.4 0.8 7.4 
Diseases of the circulatory system 7 6 2.9 12.6 12 2.3 1.3 4.1 
Diseases of the respiratory system 23 7.2 4.8 10.8 29 2.9 2 4.2 
Diseases of the digestive system 12 1.7 1 3 32 1.3 0.9 1.8 
Diseases of the skin and subcutaneous tissue 4 2.4 0.9 6.4 6 0.9 0.4 1.9 
Diseases of the musculoskeletal system and connective 
tissue 
25 9.6 6.5 14.1 25 2.1 1.4 3.2 
Diseases of the genitourinary system 12 3.6 2 6.4 20 2.3 1.5 3.5 
Pregnancy, childbirth and the puerperium 6 0.7 0.3 1.5 6 0.7 0.3 1.6 
Congenital malformations, deformations and chromosomal 
abnormalities 
5 11.3 4.7 27.3 5 5.2 2.2 12.6 
Symptoms, signs and abnormal clinical and laboratory 
findings, not elsewhere classified 
34 5.6 4 7.8 46 2.2 1.7 3 
Injury, poisoning and certain other consequences of 
external causes 
13 11.6 6.7 20 19 5.7 3.6 8.9 
Factors influencing health status and contact with health 
services 
92 23.9 19.4 29.3 171 20 17.2 23.3 
Abbreviations: N = observed number of cases; SHR = standardise hospital ratio; LCI: 95% lower confidence interval; ULI= 95% upper confidence interval; 
STS = soft tissue sarcoma; NA = not applicable  
* not a total of admissions as each survivor admitted more than once for different causes 
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Figure 86: Standardised hospitalisation ratio with 95% confidence interval after treatment completion by cancer type at diagnosis and cause 
of admission (ICD-10) 
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Figure 87: Standardised hospitalisation ratio with 95% confidence interval after 
treatment completion by age at diagnosis and cause of admission (ICD-10) 
  
-5 15 35 55 75 95 115 135 155 175 195
Certain infectious and parasitic diseases
Neoplasms
Diseases of the blood and blood-forming
organs
Endocrine, nutritional and metabolic diseases
Mental and behavioural disorders
Diseases of the nervous system
Diseases of the eye and adnexa
Diseases of the ear and mastoid process
Diseases of the circulatory system
Diseases of the respiratory system
Diseases of the digestive system
Diseases of the skin and subcutaneous tissue
Diseases of the musculoskeletal system and
connective tissue
Diseases of the genitourinary system
Pregnancy, childbirth and the puerperium
Congenital malformations deformations
Symptoms, signs and abnormal clinical and
laboratory findings
Injury,poisoning and other consequences of
external causes
Factors influencing health status and contact
with health services
All diagnoses combined
Standardise hospitalisation ratio
0-14 years 15-29 years
SHR=1
249 
 
 
 
Figure 88: Standardised hospitalisation ratio with 95% confidence interval after 
treatment completion by gender and cause of admissions (ICD-10) 
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8.5 Summary 
Morbidities that lead to hospitalisation were classified using primary and secondary 
diagnoses, in HES some causes always reported the main diagnosis while others did 
not. Therefore, the patterns of admission were assessed using primary and secondary 
diagnosis to ensure consistency in identifying common causes, without ignoring minor 
causes. Using both diagnoses (primary and secondary) ‘neoplasms’ were consistently 
the commonest reason for admission, followed by causes classified as ‘factors 
influencing health’. Leukaemia cases had the highest number of admissions compared 
with other diagnostic groups. 
The ranking of cause of admission from the highest percentage to lowest were similar 
during the on treatment and post-treatment phases, however, some causes had lower 
percentages of admissions after completion of cancer treatment, such as admissions for 
‘neoplasm’ causes, which decreased from 83% to 47% of total admissions during the on 
treatment and post-treatment phases, respectively. While the remaining percentage of 
cause of admission was slightly higher during the post-treatment phase than on 
treatment period. 
The percentages of admissions for ‘certain infectious and parasitic diseases’, ‘diseases 
of the blood’, ‘symptoms, signs and abnormal clinical and laboratory findings’, ‘injury, 
poisoning and certain other consequences of external causes’ and ‘factors influencing 
health status’ were higher during the on treatment phase than post-treatment phase for 
the majority of diagnostic groups, except for germ cell tumours. Similarly, the rate of 
admissions for ‘respiratory diseases’ was higher during the on treatment phase, except 
for lymphoma, CNS, renal tumours and germ cell tumours. 
Three-quarters of the cancer survivors were readmitted to hospital after completion of 
cancer treatment and those were mainly for causes coded as ‘factors influencing health’. 
Within which, children were admitter significantly earlier than TYAs for the majority of 
causes (median overall was 0.17 and 1.17 respectively, P-value=<0.001), except for 
admissions due to ‘mental and behavioural disorders’ and ‘diseases of the eye’, not 
significantly though. Leukaemia and bone tumour survivors had the earliest admissions 
after completion of cancer treatment. 
After completion of cancer treatment, about a third of the cases were admitted for 
neoplasm proposes (disease of the recurrent malignancy or subsequent primaries 
combined), in which the median time to first admission for those cases for all cancers 
combined was within one year of treatment completion, and it was shorter for children 
than TYAs, and was significantly shorter for leukaemia, lymphoma and CNS tumours. 
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The cancer cohort had about three times the number of admissions than the background 
population, and mainly for ‘diseases of the blood’ and ‘neoplasms’.  
Leukaemia, bone tumour and CNS tumour survivors had the highest SHR compared with 
other diagnostic groups. While, germ cell tumour survivors had the lowest standardised 
incidence rate. Leukaemia and bone tumour survivors had the highest SHR for 
‘endocrine, nutritional and metabolic diseases’ and ‘diseases of the circulatory system’ 
apart from neoplasms. While among CNS survivors, the SHR was highest among 
‘diseases of the nervous system’ just after neoplasm-related admissions. 
The SHR was higher among children than TYAs, apart from endocrine-related causes. 
The three highest causes of admission among children were ‘neoplasms’, ‘diseases of 
the blood’ and ‘circulatory diseases’, while among TYAs were for ‘diseases of the blood’, 
‘neoplasms’ and’ endocrine diseases’. The rate of pregnancy was lower among cancer 
survivors than the background population, and was lower among children than TYAs. 
For all causes combined, males had a higher SHR than females, however looking at 
detailed causes of admission, males had higher rates of admission only for ‘neoplasms’, 
‘diseases of the blood’ and ‘diseases of the nervous system’. 
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 Discussion  
9.1 Introduction 
This study primarily aimed to investigate patterns of hospital admissions among children 
and young people (CYP) with cancer following their diagnosis and during their treatment. 
It also aimed to identify hospital-related comorbidities upon treatment completion using 
a high-quality, specialist population-based cancer register and linked hospital activity 
data. 
Healthcare commissioners in England set an aim to improve the quality of life for cancer 
survivors, a population which is expected to grow to over three million people in England 
by 2030, by enhancing planning for services to meet their needs [16]. In order to plan for 
services, it is vital to understand the healthcare utilisation of cancer survivors and their 
related comorbidities. Therefore, this thesis, for the first time, provides a comprehensive 
analysis of cancer care, healthcare burden and related morbidity among cancer survivors 
from date of diagnosis and beyond for children and young people. The focus on morbidity 
that leads to hospitalisation emerged during the 20th century, and to date, research had 
mainly concentrated on long-term survivors, who were cancer free for more than five 
years following diagnosis [15, 23, 87, 92, 101, 140, 147, 149, 150]. However, little 
attention had been paid to the shorter term healthcare burden among survivors of CYP 
cancers [24]. 
Therefore, this thesis addresses a key knowledge gap by analysing the healthcare 
burden for all hospital-related causes among cancer cases during the treatment period 
following cancer diagnosis, as well as the period following treatment completion within 
and beyond five years from diagnosis. The purpose was to understand the risk of future 
hospitalisation and the size of the hospital burden on NHS services, so these can be 
planned locally and regionally in Yorkshire, given the unique population and ethnic 
diversity. The burden from hospital admissions during and after cancer treatment varied 
by cancer type, age group, gender, ethnicity, deprivation, and according to the proportion 
of time in specialist care services. The key novel findings which have arisen from this 
thesis are summarised below. These representing observational finding, and could be 
used as benchmark for future study to identify the reasons behind increasing the hospital 
burden among the below specified groups. 
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Finding 1: Bone tumour and leukaemia survivors had the highest risk of hospital 
admissions, and stayed longer in hospital during the treatment period and after treatment 
completion. 
Finding 2: TYAs aged 15-29 years at diagnosis had significantly (2%) lower levels of 
hospitalisation than children aged 0-14 years for all cancers combined, and for the 
majority of cancer types, except for leukaemia and renal tumours. Children received the 
vast majority of their care in specialist settings, and had a higher amount of specialist 
care compared with TYAs. Furthermore, children were more likely to return to hospital 
after completing their treatment, earlier and more often than TYAs. 
Finding 3: Females had higher levels of hospital activity in terms of length of stay 
compared with males, except for cases diagnosed with CNS tumours, where the 
opposite effect was found. Although the incidence rates of cancer were higher among 
males than females in the 0-29 years age range, especially for lymphoma and germ cell 
tumours, females with lymphoma and germ cell tumours had a higher median rate of 
admissions than males. Both males and females had a higher rate of admission than the 
background population, and males had a higher excess rate of admissions after 
treatment completion compared to females, especially those classified as for 
‘neoplasms’, ‘diseases of the blood’ and ‘diseases of the nervous system’. 
Finding 4: Although South Asians had higher rates of admission compared with non-
South Asians for all cancers combined, this difference was not significant after adjusting 
for patient case mix, except for STS where South Asians had 42% lower admission rates 
than non-south Asians.  A relationship between ethnicity and disease severity was found 
in previous studies, such that Asians with leukaemia, CNS or germ cell tumours were 
likely to have a poor prognosis, which may explain the higher rate of admissions 
observed in this thesis [49]. 
Finding 5: Socioeconomic status did not have a significant effect on the frequency of 
hospital admissions apart from those diagnosed with CNS tumours: cases from the least 
affluent areas were more likely to be admitted to hospital and stayed longer than cases 
from the most affluent areas, an effect which remained after adjusting for disease 
severity. 
Finding 6: The common causes of post-treatment admissions among cancer survivors 
varied by cancer type, age group and gender. Such admissions were mainly attributed 
to ‘neoplasms’ and ‘diseases of the blood’. 
Finding 7: Cancer survivors were at a higher risk of hospitalisation than the background 
population for various reasons after treatment completion. 
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A detailed discussion of the main findings is presented in the following sections by 
comparing the results with the available literature. The burden of hospital activity and 
related morbidity after diagnosis with cancer was analysed in two distinct phases, and 
results relating to each phase are discussed in the following sections: 1) on treatment 
period (Section 9.2), and 2) post-treatment period (Section 9.3). Within each section, the 
main findings are discussed relating to the hospital burden (the number of admissions 
and length of stay) and the cancer-related morbidities (focusing on the causes of 
admission). 
The factors that influenced hospital activity during the complete follow-up period are 
summarised separately by cancer types and for all cancers combined in Section 9.4.  
Finally, the clinical implications of the work are discussed in Section 9.5, the strengths 
and limitations of the work in Section 9.6 and 9.7, recommendations for future work in 
Section 9.8 and an overall conclusion is provided in Section 9.9.  
9.2 Hospital admissions during the treatment period 
This thesis comprises the first health services research study to analyse the in-hospital 
burden of healthcare utilisation during the treatment period for CYP diagnosed with 
cancer. Importantly, the analysis accounted for variations in treatment duration when 
assessing rates of hospitalisation. Furthermore, the cause of admission during the 
treatment period was studied in detail to help understand the scope of services needed, 
according to cancer type and age group. 
During the treatment period, there were 2,645 individuals with 49,831 admissions, with 
a median of 12 admissions per person (median of one follow-up-year per person, IQR 1-
2 years). In addition, cancer patients were in hospital for a total of 180,385 bed days 
during their treatment period, with a median of eight bed days per 100 person-days. 
Overall, children had a higher median number of admissions than TYAs for all cancers 
combined, having 16 and 9 admissions per person per year, respectively. In addition, 
children also had longer hospital stays during the treatment period than TYAs in all 
cancer types, except for leukaemia survivors (median length of stay = 11 and 27 days 
per 100 person-days for children and TYAs, respectively). 
Leukaemia survivors had the shortest time interval from diagnosis to first treatment with 
a median of one day among children and seven days among TYAs; 85% of leukaemia 
survivors were initially treated with chemotherapy. This, therefore, may have partly 
explained the highest pattern of admissions seen among leukaemia survivors compared 
with all other TYA survivors and the second highest admission rates among children. 
Patients receiving chemotherapy require frequent visits to hospital to receive their 
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treatment. Therefore, patients receiving chemotherapy are expected to have a higher 
number of admissions. 
Bone tumours had the highest median number of admissions among children and the 
second highest among TYAs, having 21 and 14 admissions per person per year, 
respectively. Additionally, CYP diagnosed with bone tumours had the longest hospital 
stays of 20 days on per 100 person-days during the treatment period compared with all 
other cancer types, where the median length of stay ranged from 4 to 17 days per 100 
person-days. 
During the treatment period, the most common causes of admissions were for treatment-
related conditions, including ‘certain infectious diseases’, ‘neoplasms’, ‘diseases of the 
blood’ and ‘respiratory diseases’, which varied by cancer type. Most cancers saw hospital 
admissions with such causes during the treatment period, however some other causes 
also commonly occurred both during the treatment period and after treatment completion 
for certain cancer types. These were: ‘diseases of the nervous system’ among leukaemia, 
bone tumour and germ cell tumour cases; ‘diseases of the digestive system’ among 
leukaemia, neuroblastoma, bone tumour and STS cases; ‘disease of the circulatory 
system’ among CNS and neuroblastoma cases; ‘diseases of the skin’ among leukaemia, 
CNS and neuroblastoma cases; and ‘diseases of the musculoskeletal system’ among 
leukaemia and bone tumour cases. The cause and the pattern of hospital usage before 
treatment completion had not been studied up to now. Therefore, this novel finding could 
highlight the complications that short-term survivors may experience and, therefore, the 
appropriate services that need to be available to manage these complications and meet 
the needs of young people. 
9.3 Hospital admissions during the post-treatment period  
One of the unique features of this work is the ability to help understand the hospital 
burden among cancer survivors from the point of treatment completion. Findings provide 
new knowledge on the frequency of admissions and length of stay in hospital, as well as 
the related causes of admissions, in order to plan for services immediately after 
completing cancer treatment and in the subsequent follow-up period.  
There were 2,304 cases who survived after treatment completion, 1,723 (75%) of which 
were admitted at least once after treatment completion and contributed to 12,140 
admissions with a median of three admissions per survivor. Additionally, they were 
hospitalised for 34,943 person-days with a median of six bed days per 100 person-days. 
Following treatment completion for all cancers combined, children had higher median 
rates of admission than TYAs, having 0.64 and 0.39 admissions per person-year, 
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respectively. However, TYA leukaemia and renal tumour survivors had a higher median 
number of admissions per person-year than children after treatment completion (Figure 
33). In terms of the number of days spent in hospital, children had longer hospital stays 
after completion of cancer treatment than TYAs, except for neuroblastoma and renal 
tumour cases, although TYA numbers were very small for these two latter groups. 
Children and young people with leukaemia and bone tumours had the highest hospital 
admission rates after treatment completion with 0.8 and 1.6 admissions per person-year 
on average. Additionally, CYP with bone tumours had the longest hospital stays out of 
all cancer types, with a median duration of 0.41 days per 100 person-days after 
completion of cancer treatment. 
Based on the results from the literature review in Chapter 3, only one study assessed 
the cancer-related effect during treatment phase, and focused on one specific cancer 
type (leukaemia and CNS tumours) [79]. Causes of morbidity considered as being long-
term cancer-related effects, such as ‘diseases of the circulatory system’, ‘mental 
disorders’, and ‘endocrine disorders’ [25, 49, 72, 87], were consistent with the thesis 
findings, as survivors were commonly admitted for these causes after they completed 
their treatment. Additionally, and contrary to other cancer types, ‘diseases of the 
respiratory system’ admissions occurred more often after treatment completion among 
lymphoma, CNS and renal tumour cases than during the treatment period. This suggests 
that different healthcare services need to be available at different stages of the life course 
for these cancer types.  
Using age, sex and attained year matched background population data, the excess rates 
of hospital admissions after treatment completion were analysed for all causes combined 
and separately by main causes of admissions. Cancer survivors were at a significantly 
higher risk of admission than the background population (SHR=2.37, 95% CI:2.26-2.49), 
except for pregnancy. This was a similar finding throughout the literature focused on 
long-term survivors, whereby the risk of admissions compared to a comparison or control 
group varied between 1.4 and 5.1 [12, 15, 23, 70, 71, 101, 149]. However, these studied 
focused on one age group, either childhood survivors (aged 0-20 years) [12], young 
people survivors (aged 20-24 years) [23], or on specific cancer types (HL) [70], or specific 
morbidity (cardiovascular diseases) [71]. Common causes that showed the highest 
frequency of admissions after completion of cancer treatment were ‘neoplasms’, 
‘diseases of the blood’ and ‘other factors influencing health’.  
The rate of pregnancy was lower among the cancer cohort compared with the 
background population (SHR=0.9, 95% CI: 0.7-1.2), probably explained by the higher 
prevalence of infertility within the cancer cohort, especially among TYAs due to the type 
of treatment received and the associated toxicity. When assessing the frequency of 
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admission for pregnancy causes by age at diagnosis, TYAs had a higher rate of 
admissions compared with children, adjusting for rates of admissions among the 
background population. This could reflect the fact that TYA survivors might suffer from 
infertility and delays in pregnancy more than childhood survivors, for example,  some 
studies found that females aged 13-20 years suffered from ovarian failure more than 
females aged less than 13 years old [204]. 
Childhood survivors were admitted earlier after treatment completion than TYA survivors 
for all causes combined (median=0.17 and 1.17 years, respectively). Additionally, 
children had a higher risk of excess hospitalisation than TYAs. This could be related to 
the fact that children were either more sensitive to the effects of chemotherapy or 
radiation therapy, or they had an excess risk of developing treatment-related 
complications, such as obesity, endocrine disorders and cardiomyopathy, in relation to 
the type of treatment received [14, 154, 205]. 
For all causes combined, males had a higher excess rate of admissions than females, 
having 2.8 and 2.0 times higher chance of hospitalisation, respectively, compared to the 
background population. However, the causes of these admissions were mainly for 
‘neoplasms’, ’diseases of the blood’,’ diseases of the nervous system’ and ‘factors 
influencing health status’.  The hospital admissions among 20,275 five-year survivors 
between 1992 and 1999 in Ontario, Canada, was studied and it was found a slightly 
higher relative rate of admissions among males than females of 1.7 and 1.5 respectively, 
compared with the background population [149]. Similarly, in another study of 1,564 five-
year survivors in 1996 to 1999 in Amsterdam, Netherlands, males displayed higher 
relative rates of admissions than females compared with the background of 2.4 and 2.0 
times higher, respectively [150]. Based on these findings, it can be assumed that males 
are more likely to suffer from cancer-related diseases resulting in hospitalisation almost 
immediately after completing cancer treatment, compared to females. 
Bone tumour and leukaemia cases had the earliest readmissions to hospital after 
completing cancer treatment out of all types. Furthermore, leukaemia survivors had the 
highest excess rate of admission followed by renal tumours, bone tumours and CNS 
tumours for all causes combined, when compared with the background population. 
Similarly,  in previous studies it was found that the hospitalisation rate among young 
people with leukaemia exhibited the highest relative rate of admission compared with the 
matched control group as found in previous studies [148]. Their study focused on 
morbidity among long-term survivors of cancer aged 20-24 years at diagnosis. They 
found that the common causes of admissions were for blood diseases, excluding 
admissions for recurrent neoplasm, this was similar to this thesis finding, as admissions 
for blood disorders were responsible for the second highest number of admissions after 
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neoplasms. Neoplasms had the highest excess rate of admissions among young people 
survivors in the study conducted in British Columbia, Canada comprising 902 survivors 
[23], which supports the finding of this thesis. One other long-term cancer survivor study 
found that CNS survivors had the highest excess rate of admissions compared with the 
background population [150], possibly due to the time frame that was used to estimate 
the health burden. In this study, they only considered five-year and beyond survivors 
from the date of diagnosis, whilst in this thesis, health burden was calculated from the 
date of treatment completion and that could be one year after diagnosis, i.e. it considered 
admissions occurring before five survival years after diagnosis. 
The most common form of morbidity that lead to hospitalisation varied by cancer types. 
Leukaemia had the highest excess rate of admissions due to the following causes, 
‘certain infectious diseases’, ‘diseases of the blood’, ‘diseases of the respiratory disease’, 
‘symptoms and signs of abnormal clinical findings’, ‘injury, poisoning and other external 
causes’, and ‘factors influencing health’. CNS tumours had the highest excess rate of 
admissions for the following causes: ‘endocrine, nutritional and metabolic disease’, 
‘diseases of the nervous system’, and ‘diseases of the eye’. Neuroblastoma survivors 
had the highest excess hospitalisation rate for ‘mental and behavioural disorders’, and 
‘diseases of the musculoskeletal system’. Renal tumour survivors had the highest excess 
risk of admissions for ‘diseases of the circulatory system’ and ‘congenital malformation’ 
compared with all other cancer types. 
9.4 Hospital admissions during the complete follow-up period 
The study comprised a total of 3,184 tumours pertaining to 3,151 individuals who 
contributed 22,104 person-years in the period from 1996 to 2009 in the former region of 
Yorkshire, with at least one post-diagnosis inpatient hospital admission. These 
individuals were responsible for 65,925 inpatient hospital episodes between January 
1997 and December 2011, with a median of 6.3 admissions per person per year. The 
total outpatient admissions were 114,496 hospital visits, with a median of 39 and 19 visits 
per person for children and TYAs, respectively. Additionally, the cancer cohort remained 
in the hospital as an inpatient and stayed for 215,328 person-days with a median of one 
day following diagnosis with cancer per 100 person-days. 
The factors that could affect the likelihood of hospital admission and length of stay 
following the point of diagnosis were analysed using descriptive and multivariable 
analysis. The univariable analysis was the focus of Chapter 6 and included a detailed 
analysis of the median number of admissions, adjusting for person-years of follow-up 
according to various explanatory variables, such as age at diagnosis, gender, ethnicity, 
deprivation and relapse status. The multivariable analysis used to estimate the rate ratio 
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of admissions and duration of inpatient admissions adjusting for patient demographics 
and clinical characteristics using negative binomial regression formed the basis of 
Chapter 7. These characteristics were: age at diagnosis, gender, ethnicity, deprivation, 
year of diagnosis, relapse status, proportion of specialist admissions/stays, and type of 
initial treatment. Their impact on admissions and length of stay varied by cancer type, 
therefore each main cancer typed is discussed separately in the following sections. The 
study focused on eight main cancer groups which accounted for the majority of cancers 
occurring among 0-29 year olds: leukaemia, lymphoma, CNS, neuroblastoma, renal 
tumours, bone tumours, STS, and germ cell tumours. Further justification for choosing 
these cancer types is mentioned in Chapter 4, Section 4.5. 
9.4.1 Leukaemia 
In univariable and multivariable analysis the age had an effect on the length of stay, 
TYAs had more than double the lengths of stay compared to children post diagnosis. 
This could be due to the fact that TYAs are more likely to be diagnosed with AML more 
often than ALL, in contrast to children where ALL is more common. As explained in 
Section 2.3.6, AML has a much poorer prognosis than ALL.  
After adjusting for demographic and clinical factors (age, sex, year of diagnosis, ethnicity , 
deprivation, proportion of specialist care, relapsed status and type of initial treatment), 
year of diagnosis, relapse status and type of initial treatment were all significant 
predictors of hospital admissions among leukaemia cases. Relapse cases represent 
higher risk cases than those who did not relapse, and are usually treated with intensive 
treatment, such as a bone marrow transplantation. Approximately 15% of leukaemia 
survivors received a BMT, of whom 47% relapse at least once. Survivors having a BMT 
may suffer from a weak immune system, and consequently be admitted to hospital due 
to infectious diseases, bleeding and liver disease [206].  
Cases treated with chemotherapy and radiotherapy, or with chemotherapy and surgery 
had significantly higher hospitalisation rates than cases treated with chemotherapy alone, 
after accounting for person follow-up years, patient demographic factors, relapse status 
and the level of specialist care. This finding was similar to what has been found 
previously, in that survivors treated with chemotherapy and surgery required a higher 
level of day care during treatment compared with survivors who had received other 
treatment modalities, with double the hospitalisation rate compared to cases with another 
treatment modality [140]. On the other hand, results showed that survivors treated with 
radiotherapy alone were found to have significantly lower admission rates than survivors 
treated with chemotherapy alone. In contrast,  other studies found that survivors treated 
with radiotherapy had higher hospital admissions than survivors treated with surgery 
alone [140]. However, in their analysis the effect of treatment on hospitalisation was 
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limited to long-term survivors and their analyses were not separated by cancer type. 
Additionally, they used surgery alone as a reference group in their statistical modelling, 
instead of chemotherapy, and their finding was not significant. In this thesis, leukaemia 
survivors treated with chemotherapy alone were the most common treatment modality 
grouping and, therefore, chosen as the reference group to ensure robust parameter 
estimates. As explained in Chapter 2, leukaemia survivors were expected to have 
concurrent admissions during their treatment period to receive chemotherapy in different 
cycles or regimes at different time points for around six cycles that could last up to 10 
months for ALL tumours, compared with one cycle of radiotherapy [29]. In comparison 
to leukaemia cases who were initially treated with chemotherapy alone, survivors treated 
with radiotherapy had shorter hospital stays. This could be explained by the limited 
number of survivors treated with radiotherapy in this study compared with survivors 
treated with chemotherapy. Additionally, the chemotherapy regime included multiple 
treatment cycles during the remission stage, and it was found that survivors of AML on 
average stayed for around 30 days per cycle [206]. Chemotherapy is usually 
administered as a day care surgery procedure or an outpatient admission [79, 140], while 
surgical procedures require longer inpatient stays to monitor patients’ health before and 
after surgery. 
9.4.2 Lymphoma 
Lymphoma cases contributed to 22% of all admissions from the Yorkshire registry cohort 
with a median of 16 inpatient admissions per person. This was the most common cancer 
type among TYAs. A study, conducted in the USA, assessed the prevalence of 
admissions among long-term survivors of childhood and young adult cancer aged 0-20 
years and found that the risk of hospitalisation was highest among lymphoma, rather 
than leukaemia survivors [12]. However, their analysis was based on questionnaires 
rather than (electronic) hospital records, therefore may have been prone to typographical 
and other recording errors during the transcription process. It also highlights the level of 
morbidity that might exist among these survivors, emphasising the importance in 
understanding the hospital burden and, accordingly, planning of appropriate services. 
Age at diagnosis, gender, deprivation, ethnicity and proportion of time spent within 
specialist hospital providers had no impact on the patterns of hospital admissions for this 
cancer group. However, the type of initial treatment had a significant effect on the rate of 
admission after adjusting for demographic and clinical factors. Survivors who received 
chemotherapy had the highest admission rates compared with any other treatment 
modality. This was similar to leukaemia survivors, suggesting that the management of 
chemotherapy included more frequent visits to hospital to receive treatment and to 
recover from certain side effects of treatment, compared to other treatment modalities.  
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Lymphoma survivors were one of the cancer types that received relatively limited levels 
of admissions to specialist centres. However, length of stay was longer among survivors 
receiving more of their care from specialist units during the off-treatment and follow-up 
period. This could suggest that lymphoma survivors who received most of their care in 
specialist units had longer stays in hospital after diagnosis of their cancer than those who 
were primarily seen in non-specialist units. This could be due to the stage or severity of 
disease among cases treated in specialist units, as there is evidence that patients treated 
in principal treatment centres had a poor prognosis compared to those seen in non-PTC 
units [127]. However, in the current analysis disease severity was adjusted for using type 
of initial treatment and relapse status. Survivors with a poor prognosis often experienced 
relapses of the disease and were treated on more aggressive regimes than other 
tumours with a better prognosis. In the current analysis these factors were taken into 
account, drawing the conclusion that there is a clear relationship between level of 
specialist care and length of stay. 
9.4.3 CNS tumours 
Children diagnosed with CNS tumours had significantly higher rates of admission than 
TYAs, indicating that either children needed to be treated quite often in an inpatient 
setting compared to TYAs, or that they were more susceptible to treatment side effects 
than TYAs. 
Female CNS tumour survivors had significantly shorter hospital stays than males in the 
multivariable analysis. This was a novel finding as there have been no previously 
published studies which compared cancer-specific hospital activity by gender or other 
patient characteristics. 
The other significant predictor of hospitalisation was deprivation, such that those 
diagnosed in the most deprived areas had more hospital admissions than those from the 
least deprived areas after adjusting for relapse status, disease severity and place of care.  
The percentage of CNS tumour cases in Yorkshire was found to be varied by place of 
care and management of treatment over the study period (1990-2009) [127]. Year of 
diagnosis was adjusted for in the current analysis to reduce the effect of confounding 
data due to changes in healthcare delivery over time, with results showing that the 
number of admissions increased by 4% (95%CI:2-7%) throughout the study period. 
CNS tumour patients from the most deprived areas at diagnosis had higher admission 
rates compared to those from the least deprived areas. There have been no published 
studies to analyse the pattern of healthcare activity among CNS tumours specifically in 
relation to socioeconomic status. However, a study from Taiwan included 32,800 cancer 
deaths and found that cases associated with low socioeconomic status were more likely 
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to receive more aggressive care in terms of hospitalisation and type of treatment 
received than cases with high socioeconomic status during the end of their life [207]. 
Although not specific to CNS survivors, long-term admissions for ‘respiratory diseases’ 
and ‘other external causes of morbidity’ significantly increased with levels of deprivation 
[101]. Although to date no reasonable explanation has been presented for this fact, it 
could be understood that cases with low socioeconomic status might be presented with 
more aggressive/advanced cancer types.   
Surgery alone was the most common form of treatment for CNS survivors within the 
study population, whereby these cases had lower admission rates than those who were 
treated initially with chemotherapy alone. Similar to leukaemia survivors, this could have 
occurred due to the nature of  chemotherapy, which requires a longer hospital stay than 
surgery alone, and may also require monitoring for longer periods in case of any 
subsequent treatment-related admissions, as compared to surgery alone. 
The amount of time seen within specialist care services also had a significant effect on 
length of hospital stay, so that those receiving mostly specialist care services had a 
shorter hospital stay than those who had limited or no specialist care. Those who 
received their care based within high-volume oncology departments had shorter hospital 
stays on average compared to those who did not [22]. 
9.4.4 Neuroblastoma 
Due to the limited number of diagnoses within this group, it was not possible to identify 
significant factors associated with the likelihood of admissions and hospital duration. This 
could be the focus of a future study by including more cases derived from either national 
or international datasets to identify the predictors of hospital activity for survivors of 
neuroblastoma. 
9.4.5 Renal tumours 
Contrary to what was observed for CNS survivors, TYAs diagnosed with renal tumours 
had higher rates of admissions compared with children based on results from the 
multivariable analysis. Renal tumour patients received mostly specialist care, and had 
significantly higher rates of admissions and longer hospital stays compared to those who 
received only limited specialist care. 
9.4.6 Bone tumours 
In addition to the year of diagnosis and relapse status (where the number of admissions 
and lengths of stay increased for more recent years of diagnosis and for those who 
relapsed), children had higher rates of admission than TYAs. This finding is supported 
by earlier work explained in the literature review in Chapter 3, that children are sensitive 
to the treatment side-effects for radiotherapy and chemotherapy, such as a higher risk 
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of cardiac complications due to chemotherapy agents, and other mental diseases as a 
result of radiation exposure [12, 14, 33, 154]. 
9.4.7 Soft tissue sarcoma  
STS was the only cancer type that showed an association between ethnic group and 
admission rate and length of hospital stay. South Asians had lower rates of admissions 
and lengths of stay than non-South Asians. The only other vaguely similar study from 
the literature which supported this finding was from a study conducted in Spain, which 
found that foreign citizens who came from high or low economic countries had lower 
rates of admissions than local citizens [208]. However, two key limitations of the study 
was that the analyses related only to adult admissions and they did not specifically refer 
to cancer survivors. 
9.4.8 Germ cell tumours 
Children aged 0-4 at diagnosis had higher rates of admission than older children and 
TYAs. Additionally, older children had shorter hospital stays than younger children. 
Survivors who received most of their admissions in specialist care settings had fewer 
hospital admissions and a shorter length of stay than survivors who receive limited 
specialist care admissions.  
9.4.9 Overall cancers combined 
9.4.9.1 Cancer types 
Leukaemia diagnoses accounted for 40% (24,502 admissions) of total post diagnosis 
inpatient admissions and 36% (40,959 admissions) of outpatient admissions. Survivors 
treated with both chemotherapy and surgery were found to be at a higher risk of an 
inpatient admission compared to any other treatment modality [140]. This supports the 
fact that higher admission rates were seen among leukaemia cases compared with other 
cancer types, since 88% of these individuals received chemotherapy and surgery as part 
of their main treatment. Among those cases, inpatient admissions and outpatient 
admissions were higher among children than TYAs, with a median of 41 and 20 inpatient 
admissions, respectively, and 80 and 21 outpatient admissions, respectively (Chapter 6, 
Figure 33 and Table 35). Children had a pronounced difference in inpatient admission 
patterns compared with outpatient admissions, while the difference was much less 
marked among TYAs. This was supported by findings from other studies who showed 
that leukaemia survivors experienced more outpatient admissions than inpatient 
admissions [79]. This could be explained by the type of treatment received, as childhood 
leukaemia patients commonly receive their chemotherapy in an outpatient setting [160]. 
There are several reasons which could explain the difference in inpatient and outpatient 
admissions between children and TYAs: one reason could be because of compliance to 
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treatment, whereby TYAs could be less compliant with their treatment regime [209], 
thereby also affecting compliance with outpatient admissions. Another reason might be 
the difference in leukaemia histological subgroups: ALL is a more common subtype 
among children while AML is common among TYAs, resulting in different treatment 
management. Furthermore, the cytogenetic characteristics of leukaemia are different 
among children compared to adolescents and young adults, with more favourable 
cytogenetic profiles commonly seen in children compared to TYAs [210]. Additionally, in 
contrast to children, TYAs are less likely to receive most of their care in a specialist unit 
given the variation in place of care for this age group, possibly leading to different 
outcomes [134]. For example, in this study, only 42% of TYAs received the majority of 
their admissions in specialist centres, compared with 85% of children (Chapter 5, Section 
5.3.3.5 ). 
Although bone tumour survivors accounted for only 7% of total admissions, they were 
responsible for the highest median number of admissions among children, and the 
second highest number of admissions among TYAs. This was similar to what has been 
reported in a study conducted among long-term childhood and adolescent survivors, 
where bone tumours had the highest ratio of admissions adjusting for the background 
population than other cancer types [15]. In their paper, Kirchhoff, et al. argued that bone 
tumour survivors may suffer from severe long-term side-effects of treatment, such as 
cardiomyopathy and other physical complications that explain the elevated risk of 
admission [15]. Furthermore, bone tumour patients may experience higher rates of 
admissions for second malignancies compared with leukaemia, as reported in a study 
which focused on childhood bone tumour survivors [24]. Results from this thesis support 
these findings, such that bone tumour survivors had the highest rate of relapse with 
around 25% of cases experiencing recurrent disease in the current analysis.  
9.4.9.2 Age group at diagnosis 
Children had a higher median number of admissions adjusted for person-years of follow-
up than TYAs, with an average of four and two admissions, respectively, per person. 
This was consistent with the literature [12], with children more likely to require higher 
levels of hospital admissions due to the complexity of the disease. Additionally, the 
increased risk of hospitalisation among children may also be related to the fact that they 
are still growing, and their organs may be more sensitive to the type of treatment received, 
therefore more likely to develop long-term effects on organ development [12]. 
Additionally, the nature of the treatment could elevate the frequency of admissions and 
length of stay for the younger age group, where their treatment is usually more intensive 
than TYAs [101]. 
9.4.9.3 Ethnicity 
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South Asians had a higher median number of admissions than non-South Asians for all 
cancer types, except for STS. However, the multivariable analysis results showed that 
the effect of ethnicity was only significant among STS. The limited number of cases and, 
therefore, power could have led to a failure to identify the influence of ethnicity on hospital 
activity for other cancer types. Nevertheless, this finding warrants further investigation in 
larger populations according to ethnic group, to confirm whether this effect can be 
replicated. 
9.4.9.4 Deprivation 
The rate of admissions was significantly higher among those from the most deprived 
areas, compared to those originating from the least deprived areas. In a Canadian study 
that investigated hospital activity and socioeconomic disparities, income was used as a 
proxy for deprivation [211]. Similar results were seen, such that those with lower incomes 
tended to have higher hospital admissions than those with higher incomes, suggesting 
that individuals from lower income households require more hospital care, even after a 
cure from their cancer.  
9.4.9.5 Year of diagnosis 
For all cancers combined and for all cancer subtypes, the rate of admission and length 
of stay significantly increased by year of diagnosis. This finding could be explained by 
improvements in the recording of admissions within HES data over time. The payment 
by results system was introduced in 2002/2003. It was issued as a tool to monitor health 
service quality among NHS settings, and consequently, as a mechanism through which 
NHS trusts received their annual funding. The rate of admissions based on year of 
diagnosis increased from 3% in 1997 to 7% in 2009 (Figure 29), with a slight increase in 
admissions after 2003; 48% of total admissions occurred before 2003 and 52% after 
2003. The results from the multivariable modelling (adjusting for person-years) showed 
that after separating cases into those diagnosed before and after 2003, the rate of 
admission increased significantly by 53% per person (95% CI: 41-66%) among cases 
diagnosed after introducing payment by results. This artefactual increase in recording of 
HES records needs to be borne in mind when interpreting findings from this thesis.  
9.4.9.6 Gender  
Differences in the median number of inpatient admissions by gender were fairly modest 
with a slight excess among females compared to males (medians of 2.5 and 2 per person 
per year for females and males, respectively). This was consistent with some of the 
previous studies , that reported a similar rate of admission between males and females 
[149]. Another study, conducted in the USA, found a slight increase in the incidence of 
admissions among females compared to males, with incidence rates of 108.5 and 177.3 
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admissions per 1,000 person-years for males and females, respectively. Both of these 
studies refer to five-year cancer survivors, therefore information on admissions during 
treatment or immediately after treatment completion was not included. As yet, there have 
been no reported studies to analyse hospital activity beyond the date of diagnosis, thus 
precluding any formal comparisons with the current work reported in this thesis. Thus, 
the results of this current work provide the first detailed health services research study 
on hospital use from the date of diagnosis and beyond. 
9.4.9.7 Year of admission  
During the admission study period from 1997 to 2011, the percentage of admissions by 
year of admission increased from 4% in 1998 to 6% in 2010 (Chapter 6). This percentage 
fluctuated during the study period and peaked during 2005 to 2007 with 9% of total 
admissions, reflecting the increase in cancer incidence rates observed in 2005, when 
rates also peaked at 205 per million person-years. 
After adjusting for person-years, the median number of admissions and length of stay 
decreased over time for the majority of main cancer types (Chapter 6, Figure 49 and 
Figure 53). This was supported by findings in Canada, where the rate of hospital 
admissions also decreased over time [149]. However, their analysis was limited to  
survivors of young adult cancer aged 20-44 years at diagnosis, and who survived more 
than five years from diagnosis. 
However, the pattern of admissions among childhood bone tumour patients began to 
increase more than eight years after treatment completion. This could raise future clinical 
concerns for long-term bone tumour survivors, so that appropriate services can be 
planned and made available.  
9.4.9.8 Level of specialist care 
The National Institute for Health and Care Excellence (NICE) set out guidelines to trusts 
in England, in order to provide optimal cancer care and outcomes for children and young 
people [11]. The guidelines included recommendations for specific age-appropriate 
cancer services, as described in Section 2.4.  
Cases were classified as receiving specialist care if they were admitted to a PTC or 
cancer specialist centre (more detail in Chapter 4). For all cancers combined, around 45% 
of survivors received most of their admissions in specialist units (Chapter 5, Figure 21). 
Children aged 0-14 years had a higher percentage of admissions in specialist units 
compared to TYAs aged 15-29 years. This could be explained by the lack of consistency 
in cancer referrals to specialist units for TYAs. Although the majority of children and TYAs 
in the current study received their care in specialist centres, mainly Leeds General 
Infirmary and St James's University Hospital, other specialist centres where patients 
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were managed included Sheffield Children's Hospital and Birmingham Children's 
Hospital (Chapter 4, Section 4.11.6).  
The median number of admissions was higher among those who had the majority of their 
admissions in specialist cancer units (median=21, IQR=8-40). The difference in the 
median number of admissions was more pronounced during the treatment period for 
those seen mostly in specialist units, receiving a median of 18 admissions during the 
treatment period, compared with seven admissions among those seen much less often 
in specialist services. The difference in admissions was more modest after treatment 
completion, with median numbers of four and three admissions, respectively. This could 
suggest that cases referred to specialist centres might be cases with more advanced 
disease or may be being treat with more complex modalities. 
The impact of level of specialist care units on hospital admissions and length of stay was 
similar before and after adjusting for age, sex, ethnicity, deprivation and type of initial 
treatment: cases receiving a higher proportion of specialist care had an increased 
number of hospital admissions and a longer stay in hospital. This varied by cancer type, 
as explained previously in Sections 9.4.1 to 9.4.8. 
9.4.9.9 Initial treatment 
Cases initially treated with chemotherapy and radiotherapy in combination had higher 
rates of admission and stayed longer in hospital than cases treated with chemotherapy 
alone. In contrary, other type of initial treatment such as surgery alone, radiotherapy 
alone, or combination of both had lower ate of admissions and stay for shorter period 
than cases treated with chemotherapy alone. This could indicate that those who received 
chemotherapy visited hospital more often to receive treatment, or perhaps could be due 
to complications of the treatment [12].  It was found that out of all long-term survivors, 
those treated with chemotherapy had the highest hospitalisation rate, ranging from 135.9 
to 185.3 per 1,000 person-years dependent on the chemotherapy agents used 
(Anthracyline, Bleomycin and Cisplatinum) in previous studies[12]. However, in their 
study only radiation therapy was significantly associated with an increase in 
hospitalisation rates compared with the background population, after adjusting for 
demographic characteristics. Similarly,    some studies found an increase in the number 
of admissions among long-term survivors treated with radiotherapy [70, 140, 150]. This 
finding does not necessarily contradict those within this thesis, as the data structure and 
analysis was different, focusing on the effect of treatment on both short- and long-term 
survivors after being diagnosed with cancer. Therefore, the increase in hospitalisation 
among cases treated with chemotherapy compared with other treatment modalities could 
have arisen due to consideration of the period before completion of cancer treatment. 
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In this thesis, several data sources were used to identify the type of initial treatment, 
notably a specialist population-based cancer register, HES and direct abstractions from 
medical records. The recording of treatment in the cancer register was significantly better 
than HES, as around 91% and 97% of total cases were recorded as receiving 
chemotherapy and radiotherapy, respectively, compared to only 75% and 5% from within 
HES. Furthermore, there were still 9% of cases who had no reported treatment despite 
cross-checks from multiple sources, as listed above.  
It was found that cases with no record of any initial treatment had significant lower rates 
of admission than cases treated with chemotherapy alone when diagnosed with 
lymphoma, CNS, neuroblastoma, bone tumours, STS and gem cell tumours. Additionally, 
these individuals had a significantly shorter hospital stay compared with those treated 
with chemotherapy alone among CNS, bone tumours and germ cell tumours. Cases with 
CNS tumours had the highest percentage of cases with no recorded initial treatment, 
possibly explained by the fact that this group would include certain benign tumours, 
necessitating patients being monitored for any tumour progression.  
9.4.9.10 Relapsed disease 
This study identified the pattern of admissions among relapsed cases, in contrast to 
those who did not experience a relapse of their disease, from the date of primary 
diagnosis to date of relapse. The purpose was to provide information on hospital burden 
from relapse for healthcare planners. The majority of relapsed cases were diagnosed 
with bone tumours. The median time to relapse varied by diagnostic group: for all cancers 
combined this was 17 months after diagnosis, and ranged from 8-20 months according 
to cancer subtype. For diagnostic groups such as leukaemia, where the median time to 
relapse was 20 months from diagnosis, the pattern of admissions overall was higher 
among relapsed cases than those who never relapsed, evident even from the date of 
diagnosis. The difference in the median number of admissions for those who relapsed 
compared to non-relapsed cases was significant 48 months after diagnosis.  
The difference in the pattern of admissions over time among relapsed and non-relapsed 
cases was pronounced in terms of length of stay, since relapsed survivors had 
significantly longer hospital stays compared to non-relapsed survivors, especially among 
cases with lymphoma. However, this difference was less pronounced among leukaemia, 
CNS and bone tumour cases.  
Cases who relapsed had significantly higher rates of admission and stayed longer in 
hospital than those who did not relapse. Excluding relapsed cases from the analysis did 
not affect the factors that impacted the rate of hospitalisation, for example the rate of 
admissions decreased by each single year increase in age. 
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The predictors of admissions among relapsed and non-relapsed cases were similar, 
except for the proportion of specialist care. Relapsed cases had shorter hospital stays 
among cases receiving totally specialist care, compared to cases receiving non-
specialist care, while the opposite pattern occurred among non-relapsed cases. This 
could suggest that survivors with poor disease prognosis at diagnosis were more likely 
to receive their care in non-specialist units, while non-relapsed survivors, who may be 
more likely to have less advanced disease at diagnosis receive the majority of their care 
in specialist cancer settings. Moreover, those with a very poor prognosis may have been 
transferred to a hospice or other palliative care service to deal with terminal illness. PTCs 
or specialist centres could be more properly plan for cases with advanced disease by 
reducing the treatment intensity, thus reducing complications and more likely 
encouraging cases with terminal disease to be treated in hospices or at home [11], 
whereby their admission to hospital decreases, respectively [212, 213].  
9.4.9.11 Bone marrow transplant 
It is recommended that patients treated with radiotherapy as a part of a bone marrow 
transplant need to be followed up beyond five years after treatment completion [214]. 
This was highlighted because bone marrow transplant patients are at a higher risk of 
cancer recurrence than those who have not undergone such a procedure [214].  
Neuroblastoma cases (25%) were the most likely to be treated with a BMT, followed by 
leukaemia (15%). After completion of cancer treatment, cases treated with a BMT had a 
significantly higher rate of admissions compared to cases who had not been treated with 
a BMT, after adjusting for age, sex, ethnicity, deprivation and type of initial treatment 
modality. Cases with a BMT had 54% higher admissions after completion of cancer 
treatment than cases who did not receive a BMT. Cases treated with a BMT and 
classified as receiving ‘some’ of their care at specialist units were found to have 
significant lower rates of admission after completion of treatment, compared to cases 
who received a ‘limited’ amount of specialist care. 
9.4.9.12 Deceased patients 
It was clear from the results of the literature review (Chapter 3), that there is very little 
information on hospital usage for those living with and beyond cancer, especially in terms 
of the effects of place of care, relapse status and type of treatment received during end 
of life care [152]. Understanding the range of services needed for those with terminal 
disease is vital for healthcare providers and commissioners, in order to plan services 
effectively. The aim was to identify whether the pattern of admissions differed among 
those who survived compared to deceased individuals. Deceased cases were analysed 
separately, as these individuals may represent a particular ‘high risk’ group of cancer 
patients, which may confound hospital activity analyses.  
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In this study, 21% of cases died during the follow-up period, and their median number of 
admissions increased from the date of diagnosis towards the last year of their life, such 
that the median number increased to nine admissions per person per year during the 
last year of life (Figure 48). This was supported by a systematic review based on 78 
studies, that found that hospital admissions increased sharply near the date of death 
[152]. However, their study did not include children or young adults in their analysis. 
Therefore, the current analysis provides unique information on the CYP age range. 
In the multivariable analysis, the ratio of admissions was similar according to patient 
characteristics for both the deceased and non-deceased groups. The only clear 
difference was for the volume of specialist care admissions, such that the non-deceased 
group had significantly higher admission rates among cases with higher levels of 
specialist care compared to cases with no specialist care, whilst among the deceased 
population, the rate of admission was significantly higher for those who received no 
specialist care. This could be explained by the fact that cases with more severe and 
advanced disease may be referred to palliative care services, so that care can be 
delivered in the home, rather than in the hospital setting.   Cancer survivors that were 
transferred to specialist paediatric palliative care services had lower hospital admissions 
than those who were not, and this correlates with the decrease in the number of 
admissions for those who died during the follow-up period and received most of their 
care in specialist units [48].  
Deceased individuals and those who relapsed had lower admissions when receiving the 
majority of their care in specialist cancer services, compared with those who received 
most of their care outside dedicated units. This suggests that specialist centres were 
more likely to provide care for those with a poor prognosis. Furthermore, these 
individuals might be more likely to be transferred to other healthcare settings that deal 
with terminal diseases, such as hospices. Future studies might therefore wish to look at 
hospital burden and the relationship between the level of specialist care and disease 
severity.  
9.5 Clinical implications of the work 
This sections include some recommendations based on the thesis key findings, to be 
addressed by healthcare providers and healthcare commissioners to provide appropriate 
services among the cancer cohort, and for patients and their families to cope with cancer 
and its related influence on their health, education and future career. 
The hospital admissions for children and young people diagnosed with cancer and were 
linked to HES appeared to be slightly increased over time, ranging from 2% to 3% of 
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admissions in the period from 1997 to 2011 (Chapter 6), and the rate of admissions and 
length of stay significantly increased by diagnosis year (Chapter 7). This highlights an 
increased need for hospital resources in the future. Despite the results being tailored to 
cases diagnosed between 1996 and 2009, this thesis is the first baseline clinical data on 
hospital admissions both during and after the treatment phase for CYP, and can be used 
as a benchmark for future studies both in the UK and internationally.  
The study highlighted the characteristics that can impact upon the risk of admission and 
length of stay. These were summarised as follows: 1) Children had higher rates of 
admissions and stayed for longer periods in hospital than TYAs for all cancers combined; 
2) females had significantly longer hospital stays than males when diagnosed with 
leukaemia; 3) South Asians with STS had significantly lower hospital admissions and 
shorter lengths of stay than non-South Asians; 4) for all cancers combined, the most 
deprived cases had the highest hospital admissions and longest hospital stays, and that 
was significant among CNS cases; 5) cases receiving mostly specialist admissions were 
likely to stay for longer periods in hospital than cases receiving limited specialist 
admissions, demonstrating a disproportion in hospitalisation use by place of care; 6) 
cases with relapsed disease had a greater risk of hospitalisation and stayed for longer 
periods in hospital compared with non-relapsed cases, and that difference was present 
one year after date of diagnosis, especially for lymphoma cases and bone tumour cases 
although the rate of admissions sharply decreased after the date of the relapse, those 
cases were at continuous risk of hospitalisation, even four years after relapse; 7) bone 
tumour and leukaemia cases represented the tumour groups with the highest level of 
hospital activity for both children and TYAs – healthcare providers in Yorkshire need to 
be aware of the hospital burden among CYP diagnosed with bone tumours and 
leukaemia in particular. Future studies should attempt to identify the causes of the 
increase in admissions by looking at national cancer registry and linked HES data. The 
effect on survival and other health outcomes from those receiving different levels of 
specialist care especially for TYA should also be investigated in the future more closely 
to try to explain the finding of higher rates of admissions and a longer hospital stay 
associated with those having a higher proportion of their care in specialist settings. The 
ongoing BRIGHTLIGHT study may provide answers to some of these questions [216]. 
Healthcare commissioners need to ensure that capacity exists within their local clinical 
teams to meet the needs of these individuals. Dealing effectively with any treatment-
related effects resulting in a hospital admission will have a benefit to young cancer 
survivors, given the potential life years to be gained in living beyond childhood and young 
adulthood. 
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The level of specialist care received was found to impact upon health outcomes among 
TYA survivors in earlier studies [8]. In this thesis, the CYP outcome was similarly 
impacted by the specialist centre, from the date of diagnosis throughout the follow-up 
period, where cases treated in specialist centres had higher rates of admissions and 
longer lengths of stay for all cancers combined. However, TYAs received lower levels of 
specialist care than children, this increases awareness of the fact that TYAs still lack 
centralised services. This finding could feed in to the BRIGHTLIGHT 
(www.brightlightstudy.com) objectives, by providing an evidence-based study 
emphasising the continuous work needed to allocate centralised services for TYAs aged 
15-29. BRIGHLIGHT is a national collaboration focusing on assessing the impact of 
specialist centres on TYA outcomes. 
Deceased cases had the highest median number of admissions one year prior to death 
(Chapter 6), and the rate of admissions was lower among cases treated mostly in 
specialist centres than cases with limited specialist care (Chapter 7). This highlights the 
fact that treating cases with terminal illness in specialist centres reduces hospital 
admissions, thus specialist centres have the advantage of providing CYP with a better 
quality of life after being diagnosed with cancer. This is evidenced by earlier work in 
Yorkshire, which assessed the impact of specialist palliative care in reducing hospital 
admissions among childhood survivors aged 0-19 and diagnosed between 1990 and 
2009 [48]. Therefore, collaboration between professionals, including healthcare 
providers (doctors) and commissioners, is necessary to implement regulations to ensure 
that CYP with terminal illness are referred to specialist palliative care services or 
hospices to reduce unnecessary admissions, as this allows patients to be treated at 
home with the availability of 24/7 nursing support, thus personal, economic and social 
benefits might be attained by such cases. 
Most of the cancer epidemiological studies focused on cancer’s late effects using five-
year survival outcomes as a cut-off point indicative of ‘cure’, irrespective of treatment 
modality or duration [15, 71, 101, 140, 150]. Using the arbitrary five-year survival could 
hide the true burden of health among survivors after completing their treatment – 12,474 
admissions in this thesis occurred after treatment completion within five-years of 
diagnosis, which might be omitted in the analysis in earlier published studies. Additionally, 
the treatment duration varies by cancer type, where leukaemia cases often require up to 
three years of chemotherapy treatment, whilst some CNS tumours require 18 to 27 
months of chemotherapy and/or radiotherapy [79]. The Teenagers and Young Adults 
with Cancer (TYAC) group includes multi-disciplinary professionals, and was established 
in 2004 with the aim of improving quality of life among young people with cancer at a 
national level. This group, in 2014, highlighted the importance of the availability of a 
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detailed summary of the treatment plan, including date of treatment completion from 
every healthcare centre, to provide young people with cancer with a better quality of life, 
by supporting the patient after the end of treatment. This also allows them to assess the 
influence of treatment change on patient outcome, in terms of length of stay and survival 
rate after treatment is completed. This thesis is the first health services study to estimate 
approximate treatment duration by cancer type, hence, assign date of treatment 
completion for each case. This provide a more accurate estimate of hospital admissions 
occurring during and after treatment completion, where it was found that the majority of 
admissions occurred during the first three years after treatment completion (Chapter 6). 
Therefore, this thesis has identified a critical phase in the care pathway for survivors 
immediately after the end of their main treatment phase, resulting in a significant burden 
on secondary care services, and supports further health services research to establish 
the causes of these hospitalisations. However, the estimation of date of treatment 
completion was tailored to the specific cancer types due to the limited number of cases, 
hence this needs to be replicated at a national level to include more cases sufficient to 
assess the impact of treatment changes on hospital usage among all cancers occurring 
among CYP. 
Finally, a third of the cases were admitted at least once after treatment completion, and 
had double the rate of admissions compared to the background population after 
completion of cancer treatment. The majority of cases were related to diseases of the 
blood, neoplasms and endocrine diseases. Leukaemia survivors had the highest rate of 
admissions than other cancer groups and was six-times higher among children than 
TYAs, apart from endocrine diseases. Females had the highest excess rate of endocrine 
illness compared to males after treatment completion. Health strategies need to be 
issued to encourage TYAs, along with children, to take part in short- and long-term health 
surveillance, particularly for endocrine and metabolic diseases, and to increase 
awareness among survivors and their healthcare providers to ensure appropriate 
services are available to improve survivors’ quality of life beyond cancer. 
9.6 Strengths 
A key strength was the ability to extract data from a population-based cancer register 
with high levels of case ascertainment and with active follow-up every two years for 
almost all current survivors (0.8% lost to follow-up, [172]). Details included relapse, 
recurrence of malignancy, death and any subsequent treatment. A unique feature of the 
cancer register is the inclusion of all newly diagnosed cases aged up to 30 years, 
providing important new information on hospital activity patterns within the entire 
childhood, teenage and young adult age range.  
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Electronic linkage of cases between the cancer registry and hospital records allowed an 
efficient and comprehensive analysis on health burden to be described. Most previous 
reports on health outcomes from the epidemiological research literature have mainly 
emerged from two large-scale retrospective cohort studies: the Childhood Cancer 
Survivorship Study (CCSS) in the United States [12, 147], and the British Childhood 
Cancer Survivorship Study (BCCSS) [217]. Information on survivors’ late comorbidity 
was extracted from self-reported questionnaires, in contrast to this thesis. Data gained 
from questionnaires pertaining to long-term survivors is prone to recall bias and is likely 
to be subjective, whilst data drawn from administrative sources tend to be more objective, 
and relatively consistent between hospital attendees. 
Individuals treated in PTCs should be treated according to recognised national clinical 
guidelines and standards [11]. However, there will be more heterogeneity within the TYA 
age group since a higher proportion were/will be treated outside of PTCs. So, results 
should be reasonably generalizable for the study population of 0-24 year olds seen within 
PTCs. Additionally, cases were extracted from a single population-based specialist 
childhood and young adult cancer register that used multiple sources of ascertainment 
[159], thus minimising any selection bias or any duplication of cancer registrations. 
There was a small but limited published literature on hospital admissions describing the 
health burden among children and young adults with cancer [15, 22, 23, 70, 79, 87, 101, 
140, 148-150], and none assessed health burden specifically following the date of 
diagnosis and date of treatment completion. Therefore, this thesis has strength in 
providing new evidence on the burden of healthcare activity associated with cancer 
treatment in young people both during treatment and after its completion. The published 
literature either assessed the paediatric or TYA age group [23, 87], but not the entire 0-
29 year population, or specific cancer types, or related consequences [22, 79, 148]. 
Additionally, their analyses were limited to long-term cancer-related comorbidities [15, 
101, 140, 148, 150]. 
9.7 Limitations 
This thesis provided comprehensive and original findings of the hospital services burden 
among CYP in Yorkshire, from date of diagnosis, through treatment, and after treatment 
completion. The factors that influence hospital admissions and length of stay were 
identified, and the excess risk of morbidity, compared with the background population, 
was described based on cancer type, age at diagnosis and gender. However, there are 
limitations of the study that need to be considered. 
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The cases in this study were extracted from a population-based cancer register, including 
3,447 cases diagnosed between 1996 and 2009; 96% were successfully electronically 
linked to at least one hospital record. The characteristics of the unlinked cases were not 
statistically different to the linked cases in terms of the distribution of cancer type, gender 
and deprivation score. However, there were significant differences by year of diagnosis, 
with cases who were diagnosed in the earlier period more likely to be unlinked, which 
might limit the study power and bias the result. This could be as a result of linkage errors, 
however any mismatch linkage would be less likely to occur as the linkage was based 
upon four separate patient identifiers: NHS number, date of birth, sex and postcode at 
the time of diagnosis. Additionally, some of the linked cases were eliminated from the 
study as they were not admitted after diagnosis i.e. all their admissions occurred before 
the recorded date of diagnosis. This could denote documentation errors in the cancer 
register based upon information extracted from the medical notes as certain cases might 
have a delayed entry of date of diagnosis due to the time taken for histopathological 
confirmation. Consequently, this could lead to an underestimation of the total burden of 
hospital admissions among the cancer cohort. However, such cases represented only 5% 
of total linked cases and their socioeconomic status was not significantly different from 
those which were linked and included in the analyses. 
Despite the cancer register ascertaining childhood cases (ages 0-14 years) diagnosed 
as far back as 1974, the current study was limited to those diagnosed since 1996, due 
to the appropriate quality of linked HES data emerging at that time. This could limit the 
ability to assess hospital burden among extremely long-term childhood and young adult 
cancer patients and survivors. Data not analysed showed that cases diagnosed before 
1996 were less likely to be linked, which could bias the analysis of the trend in hospital 
admission levels over time. Additionally the hospital burden were assessed from 1997 
based on the available linked data, hence admissions occurred among cases diagnosed 
in 1996 might be underestimated. 
The study included 3,151 individuals with cancer and with hospital linkages, who were 
responsible for 61,971 admissions. There have been some smaller [140, 150], and larger 
sized published studies on hospital activity levels among children and young people with 
cancer [101, 149]. Treatment was grouped according to all possible combinations 
(surgery, chemotherapy, radiotherapy, BMT) based on information recorded in the 
YSRCCYP. This is likely to be accurate and complete as all initial treatment is abstracted 
directly from medical records and cases are proactively followed-up every 2 years to 
determine whether any subsequent treatment has been administered. However, a small 
minority of leukaemia cases were found to be treated with surgery alone without any 
chemotherapy and these were re-checked by the YSRCCYP data manager. 
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The study might be limited as a result of grouping cases into two age groups: children 
aged 0-14 years and young adults aged 15-29 years. This might not necessarily coincide 
with natural distinctions in place of care, as some older adolescents may be treated in 
paediatric settings and vice versa. Furthermore, the age boundary for separating children 
from teenagers and young adults varied widely in the literature [2, 8, 23, 36, 70, 71]. 
However, this cut off point did provide an equal distribution in the span of age, yielding a 
sufficient number of cases for comparative purposes.  
The main outcome investigated differences in age according to two age groups: children, 
and teenagers and young adults. This was done based on potential differences in 
management of treatment, in terms of place of care and type of treatment received. 
However, a single classification scheme of cancer was used (the ICCC [46]), rather than 
a specific TYA classification scheme [38], this facilitated relevant internal comparisons 
by main diagnostic group and also minimised the percentage of cases classified as ‘other’ 
(0.1% using ICCC and 2.0% for Birch [49]). 
The documentation of some individual’s sociodemographic characteristics (e.g. ethnicity) 
and clinical characteristics (e.g. type of initial treatment) was often poorly or 
inconsistently recorded in the UK within healthcare settings. This was evident from the 
analysis of HES data linked to the cancer register. The limitation in the recording of these 
variables was overcome in the following ways:  
The documentation of ethnicity was validated using multiple resources: the cancer 
register, HES, and name recognition software (Chapter 4) [173, 174, 176]. Cases were 
grouped according to South Asians and non-South Asians, reflecting the largest ethnic 
minority population in Yorkshire, mainly originating from Mirpur in rural Pakistan [59].  
Furthermore, the incompleteness in recording of the initial type of treatment was 
addressed and supplemented by linking HES to the cancer register. Nevertheless, some 
cancer types such as leukaemia cases were recorded as having surgery alone and that 
was not clinically accurate, highlighting possible documentation error in the data sources 
or incompleteness of recording of treatment and this was for limited number of cases. 
The date of treatment completion was not documented consistently in the cancer register 
for each patient nor was it available within the linked HES data. This was resolved by 
using a bespoke measure of treatment duration based on clinical expertise, after 
identifying the type of initial treatment and tumour diagnosis, using a novel matrix 
designed specifically for children and TYAs (Chapter 4, section 4.11.4, pages 91-). 
Furthermore, only major surgical procedures were included (so any minor or 
inconsequential interventions, such as diagnostic procedures, were excluded) to ensure 
that only cancer-related treatment was considered. This allowed the study to provide 
new information on the hospital burden during the expected treatment phase from the 
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point of diagnosis. Although this measure is more precise than simply using a standard 
cut-off of five years from diagnosis as many previous studies have used [101, 140, 150], 
it was still imperfect, as it was also based on an arbitrary cut-off point, assuming a similar 
duration of treatment for cases based on the same treatment modality and cancer type, 
therefore there will be some inaccuracy in the treatment duration and therefore the 
interpretation of findings need to be considered with some caution. 
The results describing hospital burden could also be influenced by stage, grade or other 
disease severity measures which were not consistently recorded in the cancer register 
and therefore were not directly adjusted for in the regression modelling. Additionally, 
stage of disease might influence the type of initial treatment administered and would 
influence hospitalisation rates and length of stay. However, causal inference theory 
specifically precludes adjustment of covariates which occur on the casual pathway as 
this would bias the regression coefficients [218]. Therefore in this study it would be invalid 
to adjust for both stage and initial treatment stage when the outcome is hospital burden 
(or length of stay). Initial treatment was more accurately and completely recorded on the 
register than stage, therefore the former was included in the model without stage.  Thus 
any effect of stage on the results is likely to be mitigated by adjusting for initial treatment. 
Future work, however, should be done to compare the regression modelling results using 
stage in place of initial treatment to assess its direct influence on hospital activity, once 
data quality for stage has been improved.  
The diagnosis or the cause of admission was documented at different levels within HES, 
in terms of being either the primary or secondary cause. The primary cause should be 
that identified as the main reason for admission, while a secondary diagnosis could be 
another disease that relates to the primary cause, but which is not the main reason for 
the patient being admitted to hospital (more detail is contained in Section 4.12.4). 
Restricting the analysis to consider primary causes only was not accurate in terms of 
measuring the total hospital burden among cancer survivors, as it would overestimate 
the burden of admissions for recurrent disease, while underestimating the cancer-related 
effects of other causes, such as respiratory illness. This could also lead to a potential 
recording limitation in HES, as most cancer patients would have their malignancy coded 
as the primary cause of admission, which could mask the actual burden due to other 
causes among this population. This highlights the importance in understanding the HES 
data structure and the quality of the coding before estimating hospital burden. 
In this thesis, a natural comparison group was identified from an age-sex-period matched 
denominator population to estimate the excess rate of hospitalisation, derived from all 
HES admissions over a follow-up period matched to the Yorkshire register cohort (1997-
2011). Estimation of excess hospitalisation rates could be biased towards the null by 
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comparing cancer survivors to the general population, some of whom may have a history 
of previous disease.   From the founded literature some randomly selected a comparison 
group from a registry of health insurance [140],  similarly others extracted a comparison 
group randomly from an administrative database that holds information on individuals 
who are permanent residents in the Netherlands [150], and both found an excess risk of 
hospitalisation among cancer survivors of 2.2 (95%CI:1.90–2.50), similar to the current 
finding of 2.4 (95%CI: 2.26-2.49). Selection bias might also be present as hospital activity 
was limited to information obtained from NHS healthcare providers (i.e. non-private 
hospitals), although this level of bias is likely to be small due to the high matching rates 
(96%) and the high proportion of young people referred to NHS providers for their cancer 
care and follow-up. 
A degree of multiple testing was carried out on the same study population within similar 
subgroups which could result in increasing the possibility of type I decision errors through 
spurious statistically significant findings. Additionally, due to the small number of cases 
in some of the analyses, such as for BMT, results produced imprecise estimates with 
wide confidence intervals, so some degree of caution is required, particularly when 
making any clinical inferences. 
Initially, it was planned to assess the relative risk of the total burden of admissions, i.e. 
multiple-admissions per patient adjusted for the background population denominator. 
However, flexible relative survival analyses, such as the Royston-Parmar model [219], 
which takes into account the difference in baseline hazard by adjusting for the population 
denominator, could not account for the multilevel structure of the data at the time of 
analysis. 
The current study focused on inpatient activity with little information about outpatient 
activity, although the ratio of inpatient to outpatient admissions was 1:1.8. However, the 
level of detail associated with outpatient admissions was poor, especially the recording 
of causes or diagnoses during hospital visits, such that around 99.5% of hospital visits 
were coded as ‘factors influencing health’. 
The study included cases diagnosed during 1996 to 2009, providing a retrospective 
cancer cohort, a period during which the management of treatment might have altered 
and could change also in the future. Despite all these caveats, this thesis documents the 
first comprehensive observational data on hospital activity patterns that can be used as 
a benchmark for future health services research studies. 
9.8 Future work 
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As discussed in Section 9.5 above, : the date of treatment completion was a key variable 
derived in the current analyses, as to date there has been no published information on 
the health burden before and after treatment completion. Clearly, it would have been 
preferable and more accurate if the date of treatment completion was documented in the 
cancer registry for each individual, and this is something currently being undertaken at a 
national level, as a priority in work being overseen by the TYAC professional work. In 
this study, the information regarding treatment detail, such as dose and type of treatment 
administered were not included, due to the incomplete recording of these treatment 
details for both the cancer register and HES. It is encouraging for future studies that are 
investigating how hospital activity is affected by detailed type of treatment modality, i.e. 
the same treatment modality but with a more moderate dose, that in a few years’ time, 
they will be able to link the national cancer registry dataset, Cancer Outcome and 
Services Dataset with other treatment national datasets such as the National 
Radiotherapy Dataset and Systemic Anti-Cancer Therapy Dataset (Chemotherapy), 
once the datasets have had time to mature in terms of quality and patient years. 
Hospital activity (episodes) among individuals with cancer were followed-up in this study 
until 2011, based on the available data at the time of analysis. It will be useful to assess 
admissions beyond this date and complementary work has begun to exploit newly 
available data on HES admissions up to 2015 for the Yorkshire cohort, focusing on 
respiratory and mental health admissions. Assessment of the impact on hospital 
admission patterns through any recent changes in treatment management over the last 
five years would also be instructive. 
All CYP diagnosed in the period 1996 to 2009 whilst living in the Yorkshire region were 
included in this population-based record-linkage study (assuming they had at least one 
hospital inpatient record). It found that bone tumour and leukaemia cases had the highest 
hospitalisation rates among children and TYAs, respectively. However, the numbers of 
cases within each main diagnostic group were limited due to the rarity of this disease in 
this age group, limiting the ability for subgroup analyses among tumours, such as 
lymphoblastic leukaemia, acute myeloid leukaemia and CNS embryonal tumours. This 
precluded analyses investigating detailed patterns according to sociodemographic and 
patient variables, including the presence of interaction effects. Nonetheless, a focus on 
these subgroups would be valuable as part of future work using national or international 
datasets. 
The health burden was primarily based on health activity which took place in inpatient 
settings, which comprises a major proportion of the annual NHS budget [220]. However, 
alternative healthcare services which deal with short- and long-term survivors, such as 
primary care, were not considered. Future work could be done to expand the knowledge 
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of the healthcare burden associated with cancer accounting for care occurring away from 
inpatient settings. 
In this study, the quantity of hospital activity was assessed across the childhood and 
young adult age group. However, it is also important to consider the psychological and 
emotional needs of young people during diagnosis, treatment, shortly after treatment 
completion and among long-term survivors. This would complement the current focus on 
quantifying hospital activity. The cost burden might also be helpful for healthcare 
commissioners and planners, especially as current UK government spending is being 
tightened.  
9.9  Conclusion 
In this study, a bespoke electronic patient-level linkage was used to assess the actual 
hospital burden and related morbidity of childhood and young adult cancer patients and 
survivors.  
Childhood and young adult cancer survivors were at a sustained high risk of admissions 
compared to the age, sex and attained year of admission matched general population. 
A significant proportion presented with serious complications after completing cancer 
treatment resulting in subsequent hospitalisation. The rate of hospital admissions 
remained stable over time, however the rate of admissions increased more recently, 
partly due to changes in hospital episode recording methods. This study identified both 
the short- and long-term health effects among cancer survivors diagnosed as young 
people, yet have the potential to lead a long and healthy life, assuming sufficient 
healthcare services are in place to deal adequately with conditions that require 
hospitalisation. 
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Appendix A  Recode of cancer types, and causes of 
admissions  
 
Table A-I: Recording of cancer types based on Classification of Childhood Cancer. 
Diagnostic group Morphology  Topography Recode 
I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases 
a. Lymphoid leukemias 
9820, 9823, 9826, 9827, 9831–
9837, 9940, 9948 
C000-C809 11 
b. Acute myeloid 
leukemias 
9840, 9861, 9866, 9867, 9870–
9874, 9891, 9895–9897, 9910, 
9920,9931 
C000-C809 12 
c. Chronic 
myeloproliferative 
diseases  
9863, 9875, 9876, 9950, 9960–
9964 
C000-C809 13 
d. Myelodysplastic 
syndrome and other 
myeloproliferative 
diseases 
9945, 9946, 9975, 9980, 9982–
9987, 9989 
C000-C809 14 
e. Unspecified and 
other specified 
leukemias  
9800, 9801, 9805, 9860, 9930 C000-C809 15 
II. Lymphomas and 
reticuloendothelial 
neoplasms 
   
a. Hodgkin lymphomas 
9650–9655, 9659, 9661–9665, 
9667 
C000-C809 21 
b. Non-Hodgkin 
lymphomas (except 
Burkitt lymphoma)  
9591, 9670, 9671, 9673, 9675, 
9678–9680, 9684, 9689–9691, 
9695,9698–9702, 9705, 9708, 
9709, 9714, 9716–9719, 9727–
9729,9731–9734, 9760–9762, 
9764–9769, 9970 
C000-C809 22 
c.Burkitt lymphoma  9687 C000-C809 23 
d. Miscellaneous 
lymphoreticular 
neoplasms  
9740–9742, 9750, 9754–9758 C000-C809 24 
e. Unspecified 
lymphomas  
9590, 9596 C000-C809 25 
III. CNS and 
miscellaneous 
intracranial and 
intraspinal neoplasms 
   
a. Ependymomas and 
choroid plexus tumor  
9383, 9390–9394a C000-C809 31 
b. Astrocytomas 
9380a, 9384, 9400–9411, 9420, 
9421–9424, 9440–9442a 
 C72.3 32 
c. Intracranial and 
intraspinal embryonal 
tumors  
9470–9474, 9480, 9508a  C70.0–C72.9 33 
 9501–9504a C000-C809 33 
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Diagnostic group Morphology  Topography Recode 
d. Other gliomas  9380a 
C70.0–C72.2, C72.4–
C72.9,C75.1, C75.3 
34 
 9381, 9382, 9430, 9444, 9450, 
9451, 9460a 
 34 
e. Other specified 
intracranial and 
intraspinal neoplasms  
8270–8281, 8300, 9350–9352, 
9360–9362, 9412, 9413, 9492, 
9493,9505–9507, 9530–9539, 
9582a 
C000-C809 35 
f. Unspecified 
intracranial and 
intraspinal neoplasms  
8000–8005a  
C70.0–C72.9, C75.1–
C75.3 
36 
IV. Neuroblastoma and 
other peripheral 
nervous cell tumours 
   
a. Neuroblastoma and 
ganglioneuroblastoma  
9490, 9500 C000-C809 41 
b. Other peripheral 
nervous cell tumours 
 8680–8683, 8690–8693, 8700, 
9520–9523 
C000-C809 42 
 9501–9504 
 C00.0–C69.9, 
C73.9–C76.8,C80.9 
42 
V. Retinoblastoma  9510–9514 C000-C809 51 
VI. Renal tumours    
a. Nephroblastoma 
(Wilms’ tumour) and 
other nonepithelial 
renal tumours 
8963 C64.9, C80.9 61 
  8959, 8960, 8964–8967, 9364  C64.9 61 
b. Renal carcinomas  
8010–8041, 8050–8075, 8082, 
8120–8122, 8130–8141, 8143, 
8155,8190–8201, 8210, 8211, 
8221–8231, 8240, 8241, 8244–
8246,8260–8263, 8290, 8310, 
8320, 8323, 8401, 8430, 8440, 
8480–8490, 8504, 8510, 8550, 
8560–8576 
C64.9 62 
 8311, 8312, 8316–8319, 8361 C000-C809 62 
c. Unspecified 
malignant renal 
tumours 
 8000–8005  C64.9 63 
VII. Hepatic tumours    
a. Hepatoblastoma 8970 C000-C809 71 
b. Hepatic carcinomas  
8010–8041, 8050–8075, 8082, 
8120–8122, 8140, 8141, 8143, 
8155,8190–8201, 8210, 8211, 
8230, 8231, 8240, 8241, 8244–
8246,8260–8264, 8310, 8320, 
8323, 8401, 8430, 8440, 8480–
8490,8504, 8510, 8550, 8560–
8576 
C22.0, C22.1 72 
 8160–8180 C000-C809 72 
c. Unspecified 
malignant hepatic 
tumours  
8000–8005  C22.0, C22.1 73 
VIII. Malignant bone 
tumours 
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Diagnostic group Morphology  Topography Recode 
a. Osteosarcomas  9180–9187, 9191–9195, 9200  
C40.0–C41.9, C76.0–
C76.8,C80.9 
81 
b. Chondrosarcomas  9210, 9220, 9240 
 C40.0–C41.9, 
C76.0–C76.8,C80.9 
82 
 9221, 9230, 9241–9243 C000-C809 82 
c. Ewing tumour and 
related sarcomas of 
bone 
9260 
C40.0–C41.9, C76.0–
C76.8,C80.9 
83 
 9363–9365 C40.0–C41.9 83 
d. Other specified 
malignant bone 
tumours  
8810, 8811, 8823, 8830,8812, 
9250, 9261, 9262, 9270–9275, 
9280–9282, 9290, 9300–
9302,9310–9312, 9320–9322, 
9330, 9340–9342, 9370–9372 
C40.0–C41.9 84 
e. Unspecified 
malignant bone 
tumours  
8000–8005, 8800, 8801, 8803–
8805  
C40.0–C41.9 85 
IX. Soft tissue and 
other extraosseous 
sarcomas 
   
a. 
Rhabdomyosarcomas  
8900–8905, 8910, 8912, 8920, 
8991 
C000-C809 91 
b. Fibrosarcomas, 
peripheral nerve sheath 
tumours, and other 
fibrous neoplasms 
8810, 8811, 8813–8815, 8821, 
8823, 8834–8835 
C00.0–C39.9, C44.0–
C76.8,C80.9 
92 
 
8820, 8822, 8824–8827, 9150, 
9160, 9491, 719540–9571, 9580 
C000-C809 92 
c. Kaposi sarcoma  9140 C000-C809 93 
d. Other specified soft 
tissue sarcomas  
8587, 8710–8713, 8806, 8831–
8833, 8836, 8840–8842, 8850–
8858,8860–8862, 8870, 8880, 
8881, 8890–8898, 8921, 8982, 
8990,9040–9044, 9120–9125, 
9130–9133, 9135, 9136, 9141, 
9142,9161, 9170–9175, 9231, 
9251, 9252, 9373, 9581, 8830 
 C00.0–C39.9, 
C44.0–C76.8,C80.9 
94 
 8963 
C00.0–C63.9, C65.9–
C69.9,C73.9–C76.8, 
C80.9 
94 
 9180, 9210, 9220, 9240  C49.0–C49.9 94 
 9260 
C00.0–C39.9, C47.0–
C75.9 
94 
 9364 
C00.0–C39.9, C47.0–
C63.9,C65.9–C69.9, 
C73.9–C76.8, C80.9 
94 
 9365 
C00.0–C39.9, C47.0–
C63.9,C65.9–C76.8, 
C80.9 
94 
e. Unspecified soft 
tissue sarcomas  
8800–8805  
C00.0–C39.9, C44.0–
C76.8 
95 
X. Germ cell tumours, 
trophoblastic tumours, 
and neoplasms of 
gonads 
   
a. Intracranial and 9060–9065, 9070–9072, 9080– C70.0–C72.9, C75.1– 101 
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Diagnostic group Morphology  Topography Recode 
intraspinal germ cell 
tumours  
9085, 9100, 9101a  C75.3 
b. Malignant 
extracranial and 
extragonadal germ cell 
tumours  
9060–9065, 9070–9072, 9080–
9085, 9100–9105  
C00.0–C55.9, C57.0–
C61.9,C63.0–C69.9, 
C73.9–C63.0–C69.9, 
C73.9–C75.0, C75.4–
C76.8,C80.9 
102 
c. Malignant gonadal 
germ cell tumours  
9060–9065, 9070–9073, 9080–
9085, 9090, 9091, 9100, 9101  
C56.9, C62.0–C62.9 103 
d. Gonadal carcinomas  
8010–8041, 8050–8075, 8082, 
8120–8122, 8130–8141, 8143, 
8190–8201, 8210, 8211, 8221–
8241, 8244–8246, 8260–8263, 
8290,8310, 8313, 8320, 8323 
8380–8384, 8430, 8440, 8480–
8490, 8504, 8510, 8550, 8560–
8573, 9000, 9014, 9015, 
C56.9, C62.0–C62.9 104 
 8441–8444, 8450, 8451, 8460–
8473 
C000-C809 104 
e. Other and 
unspecified malignant 
gonadal tumours  
8590–8671  C56.9, C62.0–C62.9 105 
 8000–8005 C000-C809 105 
XI. Other malignant 
epithelial neoplasms 
and malignant 
melanomas 
 8370–8375   
a. Adrenocortical 
carcinomas 
  111 
b. Thyroid carcinomas  
8010–8041, 8050–8075, 8082, 
8120–8122, 8130–8141, 8190, 
8200,8201, 8211, 8230, 8231, 
8244–8246, 8260–8263, 8290, 
8310,8320, 8323, 8430, 8440, 
8480, 8481, 8510, 8560–8573 
C73.9 112 
 8330–8337, 8340–8347, 8350 C000-C809 112 
c. Nasopharyngeal 
carcinomas  
8010–8041, 8050–8075, 8082, 
8083, 8120–8122, 8130–8141, 
8190,8200, 8201, 8211, 8230, 
8231, 8244–8246, 8260–8263, 
8290,8310, 8320, 8323, 8430, 
8440, 8480, 8481, 8500–8576 
C11.0–C11.9 113 
d. Malignant 
melanomas  
8720–8780, 8790 C000-C809 114 
e. Skin carcinomas  
8010–8041, 8050–8075, 8078, 
8082, 8090–8110, 8140, 8143, 
8147,8190, 8200, 8240, 8246, 
8247, 8260, 8310, 8320, 8323, 
8390–8420, 8430, 8480, 8542, 
8560, 8570–8573, 8940, 8941 
C44.0–C44.9 115 
f. Other and 
unspecified 
carcinomas 
 8010–8084, 8120–8157, 8190–
8264, 8290, 8310, 8313–8315, 
8320–8325, 8360, 8380–8384, 
8430–8440, 8452–8454, 8480–
8586,8588–8589, 8940, 8941, 
8983, 9000, 9010–9016, 9020, 
9030 
C00.0–C10.9, C12.9–
C21.8,C23.9–C39.9, 
C48.0–C48.8, C50.0–
C55.9,C57.0–C61.9, 
C63.0–C63.9, C65.9–
C72.9,C75.0–C76.8, 
C80.9 
116 
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Diagnostic group Morphology  Topography Recode 
XII. Other and 
unspecified malignant 
neoplasms 
   
a. Other specified 
malignant tumours 
 8930–8936, 8950, 8951, 8971–
8981, 9050–9055, 9110 
 C00.0–C39.9, 
C47.0–C75.9 
121 
 9363 C000-C809 121 
b. Other unspecified 
malignant tumours  
8000–8005  
C00.0–C21.8, C23.9–
C39.9,C42.0–C55.9, 
C57.0–C61.9, C63.0–
C63.9,C65.9–C69.9, 
C73.9–C75.0, C75.4–
C80.9 
122 
Not classified by ICCC 
or in situ 
  999 
ICD-O-3: International Classification of Diseases for Oncology, third edition;  
CNS: central nervous system 
a: Tumours with non-malignant behaviour are included for all morphology codes on the 
line: [209] 
 
Table A-II: Recoding of causes of admissions based on ICD-10 codes. 
Analysis code ICD codes Definition  
1 A00-B99  Certain infectious and parasitic diseases 
2 C00-D48  Neoplasms 
3 D50-D89  
Diseases of the blood and blood-forming organs and 
certain disorders involving the immune mechanism 
4 E00-E90  Endocrine, nutritional and metabolic diseases 
5 F00-F99  Mental and behavioural disorders 
6 G00-G99  Diseases of the nervous system 
7 H00-H59  Diseases of the eye and adnexa 
8 H60-H95  Diseases of the ear and mastoid process 
9 I00-I99  Diseases of the circulatory system 
10 J00-J99  Diseases of the respiratory system 
11 K00-K93  Diseases of the digestive system 
12 L00-L99  Diseases of the skin and subcutaneous tissue 
13 M00-M99  
Diseases of the musculoskeletal system and 
connective tissue 
14 N00-N99  Diseases of the genitourinary system 
15 O00-O99  Pregnancy, childbirth and the puerperium 
16 P00-P96  Certain conditions originating in the perinatal period 
17 Q00-Q99  
Congenital malformations, deformations and 
chromosomal abnormalities 
18 R00-R99  
Symptoms, signs and abnormal clinical and laboratory 
findings, not elsewhere classified 
19 S00-T98  
Injury, poisoning and certain other consequences of 
external causes 
20 V01-Y98  External causes of morbidity and mortality 
21 Z00-Z99  
Factors influencing health status and contact with 
health services 
22 U00-U99  Codes for special purposes 
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Appendix B  List of diagnostics and supportive 
surgeries: main surgeries extracted from the 
cancer register and HES 
Table B-I: List of diagnostics and supportive surgeries extracted from the cancer 
register 
Operation 
code 
Code Description 
P5599 Abdominal operations, not elsewhere classified - biopsy 
P0579 Biopsy of brain 
P3870 Biopsy of breast 
P3879 Biopsy of breast 
P8290 Biopsy of buttock 
P7069 Biopsy of cervix 
P9209 Biopsy of skin and subcutaneous tissue 
P3409 Bronchoscopy with biopsy 
P9641 Endoscopy, not elsewhere classified - with biopsy, not elsewhere classified 
P4501 Enterotomy - biopsy, not elsewhere classified 
P9531 Excision - biopsy, not elsewhere classified 
P0801 Excision of cervical lymph nodes - biopsy (scalene node) 
P8321 Excision of lesion of muscle, biopsy 
P5501 Exploration and drainage of peri-renal tissue - biopsy 
P5629 Exploration of renal pelvis - biopsy 
P4311 Gastric intubation with related procedures - biopsy of duodenum, jejunum 
P4319 Gastric intubation with related procedures - endoscopy, gastroscopy 
P4319 Gastric intubation with related procedures - endoscopy, gastroscopy 
P4269 Gastro-enterostomy 
P4701 Incision of rectum, biopsy 
P6409 Incision of testis and adnexa - biopsy 
P2611 Incision of tongue - biopsy of tongue 
P3304 Incision or puncture of chest wall - thoracoscopy 
P0206 Laminotomy and laminectomy - biopsy of bone 
P4022 Laparotomy - biopsy (abdominal) (peritoneal) 
P4023 Laparotomy - exploratory 
P5019 Needle biopsy - punch biopsy  
P5601 Nephrotomy, not elsewhere classified - exploration 
P5602 Nephrotomy, not elsewhere classified - biopsy 
P0401 Neurectomy and neurotomy - biopsy 
P2941 Oesophagoscopy - with biopsy 
P3354 Operations of mediastinum - biopsy 
P3474 Operations upon bronchus, not elsewhere classified - biopsy 
P1001 Orbitotomy, biopsy of orbit 
P1891 Other operation on eye - biopsy of eye, not otherwise stated 
P7399 
Other operation on female genital organs - biopsy of labia, perineum, vulva, 
clitoris 
P2671 Other operation on mouth and palate - biopsy - faeces, palate 
P2399 Other operation on nasopharynx, biopsy 
P9299 
Other operation on skin or subcutaneous tissue, not elsewhere classified, 
biopsy 
P6591 Other operation on testis and adnexa - biopsy 
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P0691 Other operations on adrenal gland - biopsy 
P3391 Other operations on chest - biopsy 
P2091 Other operations on ear, not elsewhere classified - biopsy 
P3099 Other operations on heart-not elsewhere classified - cardioscopy 
P8221 Other operations on joints or cartilage - biopsy 
P5091 Other operations on liver, open biopsy 
P2241 Other operations on nose and face, biopsy 
P4051 Other operations on omentum and mesentery - biopsy 
P6791 Other operations on ovary - biopsy 
P1691 Other operations on retina, or choroid - biopsy of retina or choroid 
P2754 Other operations on salivary gland and duct - biopsy 
P0091 Other operations on skull and meninges, biopsy 
P0291 Other operations on spine and contents - biopsy of cord or meninges 
P0711 Partial thyroidectomy - biopsy 
P5641 Percutaneous puncture of kidney - biopsy 
P9541 Puncture - percutaneous biopsy, not elsewhere classified 
P7981 Puncture of bone - biopsy of bone 
P7982 Puncture of bone - biopsy of marrow 
P4681 Sigmoidoscopy - with biopsy 
P0019 Craniotomy, not elsewhere classified - decompression, exploration, biopsy 
P0803 Excision of cervical lymph nodes - radical cervical 
P0806 Excision of cervical lymph nodes - simple excision 
P0809 Excision of cervical lymph nodes, not elsewhere classified 
P9059 Lymphatic biopsy, not elsewhere classified 
P6081 Cystoscopy - biopsy 
 
Table B-II: List of diagnostics and supportive surgeries extracted from HES 
Operatio
n code 
Code description 
A013 Biopsy of the brain 
A045 Open biopsy of lesion of tissue of brain 
A085 Other biopsy of lesion of tissue of brain 
A559 Diagnostic spinal puncture 
C861 Biopsy of lesion of eye neck 
E095 Biopsy of lesion of external nose 
E271 Open biopsy of lesion of pharynx 
E381 Diagnostic endoscopic examination of larynx 
E491-9 Diagnostic fibrotic endoscopic examination on lower respiratory tract 
E593 Biopsy of lesion of lung neck 
E631 Diagnostic endoscopic examination of mediastinum 
F091 Surgical removal of tooth 
F115 End osseous implantation into jaw 
F135 Restoration of part of tooth using filing neck 
F145 Surgical exposure of tooth 
F164 Scaling of tooth 
F172 Operation of teeth using dental crown 
F189 Excision of dental lesion of jaw 
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F201 Operations on gingiva 
F238 Extrication of lesion of tongue 
F263 Other operation on tongue 
F342-8 Excision of osil 
G152-9 Other therapeutic fibrotic endoscopic operations on oesophagus 
G218 Other operations on oesophagus 
G241-3 Antireflux operations 
G331 Other connection of stomach to jejunum 
G344 Artificial opening into stomach 
G451-9 Diagnostic fibrotic endoscopic examination of upper gastrointestinal tract 
G478 Intubation of stomach 
G484 Other operation of stomach 
H011-9 Emergency excision of appendix 
H131 Bypass of colon 
H228 Diagnostic endoscopic examination of colon 
H524 Destruction of haemorrhoid 
J132 Diagnostic endoscopic examination of liver 
J439 Diagnostic endoscopic retrograde examination of bile duct pancreatic duct 
K635 Constrict radiology of heart 
K651-9 Catheterisation of heart 
L941 Therapeutic transluminal operations on vein 
M113 Diagnostic endoscopic examination of kidney 
M451-9 Diagnostic endoscopic examination of bladder 
N134 Biopsy of testis 
N321 Biopsy of lesion of penis 
P091 Biopsy of lesion of vulva 
Q034 Biopsy of cervix uteri 
Q034 Punch biopsy of cervix uteri  
Q181-9 Diagnostic endoscopic examination of uterus 
Q188 Diagnostic endoscopic examination of uterus 
Q553 Other examination of female genital tract 
R053 Diagnostic percutaneous examination of foetus 
R151 Other induction of labour 
R182 Other caesarean delivery 
R215 Forceps cephalic delivery 
R229 Vacuum delivery 
R232 Cephalic vaginal delivery with abdominal presentation of head at delivery 
without instrument 
S132 Punch biopsy of skin 
S151-9 Other biopsy of skin 
S551 Exploration of burnt skin of other site 
S563 Exploration of other skin of head or neck 
S571 Exploration of skin other site 
T111 Diagnostic endoscopic examination of pleura 
T122-9 Puncture of pleura 
T431-9 Diagnostic endoscopic examination of peritoneum 
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T813 Biopsy of muscle 
T861 Sampling of lymph nodes 
T911 Biopsy od sentinel lymph node neck 
U011 Diagnostic imaging of whole body 
U051-9 Diagnostic imaging of central nervous system 
U063 Diagnostic imaging of face and neck 
U071 Diagnostic imaging of chest 
U081-9 Diagnostic imaging of abdomen 
U092-9 Diagnostic imaging of pelvis 
U121-9 Diagnostic imaging of genitourinary system 
U133 Diagnostic imaging of musculoskeletal system 
U202 Diagnostic echocardiography 
U211-9 Diagnostic imaging procedures 
U221 Neuropsychology test 
U261 Diagnostic testing of genitourinary system 
U291-9 Diagnostic endocrinology 
U301 Autonomic cardiovascular testing 
U321-9 Diagnostic blood tests 
U331 Other diagnostic tests 
U354 Other diagnostic imaging of vascular system 
U372 Other diagnostic imaging of genitourinary system 
V194 Biopsy of lesion of mandible 
V478 Biopsy of spine 
W361-9 Diagnostic puncture of bone 
W879 Diagnostic endoscopic examination of knee joint 
W941 Hybrid prosthetic replacement of hip joint using cemented acetabular 
component 
X118 Amputation of toe 
X123 Operations on amputation stump 
X213 Correction of congenital deformity of hand 
X222 Correction of congenital deformity of hip 
X291-9 Continuous infusion of therapeutic substance 
X301-9 Injection of therapeutic substance 
X311-9 Injection of radiocontrast material 
X323 Exchange blood transfusion 
X331-9 Other blood transfusion 
X348 Other intravenous transfusion 
X352-9 Other intravenous injection 
X361-9 Blood withdrawal 
X373-9 Trans muscular injection 
X381-9 Subcutaneous injection  
X411-8 Placement of ambulatory apparatus for compensation for renal failure 
X442 Administration of vaccine 
X528 Oxygen therapy 
X558 Other operations on unspecified organ 
X591-9 Anaesthetic without surgery 
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X851 High cost neurology drugs 
X861 Anti-effective drugs 
X891-9 Immunosuppressant and urinary drugs 
X893 High cost immunosuppressant drugs 
X901-9 Haematology and nutrition drugs 
X931 Ophthalmology drugs 
X961-9 Immunology drugs 
X381-5 Subcutaneous injection  
X411 Placement of ambulatory apparatus for compensation for renal failure 
X418 Placement of ambulatory apparatus for compensation for renal failure 
X442 Administration of vaccine 
X528 Oxygen therapy 
X558 Other operations on unspecified organ 
X598 Anaesthetic without surgery 
X851 High cost neurology drugs 
X893 High cost immunosuppressant drugs 
 
Table B-III: List of major cancer-related surgeries extracted from the cancer register 
Operation 
code 
Operation description 
P0011 Craniotomy - burr-hole 
P0012 Craniotomy - trephine 
P0014 Craniotomy - puncture of brain 
P0049 Excision of lesion of skull 
P0081 Ventricular puncture and anastomosis - drainage 
P0083 Ventricular puncture and anastomosis - ventriculo-cisternostomy 
P0084 Ventricular puncture and anastomosis - ventriculo-vascular anastomosis 
P0089 Ventricular puncture and anastomosis 
P0095 Other operations on skull and meninges - meningeal lesion 
P0169 Revision or irrigation of ventricular shunt 
P0172 Cranial puncture, not elsewhere classified-aspiration (brain substance, 
abscess) 
P0201 Laminotomy and laminectomy - laminotomy 
P0202 Laminotomy and laminectomy - excision of bone (tumour) 
P0209 Laminotomy and laminectomy not elsewhere classified 
P0262 Extirpation of intraspinal lesion - intradeduilary 
P0269 Extirpation of intraspinal lesion, not elsewhere classified 
P0289 Spinal puncture - nos 
P0292 Other operations on spine and contents - removal of foreign body 
P0293 Other operations on spine and contents - operation for spinal deformity 
P0295 Other operation on spine and contents - aspiration (cyst, abscess) 
P0402 Neurectomy and neurotomy - excision 
P0499 Other operations on peripheral nerves 
P0523 Operations on vessels of the brain - excision 
P0554 Excision of intracranial lesion - frontal approach 
P0559 Excision of intracranial lesion not elsewhere classified 
P0591 Intracranial operations, - exploration 
P0599 Intracranial operations, not elsewhere classified 
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P0633 Other operations related to pituitary or pineal gland - pineal 
P0639 Other operations related to pituitary or pineal gland - not otherwise stated 
P0659 Partial adrenalectomy 
P0669 Excision of adrenal gland, not other classify. - adrenalectomy 
(transabdominal) 
P0679 Bilateral adrenalectomy 
P0712 Partial thyroidectomy - nodule 
P0715 Partial thyroidectomy - lobectomy 
P0716 Partial thyroidectomy, not elsewhere classified 
P0719 Partial thyroidectomy 
P0721 Thyroidectomy - total 
P0729 Thyroidectomy, not elsewhere classified 
P0759 Other operations on thyroid gland 
P0899 Other operations in neck region, not elsewhere classified 
P1019 Exenterating of orbit, not elsewhere classified 
P1039 Removal of eyeball - enucleating (with implant) 
P1699 Other Operations On Retina, Or Choroid - Destruction Of Lesion 
P1899 Other operation on eye - suture of eyeball not elsewhere classified 
P1919 Excision and destruction of external ear or lesion - open operation 
P2019 Mastoidectomy and related bone exposure, not elsewhere classified 
P2099 Other operations on ear neck 
P2179 Excision of other lesions of nose and face 
P2249 Other operations on nose and face 
P2289 Drainage or excision nasal sinus not elsewhere classified 
P2342 Tonsillectomy, not otherwise stated 
P2349 Tonsillectomy 
P2359 Adenoidectomy, not otherwise stated 
P2361 Other operations on tonsil - removal foreign body 
P2391 Other operation on nasopharynx, excision of lesion 
P2439 Stripping vocal cords 
P2479 Tracheotomy (temporary) not elsewhere classified 
P2481 Tracheostomy and laryngectomy - external intubation 
P2599 Other operations on teeth, gums, and jaws 
P2669 Excision of soft tissue lesions of mouth, not elsewhere classified 
P2701 Resection of salivary gland - total parotidectomy (radical) 
P2702 Resection of salivary gland - conservative parotidectomy 
P2841 Pharyngectomy and excision of lesion - partial pharyngectomy 
P2842 Pharyngectomy and excision of lesion - excision of lesion 
P3095 Other operations on heart, not elsewhere classified-repair heart or 
pericardium 
P3301 Incision or puncture of chest wall - thoracentesis, not otherwise stated 
P3302 Incision or puncture of chest wall - aspiration (air, fluid) 
P3303 Incision or puncture of chest wall - drainage of pleural cavity (empyema) 
P3309 Incision or puncture of chest wall 
P3339 Repair of chest wall - miscellaneous 
P3351 Operations of mediastinum - mediastinoscopy, not otherwise specified 
P3352 Operations of mediastinum - mediastinotomy 
P3353 Operations of mediastinum - excision or destruction of lesion 
P3359 Operations of mediastinum 
P3361 Operations upon pleura - decortication (thoracic) 
P3364 Operations upon pleura - other pleurectomy 
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P3399 Other operations on chest - supra-sternal drainage, sternotomy 
P3411 Bronchoscopy - aspiration 
P3424 Incision or puncture of lung - puncture of lung 
P3432 Excision, destruction lesion lung-resection bulla, cyst, bloc dissection 
bronchus 
P3811 Partial mastectomy - excision of lesion (lumpectomy) 
P3821 Mastectomy - simple mastectomy 
P3829 Mastectomy- not elsewhere classified 
P3891 Other operations on breast - aspiration of breast 
P4001 Superficial operation of abdominal wall 
P4029 Laparotomy not elsewhere classified 
P4092 Operations On Abdominal Wall & Peritoneum-Incision Retroperitoneal, 
Urachal cyst 
P4093 Other operations on abdominal wall and peritoneum - excision of lesion 
P4099 Other operations on abdominal wall and peritoneum, not elsewhere 
classified 
P4231 Partial gastrectomy - with oesophago-gastrostomy 
P4269 Gastro-enterostomy 
P4399 Other operations on stomach 
P4522 Excision of small intestine or lesion - resection with re-anastomosis 
P4523 Excision of small intestine or lesion - resection with enterostomy 
P4529 Excision of small intestine or lesion not elsewhere classified 
P4602 Colectomy and resection - with anastomosis 
P4605 Colectomy and resection - excision colostomy mucosa 
P4609 Colectomy and resection, not otherwise stated - caecectomy, 
hemicolectomy 
P4619 Complete colectomy not elsewhere classified 
P4669 Excision of lesion of large intestine - caecum, sigmoid, polypectomy of 
bowel 
P4699 Other operations on intestine not elsewhere classified 
P4711 Excision of rectum, not elsewhere classifed-abdominal-anal operation or 
anastomosis 
P4712 Excision of rectum, not elsewhere classified-intra pelvic protectomy 
P4739 Excision and destruction of lesion of rectum, not elsewhere classified 
P4841 Other excision of anus or anal lesion - local excision of lesion 
P4849 Other excision of anus or anal lesion - not otherwise specified 
P4999 Other operations on anus 
P5002 Hepatectomy - destruction of lesion 
P5003 Hepatectomy - hemishepatectomy, lobectomy 
P5005 Hepatectomy - liver transplant 
P5009 Hepatectomy, not elsewhere classified 
P5399 Other operations of pancreas 
P5491 Other operations on spleen - splenectomy 
P5591 Abdominal operations, not elsewhere classified - pelvic exenterating 
P5659 Removal of kidney, complete - nephrectomy 
P5671 Excision or destruction of lesion of kidney - partial nephrectomy 
P5672 Excision or destruction of lesion of kidney - excision of cyst, tumour 
P5799 Other operations on kidney, not otherwise specified 
P6001 Cystectomy - stab cystectomy 
P6009 Cystectomy - not elsewhere classified 
P6021 Extirpation of lesion of bladder by open operation - partial cystectomy 
P6023 Extirpation of lesion of bladder by open operation - excision of lesion 
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P6379 Other operations on prostate 
P6402 Incision of testis and adnexa - incision of testis 
P6403 Incision of scrotum and adnexa - removal of foreign body 
P6419 Orchiectomy, unilateral or partial not elsewhere classified 
P6471 Extirpation of lesion of scrotum or testis - scrotum 
P6492 Repair of testis and adnexa - insertion of prosthesis 
P6599 Other operation on testis and adnexa not elsewhere classified 
P6719 Castration, female - bilateral oophorectomy 
P6721 Partial oophorectomy - wedge resection 
P6723 Partial oophorectomy - excision of lesion 
P6729 Partial oophorectomy, not elsewhere classified 
P6793 Other operations on ovary - oophorectomy, not elsewhere classified 
P6799 Other operations on ovary 
P6811 Salpinges- Oophorectomy - Unilateral 
P6812 Salpinges- Oophorectomy - Bilateral 
P6829 Salpingectomy 
P6919 Extended hysterectomy 
P6961 Hysterectomy, total 
P6969 Hysterectomy, not elsewhere classified 
P7002 Excision of lesion of uterus - polypectomy 
P7009 Excision of lesion of uterus - not elsewhere classified 
P7049 Curettage of uterus - dilation and curettage 
P7059 Excision of lesion of cervix 
P7099 Other operations on uterus 
P7909 Incision of bone, removal of foreign body, drainage, drilling, exploration 
P7929 Partial osteotomy not elsewhere classified 
P7942 Excision of lesion of bone - exocytosis 
P7949 Excision of lesion of bone 
P7983 Puncture of bone - bone marrow transplant 
P7998 Other operation on bone at other specified site 
P7999 Other operations on bone, destruction, cryosurgery, curettage 
P8011 Joint puncture aspiration/arthrocentesis 
P8329 Excision of lesion of muscle 
P8339 Excision of lesion of muscle - nec 
P8619 Removal of upper limb, forequarter amputation, disarticulation at shoulder 
P8629 Amputation of arm, through homeruns, at elbow 
P8679 Other disarticulation, upper limb, not elsewhere classified 
P8712 Amputation through thigh - above knee 
P8719 Amputation through thigh 
P8739 Amputation through lower leg - below knee - through malleoli 
P8795 Other operations on limbs not elsewhere classified - foot 
P8799 Other operations on limbs not elsewhere classified 
P9039 Lymphatic excision not elsewhere classified 
P9129 Excision of superficial cyst or fistula 
P9131 Excision of other skin growth - wide excision 
P9139 Excision of other skin growth, not elsewhere classified 
P9141 Excision of other lesion of skin or subcutaneous tissue - wide excision 
P9149 Excision of other lesion of skin or subcutaneous tissue-primary excision 
wound 
P9159 Destruction of lesion of skin not elsewhere classified 
P9169 Toilet of wound - debridement necessitating anaesthetic 
295 
 
 
P9599 Other operation with ill-defined site, not elsewhere classified 
P0171 Cranial puncture, not elsewhere classified - needle biopsy of the brain 
 
 
Table B-IV: List of major cancer-related surgeries extracted from HES 
Operation code Code discerption  
A012-9 Major excision of lesion of brain 
A038-9 Stereotactic ablation of tissue of brain 
A051-4 Drainage of lesion of tissue of brain 
A098 Neurostimulation of brain 
A107 Other operation of tissue of brain 
 
A113 Operations on tissue of brain 
A131 Attention to component of connection from ventricle of brain 
A139 Attention to component of connection from ventricle of brain 
A171 Therapeutic endoscopic operations on ventricle of brain 
A255 Intracranial transection of cranial nerve 
A291-5 Excision of lesion of cranial nerve 
A331 Neurostimulation of cranial nerve 
A361 Other operation of cranial nerve 
A383-9 Extrication of lesion of meninges of brain 
A392-4 Repair of dura 
A411-9 Drainage on subdural space 
A422 Other operations on meninges of brain 
A631 Other graft to peripheral nerve 
A681 Other release of peripheral nerve 
A709 Neurostimulation of peripheral nerve 
A734 Exploration of peripheral nerve 
B012-4 Excision of pituitary gland 
B259 Other operation of adrenal tissue 
B279 Total excision of breast 
B284 Other excision of breast 
B285-8 Other excision of breast 
B295 Reconstruction of breast 
B301 Prosthesis for breast 
B311-2 Other plastic operation on breast 
C012 Excision of eye 
C021 Operation of lesion of orbit 
C043-8 Attention to prosthetic of eye 
C051 Plastic repair of orbit 
C061 Incision of orbit 
C111-8 Operation on canthus 
C161 Other plastic repair of eyelid 
C181-9 Correction of ptosis of eyelid 
C191 Incision of eyelid 
C311-9 Combined operations on muscles of eye 
C326 Recession of muscle of eye 
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C332-6 Resection of muscle of eye 
C345-6 Partial division of tendon of muscles of eye 
C359 Other adjustment to muscle of eye 
C378 Other operations on muscle of eye 
C401 Repair of conjunctiva 
C438 Other operations on conjunctiva 
C452 Extrication of lesion of cornea 
C468 Plastic operations on cornea 
C828 Distraction of lesion of retina 
C866 Examination of eye under anaesthetic 
D063 Repair of external ear neck 
D078 Clearance of external auditory canal 
D131-4 Attachment of bone anchored hearing prosthesis 
D151 Drainage of middle ear 
D203 Other operation of middle ear 
D241-3 Operations on cochlea 
E018 Excision of nose 
E333 Other open operations on larynx 
E357 Other therapeutic endoscopic operations on larynx 
E398 Partial excision of trachea 
E429 Exteriorisation of trachea 
F028 Extirpation of lesion of lip 
F032-3 Correction of deformity of lip 
F053 Other repair of lip 
F363 Other operation on tonsil 
F388 Extirpation of lesion of other part of the mouth 
F409 Other repair of part of the mouth 
F442-3 Other operation on mouth 
F452 Extrication of lesion of salivary gland 
G021 Total excision of oesophagus 
G401 Incision of pylorus 
G649 Therapeutic endoscopic operations on jejunum 
H143 Exteriorisation of caecum 
H299 Subtotal excision of colon 
H333 Excision of rectum 
H463 Other operations of rectum 
H483 Excision of lesion of anus 
H491 Destruction of lesion of anus 
H608 Other operations on pilonidal 
H628 Other operations on bowel 
J021 Partial excision of liver 
J273 Excision of bile duct 
J388 Endoscopic incision of sphincter of duct 
J575 Other partial excision of pancreas 
J582 Extirpation of lesion of pancreas 
J692 Total excision of spleen 
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J723 Other operations on spleen  
K021 Other transplantation f heart 
K192 Creation of other cardiac conduit 
K571-2 Other therapeutic transluminal operations on heart 
K661 Other operations on heart 
K692 Incision of pericardium 
L091 Other connection to pulmonary artery 
L351 Transluminal operations on cerebral artery 
L631 Transluminal operations on femoral artery 
L773 Connection of vein cava or branch of vena cava  
L793 Other operations on vena cava 
L852 Ligation of varicose vein of leg 
L918 Other vein related operations 
M013 Transplantation of kidney 
M021-3 Total excision of kidney 
M042 Open extirpation of lesion of kidney 
M051 Open repair of kidney 
M094 Therapeutic endoscopic operations on calculus of kidney 
M132 Percutaneous puncture of kidney 
M149 Extracorporeal fragmentation of calculus of kidney 
M261 Therapeutic nephoscopy operations on ureter 
M271 Therapeutic ureteroscopic operations on ureter 
M293 Other therapeutic removal of calculus from ureter 
M362 Enlargement of bladder 
M432 Endoscopic operations to in increase capacity of bladder 
M494-8 Other operations on bladder 
M523 Abdominal operations to support outlet of female balder 
M582 Other operations on outlet of female bladder 
M733 Repair of urethra 
M768 Therapeutic endoscopic operations on urethra 
N064 Excision of testicular appendage 
N089 Bilateral placement of tests in scrotum 
N132 Other operations on testis 
N153 Operation on epididymis 
N242 Operations on male perineum 
N273 Extirpation of lesion of penis 
Q024 Destruction of lesion of cervix uteri 
Q071 Abdominal excision of uterus 
Q078 Abdominal excision of uterus 
Q233 Unilateral excision of adnexa of uterus 
Q241 Other excision of adnexa of uterus 
Q388 Other therapeutic endoscopic operations on fallopian tube 
Q484 Oocyte recovery 
Q493 Therapeutic endoscopic operations on ovary 
Q558 Other examination of female genital tract 
S069 Other excision of lesion of skin 
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S089 Curettage of lesion of skin 
S179 Distal flap of skin and muscle 
S308 Other operations of flap of skin to header neck 
S315 Other operations of flap of skin to other site 
S318 Other operations of flap of skin to other site 
S433 Removal of repair material from skin 
S442 Removal of other inorganic substance from skin 
T013 Partial excision of chest wall 
T201 Primary repair of inguinal hernia 
T243 Primary repair of umbilical hernia 
T273 Repair of hernia of abdominal wall 
T288 Other repair of anterior abdominal wall 
T311 Other operations on anterior abdominal wall 
T312 Other operations on anterior abdominal wall 
T418 Other open operations on peritoneum 
T421-2 Therapeutic endoscopic operations on peritoneum 
T461 Other drainage of peritoneal cavity 
T501 Transplantation of fascia 
T531 Excision of other fascia 
T648 Transposition of tendon 
T698 Freeing of tendon 
T702 Adjustment of length of tendon 
T723 Other operations on sheath of tendon 
T761 Transplantation of muscles 
T921 Other operations on lymphatic tissue 
V011 Plastic repair of cranium 
V092 Reduction of fracture of other bone of face 
V131 Other operations on bone of face 
V161 Division of mandible 
V171 Fixation of mandible 
V242 Decompression operations on thoracic spine 
V439 Extirpation of lesion of spine 
V543 Other operations on spine 
W093-6 Extirpation of lesion of bone 
W174 Other reconstruction of bone 
W191-5 Primary open reduction of fracture of bone and intramedullary fixation 
W205 Primary bone reduction of fracture of bone and extramedullary fixation 
W241 Closed reduction of fracture of bone and internal fixation 
W251 Closed reduction of fracture of bone and external fixation 
W264 Other closed reduction of fracture of bone 
W282 Other internal fixation of bone 
W321 Other graft of bone 
W336 Other open operations on bone 
W341-9 Graft bone marrow 
W593-5 Fusion of joint of toe 
W611 Primary arthrodesis and articular bone graft neck 
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W693 Open operations on synovial membrane of joint 
W742 Other reconstruction of ligament 
W768 Other operations of ligament 
W774-9 Stabilising operations on joint 
W802 Debridement and irrigation of joint 
W815 Other open operations on joint 
W823 Therapeutic endoscopic operations on semilunar cartilage 
W844 Therapeutic endoscopic operations on other joint structure 
W919 Puncture of joint 
Z921 Operation on head 
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